<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> CYTRX CORP (Form: 10-K, Received: 03/11/2016 06:02:44) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_AUDITORS_OPINION **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_OPTIONS **FIS_OPTIONS_AGGREGATE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_EXHIBIT_INDEX **FIS_SIGNATURES **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_BALANCE_SHEET_2 FIS_EXHIBIT_4 FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_10_3 FIS_EXHIBIT_10_4 FIS_EXHIBIT_10_5 FIS_EXHIBIT_10_6 FIS_EXHIBIT_10_7 FIS_EXHIBIT_10_8 FIS_EXHIBIT_10_9 FIS_EXHIBIT_10_10 FIS_EXHIBIT_10_11 FIS_EXHIBIT_32 FIS_EXHIBIT_10_12 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_3 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="153">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="FORM10-K_2015_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<DIV>
<DIV>
<DIV>
<HR STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; HEIGHT: 10PX; COLOR: #FFFFFF; MARGIN-LEFT: AUTO; BORDER-TOP: BLACK 4PX SOLID; MARGIN-RIGHT: AUTO">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Washington, D.C. 20549
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 18PT; FONT-WEIGHT: BOLD">
	Form 10-K
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(Mark One)
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3094E585A49D44E490F61938D5A03ABD" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	T
</DIV>
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	EXCHANGE ACT OF 1934
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	For the fiscal year ended December 31, 2015
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	or
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</DIV>
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	EXCHANGE ACT OF 1934
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 9.93%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 90.07%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	For the transition period from
</FONT>
<FONT STYLE="FONT-SIZE: 5.05PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	to
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</FONT>
</DIV>
</TD>
</TR>
</TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Commission file number 0-15327
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 20PT; FONT-WEIGHT: BOLD">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(Exact name of Registrant as specified in its charter)
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="33C426F150284F23A8CCE916A014BDFB" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Delaware
</DIV>
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	58-1642740
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(State or other jurisdiction of
</DIV>
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(I.R.S. Employer
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	incorporation or organization)
</DIV>
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Identification No.)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	11726 San Vicente Blvd, Suite 650,
</DIV>
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Los Angeles, California
</DIV>
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	90049
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.24%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(Address of principal executive offices)
</DIV>
</TD>
<TD STYLE="WIDTH: 48.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(Zip Code)
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Registrant's telephone number, including area code: (310) 826-5648
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; MARGIN-TOP: 3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	________________
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Securities registered pursuant to Section 12(b) of the Act:
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C9A670D0321D4DD98939E2C1C4DE54BC" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 51.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Title of each class
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 48.6%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name of exchange on which registered
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Common Stock, $0.001 par value per share
</DIV>
</TD>
<TD STYLE="WIDTH: 48.6%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	The NASDAQ Capital Market
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 51.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Series A Junior Participating Preferred Stock Purchase Rights
</DIV>
</TD>
<TD STYLE="WIDTH: 48.6%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Securities Registered Pursuant to Section 12(g) of the Act:
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	None
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark if the Registrant is a well-known seasoned issuer (as defined in Securities Act Rule 405). Yes
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	Yes
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
	No
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
	No
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D1EFF87BF5A049DF8398A0319C19E7FF" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 29.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Large accelerated filer
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 18.76%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Accelerated filer
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 31.32%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Non-accelerated filer
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 20.16%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Smaller reporting company
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 29.76%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 18.76%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 31.32%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(Do not check if a smaller reporting company)
</DIV>
</TD>
<TD STYLE="WIDTH: 20.16%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	&#163;
</FONT>
	No
<FONT STYLE="FONT-FAMILY: 'WINGDINGS 2', SERIF; FONT-SIZE: 10PT">
	R
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Based on the closing price of the Registrant's common stock as reported on The NASDAQ Capital Market, the aggregate market value of the Registrant's common stock held by non-affiliates on June 30, 2015 (the last business day of the Registrant's most recently completed second fiscal quarter) was approximately $123 million. Shares of common stock held by directors and executive officers and any ten percent or greater stockholders and their respective affiliates have been excluded from this calculation, because such stockholders may be deemed to be "affiliates" of the Registrant. This is not necessarily determinative of affiliate status for other purposes. The number of outstanding shares of the Registrant's common stock as of March 11, 2016 was 66,480,065.
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<HR STYLE="BORDER-BOTTOM: BLACK 4PX SOLID; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; HEIGHT: 10PX; COLOR: #FFFFFF; MARGIN-LEFT: AUTO; BORDER-TOP: BLACK 1PX SOLID; MARGIN-RIGHT: AUTO">
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015 ANNUAL REPORT ON FORM 10-K
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	TABLE OF CONTENTS
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="88EE28191A3B45B2AC7C6BDC97FDFA81" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Page
</DIV>
</TD>
<TD STYLE="WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	NOTE ON FORWARD-LOOKING STATEMENTS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[1]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	PART I
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 1. BUSINESS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[2]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 1A. RISK FACTORS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[8]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 1B. UNRESOLVED STAFF COMMENTS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[24]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 2. PROPERTIES
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[24]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 3. LEGAL PROCEEDINGS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[25]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 4. MINE SAFETY DISCLOSURES
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[27]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	PART II
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[28]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 6. SELECTED FINANCIAL DATA
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[30]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[31]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[39]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[39]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[39]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 9A. CONTROLS AND PROCEDURES
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[39]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 9B. OTHER INFORMATION
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[41]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	PART III
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[42]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 11. EXECUTIVE COMPENSATION
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[46]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[63]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[64]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[64]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	PART IV
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[65]
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 90.49%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	SIGNATURES
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 5.63%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[68]
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 3.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage2"></A>
</DIV>
<DIV>
<BR>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	NOTE ON FORWARD-LOOKING STATEMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	References in this Annual Report to the "company," "we," "us" or "our" refer to CytRx Corporation.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Some of the information contained in this Annual Report may include forward-looking statements that reflect our current views with respect to our research and development activities, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology sector, in general. We make these statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include the words "expect," "intend," "plan," "believe," "project," "estimate," "may," "should," "anticipate," "will" and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities laws or otherwise.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, those factors set forth in the sections entitled "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures About Market Risk" and "Controls and Procedures" in this Annual Report, all of which you should review carefully. Please consider our forward-looking statements in light of those risks as you read this Annual Report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If one or more of these or other risks or uncertainties materializes, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by this Note.
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	INDUSTRY DATA
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Unless otherwise indicated, information contained in this Annual Report concerning our industry, including our general expectations and market opportunity, is based on information from our own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, assumptions and estimates of our and our industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described below in the "Risk Factors" section of this Annual Report.&#160; These and other factors could cause our future performance to differ materially from our assumptions and estimates.
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	TRADEMARKS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	CytRx is one of our trademarks used in this Annual Report. This Annual Report also includes trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this Annual Report sometimes appear without the &#174; and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-1-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage3"></A>
</DIV>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	PART I
</DIV>
<DIV>
<BR>
</DIV>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 1.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	BUSINESS
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	COMPANY OVERVIEW
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We have reported positive top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates, hazard ratios and overall survival) from our completed, global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable STS. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3&#189; to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the first quarter of 2014, we initiated a pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with STS whose tumors have progressed following treatment with chemotherapy, and we have received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. The Phase 3 trial is being conducted under a Special Protocol Assessment, or SPA, granted by the U.S. Food and Drug Administration, or FDA. The SPA means that the FDA agrees that the design and analyses proposed in the Phase 3 trial protocol are acceptable to support regulatory approval of the product candidate with respect to effectiveness of the indication studied, and will not subsequently change its perspective on these matters, unless previously unrecognized public or animal health concerns were to arise or we were to subsequently modify the protocol.&#160;Thus, if the study demonstrates an acceptable benefit-risk profile as determined by the FDA, it would suffice as the single pivotal trial to demonstrate effectiveness and would support registration of aldoxorubicin for this indication. The clinical trial has completed its target enrollment of 400 patients at approximately 79 clinical sites in the U.S., Europe, Canada, Latin America and Australia. We expect to report the top-line results on PFS the trial's primary endpoint, in the first half of 2016.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We are currently evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. We have completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for STS, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In addition to aldoxorubicin, we are currently completing pre-clinical development for DK049, a novel anti-cancer drug conjugate that utilizes our Linker Activated Drug Release (LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	) technology.&#160; DK049 was created at our laboratory facility in Freiburg, Germany, and employs a proprietary linker that is both pH sensitive and requires a specific enzyme for the release of the cytotoxic payload.&#160; DK049 has demonstrated significant anti-tumor activity in multiple animal models implanted with human tumors, including non-small cell lung, ovarian and pancreatic cancers.&#160; We anticipate filing an Investigational New Drug Application (IND) in the second half of 2016 prior to initiating a Phase 1 clinical trial.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We plan to expand our pipeline of oncology candidates utilizing our LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	technology by creating both albumin-binding drug conjugates and antibody-drug conjugates. This technology allows for targeting to the tumor either by albumin or antibodies and can deliver anti-cancer agents that are 10-1000 times more potent than traditional chemotherapies.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are a Delaware corporation, incorporated in 1985. Our corporate offices are located at 11726 San Vicente Boulevard, Suite 650, Los Angeles, California 90049, and our telephone number is (310) 826-5648.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 8PT">
	-2-
</FONT>
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage4"></A>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	OUR PRODUCT CANDIDATE PIPELINE
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table summarizes our product candidates and their current or impending stages of development:
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="B9DF1DB43FB14E64B41F2A8D6C2515C7" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Technology
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Product candidate
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Indication(s)
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stage of Development
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Doxorubicin conjugate
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Aldoxorubicin
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Soft Tissue Sarcoma
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Pivotal Global Phase 3 ongoing
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
	&#160;&#160;&#160;&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Small-Cell Lung Cancer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Global Phase 2b ongoing
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
	&#160;&#160;&#160;&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Glioblastoma Multiforme
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 2 ongoing
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
	&#160;&#160;&#160;&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Kaposi's Sarcoma
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 2 ongoing
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
	&#160;&#160;&#160;&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Combination with ifosfamide
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 1b ongoing
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
	&#160;&#160;&#160;&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Combination with gemcitabine
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Phase 1b ongoing
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	DK049
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To be announced
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Pre-clinical
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	for albumin-binding drug conjugates
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To be announced
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To be announced
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Pre-clinical
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	for antibody-drug conjugates
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To be announced
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To be announced
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Pre-clinical
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	OUR CLINICAL DEVELOPMENT PROGRAMS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our current clinical development programs are discussed below.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Aldoxorubicin
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is believed to concentrate the drug at the site of tumors.&#160; Specifically, it is comprised of (6-maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. In the first quarter of 2014, we initiated under an SPA granted by the FDA a pivotal, global Phase 3 trial of aldoxorubicin as a therapy for patients with STS whose tumors have progressed following treatment with chemotherapy.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Aldoxorubicin for the Treatment of Cancer. Anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer. Doxorubicin, the first anthracycline to gain FDA approval, has demonstrated efficacy in a wide variety of cancers, including breast cancer, lung cancer, ovarian cancer, sarcomas, and lymphomas. However, due to the uptake of doxorubicin by various parts of the body, it is associated with side effects such as cumulative cardiotoxicity, myelosuppression (decreased production of blood cells by bone marrow), gastrointestinal disorders, mucositis (inflammation of the mucous membranes lining the mouth and digestive tract), stomatitis (inflammation of soft tissue of the mouth), and necrotizing extravasation (damage due to the leakage of intravenous drugs from the vein into the surrounding tissue).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We believe aldoxorubicin has attributes that may improve on doxorubicin, alone, which we sometimes refer to as native doxorubicin, including the potential to increase the total doxorubicin dose, reduce certain adverse events associated with native doxorubicin, achieve increased drug concentration at tumor sites and improve efficacy.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our postulated mechanism of action for aldoxorubicin is as follows:
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT" ID="5051B0ACC7FC4A688E027792E5DCA0C6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 6PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	after administration, aldoxorubicin rapidly forms a covalent bond to circulating albumin through an acid-sensitive linker;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT" ID="0FBAF7CB676649348B2E939F77CCE7AB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 6PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	circulating albumin preferentially accumulates in tumors, bypassing concentration in other non-tumor sites, including the heart, liver and gastrointestinal tract due to a mechanism called "Enhanced Permeability and Retention by Solid Tumors";
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT" ID="D7FC0B8B1CB44471A56CA89CBA565750" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 6PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	once albumin-bound aldoxorubicin is taken up by the tumor, the acidic environment within the tumor and in the cancer cells themselves causes cleavage of the acid-sensitive linker; and
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT" ID="248A66E0D6314A4EA57244319035067D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 6PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	free doxorubicin is then released in the tumor.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH">
<EM>
	Pre-clinical data
</EM>
	. In a variety of preclinical models, aldoxorubicin was superior to doxorubicin at equitoxic doses in its ability to allow an increase in the total doxorubicin dose, its antitumor efficacy and its safety, including a reduction in cardiotoxicity. Animal studies conducted by aldoxorubicin inventor Dr. Felix Kratz demonstrated statistically significant efficacy compared to both placebo and native doxorubicin against breast, ovarian, pancreatic and small cell lung cancers growing in immunodeficient mice.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	We have also announced additional data from a study of aldoxorubicin in immunodeficient mice transplanted with human glioblastoma cells in their brain that showed those animals treated with aldoxorubicin had a median survival rate of more than 63 days, compared with approximately 25 days for animals treated with doxorubicin or saline. The data, published in the journal Neoplasia in October 2014, also indicated evidence of drug concentration inside tumors growing in the brain, but not in normal brain tissue, and significant tumor regression in aldoxorubicin-treated animals, while doxorubicin did not appear to enter the tumor or brain to any significant degree and showed little or no efficacy in the progression of these brain tumors. Aldoxorubicin significantly reduced the number of dividing cells within the brain tumors in this trial and showed a statistically relevant increased expression of apoptosis or cell death markers.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH">
<FONT STYLE="FONT-STYLE: ITALIC">
	Clinical data
</FONT>
	. A Phase 1 study of aldoxorubicin that demonstrated safety and objective clinical responses in several tumor types was completed in 2005, presented at the March 2006 Krebskongress meeting in Berlin, Germany, and published in Clinical Cancer Research in August 2007. In this study, doses were administered every three weeks at up to six times the standard dose of doxorubicin without an increase in the types of side effects compared with those historically observed with native doxorubicin. Of 35 evaluable patients, 23 had either an objective clinical (partial) response or stable disease. Objective clinical responses were observed in patients with STS, breast and small cell lung cancers.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We completed a Phase 1b/2 clinical trial with aldoxorubicin in patients with advanced solid tumors who had either relapsed or failed to respond to their prior chemotherapy and presented favorable data at the American Society for Clinical Oncology Meeting in June 2012. In that Phase 1b/2 clinical trial, clinical benefit (defined as partial response or stable disease of more than four months) was shown in ten of 13 (76.9%) evaluable patients with relapsed or refractory STS. The median number of cycles of aldoxorubicin administered at the maximum tolerable dose was eight.&#160; The results of this clinical trial were published in February 2015 in the peer-reviewed journal Cancer (Cancer, 2015 Feb 15; 121(4); 570-9).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In addition, best responses for the 13 evaluable STS trial subjects included the following: five (38.5%) achieved partial response, as defined as shrinkage of target tumors of more than 30%; six (46%) showed prolonged stable disease (defined as tumor shrinkage &lt;30% from baseline or tumor growth &lt;20% from the nadir); eight (61.5%) had tumor shrinkage; and five of eight patients (62.5%) who demonstrated either partial responses or prolonged stable disease after treatment with aldoxorubicin had been previously treated with doxorubicin and had failed to respond. There were no observed cardiac toxicities and no drug-related patient deaths. The most common adverse event, neutropenia, also observed with doxorubicin treatment, resolved prior to the start of the next treatment. Final observed median PFS for advanced STS patients in the trial was 11.25 months, and median overall survival was 21.71 months (Publication in Cancer, 2015 Feb 15). In addition, following 8 cycles of aldoxorubicin, two patients experienced no progression of disease for 23 and 15 months, respectively, despite no further treatment.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In connection with our Phase 1b pharmacokinetics clinical trial evaluating the pharmacokinetics and safety of aldoxorubicin in patients with metastatic solid tumors who have either relapsed or not responded to treatment with standard therapies, we announced data demonstrating that aldoxorubicin has a distribution half-life of approximately 20 to 24 hours, with a narrow volume of distribution to healthy tissue and slow clearance from the circulation. These characteristics distinguish aldoxorubicin from doxorubicin, which has a distribution half-life of about five minutes according to its package insert.&#160; Complete details from this Phase 1b trial were published online in the journal Investigational New Drugs in November 2014 (Publication in Invest New Drugs, 2015 Apr 15; (33(2):341-8).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We completed our global Phase 2b clinical trial to evaluate the preliminary efficacy and safety of aldoxorubicin as a first-line therapy in patients with advanced STS who are ineligible for surgery, which was initiated in December 2011. The Phase 2b clinical trial provided the first direct clinical trial comparison of aldoxorubicin and native doxorubicin, which is dose-limited due to toxicity, as a first-line therapy.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	The Phase 2b clinical trial with aldoxorubicin in patients with STS was an international trial in 31 treatment centers under the direction of Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California. The Phase 2b clinical trial's primary objectives were to measure the PFS, tumor response and overall survival of patients with advanced STS treated with aldoxorubicin. This clinical trial also assessed the safety of aldoxorubicin compared to doxorubicin in this patient population through a number of indicators, including the frequency and severity of adverse events.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In our 123-subject clinical trial, subjects with advanced STS were administered either 350 mg/m2 of aldoxorubicin (83 subjects) or 75 mg/m2 of doxorubicin (40 subjects) every three weeks for up to six cycles. Subjects were followed every six weeks with CT scans to monitor tumor size. The primary endpoint was PFS as determined by a blinded radiology review performed at an independent central radiology laboratory. Secondary endpoints included overall response rates (complete and partial) and PFS at six months for each group, and overall survival. The results from this trial were published in the Journal of the American Medical Association (JAMA) Oncology in September 2015 (JAMA Oncol. 2015 Sep 17:1-9.).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	The central radiology review, as well as the investigators' own assessments, showed an 80% to 100% improvement in PFS among patients treated with aldoxorubicin. In an intent-to-treat analysis, the investigator-assessed median PFS was 8.3 months for aldoxorubicin patients versus 4.6 months for doxorubicin patients (p=0.0006), while the blinded central radiology review indicated that median PFS for aldoxorubicin patients was 5.6 months versus 2.7 months for doxorubicin patients (p=0.0228). Per investigators, 68.1% of aldoxorubicin patients had not progressed at six months, compared with 33.0% of doxorubicin-treated patients (p=0.008). By blinded central radiology review, 45.7% of aldoxorubicin patients had not progressed at six months, compared with 22.9% of doxorubicin patients (p=0.02).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	The overall response rate as determined by the investigators was 22.9% for aldoxorubicin subjects (2.0% complete response and 21.3% partial response) versus 5.0% for doxorubicin subjects (0% complete response and 5.0% partial response). As assessed by blinded central radiology review, 25.0% of aldoxorubicin subjects had a partial response while none of the doxorubicin subjects exhibited any objective response.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Additional analysis determined hazard ratios for the primary endpoint of PFS by both investigators at study sites and by the blinded radiology review. The hazard ratio for investigator-read scans is 0.37 (95% confidence interval, range of 0.212 to 0.643) (p=0.0004), reflecting a 63% reduction in the risk of disease progression for patients treated with aldoxorubicin; and the hazard ratio for central lab scans is 0.586 (95% confidence interval, range of 0.358 to 0.960) (p=0.034), reflecting a 41% reduction in the risk of disease progression for the aldoxorubicin-treated patients. Hazard ratios are an important measure of the reliability and uniformity of the data for PFS, and where the upper limit is less than one indicates that there is a significant difference between the two study groups.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We also reported that a Kaplan-Meier analysis of the trial results, which analysis describes the time it takes for tumors to progress in individual patients, showed significant improvement in subjects treated with aldoxorubicin versus subjects treated with doxorubicin.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	The overall survival results from the clinical trial demonstrated a 27 percent reduction in the risk of death compared to patients treated with doxorubicin (HR 0.73: 95% confidence interval 0.44-1.20), the current standard-of-care in this indication. In addition, aldoxorubicin-treated patients demonstrated a 41% likelihood of surviving more than 2 years, a 2-fold increase, compared to a 20% probability for doxorubicin-treated patients. Median overall survival was 15.8 months (95% confidence interval 13.1-not reached) for aldoxorubicin-treated patients versus 14.3 months (95% confidence interval 8.6-20.6) for doxorubicin treated patients (p=0.21). For treatment-naive patients, representing 90% of the patients in the clinical trial, median overall survival was 15.8 months (95% confidence interval 13.0-not reached) for aldoxorubicin-treated patients versus 13.8 months (95% confidence interval 8.6-19.8) for doxorubicin treated patients (p=0.14).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In the Phase 2b clinical trial, aldoxorubicin was found to be relatively safe and well-tolerated. Subjects treated with aldoxorubicin had an approximately two-fold increase in severe neutropenia compared with doxorubicin-treated subjects, but there was no difference in the incidence of febrile neutropenia (indicating an infection may be present) between the two groups. All adverse events in subjects treated with aldoxorubicin were consistent with the known side effects of doxorubicin, usually resolved before the administration of the next dose and did not require treatment discontinuation. There were no treatment-related deaths in the aldoxorubicin group.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In the first quarter of 2014, we initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. This multicenter, randomized, open-label Phase 3 clinical trial is designed to enroll approximately 400 patients with metastatic, locally advanced or unresectable soft tissue sarcomas who have either not responded to, or have progressed following treatment with, one or more systemic regimens of non-adjuvant chemotherapies. Trial patients will be randomized 1:1 to be treated with aldoxorubicin or the investigator's choice of an approved chemotherapeutic regimen, including doxorubicin, ifosfamide dacarbazine, pazopanib (Votrient&#174;), or gemcitabine plus docetaxel, with up to three comparator regimens to be selected by the investigator at each clinical site. The primary endpoint of the study is progression-free survival (PFS), and secondary endpoints include overall survival, response rates and safety. In January 2014, the Company announced it has received approval from the FDA to amend the Phase 3 protocol to continue dosing patients with aldoxorubicin until disease progression (defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion), which creates the potential for substantially improved Phase 3 efficacy results.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Following discussions with the FDA, the Phase 3 protocol was agreed upon under a Special Protocol Assessment (SPA). As part of that assessment, the FDA agreed that, barring unrecognized public or human health concerns, the design and planned analysis of the study adequately addresses the objectives necessary to support a regulatory submission for approval.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	The clinical trial has completed its target enrollment of 400 patients at approximately 79 clinical sites in the U.S., Europe, Canada, Latin America and Australia. CytRx expects to report the top-line results on progression-free survival, the trial's primary endpoint, in the first half of 2016.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In September 2014, we initiated a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy. The open-label Phase 2b clinical trial is expected to enroll approximately 132 patients (1:1 randomization).&#160; The primary endpoint is PFS and the secondary endpoints are OS, overall response rates (partial and complete) and the safety of aldoxorubicin compared to topotecan in this population.&#160; The study is expected to involve approximately 40 clinical trial sites in the U.S., Spain and Hungary.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We are conducting a Phase 2 clinical trial to evaluate the preliminary efficacy and safety of aldoxorubicin in patients with unresectable glioblastoma whose tumors have progressed following prior treatment with surgery, radiation and with the drug temozolomide. The clinical trial has enrolled its target of 28 patients at sites including the John Wayne Cancer Center in Santa Monica, California, City of Hope in Duarte, California, and the LSU Medical Center in New Orleans, Louisiana.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We are conducting a Phase 2 clinical trial evaluating the preliminary efficacy of aldoxorubicin in patients with AIDS-related Kaposi's sarcoma, a tumor usually associated with HIV infection in the U.S. The current standard-of-care for severe dermatological and systemic Kaposi's sarcoma is liposomal doxorubicin (Doxil); however, a significant proportion of patients exhibit minimal or no clinical response to this agent, and the drug's toxicity often prevents continued therapy. The Phase 2 trial is expected to enroll up to 30 patients and is being conducted at the LSU Medical Center in New Orleans, Louisiana.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	We are also conducting a Phase 1b trial in combination with ifosfamide in patients with STS, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. Since most chemotherapy agents are administered in combination with other chemotherapeutics, these studies will demonstrate the dose of aldoxorubicin that can be safely combined with two other chemotherapies that are commonly used to treated patients with sarcomas, pancreatic cancer, ovarian cancer and lung cancer.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-3-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage5"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Drug Discovery Laboratory
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Our laboratory, located in Freiburg, Germany, is conducting discovery and translational research to create drug candidates that utilize our LADR&#8482; technologies to couple cytotoxic agents and proteins either inside the body or externally, and then concentrate drug in tumors.&#160; Led by Felix Kratz, Ph.D., Vice President of Drug Discovery and inventor of aldoxorubicin, and Andre Warnecke, Ph.D., Senior Director of Drug Discovery, the discovery team is working to expand our novel albumin-binding anti-cancer drug pipeline and using LADR&#8482; linkers to create unique antibody-drug conjugates.&#160;&#160; We recently announced the development of DK049, a novel anti-cancer drug conjugate that utilizes our LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	technology, and anticipate filing an IND for DK049 in the second half of 2016 prior to initiating a Phase 1 clinical trial.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Disposition of Molecular Chaperone Assets
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Until 2011, we owned the rights to two drug candidates, arimoclomol and iroxanadine, based on molecular chaperone regulation technology that were designed to repair or degrade mis-folded proteins associated with disease. On May 13, 2011, we sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS in exchange for a cash payment of $150,000 and the right to receive various future payments that are contingent upon the achievement of specified regulatory and business milestones, as well as royalty payments based on a specified percentage of any eventual net sales of products derived from the assets.&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Innovive Acquisition Agreement
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On September 19, 2008, we completed our merger acquisition of Innovive Pharmaceuticals, Inc., or Innovive, and its clinical-stage cancer product candidates, including aldoxorubicin and tamibarotene. Under the merger agreement by which we acquired Innovive, we agreed to pay the former Innovive stockholders up to approximately $18.3 million of future earnout merger consideration, subject to our achievement of specified net sales under the Innovive license agreements. The earnout merger consideration, if any, will be payable in shares of our common stock, subject to specified conditions, or, at our election, in cash or by a combination of shares of our common stock and cash. Our common stock will be valued for purposes of any future earnout merger consideration based upon the trading price of our common stock at the time the earnout merger consideration is paid. The earnout will be accrued if and when earned.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Research and Development
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Expenditures for research and development activities related to continuing operations were $43.4 million, $36.7 million and $17.5 million for the years ended December 31, 2015, 2014 and 2013, respectively, or approximately 68%, 74% and 63%, respectively, of our total expenses. For further information regarding our research and development activities, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" below.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Manufacturing
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We do not have the facilities or expertise to manufacture clinical supplies of aldoxorubicin or any of our other product candidates, and we lack the resources and capability to manufacture any of our product candidates on a commercial scale. Accordingly, we are dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. We have manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. In September, 2015, we entered into an agreement with a supplier to purchase doxorubicin hydrochloride both on a clinical as well as a commercial scale. However, we currently have no other supply arrangements for the commercial manufacture of aldoxorubicin or any manufacturing supply arrangements for any other potential product candidates, and we may not be able to secure needed supply arrangements on attractive terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of our products or to commercialize them.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Commercialization and Marketing
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We recently hired Olivia Ware as our Chief Commercial Officer and have initiated activities to build our sales, marketing and commercial product distribution capabilities in preparation for the US launch of aldoxorubicin.&#160; If aldoxorubicin is approved, we expect to commercialize it in the U.S. with a small internal commercial group and an outsourced specialty field sales force.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We&#160;intend to commercialize aldoxorubicin outside the US starting in the EU-5 countries.&#160; Our commercial strategy may include the use of strategic partners, distributors, a contract sales force or the establishment of our own sales force.&#160; We plan to further evaluate these alternatives as we approach approval for aldoxorubicin.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As additional product candidates advance through our pipeline, our commercial plans may change. In particular, some of our pipeline assets target potentially large solid tumor indications.&#160; Factors such as clinical data, the size of the development programs, the size of the target market, the size of a commercial infrastructure, and manufacturing needs may influence our strategies in the U.S., the European Union, and other territories.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-4-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage6"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Patents and Proprietary Technology
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We actively seek patent protection for our technologies, processes, uses, and ongoing improvements and consider our patents and other intellectual property to be critical to our business. We regularly evaluate the patentability of new inventions and improvements developed by us or our collaborators, and, whenever appropriate, will endeavor to file U.S. and international patent applications to protect these new inventions and improvements. We cannot be certain that any of the current pending patent applications we have filed or licensed, or any new patent applications we may file or license, will ever be issued in the U.S. or any other country. There also is no assurance that any issued patents will be effective to prevent others from using our products or processes. It is also possible that any patents issued to us, as well as those we have licensed or may license in the future, may be held invalid or unenforceable by a court, or third parties could obtain patents that we would need to either license or to design around, which we may be unable to do. Current and future competitors may have licensed or filed patent applications or received patents, and may acquire additional patents and proprietary rights relating to compounds, products or processes that may be competitive with ours.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In addition to patent protection, we attempt to protect our proprietary products, processes and other information by relying on trade secrets and non-disclosure agreements with our employees, consultants and certain other persons who have access to such products, processes and information. Under the agreements, all inventions conceived by employees are our exclusive property, but there is no assurance that these agreements will afford significant protection against misappropriation or unauthorized disclosure of our trade secrets and confidential information.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As of December 31, 2015, we held rights in four granted U.S. patents, 55 granted foreign patents, three pending U.S. applications, and twenty-two pending foreign patent applications covering aldoxorubicin and related technologies. Our intellectual property
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	holdings relating to aldoxorubicin and related technologies include an exclusive license from KTB Tumorforschungs GmbH, or KTB, to U.S. and foreign patents and patent applications. Patents and applications that cover pharmaceutical compositions of aldoxorubicin, processes for their production, and their use in treatment methods (e.g., cancer (including glioblastoma), viral diseases, autoimmune diseases, and acute or chronic inflammatory diseases) have unextended patent terms expiring between June 2020 and June 2034.&#160; Additionally, we have three pending U.S. provisional patent applications covering our LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	technology and DK049.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	LICENSE AGREEMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Aldoxorubicin
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have an agreement with KTB for the license of patent rights held by KTB for the worldwide development and commercialization of aldoxorubicin. The license is exclusive and applies to all products that may be subject to the licensed intellectual property in all fields of use. We may sublicense the intellectual property in our sole discretion. Pursuant to an amendment to the license agreement entered into in March 2014, we also have a non-exclusive worldwide license to any additional technology that is claimed or disclosed in the licensed patents and patent applications for use in the field of oncology.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Under the agreement, we must make payments to KTB in the aggregate of up to $7.5 million upon meeting clinical and regulatory milestones, and up to and including the product's second final marketing approval. We also agreed to pay:
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="97630F7B079C4EF380DD94FA4E8FB54D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 54PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="373D47CD1DF941E49843E1E29C119AF0" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 54PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	a percentage of any non-royalty sub-licensing income (as defined in the agreement); and
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="B76F5DF1A7264FDD900FDAE50CBA17B6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 72PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 54PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	milestones of $1 million for each additional final marketing approval that we obtain.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Pursuant to the March 2014 license amendment, we agreed to make a $500,000 milestone payment upon first dosing of a patient in a first phase I clinical trial for each product using the additional technology.&#160;&#160;In the event that by February 28, 2017, no such payment has become due, we have agreed to pay KTB $500,000, which payment can be made, in our discretion, in cash or in shares of our common stock.&#160;&#160;If we elect to make the payment in shares of common stock, our shares will be valued at the volume-weighted average price (VWAP) over the preceding 60 trading days, to be calculated on February 28, 2017.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the event that we must pay a third party in order to exercise our rights to the intellectual property under the agreement, we are entitled to deduct a percentage of those payments from the royalties due KTB, up to an agreed upon cap.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Under the agreement with KTB, we must use commercially reasonable efforts to conduct the research and development activities we determine are necessary to obtain regulatory approval to market aldoxorubicin in those countries that we determine are commercially feasible. Under the agreement, KTB is to use its commercially reasonable efforts to provide us with access to suppliers of the active pharmaceutical ingredient, or API, of aldoxorubicin, on the same terms and conditions as may be provided to KTB by those suppliers.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The agreement will expire on a product-by-product basis upon the expiration of the subject patent rights. We have the right to terminate the agreement on 30 days' notice, provided we pay a cash penalty to KTB. KTB may terminate the agreement if we are in breach and the breach is not cured within a specified cure period, or if we fail to use diligent and commercial efforts to meet specified clinical milestones.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-5-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage7"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Competition
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Aldoxorubicin is a conjugate of doxorubicin, a widely used anti-cancer drug. Doxorubicin is part of the anthracycline class of chemotherapy agents. Anthracyclines, many of which, including doxorubicin are generic, have been used throughout the world to treat various cancers for several decades. Due to their track record of broad anti-cancer activity, new types of anthracyclines and modified or reformulated versions continue to be developed to overcome toxicities which limit the use of these drugs.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Aldoxorubicin is a chemically modified version of doxorubicin that incorporates an acid sensitive linker technology to improve concentration in the tumor. We believe that the albumin-binding ability of aldoxorubicin will allow the compound to overcome many
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	of the side effect issues typically associated with anthracyclines. We also believe that using albumin as a targeted carrier will allow for higher dosing, greater concentration of the drug in tumors and greater efficacy.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	STS patients are typically treated with surgery followed by radiation therapy. For patients ineligible for surgery, radiation or both, chemotherapy is the only option. Doxorubicin is the only approved first-line drug for treating STS patients who are ineligible for surgery and is often used in combination with radiation. The National Comprehensive Cancer Network also includes the use of ifosfamide, epirubicin, gemcitabine, gemcitabine with docetaxel, dacarbazine and liposomal doxorubicin marketed in the United States as Doxil&#174; by Johnson &amp; Johnson. GlaxoSmithKline's pazopanib (Votrient&#174;) was approved in the United States and Europe in 2012 for the treatment of certain types of advanced STS following prior chemotherapy. In October 2015, the Janssen unit of Johnson &amp; Johnson received approval for trabectedin (Yondelis&#174;) for the treatment of patients with leiomyosarcoma and liposarcoma,that have previously received an anthracycline and ifosfamide or an anthracycline followed by another chemotherapy.&#160; In January 2016, the FDA approved Eisai's eribulin (Halaven&#174;) as a treatment for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline.&#160; Eli Lilly is conducting a Phase 3 clinical trial with olaratumab in combination with doxorubicin in first-line STS.&#160; Eli Lilly stated in October 2015 that they plan to submit a rolling new drug application based on the Phase 2 clinical trial results in STS.&#160; There are other approaches to treating STS in clinical development, including Morphotek's ontuxizumab in combination with chemotherapy,and Tracon Pharmaceuticals' TRC-105 in combination with pazopanib.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Patients with glioblastoma multiforme, or GBM, generally undergo invasive brain surgery, although disease progression following surgery is nearly 100%. The front-line therapy for GBM following surgery is radiation in combination with temozolomide (Temodar&#174;). Bevacizumab (Avastin&#174;) has been approved for the treatment of GBM in patients progressing after prior therapy. Drugs in development to treat GBM include nivolumab by Bristol-Myers Squibb, DCVax by Northwest Biotherapeutics, DelMar Pharmaceuticals' VAL-083, TRC-105 from Tracon Pharmaceuticals, veliparib by AstraZeneca and buparlisib by Novartis.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Treatment for newly diagnosed SCLC typically consists of cisplatin or carboplatin in combination with etoposide. Radiation may also be given for extensive-stage disease.&#160; While first-line treatment can yield overall response rates of 50-80%, the duration of response is often less than 90 days.&#160; For recurrent SCLC, topotecan (Hycamtin&#174;) is standard therapy.&#160; SCLC patients who are sensitive to first-line treatment may receive topotecan or the generic chemotherapeutic drugs irinotecan, taxanes, gemcitabine or vinorelbine.&#160; Drugs in development for second-line SCLC include Bristol-Myers Squibb's nivolumab (Opdivo&#174;) and ipilumimab (Yervoy&#174;) and SC16LD6.5 by Stem CentRx, Inc.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;Kaposi's sarcoma is generally treated with radiation, surgery and/or liposomal doxorubicin.&#160; Liposomal daunorubicin (DaunoXome&#174;, Galen US), with or without paclitaxel, is also recommended as treatment for advanced disease. Other drugs in development for Kaposi's sarcoma include selumetinib by AstraZeneca and pomalidamide by Celgene.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Many companies, including large pharmaceutical and biotechnology firms with financial resources, research and development staffs, and facilities that may be substantially greater than those of ours or our strategic partners or licensees, are engaged in the research and development of pharmaceutical products that could compete with our potential products. To the extent that we seek to acquire, through license or otherwise, existing or potential new products, we will be competing with numerous other companies, many of which will have substantially greater financial resources, large acquisition and research and development staffs that may give those companies a competitive advantage over us in identifying and evaluating these drug acquisition opportunities. Any products that we acquire will be competing with products marketed by companies that in many cases will have substantially greater marketing resources than we have. The industry is characterized by rapid technological advances and competitors may develop their products more rapidly and such products may be more effective than those currently under development or that may be developed in the future by our strategic partners or licensees. Competitive products for a number of the disease indications that we have targeted are currently being marketed by other parties, and additional competitive products are under development and may also include products currently under development that we are not aware of or products that may be developed in the future.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Government Regulation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The U.S. and other developed countries extensively regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The FDA, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, regulates pharmaceutical and biologic products.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-6-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage8"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	To obtain approval of our product candidates from the FDA, we must, among other requirements, submit data supporting safety and efficacy for the intended indication as well as detailed information on the manufacture and composition of the product candidate. In most cases, this will require extensive laboratory tests and preclinical and clinical trials. The collection of these data, as well as the preparation of applications for review by the FDA involve significant time and expense. The FDA also may require post-marketing testing to monitor the safety and efficacy of approved products or place conditions on any approvals that could restrict the therapeutic claims and commercial applications of these products. Regulatory authorities may withdraw product approvals if we fail to comply with regulatory standards or if we encounter problems at any time following initial marketing of our products.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The first stage of the FDA approval process for a new drug involves completion of preclinical studies and the submission of the results of these studies to the FDA. These data, together with proposed clinical protocols, manufacturing information, analytical data and other information submitted to the FDA, in an investigational new drug application, or IND, must become effective before human clinical trials may commence. Preclinical studies generally involve FDA regulated laboratory evaluation of product characteristics and animal studies to assess the efficacy and safety of the product candidate.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	After the IND becomes effective, a company may commence human clinical trials. These are typically conducted in three sequential phases, but the phases may overlap. Phase 1 trials consist of testing of the product candidate in a small number of patients or healthy volunteers, primarily for safety at one or more doses. Phase 2 trials, in addition to safety, evaluate the efficacy of the product candidate in a patient population somewhat larger than Phase 1 trials. Phase 3 trials typically involve additional testing for safety and clinical efficacy in an expanded population at multiple test sites. A company must submit to the FDA a clinical protocol, accompanied by the approval of the Institutional Review Boards at the institutions participating in the trial, prior to commencement of each clinical trial.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	To obtain FDA marketing authorization, a company must submit to the FDA the results of the preclinical and clinical testing, together with, among other things, detailed information on the manufacture and composition of the product candidate, in the form of a new drug application, or NDA.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The amount of time taken by the FDA for approval of an NDA will depend upon a number of factors, including whether the product candidate has received priority review, the quality of the submission and studies presented, the potential contribution that the compound will make in improving the treatment of the disease in question, and the workload at the FDA.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The FDA may, in some cases, confer upon an investigational product the status of a fast-track product. A fast-track product is defined as a new drug or biologic intended for the treatment of a serious or life-threatening condition that demonstrates the potential to address unmet medical needs for this condition. The FDA can base approval of an NDA for a fast-track product on an effect on a surrogate endpoint, or on another endpoint that is reasonably likely to predict clinical benefit. If a preliminary review of clinical data suggests that a fast-track product may be effective, the FDA may initiate review of entire sections of a marketing application for a fast-track product before the sponsor completes the application.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We anticipate that our products will be manufactured by our strategic partners, licensees or other third parties. Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities are in compliance with the FDA's cGMP, which are regulations that govern the manufacture, holding and distribution of a product. Our manufacturers also will be subject to regulation under the Occupational Safety and Health Act, the National Environmental Policy Act, the Nuclear Energy and Radiation Control Act, the Toxic Substance Control Act and the Resource Conservation and Recovery Act. Following approval, the FDA periodically inspects drug and biologic manufacturing facilities to ensure continued compliance with the good manufacturing practices regulations. Our manufacturers will have to continue to comply with those requirements. Failure to comply with these requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing or recall or seizure of product. Adverse patient experiences with the product must be reported to the FDA and could result in the imposition of marketing restrictions through labeling changes or market removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The labeling, advertising, promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA and Federal Trade Commission requirements which include, among others, standards and regulations for off-label promotion, industry sponsored scientific and educational activities, promotional activities involving the internet, and direct-to-consumer advertising. We also will be subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. In addition, we will be subject to various laws and regulations governing laboratory practices and the experimental use of animals. In each of these areas, as above, the FDA has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of product approvals, seize or recall products, and deny or withdraw approvals.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We will also be subject to a variety of regulations governing clinical trials and sales of our products outside the U.S. Whether or not FDA approval has been obtained, approval of a product candidate by the comparable regulatory authorities of foreign countries and regions must be obtained prior to the commencement of marketing the product in those countries. The approval process varies from one regulatory authority to another and the time may be longer or shorter than that required for FDA approval. In the European Union, Canada and Australia, regulatory requirements and approval processes are similar, in principle, to those in the U.S.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-7-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage9"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employees
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As of March 11, 2016, we had thirty-one employees, nine of whom were engaged in clinical development activities, ten of whom were engaged in preclinical research at our Freiburg, Germany laboratory, and eleven of whom were involved in management and administrative operations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Available Information
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We maintain a website at www.cytrx.com and make available there, free of charge, our periodic reports filed with the Securities and Exchange Commission, or SEC, as soon as is reasonably practicable after filing. The public may read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at http:/www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers such as us that file electronically with the SEC. Among other things, we post on our website our Code of Business Conduct and Ethics.
</DIV>
</EFX_BUSINESS>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 1A. RISK FACTORS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	You should carefully consider the risks and uncertainties facing our business. The risks described below are not the only ones facing us. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions and geopolitical events.&#160; Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Risks Associated With Our Business
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We have operated at a loss and will likely continue to operate at a loss for the foreseeable future.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have operated at a loss due to our ongoing expenditures for research and development of our product candidates and for general and administrative purposes, and lack of significant recurring revenues. We incurred a net loss of $58.6 million for the year ended December 31, 2015 and $30.1 million for the year ended December 31, 2014 and had an accumulated deficit as of December 31, 2015 of $365.1 million. We are likely to continue to incur losses unless and until we are able to commercialize aldoxorubicin or one or more of our other existing or possible future product candidates. These losses, among other things, have had and will continue to have an adverse effect on our stockholders' equity and working capital. Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when we may become profitable, if at all. If we do not become profitable or are unable to maintain future profitability, the market value of our common stock will be adversely affected.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Because we have no source of significant recurring revenue, we must depend on financing to sustain our operations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Developing products and conducting clinical trials require substantial amounts of capital. To date, we have relied primarily upon proceeds from sales of our equity securities and proceeds from the exercise of options and warrants to generate funds needed to finance our business and operations. We will need to raise additional capital to, among other things:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5B8194C7D07F4811A7B68CDDBE1663AF" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	fund our clinical trials and pursue regulatory approval of aldoxorubicin and fund development of product candidates based on our LADR&#8482; technology;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BC4928C7E79344D69CF640BFE22EB382" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	expand our research and development activities;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-8-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage10"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="ECC83421F6AA4D29886E9ED3D575E099" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	finance our general and administrative expenses;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BA2C1F8EC6AF4E6F847A65AAE14017EA" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	acquire or license new technologies;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5B42DBF32F8849F2AB4B7CDB43F067A5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	prepare, file, prosecute, maintain, enforce and defend our patent and other proprietary rights; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5824A5BA5DE9495E82DA2ADFBF646EAF" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	develop and implement sales, marketing and distribution capabilities to successfully commercialize any product for which we obtain marketing approval and choose to market ourselves.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our revenue was $0.1 million, $0.1 million and $0.3 million, respectively, for the years ended December 31, 2015, 2014 and 2013. We will have no significant recurring revenue unless we are able to commercialize aldoxorubicin, our lead product candidate, or one or more of our existing or possible future product candidates, which may require us to first enter into license or other strategic arrangements with third parties.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, we had cash and cash equivalents of approximately $22.3 million and short-term investments of $35.0 million. On February 6, 2016, we announced the signing of a long-term loan agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40.0 million in financing, of which we have received $25.0 million. Management believes that
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our current resources, will be sufficient to fund our operations for the foreseeable future.
</FONT>
	The belief is based, in part, upon our currently projected expenditures for 2016 of approximately $58.9 million
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	,
</FONT>
	which
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	includes approximately $34.3 million for our clinical programs for aldoxorubicin, approximately $5.4 million for pre-clinical development of new albumin-binding cancer drugs, including DK049, approximately $4.2 million for general operation of our clinical programs and approximately $15.0 million for other general and administrative expenses, including pre-commercialization. These projected expenditures are based upon numerous assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If we obtain marketing approval and successfully commercialize aldoxorubicin, or other product candidate, we anticipate it will take a minimum of two years, and likely longer, for us to generate significant recurring revenue, and we will be dependent on future financing until such time, if ever, as we can generate significant recurring revenue. We have no commitments from third parties to provide us with any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. Failure to obtain adequate financing would adversely affect our ability to operate as a going concern. If we raise additional funds by issuing equity securities, dilution to stockholders may result and new investors could have rights superior to holders of the shares issued in this offering. In addition, debt financing, if available, may include restrictive covenants. If adequate funds are not available to us, we may have to liquidate some or all of our assets or to delay or reduce the scope of or eliminate some portion or all of our development programs or clinical trials. We also may have to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourselves.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	If we do not achieve our projected development goals in the time frames we estimate, the commercialization of our products may be delayed and our business prospects may suffer. Our financial projections also may prove to be materially inaccurate.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings such as the discussion in this prospectus supplement of the expected timing of certain milestones relating to our aldoxorubicin clinical development programs.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We also may disclose projected expenditures or other forecasts for future periods. These and other financial projections are based on management's current expectations and do not contain any margin of error or cushion for any specific uncertainties, or for the uncertainties inherent in all financial forecasting.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The actual timing of milestones and actual expenditures or other financial results can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet milestones or financial projections as announced from time to time, the development and commercialization of our products may be delayed and our business prospects may suffer. The assumptions management has used to produce these projections may significantly change or prove to be inaccurate. Accordingly, you should not unduly rely on any of these financial projections.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-9-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage11"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	The regulatory approval process is lengthy, time consuming and inherently unpredictable, and if our products are not successfully developed and approved by the FDA or foreign regulatory authorities, we may be forced to reduce or curtail our operations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	All of our product candidates in development must be approved by the FDA or corresponding foreign governmental agencies before they can be marketed. The process for obtaining FDA and foreign government approvals is both time-consuming and costly, with no certainty of a successful outcome. This process typically includes the conduct of extensive pre-clinical and clinical testing, including post-approval testing, which may take longer or cost more than we or our licensees, if any, anticipate, and may prove unsuccessful due to numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate's clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Numerous factors could affect the timing, cost or outcome of our product development efforts, including the following:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9A219404919D4AB2ACCBB7C00120B819" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	difficulty in enrolling patients in conformity with required protocols or projected timelines;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F9B9114439C54BD2A80B1C655F6B0E60" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	requirements for clinical trial design imposed by the FDA;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9E52A41CE4214C56BF56163838DBEAB1" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	unexpected adverse reactions by patients in trials;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F7A7E12374EB4852BFF26B4D71B5F812" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	difficulty in obtaining clinical supplies of the product;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C950DC41A35741E3A00438A6A44A38DA" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	changes in or our inability to comply with FDA or foreign governmental product testing, manufacturing or marketing requirements;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D0CCF2D4F8C4495DBF6BBE36A93A8580" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	regulatory inspections of clinical trials or manufacturing facilities, which may, among other things, require us or our manufacturers or licensees to undertake corrective action or suspend or terminate the affected clinical trials if investigators find them not to be in compliance with applicable regulatory requirements;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="AB6EADA70F604CDDABF231CDE72EADEA" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	inability to generate statistically significant data confirming the safety and efficacy of the product being tested;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="083C93659EFD4F4A9B9290115D97180B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	modification of the product during testing; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2A1F52DE14F847509B0A904EA7309705" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	reallocation of our limited financial and other resources to other clinical programs.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-10-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage12"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	It is possible that none of the product candidates we develop will obtain the regulatory approvals necessary for us to begin selling them. The time required to obtain FDA and foreign governmental approvals is unpredictable, but often can take years following the commencement of clinical trials, depending upon the complexity of the product candidate. Any analysis we perform on data from clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Furthermore, even if we obtain regulatory approvals, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices, or cGMPs, and good clinical practices, or cGCPs, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="898BBD4A27C348E0BFEDAD5D02BE5648" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="A80FB1E248A746BC8FF82F59A5DFDD46" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	fines, warning letters or holds on clinical trials;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="1561A7231E894873A8FA4B4AFB97B957" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners, or suspension or revocation of product license approvals;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="EFC2C7B03E5F4880A45397EF0A0386EB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	product seizure or detention, or refusal to permit the import or export of products; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5DB337C634C14BF1A51593B29D63DF7E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	injunctions or the imposition of civil or criminal penalties.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The FDA's policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. We will also be subject to periodic inspections and the potential for mandatory post- approval clinical trials required by the FDA and other U.S. and foreign regulatory authorities. Any delay or failure in obtaining required approvals or to comply with post-approval regulatory requirements could have a material adverse effect on our ability to generate revenue from the particular product candidate. The failure to comply with any post-approval regulatory requirements also could result in the rescission of the related regulatory approvals or the suspension of sales of the offending product.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 3PT; FONT-FAMILY: 'ARIAL UNICODE MS WESTERN', SANS-SERIF; FONT-SIZE: 1PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Our current and planned clinical trials of our lead product candidate may fail to show that it is clinically safe and effective, or that it is better than alternative treatments.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical development may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials. For example, aldoxorubicin has shown encouraging preliminary clinical results in our Phase 2b clinical trial as a treatment for STS; however, these conclusions may not be reproduced in future clinical trial results, including the Phase 3 clinical trial testing aldoxorubicin as a treatment for STS. Accordingly, we, or any development partners, may ultimately be unable to provide the FDA with satisfactory data on clinical safety and efficacy sufficient to obtain FDA approval of aldoxorubicin for any indication.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-11-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage13"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Further, we may experience delays in clinical trials of our product candidates. We do not know whether ongoing clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="88072E797E9249B498E3E60F30A2D3B7" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	obtaining regulatory approval to commence a trial;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="EEF513467FA84A8D82F6094919AE76FB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="147919E6778041699366061532D02402" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	obtaining institutional review board approval at each clinical trial site;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F15E45D7CF61452282C9E1DAAF6B90F8" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	recruiting suitable patients to participate in a trial;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="06E1795C34864ABAACFD122AF2D7C582" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	having patients complete a trial or return for post-treatment follow-up;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F7AE0E7016324BC9905CD604A155B52D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	clinical trial sites deviating from trial protocol or dropping out of a trial;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6C18C6755535426C8A165CFDBD8D219E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	adding new clinical trial sites; or
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="14B6F5C599C54BC39AD713FDC7E37A9D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	manufacturing sufficient quantities of product candidate for use in clinical trials.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients' perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Furthermore, we rely on third parties, such as CROs and clinical trial sites, to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our collaborators, the institutional review boards, or IRBs, if the institutions in which such trials are being conducted, the Data Safety Monitoring Board, or DSMB, for such trial, or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, the FDA placed a partial clinical hold on our on-going clinical trials of aldoxorubicin in November 2014 following the death of an individual who was not enrolled in any of our clinical trials but who received aldoxorubicin pursuant to our compassionate use policy under a single-patient IND held by one of the clinical sites participating in our Phase 3 trial of aldoxorubicin in STS. The clinical hold resulted in our inability to enroll new patients in our aldoxorubicin studies until the hold was removed in February 2015. Although we have resumed enrollment in our studies, enrollment in our clinical trials and our projected development timelines may be adversely affected by residual effects of the former clinical hold or possible future clinical holds.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-12-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage14"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Our SPA with the FDA for our pivotal study of aldoxorubicin does not guarantee marketing approval in the U.S.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have an SPA with the FDA for the pivotal trial of aldoxorubicin for the treatment of STS. The SPA means that the FDA agrees that the design and analyses proposed in a protocol are acceptable to support regulatory approval of the product candidate with respect to effectiveness of the indication studied. However, an SPA agreement does not guarantee approval of a product candidate, and even if the FDA agrees to the design, execution, and analysis proposed in protocols reviewed under the SPA process, the FDA may revoke or alter its agreement in certain circumstances. In particular, an SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, the sponsor fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by the sponsor in a request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement. Moreover, a final determination that the agreed-upon protocol satisfies a specific objective, such as the demonstration of efficacy and safety (positive benefit-risk ratio), or supports an approval decision, will be based on a complete review of all the data submitted to the FDA.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Undesirable side effects caused by our product candidates could result in the delay, suspension or termination of our clinical trials by us, our collaborators, IRBs, the FDA or other regulatory authorities. If we elect or are required to delay, suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	To date, patients treated with aldoxorubicin have experienced some of the same drug-related side effects associated with doxorubicin, including myelosuppression (decreased production of blood cells by bone marrow), gastrointestinal disorders (nausea and vomiting), mucositis (inflammation of the mucous membranes lining the digestive tract, including the mouth), stomatitis (inflammation of the mouth's soft tissue), fatigue, fever and other signs of infection associated with neutropenia (an abnormally low count of a type of white blood cells) and alopecia (hair loss). Results of our trials could reveal an unacceptable incidence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. In addition, the drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Furthermore, if we or others later identify undesirable side effects caused by the product, a number of potentially significant negative consequences could result, including:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6E00E9FB3F954091853A651CE6D5CE4E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	If our product candidates receive marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy to ensure that the benefits of any approved product candidate outweigh its risks;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="DDF54ECE3C7C4FC0AAF4DA1C22488183" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	regulatory authorities may withdraw approvals of such product;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="120649E45A4E45FB8300117B08061464" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	regulatory authorities may require additional warnings on the label;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8BFD515A3C5144A4BA27A05801BB95A9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C94FB96DDB5F4142A49133A57C2E15B2" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	we could be sued and held liable for harm caused to patients; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9C78CB11B93B4EE79A11D433802BE3E6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	our reputation may suffer.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Any of these events could prevent us from achieving or maintaining market acceptance of aldoxorubicin or the particular product candidate at issue, if approved, and could significantly harm our business, results of operations and prospects.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-13-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage15"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have agreements with third-party CROs to monitor and manage data for our preclinical and clinical programs. We rely heavily on these parties for execution of our preclinical and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with cGCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these CROs fails to comply with applicable cGCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the cGCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations, and will require a large number of test subjects. Our or our CROs' failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for aldoxorubicin would be harmed, our costs could increase and our ability to generate revenues could be delayed.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Switching or adding additional CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We rely upon third parties for the manufacture of our clinical product supplies, and we intend to rely on third parties to produce commercial supplies of any approved product candidate, and our commercialization of any product candidates, including aldoxorubicin, could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA, fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality levels or prices.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We do not have the facilities or expertise to manufacture supplies of aldoxorubicin or any of our other product candidates, and we lack the resources and capability to manufacture any of our product candidates on a clinical or commercial scale. Accordingly, we are dependent upon third-party manufacturers, or potential future strategic alliance partners, to manufacture these supplies. We have manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. In September 2015, we entered into an agreement with a supplier to purchase doxorubicin hydrochloride both for clinical and commercial use. However, we have no other supply arrangements for the commercial manufacture of this product candidate or any manufacturing supply arrangements for any other potential product candidates, and we may not be able to secure needed supply arrangements on attractive terms, or at all. Our failure to secure these arrangements as needed could have a materially adverse effect on our ability to complete the development of our products or to commercialize them.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-14-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage16"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be completed after we submit our NDA to the FDA. We do not control the manufacturing process of aldoxorubicin and are completely dependent on our contract manufacturing partners for compliance with the FDA's requirements for manufacture of aldoxorubicin. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA's strict regulatory requirements, they will not be able to secure and/or maintain FDA approval for the manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If aldoxorubicin, our lead product candidate, or our other product candidates cannot be manufactured in suitable quantities and in accordance with regulatory standards, our clinical trials, regulatory approvals and marketing efforts for such products may be delayed. Such delays could adversely affect our competitive position and our chances of generating significant recurring revenues. If any of our products that are approved for marketing cannot be manufactured at an acceptable cost, the commercial success of such product candidates may be adversely affected.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We may rely upon third parties in connection with the commercialization of our products.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 6PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The marketing and commercialization of aldoxorubicin may require us to enter into strategic alliances or other collaborative arrangements with other pharmaceutical companies under which those companies will be responsible for one or more aspects of the eventual marketing and commercialization of aldoxorubicin, if it is approved for marketing.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Any future product candidate, if approved for marketing, may not have sufficient potential commercial value to enable us to secure strategic arrangements with suitable companies on attractive terms, or at all. If we are unable to enter into such arrangements, we may not have the financial or other resources to commercialize our products and may have to sell our rights in them to a third party or abandon their commercialization altogether.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To the extent we enter into collaborative arrangements, we will be dependent upon the timeliness and effectiveness of the development and marketing efforts of our contractual partners. If these companies do not allocate sufficient personnel and resources to these efforts or encounter difficulties in complying with applicable FDA and other regulatory requirements, we may not obtain regulatory approvals as planned, if at all, and the timing of receipt or the amount of revenue from these arrangements may be materially and adversely affected. By entering into these arrangements rather than completing the development and then marketing these products on our own, the profitability to us of these products may decline.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We may be unable to protect our intellectual property rights, which could adversely affect our ability to compete effectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: NORMAL; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	We will be able to protect our technologies from unauthorized use by third parties only to the extent that we have rights to valid and enforceable patents or other proprietary rights that cover them. Although we have rights to patents and patent applications directed to aldoxorubicin and other product candidates, these patents and applications may not prevent third parties from developing or commercializing similar or identical technologies. In addition, our patents may be held to be invalid if challenged by third parties, and our patent applications may not result in the issuance of patents.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: NORMAL; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date in the United States and in many foreign countries. The application and enforcement of patent laws and regulations in foreign countries is even more uncertain. Accordingly, we may not be able to effectively file, protect or defend our proprietary rights on a consistent basis. Many of the patents and patent applications on which we rely were issued or filed by third parties prior to the time we acquired rights to them. The validity, enforceability and ownership of those patents and patent applications may be challenged, and if a court decides that our patents are not valid, we will not have the right to stop others from using our inventions. There is also the risk that, even if the validity of our patents is upheld, a court may refuse to stop others on the ground that their activities do not infringe our patents.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: NORMAL; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	Any litigation brought by us to protect our intellectual property rights could be costly and have a material adverse effect on our operating results or financial condition, make it more difficult for us to enter into strategic alliances with third parties to develop our products, or discourage our existing licensees from continuing their development work on our potential products. If our patent coverage is insufficient to prevent third parties from developing or commercializing similar or identical technologies, the value of our assets is likely to be materially and adversely affected.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: NORMAL; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	We also rely on certain proprietary trade secrets and know-how, especially where we believe patent protection is not appropriate or obtainable. However, trade secrets and know-how are difficult to protect. Although we have taken measures to protect our unpatented trade secrets and know-how, including the use of confidentiality and invention assignment agreements with our employees, consultants and some of our contractors, it is possible that these persons may disclose our trade secrets or know-how or that our competitors may independently develop or otherwise discover our trade secrets and know-how.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-15-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage17"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	If our product candidates infringe the rights of others, we could be subject to expensive litigation or be required to obtain licenses from others to develop or market them.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our competitors or others may have patent rights that they choose to assert against us or our licensees, suppliers, customers or potential collaborators. Moreover, we may not know about patents or patent applications that our products would infringe. For example, because patent applications do not publish for at least 18 months, if at all, and can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents that our product candidates would infringe. In addition, if third parties file patent applications or obtain patents claiming technology also claimed by us or our licensors in issued patents or pending applications, we may have to participate in interference proceedings in the U.S. Patent and Trademark Office to determine priority of invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our foreign patent applications.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If a third party claims that we infringe its proprietary rights, any of the following may occur:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0F46838F98414F2388BFA4114D00E440" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	we may become involved in time-consuming and expensive litigation, even if the claim is without merit;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D55E78AFFF48451E95D0297179662850" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	we may become liable for substantial damages for past infringement if a court decides that our technology infringes a competitor's patent;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0955AB05AA6F4AE2AB1B80F8B4D85607" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	a court may prohibit us from selling or licensing our product without a license from the patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross licenses to our patents; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2BECC5F607F2476F872D2FE4F4CBDC55" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	we may have to redesign our product candidates or technology so that it does not infringe patent rights of others, which may not be possible or commercially feasible.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If any of these events occurs, our business and prospects will suffer and the market price of our common stock will likely decline substantially.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Any products we develop may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could have a material adverse effect on our business.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We intend to sell our products that may be approved for marketing primarily to hospitals, which generally receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare, Medicaid and other domestic and international government programs, private insurance plans and managed care programs.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We currently expect that any drugs we develop may need to be administered under the supervision of a physician. Under currently applicable law, drugs that are not usually self-administered may be eligible for coverage by the Medicare program if:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="95AAE3759E444B8E965A71C5B5C05258" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	they are "incidental" to a physician's services;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4DB632189B314CC98D843867EB04EDCB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	they are "reasonable and necessary" for the diagnosis or treatment of the illness or injury for which they are administered according to accepted standard of medical practice;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3A8412D361CD407A99CB5F4DD1AE3D9E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	they are not excluded as immunizations; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="437EF147931A445CBD9E20D3929007E6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	they have been approved by the FDA.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. The Medicare program covers certain individuals aged 65 or older, disabled or suffering from end-stage renal disease. The Medicaid program, which varies from state-to-state, covers certain individuals and families who have limited financial means. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Most third-party payors may deny coverage or reimbursement if they determine that a medical product was not used in accordance with cost-effective treatment methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to cover and reimburse for experimental procedures and devices. Furthermore, because our programs are in the early stages of development, we are unable at this time to determine their cost-effectiveness and the level or method of reimbursement. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices, and are challenging the prices charged for medical products. If the price we are able to charge for any products we develop is inadequate in light of our development and other costs, our profitability could be adversely affected.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-16-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage18"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Healthcare legislative reform measures could hinder or prevent the commercial success of our products and product candidates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future revenues and profitability. Federal and state lawmakers regularly propose and, at times, enact legislation that results in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, in March 2010, President Obama signed one of the most significant healthcare reform measures in decades, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act. It contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs. The Affordable Care Act, among other things, (i) increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extends the rebate program to individuals enrolled in Medicaid managed care organizations, and addresses new methodologies by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and for drugs that are line extension products; (ii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and (iii) enacts a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer's outpatient drugs to be covered under Medicare Part&#160;D.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect on April 1, 2013. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We may also be subject to healthcare laws, regulation and enforcement and our failure to comply with those laws could adversely affect our business, operations and financial condition.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8C5BDD66F9754003A4F3F66A4AB56336" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9498786B7648418CB9024A0F59151690" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government, and which may apply to entities that provide coding and billing advice to customers;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D4BCAC19ABD5457EA163264B7025E86F" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4281C118AA124093BE9217FE25BC45A5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	the federal physician sunshine requirements under the Affordable Care Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="94E82127AE544C0C9A9AFC461A0289E4" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C025B3145AF742ECA8AE28F54FA8B8E9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-17-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage19"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the recently enacted Affordable Care Act, among other things, amends the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Achieving and sustaining compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the exclusion from participation in federal and state healthcare programs, imprisonment, or the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We are subject to intense competition, and we may not compete successfully.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Aldoxorubicin is a conjugate of doxorubicin, a widely used anti-cancer drug. Doxorubicin is part of the anthracycline class of chemotherapy agents. Anthracyclines, many of which, including doxorubicin are generic, have been used throughout the world to treat various cancers for several decades. Due to their track record of broad anti-cancer activity, new types of anthracyclines and modified or reformulated versions continue to be developed to overcome toxicities which limit the use of these drugs.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Aldoxorubicin is a chemically modified version of doxorubicin that incorporates an acid sensitive linker technology to improve concentration in the tumor. We believe that the albumin-binding ability of aldoxorubicin will allow the compound to overcome many of the side effect issues typically associated with anthracyclines. We also believe that using albumin as a targeted carrier will allow for higher dosing, greater concentration of the drug in tumors and greater efficacy.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	STS patients are typically treated with surgery followed by radiation therapy. For patients ineligible for surgery, radiation or both, chemotherapy is the only option. Doxorubicin is the only approved first-line drug for treating STS patients who are ineligible for surgery and is often used in combination with radiation. The National Comprehensive Cancer Network also includes the use of ifosfamide, epirubicin, gemcitabine, gemcitabine with docetaxel, dacarbazine and liposomal doxorubicin marketed in the United States as Doxil&#174; by Johnson&#160;&amp; Johnson. Pazopanib (Votrient&#174;), developed by GlaxoSmithKline and now marketed by Novartis, was approved in the United States and Europe in 2012 for the treatment of certain types of advanced STS following prior chemotherapy. In October 2015, the Janssen unit of Johnson &amp; Johnson received approval for trabectedin (Yondelis&#174;) for the treatment of patients with leiomyosarcoma and liposarcoma,that have previously received an anthracycline-containing regimen. In January 2016, the FDA approved Eisai's eribulin (Halaven&#174;) as a treatment for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline.&#160; Eli Lilly is conducting a Phase 3 clinical trial with olaratumab in combination with doxorubicin in first-line STS.&#160; Eli Lilly stated in October 2015 that they plan to submit a rolling new drug application based on the Phase 2 clinical trial results in STS. There are other approaches to treating STS in clinical development, including Morphotek's ontuxizumab in combination with chemotherapy, and Tracon Pharmaceuticals' TRC-105 in combination with pazopanib.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Patients with glioblastoma multiforme, or GBM, generally undergo invasive brain surgery, although disease progression following surgery is nearly 100%. The front-line therapy for GBM following surgery is radiation in combination with temozolomide (Temodar&#174;). Bevacizumab (Avastin&#174;) has been approved for the treatment of GBM in patients progressing after prior therapy. Drugs in development to treat GBM include rindopepimut by Celldex Therapeutics, nivolumab by Bristol-Myers Squibb, DCVax by Northwest Biotherapeutics, TRC-105 from Tracon Pharmaceuticals, veliparib by AstraZeneca and buparlisib by Novartis.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-18-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage20"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Treatment for newly diagnosed SCLC typically consists of cisplatin or carboplatin in combination with etoposide. Radiation may also be given for extensive-stage disease.&#160; While first-line treatment can yield overall response rates of 50-80%, the duration of response is often less than 90 days.&#160; For recurrent SCLC, topotecan (Hycamtin&#174;) is standard therapy.&#160; SCLC patients who are sensitive to first-line treatment may receive topotecan or the generic chemotherapeutic drugs irinotecan, taxanes, gemcitabine or vinorelbine.&#160; Drugs in development for second-line SCLC include Bristol-Myers Squibb's ipilumimab (Yervoy&#174;) and SC16LD6.5 by Stem CentRx, Inc.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;Kaposi's sarcoma is generally treated with radiation, surgery and/or liposomal doxorubicin.&#160; Liposomal daunorubicin (DaunoXome&#174;, Galen US), with or without paclitaxel, is also recommended as treatment for advanced disease. Other drugs in development for Kaposi's sarcoma include selumetinib by AstraZeneca and pomalidamide by Celgene.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Many companies, including large pharmaceutical and biotechnology firms with financial resources, research and development staffs, and facilities that may be substantially greater than those of ours or our strategic partners or licensees, are engaged in the research and development of pharmaceutical products that could compete with our potential products. To the extent that we seek to acquire, through license or otherwise, existing or potential new products, we will be competing with numerous other companies, many of which will have substantially greater financial resources, large acquisition and research and development staffs that may give those companies a competitive advantage over us in identifying and evaluating these drug acquisition opportunities. Any products that we acquire will be competing with products marketed by companies that in many cases will have substantially greater marketing resources than we have. The industry is characterized by rapid technological advances and competitors may develop their products more rapidly and such products may be more effective than those currently under development or that may be developed in the future by our strategic partners or licensees. Competitive products for a number of the disease indications that we have targeted are currently being marketed by other parties, and additional competitive products are under development and may also include products currently under development that we are not aware of or products that may be developed in the future.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As a result, these competitors may:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="28D6E5C24CF64966ABBD0F86833D0CA1" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	succeed in developing competitive products sooner than us or our strategic partners or licensees;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="FFBE39325F3649159E080B0B91542624" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	obtain FDA or foreign governmental approvals for their products before we can obtain approval of any of our products;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="88E761204CEE4B8BA368C3DDDA0127C0" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	obtain patents that block or otherwise inhibit the development and commercialization of our product candidate candidates;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4699B7E096B54CB9998EB2F6D125A3C5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	develop products that are safer or more effective than our products;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9AA13BCCBB4B47D08AE542D579808621" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	devote greater resources than us to marketing or selling products;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="CBFE4511B52E4CBCBC467231CC97C435" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	introduce or adapt more quickly than us to new technologies and other scientific advances;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="75BFB819B190489AAD111019D2D6BCED" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	introduce products that render our products obsolete;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9E64FF20E78F4A36B3883E72982A871D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	withstand price competition more successfully than us or our strategic partners or licensees;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="184C642AA6CD473DB631B35054751221" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	negotiate third-party strategic alliances or licensing arrangements more effectively than us; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D05D5D4698214391AA34AA0D25C0EBE5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	take better advantage than us of other opportunities.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-19-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage21"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We will be required to pay substantial milestone and other payments relating to the commercialization of our products.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The agreement relating to our worldwide rights to aldoxorubicin provides for our payment of up to an aggregate of $7.5 million upon meeting specified clinical and regulatory milestones up to and including the product's second, final marketing approval. We also will be obliged to pay:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="95B1BCFEDE3F48279802D565E9C1ABD5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4B53040FA3A5423EA30F9E8B3C92D9B9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	a percentage of any non-royalty sub-licensing income (as defined in the agreement); and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="726FE198E1034757B22D23C7198367DF" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	milestones of $1,000,000 for each additional final marketing approval that we might obtain.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Under the merger agreement by which we acquired Innovive, we agreed to pay the former Innovive stockholders a total of up to approximately $18.3 million of future earnout merger consideration, subject to our achievement of specified net sales under the Innovive license agreements. The earnout merger consideration, if any, will be payable in shares of our common stock, subject to specified conditions, or, at our election, in cash or by a combination of shares of our common stock and cash. Our common stock will be valued for purposes of any future earnout merger consideration based upon the trading price of our common stock at the time the earnout merger consideration is paid.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.&#160; We maintain sensitive data pertaining to our Company on our computer networks, including information about our development activities, our intellectual property and other proprietary business information. Our internal computer systems and those of third parties with which we contract may be vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures, despite the implementation of security measures. System failures, accidents or security breaches could cause interruptions to our operations, including material disruption of our development activities, result in significant data losses or theft of our intellectual property or proprietary business information, and could require substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs could be delayed, any of which would harm our business and operations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We are subject to potential liabilities from clinical testing and future product liability claims.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	If any of our products are alleged to be defective, they may expose us to claims for personal injury by patients in clinical trials of our products or, if we obtain marketing approval and commercialize our products, by patients using our commercially marketed products. Even if one or more of our products is approved by the FDA, users may claim that such products caused unintended adverse effects. We maintain clinical trial insurance for our ongoing clinical trials, and we plan to seek to obtain similar insurance for any other clinical trials that we conduct. We also would seek to obtain product liability insurance covering the commercial marketing of our product candidates. We may not be able to obtain additional insurance, however, and any insurance obtained by us may prove inadequate in the event of a claim against us. Any claims asserted against us also may divert management's attention from our operations, and we may have to incur substantial costs to defend such claims even if they are unsuccessful.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We may be unable to successfully acquire additional technologies or products. If we require additional technologies or products, our product development plans may change and the ownership interests of our shareholders could be diluted.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We may seek to acquire additional technologies by licensing or purchasing such technologies, or through a merger or acquisition of one or more companies that own such technologies. We have no current understanding or agreement to acquire any technologies, however, and we may not be able to identify or successfully acquire any additional technologies. We also may seek to acquire products from third parties that already are being marketed or have been approved for marketing, although we have not currently identified any of these products. We do not have any prior experience in acquiring or marketing products approved for marketing and may need to find third parties to market any products that we might acquire.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have focused our product development efforts on our oncology drug candidates, which we believe have the greatest revenue potential. If we acquire additional technologies or product candidates, we may determine to make further changes to our product development plans and business strategy to capitalize on opportunities presented by the new technologies and product candidates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We may determine to issue shares of our common stock to acquire additional technologies or products or in connection with a merger or acquisition of another company. To the extent we do so, the ownership interest of our stockholders will be diluted accordingly.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 3PT; FONT-FAMILY: 'ARIAL UNICODE MS WESTERN', SANS-SERIF; FONT-SIZE: 1PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-20-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage22"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="FONT-STYLE: ITALIC; FONT-WEIGHT: BOLD">
	We are conducting certain of our clinical trials in foreign countries, which exposes us to additional risks.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are conducting international clinical development of aldoxorubicin. The conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="541ABFF7F5D242DA8BCD6FD4FFB77E17" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0FA509271C5C4C42AC9D6468B2299E5B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	administrative burdens of conducting clinical trials under multiple foreign regulatory schema;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="602701E428C04DBAB27A3D87F9D69D21" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	foreign exchange fluctuations;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="838F3BFBA4A34E5E94331DC02B73F59B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	diminished protection of intellectual property in some countries; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0ACAD2345CCF460AB049F7F05D38D0F9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	possible nationalization and expropriation.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="A582B37CBDD44EBE969C32A9AE26DCA6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 32.4PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	In addition, there may be changes to our business and political position if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest, and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease, which could seriously harm the development of our current operating strategy.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	In the event of a dispute regarding our international clinical trials, it may be necessary for us to resolve the dispute in the foreign country of dispute, where we would be faced with unfamiliar laws and procedures.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The resolution of disputes in foreign countries can be costly and time consuming, similar to the situation in the United States. However, in a foreign country, we face the additional burden of understanding unfamiliar laws and procedures. We may not be entitled to a jury trial, as we might be in the United States. Further, to litigate in any foreign country, we would be faced with the necessity of hiring lawyers and other professionals who are familiar with the foreign laws. For these reasons, we may incur unforeseen expenses if we are forced to resolve a dispute in a foreign country.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Drug discovery is a complex, time-consuming and expensive process, and we may not succeed in creating new product candidates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Conducting drug discovery and pre-clinical development of our albumin-binding technology is a complex and expensive process that will take many years.&#160; Accordingly, we cannot be sure whether or when our drug discovery and pre-clinical development activities will succeed in developing any new product candidates.&#160; In addition, any product candidates that we develop in pre-clinical testing may not demonstrate success in clinical trials required for marketing approval.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Any deficiency in the design, implementation or oversight of our drug discovery and pre-clinical testing programs could cause us to incur significant additional costs, experience significant delays, prevent us from obtaining marketing approval for any product candidate that may result from these programs or abandon development of certain product candidates.&#160; If any of these risks materializes, it could harm our business and cause our stock price to decline.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We have a limited operating history in drug discovery, which is inherently risky, and we may not succeed in addressing these risks.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have operated our drug discovery laboratory and LADR&#8482; development program since October 2014.&#160; Accordingly, we have a limited operating history in conducting our own drug discovery programs. In December 2015, we announced the selection of DK049 as the first new product candidate utilizing our LADR&#8482; technology Consequently, there is limited information for investors to use as basis for assessing the viability of our drug discovery efforts.&#160; Investors must consider the risks and difficulties inherent in drug discovery and pre-clinical activities, including the following:
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="A36C81048192407AB1A238B998661F45" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 31.5PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	difficulties, complications, delays and other unanticipated factors in connection with the development of new drugs;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5BA5E20E498240D29432BE9516C887A2" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 31.5PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	competition from companies that have substantially greater assets and financial resources than we have;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-21-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage23"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8C6490F382474866ADD81CA85A3D00F7" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 31.5PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	our ability to anticipate and adapt to a competitive market and rapid technological developments;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0E247D6940DE45C7B6F7389A4174B07B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 31.5PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	our need to rely on multiple levels of complex financing agreements with outside funding due to the length of drug development cycles and governmental approved protocols associated with the pharmaceutical industry; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="10C182DBF9E84180AE5C329AAA8AC64F" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 31.5PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	our dependence upon key scientific personnel, including Felix Kratz, Ph.D., our Vice President of Drug Discovery and Andre Warnecke, Ph.D., our Senior Director of Drug Discovery.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We cannot be certain that we will successfully address these risks or that our drug discovery efforts will be successful.&#160; In the event that we do not successfully address these risks, our business, prospects, financial condition and results of operations could be materially and adversely affected.&#160; We also may be required to reduce or discontinue altogether our drug discovery and pre-clinical programs.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an "ownership change," the corporation's ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income and taxes may be limited. In general, an "ownership change" occurs if there is a cumulative change in our ownership by "5% shareholders" that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. As a result of a previous ownership change, our annual utilization of approximately $62.3 million in federal net operating loss carryforwards will be substantially limited.&#160; If we experience ownership changes as a result of future transactions in our stock, we may be further limited in our ability to use our net operating loss carryforwards and other tax assets to reduce taxes owed on the net taxable income that we earn. Any such limitations on the ability to use our net operating loss carryforwards and other tax assets could potentially result in increased future tax liability to us on any net income that we may earn in the future.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	We
</FONT>
	cannot assure investors that we will be able to fully address the material weakness in our internal controls or that remediation efforts will prevent future material weaknesses.&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	We have identified a control deficiency in our financial reporting process concerning a non-routine and unusual item that constitutes a material weakness, for the year ended December 31, 2015. We have initiated certain measures, including performing a comprehensive review of significant and unusual transactions, to remediate this weakness, and plan to implement additional appropriate measures as part of this effort. The Company had previously never had a material weakness in its history. There can be no assurance that we will be able to fully remediate our existing material weakness or that the comprehensive review of certain significant and unusual transactions will remediate or prevent these weaknesses from re-occurring in the future.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Further, there can be no assurance that we will not suffer from other material weaknesses in the future. If we fail to remediate these material weaknesses or fail to otherwise maintain effective internal controls over financial reporting in the future, such failure could result in a material misstatement of our annual or quarterly financial statements that would not be prevented or detected on a timely basis and which could cause investors and other users to lose confidence in our financial statements, limit our ability to raise capital and have a negative effect on the trading price of our common stock. Additionally, failure to remediate the material weaknesses or otherwise failing to maintain effective internal controls over financial reporting may also negatively impact our operating results and financial condition, impair our ability to timely file our periodic and other&#160;reports with the SEC, subject us to additional litigation and regulatory actions and cause us to incur substantial additional costs in future periods relating to the implementation of remedial measures.
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Risks Associated with Our Common Stock
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; MARGIN-TOP: 6PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	You may experience future dilution as a result of future equity offerings or other equity issuances.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 6PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	To raise additional capital, we may in the future offer additional shares of our common stock, preferred stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share that you may pay for the shares of our common stock offered hereby. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share that you may pay for the shares of our common stock offered hereby.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-22-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage24"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We may experience volatility in our stock price, which may adversely affect the trading price of our common stock.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The market price of our common stock in 2015 ranged from $1.98 to $5.42 per share, and it may continue to experience significant volatility from time to time. Factors that may affect the market price of our common stock include the following:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="01C7D3AEC784462DA62E88C7EAE37DD9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	announcements of interim or final results of our clinical trials or our drug discovery activities;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D5FE19B1235A4D90BBA1C3DAC42E0FEB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	announcements of regulatory developments or technological innovations by us or our competitors;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="1D16940907104DFEBB89DE272AB6517E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	changes in our relationship with our licensors and other strategic partners;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9CA8257E90EE47ECB08DB74D290EBA3E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	our quarterly operating results;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="908747A3C8CB4859A738C4CFFB5F981D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	litigation involving or affecting us;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7136A1628CE5418B915B04D6A09FE592" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	shortfalls in our actual financial results compared to our guidance or the forecasts of stock market analysts;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="24673E26F79244688D432DBB3C8EA3AE" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	developments in patent or other technology ownership rights;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3B584F011821424EA2E69BEC21964485" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	acquisitions or strategic alliances by us or our competitors;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E7390E002FB047C6832AC4D32AD753A3" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	public concern regarding the safety of our products; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C47F5AC3E2414614A21F4457D6312999" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	government regulation of drug pricing.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Our outstanding options and warrants and the availability for resale of the underlying shares may adversely affect the trading price of our common stock.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As of December 31, 2015, there were outstanding stock options and warrants to purchase approximately 21.4 million shares of our common stock at a weighted-average exercise price of $3.50 per share. Our outstanding options and warrants could adversely affect our ability to obtain future financing or engage in certain mergers or other transactions, since the holders of options and warrants can be expected to exercise them at a time when we may be able to obtain additional capital through a new offering of securities on terms more favorable to us than the terms of outstanding options and warrants. For the life of the options and warrants, the holders have the opportunity to profit from a rise in the market price of our common stock without assuming the risk of ownership. The issuance of shares upon the exercise of outstanding options and warrants will also dilute the ownership interests of our existing stockholders. Many of our outstanding warrants contain anti-dilution provisions pertaining to dividends with respect to our common stock. In the event that these anti-dilution provisions are triggered by us in the future, we would likewise be required to reduce the exercise price, and increase the number of shares underlying, those warrants, which would have a dilutive effect on our stockholders.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have registered with the SEC the resale by the holders of all or substantially all shares of our common stock issuable upon exercise of our outstanding options and warrants. The availability of these shares for public resale, as well as actual resales of these shares, could adversely affect the trading price of our common stock.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We have been, and in the future may be, subject to legal or administrative actions that could adversely affect our results of operations and our business.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We announced in December 2015 and January 2016 that we agreed to settle federal securities class actions and stockholder derivative lawsuits filed in 2014 against us and certain of our officers and directors.&#160; Securities-related class action lawsuits and derivative litigation have often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for biotechnology and biopharmaceutical companies such as ours, which often experience significant stock price volatility in connection with their product development programs.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Our anti-takeover measures may make it more difficult to change our management, or may discourage others from acquiring us, and thereby adversely affect stockholder value.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have a stockholder rights plan and provisions in our restated by-laws, as amended, that are intended to protect our stockholders' interests by encouraging anyone seeking control of our company to negotiate with our board of directors. These provisions may discourage or prevent a person or group from acquiring us without the approval of our board of directors, even if the acquisition would be beneficial to our stockholders.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have a classified board of directors, which means that at least two stockholder meetings, instead of one, will be required to effect a change in the majority control of our board of directors. This applies to every election of directors, not just an election occurring after a change in control. The classification of our board increases the amount of time it takes to change majority control of our board of directors and may cause potential acquirers to lose interest in a potential purchase of us, regardless of whether our purchase would be beneficial to us or our stockholders. The additional time and cost to change a majority of the members of our board of directors makes it more difficult and may discourage our existing stockholders from seeking to change our existing management in order to change the strategic direction or operational performance of our company.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our by-laws provide that directors may only be removed for cause by the affirmative vote of the holders of at least a majority of the outstanding shares of our capital stock then entitled to vote at an election of directors. This provision prevents stockholders from removing any incumbent director without cause. Our by-laws also provide that a stockholder must give us at least 120 days notice of a proposal or director nomination that such stockholder desires to present at any annual meeting or special meeting of stockholders. Such provision prevents a stockholder from making a proposal or director nomination at a stockholder meeting without us having advance notice of that proposal or director nomination. This could make a change in control more difficult by providing our directors with more time to prepare an opposition to a proposed change in control. By making it more difficult to remove or install new directors, these bylaw provisions may also make our existing management less responsive to the views of our stockholders with respect to our operations and other issues such as management selection and management compensation.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which may also prevent or delay a takeover of us that may be beneficial to our stockholders.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-23-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage25"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Our restated by-laws, as amended, designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our by-laws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or (iv)&#160;any action asserting a claim that is governed by the internal affairs doctrine. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our by-laws. This choice-of-forum provision may limit our stockholders' ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our amended and restated by-laws inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We may issue preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are authorized to issue shares of preferred stock in one or more series. Our board of directors may determine the terms of future preferred stock offerings without further action by our stockholders. If we issue preferred stock, it could affect your rights or reduce the value of our outstanding common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	We do not expect to pay any cash dividends on our common stock.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have not declared or paid any cash dividends on our common stock or other securities, and we currently do not anticipate paying any cash dividends in the foreseeable future. Because we do not anticipate paying cash dividends for the foreseeable future, our stockholders will not realize a return on their investment in our common stock except to the extent of any appreciation in the value of our common stock. Our common stock may not appreciate in value, or may decline in value.
</DIV>
</EFX_RISK_FACTORS>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 1B. UNRESOLVED STAFF COMMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	None.
</DIV>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 2. PROPERTIES
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We lease our headquarters in Los Angeles, California. The lease covers approximately 5,739 square feet of office and storage space and expires in February 2020.&#160; Our monthly rent is $19,226, which is subject to annual increases.&#160;In addition to the monthly rent, we are responsible for paying our allocable portion of operating expenses.&#160;We have an option to extend the term of the lease for a five-year period and a right of first offer during the extended lease term to lease any available space on the sixth floor of the premises, subject to the terms and conditions set forth in the lease agreement.&#160; We also lease additional storage space for approximately 540 square feet. This lease expires in February 2020, and requires us to make monthly payments of $1,110, subject to annual increases.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We lease laboratory space in Freiburg, Germany, covering approximately 376 square meters (4,047 square feet). In January, 2016, we signed a lease amendment increasing the space to 752 square meters (8,094 square feet), effective August 1, 2016. The amended lease expires on September 30, 2018, and will require us to increase our monthly payments from &#8364;4,498 (approximately $5,038) to &#8364;10,329 (approximately $11,568), subject to annual increases. We have an option to extend the term of the lease for up to three additional three-year periods.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<FONT STYLE="FONT-SIZE: 8PT">
	-24-
</FONT>
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage26"></A>
</DIV>
</EFX_PROPERTIES>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 3. LEGAL PROCEEDINGS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 6PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The Company is occasionally involved in legal proceedings and other matters arising from the normal course of business. As previously reported in the Company's Quarterly Report filed with the SEC on November 3, 2015, on June&#160;13, 2014, three purported securities class action lawsuits pending against us and certain of our officers and directors in the United States District Court for the Central District of California were consolidated in the matter of In re CytRx Corporation Securities Litigation, 2:14-CV-01956-GHK (PJWx) (the "Federal Class Action"), and lead plaintiff and lead counsel were appointed. On October&#160;1, 2014, plaintiffs filed a consolidated amended complaint on behalf of all persons who purchased or otherwise acquired our publicly traded securities between November&#160;20, 2013 and March&#160;13, 2014, against us, certain of our officers and directors, a freelance writer, and certain underwriters, including Jefferies LLC, Oppenheimer&#160;&amp; Co., LLC, Aegis Corp., and H.C. Wainwright&#160;&amp; Co., LLC. The complaint alleges that certain of the defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements in press releases, promotional articles, SEC filings and other public statements. The complaint further alleges that certain of the defendants violated the Securities Act of 1933 by making materially misleading statements and omitting material information in our shelf Registration Statement on Form S-3 filed with the SEC on December&#160;6, 2012 and Prospectus Supplement under Rule 424(b)(2) filed with the SEC on January&#160;31, 2014. These allegations arise out of our alleged retention of The DreamTeam Group and MissionIR, external investor and public relations firms unaffiliated with us, as well as our December&#160;9, 2013 grant of stock options to certain board members and officers. The consolidated amended complaint seeks damages, including interest, in an unspecified amount, reasonable costs and attorneys' fees, and any equitable, injunctive, or other relief that the court may deem just and proper. On December&#160;5, 2014, we and the individual defendants filed a motion to dismiss the complaint. The Court was scheduled to hear argument on this motion on March&#160;2, 2015. On February&#160;25, 2015, the Court took this motion under submission and took the hearing off calendar. On July&#160;13, 2015, the Court issued an order granting in part and denying in part the motions to dismiss filed by us, the individual defendants and the underwriters. On August 7, 2015, the plaintiffs amended their complaint and on September 8, 2015, the defendants moved to dismiss the amended complaint, in part.&#160; On October 23, 2015, the Court took the motion to dismiss under submission and, as a result of the settlement of the case as set forth below, the motion to dismiss has not been ruled on by the Court
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	On April&#160;3, 2014, a purported class action lawsuit was filed against us and certain of our officers and each of our directors, as well as certain underwriters, in the Superior Court of California, County of Los Angeles, captioned Rajasekaran v. CytRx Corporation, et al., BC541426. The complaint purports to be brought on behalf of all shareholders who purchased or otherwise acquired our common stock pursuant or traceable to our public offering that closed on February&#160;5, 2014. The complaint alleges that defendants violated the federal securities laws by making materially false and misleading statements in our filings with the SEC. The complaint seeks compensatory damages in an unspecified amount, rescission, and attorney's fees and costs. On October&#160;14, 2014, the Court granted the parties' joint ex parte motion to stay this proceeding pending resolution of motions to dismiss in the related federal action, In re CytRx Corporation Securities Litigation, 2:14-CV-01956-GHK (PJWx).&#160; On December 29, 2015, as a result of the parties informing the Court that the settlement of the Federal Class Action also resolved the claims and allegations in the Rajasekaran case, the Superior Court deemed the case closed.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On December&#160;10, 2015, we announced that we had reached an agreement to settle the federal consolidated securities class action and filed a Stipulation of Settlement with the Court. A hearing on plaintiffs' motion for preliminary approval of the settlement was held on January&#160;11, 2016. The agreement contains no admission of liability or wrongdoing and includes a full release of CytRx and the current and former directors and officers in connection with the allegations. The settlement is subject to definitive documentation, shareholder notice, and Court approval. The terms of the agreement provide for a settlement payment to the class of $4,000,000, of which at least $3,500,000 will be paid by our insurance carriers. We will also issue the equivalent number of shares of our common stock to the class of $4,500,000 at the prevailing stock price at the time of the Court's final approval of the settlement agreement, but not less than a minimum of 1,200,000 shares and not more than a maximum of 1,800,000 shares.&#160; On January 9, 2016, the Court preliminarily approved the settlement, and set a settlement fairness hearing for final approval of the settlement for May 9, 2016.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-26-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage27"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On July&#160;3, 2014, a shareholder derivative lawsuit was filed in the United States District Court for the Central District of California, captioned Fishman v. Kriegsman, et al., 2:14-cv-05169, purportedly on our behalf against certain of our officers and each of our directors. The complaint alleges breach of fiduciary duties, corporate waste, gross mismanagement, and unjust enrichment in connection with our alleged retention of DreamTeamGroup and MissionIR. The complaint seeks damages, restitution, corporate governance reforms, and attorney's fees and costs. On September&#160;3, 2014, plaintiff filed a notice to voluntarily dismiss this action against all parties without prejudice, which the Court granted on September&#160;9, 2014.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	On September&#160;10, 2014, the Delaware Court of Chancery consolidated Schwartz v. Ignarro, et al., Case No.&#160;9864, Johnson v. Ignarro, et al., Case No.&#160;9884, and Silverberg v. Kriegsman, et al., Case No.&#160;9919, three shareholder derivative lawsuits described in our Quarterly Report filed with the SEC on August&#160;6, 2014. The allegations in the Schwartz and Johnson complaints relate to our December&#160;9, 2013 grant of stock options to certain board members and officers. The allegations in the Silverberg complaint relate to our December&#160;9, 2013 grant of stock options to certain board members and officers, as well as our alleged retention of DreamTeamGroup and MissionIR. A consolidated complaint concentrated on the stock-option grant claims was filed on October&#160;9, 2014. The consolidated lawsuit is captioned In re CytRx Corp. Stockholder Derivative Litigation, C.A. No.&#160;9864-VCL. On November&#160;10, 2014, we and the individual defendants filed a motion to dismiss the consolidated complaint or, in the alternative, to stay the action. The Court heard argument on the motions on January&#160;8, 2015. The Court denied the motion to dismiss and granted in part and denied in part the motion to stay the Delaware case pending the Federal Class Action. On June&#160;2, 2015, we announced that we had reached an agreement to settle the Delaware stockholder derivative action. Under the settlement, we agreed to re-price outstanding stock options to purchase a total of 2,095,000 shares of our common stock that were granted on December&#160;10, 2013 to certain of our directors and officers from the original exercise price of $2.39 to an exercise price of $4.66 (the share price at market closing on December&#160;20, 2013). The settlement also provides that we will implement certain corporate governance changes and modify our governance practices regarding the granting of stock options. The parties reached an agreement on an award of $1.1 million of fees and expenses to plaintiffs' attorneys. On November&#160;20, 2015, the Delaware Court approved the settlement and award of attorneys' fees and expenses, and entered a final order and judgment. This amount was paid by our insurance carriers in December, 2015.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On August&#160;14, 2014, a shareholder derivative lawsuit, captioned Pankratz v. Kriegsman, et al., 2:14-cv-06414-PA-JPR, was filed in the United States District Court for the Central District of California purportedly on our behalf against certain of our officers and each of our directors. On August 15, 2014, a virtually identical complaint was filed, captioned Taylor v. Kriegsman, et al., 2:14-cv-06451.&#160; Each complaint alleges breach of fiduciary duties, unjust enrichment, gross mismanagement, abuse of control, insider selling and misappropriation of information in connection with our alleged retention of DreamTeamGroup and MissionIR, as well as our December&#160;9, 2013 grant of stock options to certain board members and officers. The complaint seeks unspecified damages, corporate governance and internal procedures reforms, restitution, disgorgement of all profits, benefits, and other compensation obtained by the individual defendants, and the costs and disbursements of the action. On October&#160;8, 2014, the Court in Pankratz and Taylor consolidated the cases and appointed lead plaintiffs and co-lead counsel. On October&#160;20, 2014, we and the individual defendants filed motions to dismiss the consolidated Pankratz and Taylor cases or, in the alternative, to stay the cases. On January&#160;9, 2015, the Court stayed the action pending the resolution of the consolidated Delaware derivative action. On February&#160;27, 2015, the Pankratz and Taylor plaintiffs filed a motion to vacate the stay. On June&#160;24, 2015, the Court granted the motion to lift the stay in light of the pending settlement of the Delaware derivative litigation discussed above. The Court further denied the motion to dismiss without prejudice and invited us to move to dismiss the case within 30 days pursuant to the doctrine of
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	forum non conveniens
</FONT>
	based on our forum-selection bylaw, which mandates that derivative actions be filed in Delaware. The Court advised that it would consider any
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	forum non conveniens
</FONT>
	motion before considering a subsequent motion to dismiss under Rule 12. On November&#160;2, 2015, the Court granted the defendants' motion on grounds of
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	forum non conveniens,
</FONT>
	and the case was dismissed without prejudice to plaintiffs refiling the action in the Delaware Court of Chancery. Plaintiffs then filed an appeal with the Ninth Circuit Court of Appeals. On January&#160;5, 2016, we announced that we reached an agreement to settle the consolidated stockholder derivative lawsuits,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In Re CytRx Corporation Stockholder Derivative Litigation
</FONT>
	, pending in the U.S. Court of Appeals for the Ninth Circuit Court, on appeal from the United States District Court for the Central District of California. The settlement includes no financial or equity compensation. It provides that we will implement certain corporate governance changes and modify certain governance practices. The settlement agreement contains no admission of liability or wrongdoing and includes a full release of the current and former directors and officers in connection with the allegations. The settlement is subject to the drafting of definitive documentation, notice to stockholders, and District Court approval.&#160; Plaintiffs' counsel is expected to petition the District Court for an award of attorneys' fees and costs.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On December&#160;14, 2015, a shareholder derivative complaint, captioned
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermeyer et al. v. Kriegsman et al.
</FONT>
	, C.A. No.&#160;11800, was filed in the Delaware Court of Chancery purportedly on the Company's behalf against certain of its officers and directors. The complaint alleges breach of fiduciary duty, unjust enrichment, and gross mismanagement in connection with the Company's alleged retention of DreamTeamGroup and MissionIR, as well as its December 2013 grant of stock options to certain board members and officers. The complaint seeks unspecified damages, corporate governance and internal procedures reforms, restitution, disgorgement of all profits, benefits, and other compensation obtained by the individual defendants, and the costs and disbursements of the action. On February 26, 2016, the Company and the defendants filed two motions with the Court of Chancery.&#160; First, we moved to dismiss because the
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermayer
</FONT>
	complaint fails to state a claim upon which relief can be granted and because the allegations and claims in the
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermayer
</FONT>
	complaint are effectively resolved by the settlement of the consolidated stockholder derivative lawsuits,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In Re CytRx Corporation Stockholder Derivative Litigation
</FONT>
	, pending in the United States District Court for the Central District of California, and the settlement of the derivative lawsuits already approved by the Delaware Court of Chancery,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In re CytRx Corp. Stockholder Derivative Litigation, C.A. No.&#160;9864-VCL
</FONT>
	.&#160; Second, we moved to stay the
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermayer
</FONT>
	case until the Central District of California completes the approval process for the settlement of the consolidated derivative actions pending in that court,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In Re CytRx Corporation Stockholder Derivative Litigation
</FONT>
</DIV>
</EFX_LEGAL_PROCEEDINGS>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 4. MINE SAFETY DISCLOSURES
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Not Applicable.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-27-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage28"></A>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	PART II
</DIV>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 5.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</FONT>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Market Information
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our common stock is traded on The NASDAQ Capital Market under the symbol "CYTR." The following table sets forth the high and low sale prices for our common stock for the periods indicated as reported by The NASDAQ Capital Market:
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="A594822334BC4809B0DF74DDD895085E" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	High
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 12PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 18PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Low
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	Fiscal Year 2015:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 12PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="WIDTH: 18PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Fourth Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.41
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.32
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Third Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.20
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.98
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Second Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.42
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.30
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	First Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.88
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.51
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	Fiscal Year 2014:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Fourth Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.20
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.08
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Third Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.25
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.54
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Second Quarter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.46
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.78
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	First Quarter
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.35
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.15
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Holders
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On March 11, 2016,&#160;there were approximately 670 holders of record of our common stock. The number of record holders does not reflect the number of beneficial owners of our common stock for whom shares are held by brokerage firms and other nominees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Dividends
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have not paid any cash dividends since our inception and do not contemplate paying any cash dividends in the foreseeable future.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Equity Compensation Plans
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table sets forth certain information as of December 31, 2015, regarding securities authorized for issuance under our equity compensation plans:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="EBAE8934BFBC4AC6917BA52B7199788F" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Plan Category
</FONT>
<FONT STYLE="FONT-SIZE: 5.04PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(a)
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of Securities
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	to be Issued Upon
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Outstanding Options,
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Warrants and Rights
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(b)
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted-Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Outstanding Options,
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Warrants and Rights
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of Securities
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Remaining Available
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	for Issuance Under
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Equity
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Plans (Excluding
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Securities Reflected
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	in Column (a))
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equity compensation plans approved by our security holders:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	2000 Long-Term Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	593,615
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.15
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	2008 Stock Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,580,251
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.91
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,419,749
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equity compensation plans not approved by our security holders:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 17.45PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding warrants (1)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,225,472
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	21,399,338
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.49
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,419,749
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	____________
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="22A50764C53F4CBE8097FD880344A2A5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	The warrants shown were issued in discrete transactions from time to time as compensation for services rendered by consultants, advisors or other third parties, and do not include warrants sold in capital-raising transactions. The material terms of such warrants were determined based upon arm's-length negotiations with the service providers. The warrant exercise prices approximate the market price of our common stock at or about the date of grant, and the warrant terms range from two to ten years from the grant date. The warrants contain customary anti-dilution adjustments in the event of a stock split, reverse stock split, reclassification or combination of our outstanding common stock and similar events and certain of the warrants contain anti-dilution adjustments triggered by other corporate events, such as dividends. On August 1, 2016, 6,371,899 warrants priced at $4.48 expire.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-28-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage29"></A>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Comparison of Cumulative Total Returns
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following line graph presentation compares cumulative total stockholder returns of CytRx with The NASDAQ Stock Market Index and The NASDAQ Pharmaceutical Index (the "Peer Index") for the five-year period from December 31, 2011 to December 31, 2015. The graph and table assume that $100 was invested in each of our common stock, The NASDAQ Stock Market Index and the Peer Index on December 31, 2010, and that all dividends were reinvested. This data was furnished by Zacks Investment Research.
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Comparison of Cumulative Total Returns
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<DIV STYLE="TEXT-ALIGN: CENTER">
<IMG STYLE="WIDTH: 780PX; HEIGHT: 466PX" SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/11/0000799698-16-000030_IMAGE0.JPG">
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4006AEBECEF140D68FC5E6CC15103484" CELLSPACING="0" CELLPADDING="0">
<TR STYLE="HEIGHT: 17PX">
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 56.95%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; WIDTH: 43.05%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; FONT-WEIGHT: BOLD" COLSPAN="5">
<DIV STYLE="TEXT-ALIGN: CENTER">
	December 31,
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 56.95%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 10.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<U>
	2011
</U>
</DIV>
</TD>
<TD STYLE="WIDTH: 8.5%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<U>
	2012
</U>
</DIV>
</TD>
<TD STYLE="WIDTH: 8.8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<U>
	2013
</U>
</DIV>
</TD>
<TD STYLE="WIDTH: 8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<U>
	2014
</U>
</DIV>
</TD>
<TD STYLE="WIDTH: 7.36%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<U>
	2015
</U>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.95%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CytRx Corporation
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27.72
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 8.5%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	26.45
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 8.8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	88.68
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	38.76
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 7.36%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	37.48
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.95%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	The NASDAQ Stock Market Index
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	99.17
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 8.5%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	116.48
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 8.8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	163.21
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	187.27
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 7.36%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200.31
</DIV>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.95%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	The NASDAQ Pharmaceutical Index
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.4%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	107.04
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 8.5%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	142.41
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 8.8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	234.79
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 8%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	306.46
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 7.36%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	324.29
</DIV>
</TD>
</TR>
</TABLE>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Recent Issuances of Unregistered Securities
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	None.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Repurchase of Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We did not repurchase any of our shares during
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	the year ended December 31, 2015
</FONT>
	.
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-29-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage30"></A>
</DIV>
</EFX_MARKET>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 6. SELECTED FINANCIAL DATA
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	General
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following selected financial data are derived from our audited financial statements. Our financial statements for these past five years have been audited by BDO USA, LLP, our independent registered public accounting firm. These historical results do not necessarily indicate future results. When you read this data, it is important that you also read our financial statements and related notes, as well as the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of this Annual Report. Financial information provided below has been rounded to the nearest thousand (except for per share data).
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="62156DD53BDF49B999C963CDA3075D1F" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2012
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2011
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Statement of Operations Data:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Revenue
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Licensing revenue
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	250,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total revenue
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	250,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net loss applicable to common stockholders
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(58,587,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(30,118,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,485,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(17,964,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(14,425,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Basic and diluted loss per share applicable to common stock
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.97
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.55
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.78
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.80
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Balance Sheet Data:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash, cash equivalents and short-term investments
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	57,297,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	77,840,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	38,568,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	38,344,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	36,046,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total assets
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,024,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,693,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	41,500,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	40,232,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	37,854,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total stockholders' equity
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	44,079,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,911,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,661,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	30,166,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	24,254,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Factors Affecting Comparability
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	In July, 2015, we completed a $28.7 million underwritten public offering, in which we sold and issued approximately10.5 million shares of common stock at a price of $2.75 per share. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received proceeds of approximately $26.8 million.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In February 2014, we completed an $86.0 million underwritten public offering, in which we sold and issued 13.2 million
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	shares of common stock at a price of $6.50 per share. Net of underwriting discounts, legal, accounting and other offering expenses, we received proceeds of approximately $80.5 million
</FONT>
	.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In October 2013, we completed a $25.9 million underwritten public offering, in which we sold and issued 11.5 million
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	shares of common stock at a price of $2.25 per share. Net of underwriting discounts, legal, accounting and other offering expenses, we received proceeds of approximately $24.1 million
</FONT>
	.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In October 2012, we completed a $23.0 million underwritten public offering, in which we sold and issued 9.2 million
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	shares of common stock at a price of $2.50 per share. Net of underwriting discounts, legal, accounting and other offering expenses, we received proceeds of approximately $21.5
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	million
</FONT>
	.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In August 2011, we completed a $20.4 million underwritten public offering in which we sold and issued 5.6 million shares of common stock at a price of $3.57 per share and warrants at a price of $0.07 per warrant to purchase up to approximately 6.4&#160;million shares of common stock at an exercise price of $4.48 per share. Net of underwriting discounts, legal, accounting and other offering expenses, we received proceeds of approximately $18.9&#160;million
</FONT>
	(without giving effect to any proceeds that we may receive upon future exercises of the warrants sold in the offering)
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-30-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage31"></A>
</DIV>
</EFX_FINANCIAL_DATA>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 7.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following discussion and analysis of our financial condition and results of operations should be read together with the discussion under "Selected Financial Data" and our financial statements included in this Annual Report. This discussion contains forward-looking statements, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under the caption "Risk Factors" and elsewhere in this Annual Report.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Overview
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We have reported positive top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates, hazard ratios and overall survival) from our completed, global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable STS. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3&#189; to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	In the first quarter of 2014, we initiated a pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with STS whose tumors have progressed following treatment with chemotherapy, and we have received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. The Phase 3 trial is being conducted under a Special Protocol Assessment, or SPA, granted by the U.S. Food and Drug Administration, or FDA. The SPA means that the FDA agrees that the design and analyses proposed in the Phase 3 trial protocol are acceptable to support regulatory approval of the product candidate with respect to effectiveness of the indication studied, and will not subsequently change its perspective on these matters, unless previously unrecognized public or animal health concerns were to arise or we were to subsequently modify the protocol.&#160;Thus, if the study demonstrates an acceptable benefit-risk profile as determined by the FDA, it would suffice as the single pivotal trial to demonstrate effectiveness and would support registration of aldoxorubicin for this indication. The clinical trial has completed its target enrollment of 400 patients at approximately 79 clinical sites in the U.S., Europe, Canada, Latin America and Australia. CytRx expects to report the top-line results on progression-free survival, the trial's primary endpoint, in the first half of 2016.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are currently evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. We have completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for STS, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In addition to aldoxorubicin, CytRx is currently completing pre-clinical development for DK049, a novel anti-cancer drug conjugate that utilizes the Company's Linker Activated Drug Release (LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	) technology.&#160; DK049 was created at our laboratory facility in Freiburg, Germany, and employs a proprietary linker that is both pH sensitive and requires a specific enzyme for the release of the cytotoxic payload.&#160; DK049 has demonstrated significant anti-tumor activity in multiple animal models implanted with human tumors, including non-small cell lung, ovarian and pancreatic cancers.&#160; CytRx anticipates filing an Investigational New Drug Application (IND) in the second half of 2016 prior to initiating a Phase 1 clinical trial.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We plan to expand our pipeline of oncology candidates through our drug development activities at our laboratory facility in Freiburg, Germany, based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater drug concentration at tumor sites.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In order to fund our business and operations, we have relied primarily upon sales of our equity securities, including proceeds from the exercise of stock options and common stock purchase warrants and we recently secured long-term financing. We also have received limited funding from our strategic partners and licensees.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-31-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage32"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, we had cash and cash equivalents of approximately $22.3 million and short-term investments of $35.0 million. On February 6, 2016, we announced the signing of a long-term loan agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40.0 million in financing, of which we received $25.0 million. Management believes that
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our current resources will be sufficient to fund our operations for the foreseeable future.
</FONT>
	The belief is based, in part, upon our currently projected expenditures for 2015 of approximately $58.9 million, which includes approximately $34.3 million for our clinical programs for aldoxorubicin, approximately $5.4 million for pre-clinical development of new albumin-binding cancer drugs, including DK049; approximately $4.2 million for general operation of our clinical programs and approximately $15.0 million for other general and administrative expenses, including pre-commercialization expenses. These projected expenditures are based upon numerous assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. We will ultimately be required to obtain additional funding in order to execute
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	long-term business plans, although we do not currently have commitments from any third parties to provide us with capital. We cannot assure that additional funding will be available on favorable terms, or at all. If we fail to obtain additional funding when needed, we may not be able to execute
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	business plans and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	business may suffer, which would have a material adverse effect on
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	financial position, results of operations and cash flows.
</DIV>
<FONT STYLE="FONT-WEIGHT: BOLD">
	Research and Development
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Expenditures for research and development activities related to continuing operations were $43.4 million, $36.7 million and $17.5 million, respectively, for the years ended December 31, 2015, 2014 and 2013, or approximately 68%, 74% and 63%, respectively, of our total expenses.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Research and development expenses are further discussed below under "Critical Accounting Policies and Estimates" and "Results of Operations."
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Our currently projected expenditures for 2016 include approximately $34.3 million for our clinical programs for aldoxorubicin, approximately $5.4 million for pre-clinical development of new albumin-binding cancer drugs, including DK049, and approximately $4.2 million for general operation of our clinical programs. The actual cost of our clinical programs could differ significantly from our current projections due to any additional requirements or delays imposed by the FDA in connection with our planned trials, or if actual costs are higher than current management estimates for other reasons, including complications with manufacturing. In the event that actual costs of our clinical programs, or any of our other ongoing research activities, are significantly higher than our current estimates, we may be required to significantly modify our planned level of operations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
	All of our product candidates in development must be approved by the FDA or corresponding foreign governmental agencies before they can be marketed. The process for obtaining FDA and foreign government approvals is both time-consuming and costly, with no certainty of a successful outcome. A discussion of these and other risks and uncertainties associated with our business is set forth in the "Risk Factors" section of this Annual Report.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Critical Accounting Policies and Estimates
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to stock options, impairment of long-lived assets, including accrued liabilities and certain expenses. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our significant accounting policies are summarized in Note 2 of the Notes to Financial Statements included in this Annual Report. We believe the following critical accounting policies are affected by our more significant judgments and estimates used in the preparation of our financial statements:
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-32-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage33"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Revenue Recognition
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Revenue consists of license fees from strategic alliances with pharmaceutical companies, as well as service and grant revenues. Service revenue
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	consists of contract research and laboratory consulting. Grant revenues
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	consist of government and private grants.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Monies received for license fees are deferred and recognized ratably over the performance period in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") ASC 605-25,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Revenue Recognition &#8211; Multiple-element Arrangements
</FONT>
	("ASC 605-25"). Milestone payments will be recognized upon achievement of the milestone as long as the milestone is deemed substantive and we have no other performance obligations related to the milestone and collectability is reasonably assured, which is generally upon receipt, or recognized upon termination of the agreement and all related obligations. Deferred revenue represents amounts received prior to revenue recognition.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Revenues from contract research, government grants, and consulting fees are recognized over the respective contract periods as the services are performed, provided there is persuasive evidence of an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Once all conditions of the grant are met and no contingencies remain outstanding, the revenue is recognized as grant fee revenue and an earned but unbilled revenue receivable is recorded.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Research and Development Expenses
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Research and development expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in our product candidates is expensed as incurred until technological feasibility has been established.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Clinical Trial Expenses
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Clinical trial expenses, which are included in research and development expenses, include obligations resulting from our contracts with various CROs in connection with conducting clinical trials of our product candidates. We recognize expenses for these activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. We believe that this method is the best measure of the efforts expended on a clinical trial with the expenses we record. We adjust our rate of clinical expense recognition if actual results differ from our estimates. If our estimates prove to be incorrect, clinical trial expenses recorded in any particular period could vary.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stock-based Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our stock-based employee compensation plans are described in Note 13 of the Notes to Financial Statements. We follow the provisions of ASC 718,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Compensation - Stock Compensation
</FONT>
	("ASC 718"), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Equity-Based Payments to Non-Employees
</FONT>
	("ASC 505-50").
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Net Income (Loss) Per Share
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding. Diluted net income (loss) per common share is computed using the weighted-average number of common shares and common share equivalents outstanding. Potentially dilutive stock options and warrants to purchase approximately 21.4 million, 17.4 million and 14.7 million shares at December 31, 2015, 2014 and 2013, respectively, were excluded from the computation of diluted net income (loss) per share, because the effect would be anti-dilutive.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-33-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage34"></A>
</DIV>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Liquidity and Capital Resources
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	General
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In order to fund our business and operations, we have relied primarily upon sales of our equity securities, including proceeds from the exercise of stock options and common stock purchase warrants and we recently secured long-term loan financing. We also have received limited funding from our strategic partners and licensees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, we had cash and cash equivalents of approximately $22.3 million and short-term investments of $35.0 million. Management believes that
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our current resources will be sufficient to fund our operations for the foreseeable future.
</FONT>
	On February 6, 2016, we announced the signing of a long-term loan agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40.0 million in financing, of which we received $25.0 million. Management believes that
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our current resources will be sufficient to fund our operations for the foreseeable future.
</FONT>
	The belief is based, in part, upon our currently projected expenditures for 2016 of approximately $58.9 million
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	,
</FONT>
	which
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	includes approximately $34.3 million for our clinical programs for aldoxorubicin, approximately $5.4 million for pre-clinical development of new albumin-binding cancer drugs, including DK049, approximately $4.2 million for general operation of our clinical programs and approximately $15.0 million for other general and administrative expenses, including pre-commercialization expenses. These projected expenditures are based upon numerous assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. We will ultimately be required to obtain additional funding in order to execute
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	long-term business plans, although we do not currently have commitments from any third parties to provide us with long term debt or capital. We cannot assure that additional funding will be available on favorable terms, or at all. If we fail to obtain additional funding when needed, we may not be able to execute
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	business plans and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	business may suffer, which would have a material adverse effect on
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	our
</FONT>
	financial position, results of operations and cash flows.
</DIV>
	If we obtain marketing approval and successfully commercialize aldoxorubicin or other product candidate, we anticipate it will take two
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	years, and possibly longer, for us to generate significant recurring revenue, and we will be dependent on future financing until such time, if ever, as we can generate significant recurring revenue. We have no commitments from third parties to provide us with any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. Failure to obtain adequate financing would adversely affect our ability to operate as a going concern. If we raise additional funds by issuing equity securities, dilution to stockholders may result and new investors could have rights superior to holders of the shares issued in this offering. In addition, debt financing, if available, may include restrictive covenants. If adequate funds are not available to us, we may have to liquidate some or all of our assets or to delay or reduce the scope of or eliminate some portion or all of our development programs or clinical trials. We also may have to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourselves.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Discussion of Operating, Investing and Financing Activities
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Net loss for the year ended December 31, 2015 was $58.6 million, and cash used for operating activities for that period was $47.6 million. The net loss for the year reflects $7.4 million for stock option and warrant expense, and non-cash gain of $4.4 million on the fair value adjustment of the warrant liability.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Net loss for the year ended December 31, 2014 was $30.1 million, and cash used for operating activities for that period was $40.6 million. The net loss for the year reflects $6.6 million for stock option and warrant expense, and non-cash gain of $19.1 million on the fair value adjustment of the warrant liability.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Net loss for the year ended December 31, 2013 was $47.5 million, and cash used for operating activities for that period was $23.8 million. The net loss for the year reflects $4.0 million for stock option and warrant expense, and a non-cash loss of $20.2 million on the fair value adjustment of the warrant liability.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For the year ended December 31, 2015, $10.3 million was provided by investing activities. This included $10.6 million net proceeds from the sale of short-term investments and the difference for purchase of equipment and furnishings, primarily for our laboratory in Freiburg, Germany.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For the year ended December 31, 2014, $19.5 million was used for investing activities. This included $18.5 million net for the purchase of short-term investments.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-34-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage35"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For the year ended December 31, 2013, $3.1 million was used for investing activities. This included $3.1 million net for the purchase of short-term investments.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Cash provided by financing activities for the year ended December 31, 2015 was $27.4 million, which included $26.8 million of net proceeds received from our July 2015 public offering.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Cash provided by financing activities for the year ended December 31, 2014 was $80.8 million, which included $80.5 million of net proceeds received from our February 2014 public offering.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Cash provided by financing activities for the year ended December 31, 2013 was $24.0 million, which was attributable to the net proceeds received from our October 2013 public offering.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Off-Balance Sheet Arrangements
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Contractual Obligations
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We acquire assets still in development and enter into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development life-cycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). We also typically have to make royalty payments based upon a percentage of the sales of the pharmaceutical product in the event that regulatory approval for marketing is obtained. Because of the contingent nature of these payments, they are not included in the table of contractual obligations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	These arrangements may be material individually, and in the event that multiple milestones are reached in the same period, the aggregate charge to expense could be material to the results of operations in any one period. In addition, these arrangements often give us the discretion to unilaterally terminate development of the product, which would allow us to avoid making the contingent payments; however, we are unlikely to cease development if the compound successfully achieves clinical testing objectives.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our current contractual obligations that will require future cash payments are as follows (in thousands):
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5D4CAE9EE1464C9DB6B91EF1E8D54122" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="18">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Payments due by periods as of December 31, 2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	Contractual Obligations
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year 1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years 2 and 3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years 4 and 5
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years 6 and beyond
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Operating lease obligations
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,401
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	318
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	746
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	337
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;Employment obligations
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,761
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,647
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,114
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;R&amp;D contract obligations
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	36,689
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,940
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,738
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;&#160;Total contractual obligations
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	43,851
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	31,905
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11,598
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	348
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
	&#160;
</DIV>
<DIV>
<TABLE STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE" ID="19B541399EE9435F84612CAE7130F87A" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 2.2%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 97.8%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Operating leases are primarily our facility lease obligations, as well as equipment and software lease obligations with third party vendors.
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 2.2%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 97.8%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 2.2%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 97.8%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employment agreements include management contracts that provide for minimum salary levels, adjusted periodically at the discretion of our Compensation Committee, as well as minimum bonuses and employee benefits, in some cases.
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 2.2%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 97.8%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 2.2%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(3)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: MEDIUM NONE; BORDER-LEFT: MEDIUM NONE; WIDTH: 97.8%; VERTICAL-ALIGN: TOP; BORDER-TOP: MEDIUM NONE; BORDER-RIGHT: MEDIUM NONE">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Research and development obligations relate primarily to our clinical trials. All of these obligations are cancelable upon notice without liability to us.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	We apply the disclosure provisions of ASC 460,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Guarantees
</FONT>
	("ASC 460"), to our contractual guarantees and indemnities. We have provided contractual indemnities to other parties against possible losses suffered or incurred by the indemnified parties in connection with various types of third-party claims, as well as indemnities to our officers and directors against third party claims arising from the services they provide to us. To date, we have not incurred material costs as a result of these indemnities, and we do not expect to incur material costs in the future; further, we maintain insurance to cover certain losses arising from these indemnities. Accordingly, we have not accrued any liabilities related to these indemnities.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-35-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage36"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Net Operating Loss Carryforwards
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, we had federal and state net operating loss carryforwards of $281.6 million and $173.7 million, respectively, available to offset against future taxable income, which expire in 2016 through 2035.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As a result of a change in-control that occurred in the CytRx shareholder base, approximately $62.3 million in federal net operating loss carryforwards became substantially limited in their annual availability. We currently believe that the remaining $219.3 million in federal net operating loss carryforwards, and the $173.7 million in state net operating loss carryforwards, are unrestricted.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As of December 31, 2015, we also had research and development and alternative minimum tax credits for federal and state purposes of approximately $14.8 million and $19.5 million, respectively, available for offset against future income taxes, which expire in 2022 through 2035. Based on an assessment of all available evidence including, but not limited to, our limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, we have concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred tax valuation allowance has been recorded against these assets.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Results of Operations
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We incurred a net loss of $58.6 million, $30.1 million and $47.5 million for the years ended December 31, 2015, 2014 and 2013, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	During 2015, 2014 and 2013, we recognized no service revenue and earned an immaterial amount of license fees and grant revenue. All future licensing fees under our current licensing agreements are dependent upon successful development milestones being achieved by our licensees. During 2016, we are not anticipating any significant service or license fees revenue.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our net loss may increase from current levels primarily due to expenses related to our ongoing and planned clinical trials, research and development programs, possible technology acquisitions, and other general corporate activities, including pre-commercialization. We anticipate, therefore, that our operating results will fluctuate for the foreseeable future and period-to-period comparisons should not be relied upon as predictive of the results in future periods.
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Research and Development
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3428BEF30A774AB78827BE70DB566D15" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years Ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(In thousands)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Research and development expenses
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	41,805
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	34,203
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17,072
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Non-cash research and development expenses
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,543
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	186
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee stock and stock option expense
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,591
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	932
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	242
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Total
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	43,396
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	36,678
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Research expenses are expenses incurred by us in the discovery of new information that will assist us in the creation and the development of new drugs or treatments. Development expenses are expenses incurred by us in our efforts to commercialize the findings generated through our research efforts.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Research and development expenses incurred during 2015, 2014 and 2013 relate to our various development programs. In 2015, our research and development expenses increased over 2014 due to a full year of costs for our pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for STS and our global Phase 2b clinical trial in small cell lung cancer. These expenses included approximately $37.0 million for our clinical programs for aldoxorubicin, approximately $1.7 million at our Drug Discovery laboratory, and approximately $3.6 million for general operation of our clinical programs. In 2014, our research and development expenses increased over 2013 as we initiated our pivotal, global Phase 3 clinical trial and completed our global Phase 2b clinical trial with aldoxorubicin as a first-line treatment for STS. In 2014, we also continued our Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer), and initiated a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. In 2014, our development costs included approximately $29.9 million for our clinical programs for aldoxorubicin, approximately $1.0 million for pre-clinical development of new albumin-binding cancer drugs and approximately $3.3 million for general operation of our clinical programs. None of our research and development costs have ever been capitalized.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-36-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage37"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As compensation to consultants, or in connection with the acquisition of technology, we sometimes issue shares of common stock, stock options and warrants to purchase shares of common stock. For financial statement purposes, we value these shares of common stock, stock options, and warrants at the fair value of the common stock, stock options or warrants granted, or the services received, whichever is more reliably measurable. In 2015, we recorded $0 of non-cash expense, as compared to $1.5 million in 2014 and $0.2 million in 2013. In 2014, we issued 200,000 common shares to the licensor of aldoxorubicin in connection with the establishment of the Company's Freiburg, Germany research and development laboratory. The fair value of the shares was $0.8 million; in addition we issued restricted stock to Dr. Dan Levitt, the Company's Chief Medical Officer with a fair value of $626,900.&#160; In 2015, we recorded $1.6 million of employee stock and stock option expense, as compared to $0.9 million in 2014 and $0.2 million in 2013.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In 2016, we expect our research and development expenses to increase as our Drug Discovery laboratory in Freiburg, Germany will be expanding its facilities and increasing the number of employees, following onto the successful development of DK049. Our pivotal Phase 3 global trial of aldoxorubicin and global Phase 2b clinical trial in small cell lung cancer continue to be a key part of these expenses.
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	General and Administrative
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E9675863F53F40B2B80D9401F45ACFB4" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year Ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(In thousands)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General and administrative expenses
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,871
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,724
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,717
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Stock, stock option and warrant expenses to non-employees and consultants
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	226
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,737
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	858
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Employee stock option expense
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,568
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,384
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,699
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Total
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19,665
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12,845
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,274
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	General and administrative expenses include all administrative salaries and general corporate expenses, including legal expenses associated with the prosecution of our intellectual property. Our general and administrative expenses, excluding common stock, stock options and warrants issued, were $13.9 million, $8.7 million and $6.7 million in 2015, 2014 and 2013, respectively. In 2015, the general and administrative expenses increased by 59.0 % or approximately $5.1 million over 2014, as the litigation settlement expense was $5.5 million (of which a non-cash amount of $4.5 million will be settled through the issuance of our common shares) and insurance premiums increased by $0.3 million, offset by a decrease in professional fees of $0.5 million, a decrease in payroll of $0.1 million and other small decreases. In 2014, these expenses increased by approximately $2.0 million over 2013 due to an increase in legal fees of $1.5 million associated with legal proceedings instituted against us, as well as an increase in payroll of approximately $0.3 million and an increase in insurance premiums of approximately $0.2 million.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	From time to time, we issue shares of our common stock or warrants or options to purchase shares of our common stock to consultants and other service providers in exchange for services. For financial statement purposes, we value these shares of common stock, stock options, and warrants at the fair value of the common stock, stock options or warrants granted, or the services received whichever we can measure more reliably. In 2015, we recorded $0.2 million of such expenses, as compared to $1.7 million and $0.9 million in 2014 and 2013, respectively. We recorded employee stock option expense of $5.6 million, $2.4 million and $2.7 million in 2015, 2014 and 2013, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Depreciation and Amortization
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Depreciation and amortization expenses for the years ended December 31, 2015, 2014 and 2013 were approximately $0.3 million, $0.2 million and $0.1 million, respectively. The depreciation expense reflects the depreciation of our equipment and furnishings.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Other Income
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In 2015, 2014 and 2013, we recognized non-cash gains (losses) of $4.4 million, $19.1 million and $(20.2) million, respectively, on the revaluation of our warrant derivative liabilities related to warrants issued in August 2011 and July 2009.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-37-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage38"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Interest Income
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Interest income was $0.2 million in 2015, $0.3 million in 2014 and $0.1 million in 2013. The variances between years are attributable primarily to the amount of funds available for investment each year and, to a lesser extent, changes in prevailing market interest rates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Recent Accounting Pronouncements
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In February 2016, the FASB issued ASU No. 2016-02, "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Leases (Topic 842)
</FONT>
	," which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. &#160;The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted.&#160;We are currently evaluating the impact that the adoption of this ASU will have on our financial statements.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In January 2016, the FASB issued ASU No. 2016-01 "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.
</FONT>
	" ASU 2016-01 amends various aspects of the recognition, measurement, presentation, and disclosure for financial instruments. With respect to our financial statements, the most significant impact relates to the accounting for equity investments. It will impact the disclosure and presentation of financial assets and liabilities. ASU 2016-01 is effective for annual reporting periods, and interim periods within those years beginning after December 15, 2017. Early adoption by public entities is permitted only for certain provisions. We are currently in the process of evaluating the impact of the adoption of this standard on our financial statements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In April 2015, the FASB issued ASU No. 2015-03,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"Simplifying the Presentation of Debt Issuance Costs"
</FONT>
	("ASU 2015-03"), which requires that debt issuance costs be reported in the balance sheet as a direction deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Further, ASU 2015-03 requires the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 must be applied retrospectively. Entities may choose to adopt the new requirements as of an earlier date for financial statements that have not been previously issued. We expect ASU 2015-03 to impact on our financial statements for periods subsequent to our long-term loan financing in February 2016.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In May 2014, the FASB issued ASU No. 2014-09, "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Revenue from Contracts with Customers
</FONT>
	" ("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in United States ("U.S. GAAP"). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In August 2015, the FASB issued ASU No. 2015-14, "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Revenue from Contracts with Customers
</FONT>
	" ("ASU 2015-14") which deferred the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date.&#160;Early adoption is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	When effective, ASU 2014-09 will use either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).&#160;We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In August 2014, the FASB issued ASU No. 2014-15, "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Presentation of Financial Statements &#8211; Going Concern (Subtopic 205-40)
</FONT>
	". The new guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our financial statements.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-38-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage39"></A>
</DIV>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 7A.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Historically, our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. Due to the short-term nature of our investments, we believe that we are not exposed to any material market risk. We do not have any speculative or hedging derivative financial instruments or foreign currency instruments. If interest rates had varied by 10% in the year ended December 31, 2015, it would not have had a material effect on our results of operations or cash flows for that period.
</DIV>
</EFX_MARKET_RISK>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 8.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our financial statements and supplemental schedule and notes thereto as of December 31, 2015 and 2014, and for each of the three years in the period ended December 31, 2015, together with the reports thereon of our independent registered public accounting firm, are set forth on pages F-1 to F- 21 of this Annual Report.
</DIV>
</EFX_FINANCIAL_STATEMENTS>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Item 9.
</FONT>
<FONT STYLE="FONT-STYLE: NORMAL">
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	None.
</DIV>
</EFX_ACCOUNTING_CHANGES>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 9A. CONTROLS AND PROCEDURES
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our management, with the participation of our principal executive officer and principal financial officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of December&#160;31, 2015, the end of the period covered by this Annual Report. Based on this evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were not effective as of December 31, 2015, as described further below.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2015 that materially affected, or are reasonably likely to have a material effect, on our internal control over financial reporting.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Management's Report on Internal Control Over Financial Reporting
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we assessed the effectiveness of our internal control over financial reporting as of December 31, 2015. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") in
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Internal Control-Integrated Framework (2013 Edition)
</FONT>
	("the Framework"). Based upon management's assessment, management identified a material weakness in our internal control over financial reporting, as described below. As a result of this material weakness, management concluded that, as of December 31, 2015, our internal control over financial reporting was not effective based on the Framework.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following control deficiency was identified and was determined to be a material weakness in our internal control over financial reporting as of December 31, 2015:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="980224A733E447B2B80437E2AF2D7B8B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50.4PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: SYMBOL, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 32.4PT; FONT-SIZE: 10PT">
	&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our internal control over a significant and unusual non-cash transaction was not designed appropriately to ensure that the related accounting conclusions were sufficiently reviewed for compliance with generally accepted accounting principles.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The material weakness resulted in an inaccurate conclusion related to the accrual and presentation of an obligation incurred in connection with the settlement of a class action lawsuit, that is payable in a variable number of shares of the Company's common stock, and for which a reasonable possibility existed that a material misstatement in our financial statements would not be prevented or detected on a timely basis. The misstatement was corrected by management prior to the issuance of our annual financial statements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;Our internal control over financial reporting as of December 31, 2015 has been audited by BDO USA, LLP, an independent registered public accounting firm, as stated in their report on the next page.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Management Remediation Plan
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	To remediate the material weakness described above, management has initiated compensating controls in the near term and are enhancing and revising the design of existing controls and procedures to properly account for significant and unusual transactions. As we continue to evaluate and work to improve our internal control over financial reporting, management may execute additional measures to address potential control deficiencies or modify the remediation plan described above and will continue to review and make necessary changes to the overall design of our internal controls.
</DIV>
</DIV>
</DIV>
<DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-39-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage40"></A>
</DIV>
</EFX_CONTROL_AND_PROCEDURES>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Board of Directors and Stockholders
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, California
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	We have audited CytRx Corporation's internal control over financial reporting as of December 31, 2015, based on criteria established in
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Internal Control &#8211; Integrated Framework (2013)
</FONT>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). CytRx Corporation's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<DIV>
	A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness regarding management's failure to design and maintain controls over the evaluation of accounting consequences of a significant, unusual transaction has been identified and described in management's assessment. This material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2015 financial statements, and this report does not affect our report dated March 11, 2016 on those financial statements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In our opinion, CytRx Corporation did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on the COSO criteria.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; COLOR: #000000; FONT-SIZE: 10PT">
	We do not express an opinion or any other form of assurance on management's statements referring to any corrective actions taken by the company after the date of management's assessment.
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; COLOR: #000000; FONT-SIZE: 10PT">
	We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the balance sheets of CytRx Corporation as of December 31, 2015 and 2014, and the related statements of operations, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2015 and our report dated March 11, 2016 expressed an unqualified opinion thereon.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	/s/ BDO USA, LLP
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, California
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	March&#160;11, 2016
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-40-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage41"></A>
</DIV>
</EFX_AUDITORS_OPINION>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 9B. OTHER INFORMATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	None.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-41-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage42"></A>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	PART III
</DIV>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 10.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table sets forth information concerning our directors and executive officers:
</DIV>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="DA736589D7244417ABBD167AC7779449" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Age
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Class of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Director(1)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Position
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	74
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	II
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director, Chairman of the Board and Chief Executive Officer
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Louis Ignarro, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	74
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	I
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director (2) (3) (4)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Joseph Rubinfeld, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	83
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	I
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Lead Director (2) (3) (4).(5)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Eric Selter
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	58
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	III
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director (2) (4)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Anita J. Chawla, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	57
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	II
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director (3) (4) (5)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cheryl Cohen
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.18%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	50
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.72%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	III
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.58%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director (2) (5)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.18%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	64
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.72%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.58%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Financial Officer
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.52%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Daniel J. Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.18%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	68
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.72%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.58%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Executive Vice President and Chief Medical Officer
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Olivia Ware
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.18%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	59
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.72%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.58%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Commercial Officer
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Wieland, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.18%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	56
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.72%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.58%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Senior Vice President-Drug Development
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Benjamin S. Levin
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.18%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	39
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.72%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 56.58%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Senior Vice President, General Counsel and Corporate Secretary
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	David J. Haen
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.18%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	37
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.72%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 56.58%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Vice President &#8211; Business Development and Investor Relations
</DIV>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="31652BA2F205495F86187E039C9FC997" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Our Class I directors serve until the 2016 annual meeting of stockholders, our Class II directors serve until the 2017 annual meeting of stockholders, and our Class III directors serves until the 2018 annual meeting of stockholders.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="47C7B7CB2CB2494088DC390CB7B8C759" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Members of our Audit Committee. Mr. Selter is Chairman of the Committee.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="A795031AE2574D3F843085265F86B5BB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Members of our Nominating and Corporate Governance Committee. Dr. Ignarro is Chairman of the Committee.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D86CFFF029A54D84A585389ACB5C52D9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Members of our Compensation Committee. Dr. Rubinfeld is Chairman of the Committee.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="B1DB2D00E9304B31B64D58D69F7CC68E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(5)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Members of our Strategy Committee. Ms. Cohen is Chairwoman of the Committee
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Steven A. Kriegsman
</FONT>
	has been CytRx's President and Chief Executive Officer and a director since July 2002. In October 2014, he was elected Chairman of the Board.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	He also serves as a director of Galena Biopharma, a listed public company, and is a member of its Compensation Committee and a member of its Strategy Committee. In June 2016, Mr. Kriegsman will retire from the Galena Biopharma board. Mr. Kriegsman previously served on the Board of Directors of Catasys, Inc. from November 2013 to August 2015. He previously served as Director and Chairman of Global Genomics from June 2000 until 2002. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. During his career, he has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies, and Maxim Pharmaceuticals. In the past five years, Mr. Kriegsman has also served on the Board of Directors of Bradley Pharmaceuticals, Inc. and Hythiam, Inc. Mr. Kriegsman has a B.S. degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors' College
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been a guest speaker and lecturer at various universities including California Institute of Technology (Caltech), Brown University, and New York University. He also was an instructor at York College in Jamaica (Queens), NY, where he taught business to a diverse group of students in York's adult education program. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the
</FONT>
	California Health Institute, the
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, the American Association of Dance Companies and the Palisades-Malibu YMCA
</FONT>
	.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr. Kriegsman's extensive history as a member of management is vital to the board of directors' collective knowledge of our day-to-day operations. Mr. Kriegsman also provides great insight as to how CytRx grew as an organization and his institutional knowledge is an invaluable asset to the board of directors in effecting its oversight of CytRx's strategic plans. Mr. Kriegsman's presence on the board of directors also allows for a flow of information and ideas between the board of directors and management.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-42-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage43"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Louis Ignarro, Ph.D.
</FONT>
	has been a director since July 2002. He previously served as a director of Global Genomics since November 20, 2000. Dr. Ignarro serves as the Jerome J. Belzer, M.D. Distinguished Professor of Pharmacology in the Department of Molecular and Medical Pharmacology at the UCLA School of Medicine. Dr. Ignarro has been at the UCLA School of Medicine since 1985 as a professor, acting chairman and assistant dean. Dr. Ignarro received the Nobel Prize for Medicine in 1998. Dr. Ignarro received a B.S. in pharmacy from Columbia University and his Ph.D. in Pharmacology from the University of Minnesota. Dr. Ignarro is a Nobel Laureate and an esteemed medical researcher whose experience enables him to offer importance scientific guidance to our Board of Directors.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Joseph Rubinfeld, Ph.D.
</FONT>
	has been a director since July 2002. He co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President and as a director since its inception until December 31, 2003. He resigned as Chairman Emeritus of SuperGen, Inc. on February 8, 2005. Dr. Rubinfeld was also Chief Scientific Officer of SuperGen from 1991 until September 1997. Dr. Rubinfeld is also a founder of JJ Pharma. Dr. Rubinfeld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director at Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company, International Division in a variety of positions. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D. in chemistry from Columbia University.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	Dr. Rubinfeld served as a senior executive of several large pharmaceutical companies before leaving to co-found SuperGen and served as Chief Executive Officer or in other senior executive capacities with highly successful companies. Dr. Rubinfeld's academic training and business experience enhances the breadth and scope of our Board's oversight of our company's management, business, strategic relationships, and other activities, while his vision adds to the long-range planning of our Board of Directors and management.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Eric Selter
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	has been a director since April 2015. He has served in many capacities as an investment advisor with Morton Capital Management, LLC, and is currently an owner and a member of their investment committee. He served as President and Chief Executive Officer of National Staff Network, a nationally recognized and major leader in the employee leasing industry, from 1996 to 1998. He received his bachelor's degree from the University of Southern California where he graduated magna cum laude in 1979. He then attended Loyola Law School in Los Angeles where he was awarded his Juris Doctor degree in 1982.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	Mr. Selter's senior executive experience in the financial services industry distinguishes him from our other directors and adds unique capabilities and a different perspective to the deliberations of our Board of Directors. He understands the credit needs, financing requirements, and operational constraints of development-stage and mature businesses, skills that he is able to utilize as the named financial expert on our Audit Committee.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Anita J. Chawla, Ph.D.
</FONT>
	joined the board in March 2015. She is an economist with&#160;more than 25 years of experience in the health care sector. She has extensive experience using economic analyses to support&#160;the business objectives&#160;of life sciences companies. In her work, Dr.&#160;Chawla has assessed&#160;the value of a wide&#160;range of therapies to inform&#160;health care decision&#160;makers.&#160; Dr. Chawla specializes in helping pharmaceutical, biotechnology,&#160;medical device, and diagnostic companies address market access challenges, particularly as they&#160;relate to coverage and reimbursement determination and evidence-based review, through all phases of product development and commercialization. Dr. Chawla graduated Phi Beta Kappa with a Bachelor of Arts degree in economics and political science from Wellesley College. She earned a PhD in economics from the University of Michigan.&#160;Dr. Chawla is a Managing Principal at Analysis Group, Inc.&#160;Prior to joining Analysis&#160;Group in 2007, she was head of the Health Economics &amp; Outcomes Research department at Genentech, Inc. from 2001 to 2006.&#160; She has also held positions at Thomson Medstat (The MEDSTAT Group), Research and Policy Division (1993-2000) and the American Medical Association, Center for Health Policy Research (1989-1993). Dr. Chawla is no relation to any other Company employees named Chawla.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Cheryl Cohen
</FONT>
	joined the board in June 2015. She previously served as the Chief Commercial Officer of Medivation, Inc. from 2011 to 2014, where she was responsible for their U.S. launch of Xtandi (enzalutamide) for metastic castration-resistant prostate cancer. Her previous experience includes over a decade at Johnson &amp; Johnson, including as vice president of its strategic commercial group, Health Care Systems, Inc. She also serves as a director of Tokai Pharmaceuticals, Inc., a listed public company. Since 2014, Ms. Cohen has been also president of CLC Consulting, her private pharmaceutical and biotechnology consulting firm specializing in new product commercialization, a position she also held from 2008 to 2011. Ms. Cohen's extensive experience in commercialization and strategic planning makes her the most qualified person to head our Strategy Committee.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-43-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage44"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Daniel J. Levitt, M.D., Ph.D.
</FONT>
	joined us in October 2009 as our Chief Medical Officer, and was promoted to the position of Executive Vice President in 2013. Dr. Levitt brings more than 24 years of senior management experience, having spearheaded numerous drug development programs to commercialization at leading biotechnology and pharmaceutical companies.&#160;Prior to joining CytRx, Dr. Levitt served from January 2007 to February 2009 as Executive Vice President, Research and Development at Cerimon Pharmaceuticals, Inc. Prior to that, from August 2003 to April 2006, he was Chief Medical Officer and Head of Clinical and Regulatory Affairs at Dynavax Technologies Corporation, managing clinical trials for four programs and overseeing multi-country regulatory strategies. From August 2002 to July 2003, Dr. Levitt was Chief Operating Officer and Head of Research and Development at Affymax, Inc., and prior to that he spent six years at Protein Design Labs, Inc., completing his tenure as that firm's President and Head of Research and Development. Dr. Levitt's past experience includes a position as Head of Drug Development at Geron Corporation, and Head of the Cytokine Development Unit and Global Clinical Oncology at Sandoz Pharmaceuticals Ltd., and as Director, Clinical Oncology and Immunology at Hoffmann-LaRoche, Inc.&#160;Dr. Levitt graduated Magna Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Brandeis University. He earned both his M.D. and his Ph.D. in Biology from the University of Chicago, Pritzker School of Medicine.&#160;Dr. Levitt has received ten major research awards and authored or co-authored nearly 200 papers and abstracts.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	John Y. Caloz
</FONT>
	joined us in October 2007 as our Chief Accounting Officer. In January of 2009 Mr. Caloz was named Chief Financial Officer. He has a history of providing senior financial leadership in the life sciences sector, as Chief Financial Officer of Occulogix, Inc, a NASDAQ listed, medical therapy company. Prior to that, Mr. Caloz served as Chief Financial Officer of IRIS International Inc., a Chatsworth, CA based medical device manufacturer. He served as Chief Financial Officer of San Francisco-based Synarc, Inc., a medical imaging company, and from 1993 to 1999 he was Senior Vice President, Finance and Chief Financial Officer of Phoenix International Life Sciences Inc. of Montreal, Canada, which was acquired by MDS Inc. in 1999. Mr. Caloz was a partner at Rooney, Greig, Whitrod, Filion &amp; Associates of Saint Laurent, Quebec, Canada, a firm of Chartered Accountants specializing in research and development and high tech companies, from 1983 to 1993. Mr. Caloz, a Chartered Professional Accountant and Chartered Accountant, holds a degree in Accounting from York University, Toronto, Canada.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Olivia Ware
</FONT>
	joined us in January 2016 as our Chief Commercial Officer. Ms. Ware brings more than 20 years of biotechnology and pharmaceutical experience. Since 2010, she has worked as an independent consultant providing strategic support and management expertise for global product launches, market assessments and coaching and mentoring for team leader sand executive teams. She was at Genentech, Inc. from 2007 to 2010, where she rose to Senior Director of Oncology and was responsible for the initial launch of Avastin in the U.S. She previously served in a senior capacity at Baxter Healthcare and Apria Healthcare. Ms. Ware has an MBA in finance and Marketing from the University of North Carolina at Chapel Hill and a B.A. from Davidson College, Davidson, North Carolina.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Scott Wieland, Ph.D.
</FONT>
	joined CytRx in 2005 as the Vice President, Clinical and Regulatory Affairs and was promoted to the position of Senior Vice President, Drug Development in December 2008. Prior to that, he served in senior level positions in the areas of Drug Development, Clinical and Regulatory Affairs at various biotech firms. He spent five years at NeoTherapeutics, Inc. serving as the Director of Product Development and was later promoted to Vice President of Product Development. From 1990 to 1997, he served as Director of Regulatory Affairs at CoCensys, Inc. Dr. Wieland has a Ph.D. in Biopsychology and an M.A. in Psychology from the University of Arizona. He has an MBA from Webster University. Dr. Wieland received his B.S. in Physiological Psychology from the University of California, Santa Barbara.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Benjamin S. Levin
</FONT>
	joined us in July 2004 as our General Counsel and Corporate Secretary, and since December 2013 has served additionally as Senior Vice President. From November 1999 to June 2004, Mr. Levin was an associate in the transactions department of the Los Angeles office of O'Melveny &amp; Myers LLP. Mr. Levin received his S.B. in Economics from the Massachusetts Institute of Technology, and a J.D. from Stanford Law School.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	David J. Haen
</FONT>
	joined CytRx in October 2003 as Director of Business Development and was promoted to Vice President of Business Development in December 2007. Since 2013, he also serves as Vice President of Investor Relations. From 1999 to 2003, Mr. Haen worked as an associate for Kriegsman Capital Group LLC, a financial advisory firm focused on emerging companies in the life sciences field. Mr. Haen received a B.A. in Communications and Business from Loyola Marymount University.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-44-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage45"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Diversity
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our board of directors, acting through the Nomination and Governance Committee, is responsible for assembling for stockholder consideration director-nominees who, taken together, have appropriate experience, qualifications, attributes, and skills to function effectively as a board. The Nomination and Governance Committee periodically reviews the composition of the board of directors in light of our changing requirements, its assessment of the board of directors' performance, and the input of stockholders and other key constituencies. The Nomination and Governance&#160; Committee looks for certain characteristics common to all board members, including integrity, strong professional reputation and record of achievement, constructive and collegial personal attributes, and the ability and commitment to devote sufficient time and energy to board service. In addition, the Nomination and Governance Committee seeks to include on the board of directors a complementary mix of individuals with diverse backgrounds and skills reflecting the broad set of challenges that the board of directors confronts. These individual qualities can include matters such as experience in our company's industry, technical experience (
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	i.e.
</FONT>
	, medical or research expertise), experience gained in situations comparable to the company's, leadership experience, and relevant geographical diversity.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Committees
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our business, property and affairs are managed by or under the direction of the board of directors. Members of the board are kept informed of our business through informal discussions with our chief executive and financial officers and other officers, by reviewing materials provided to them and by participating at meetings of the board and its committees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our board of directors currently has four committees. The Audit Committee consists of Mr. Selter, Dr. Rubinfeld, Dr. Ignarro and Ms. Cohen. The Compensation Committee consists of Dr. Rubinfeld, Dr. Ignarro, Mr. Selter and Dr. Chawla; the Nomination and Governance Committee consists of Dr. Ignarro, Dr. Rubinfeld and Dr. Chawla; and the Strategy Committee consists of Ms. Cohen, Dr. Rubinfeld, and Dr Chawla. Such committees operate under formal charters that govern their duties and conduct. Copies of the charters are available on our website at www.cytrx.com.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our board of directors has determined that Mr. Selter, one of the independent directors serving on our Audit Committee, is an "audit committee financial expert" as defined by the SEC's rules. Our board of directors has determined that Messrs. Rubinfeld, Ignarro, Selter, Dr. Chawla and Ms. Cohen are "independent" under the current independence standards of both The NASDAQ Capital Market and the SEC.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Section 16(a) Beneficial Ownership Reporting Compliance
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Each of our executive officers and directors and persons who own more than 10% of our outstanding shares of common stock is required under Section 16(a) of the Securities Exchange Act to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and to furnish us with copies of those reports. Based solely on our review of copies of reports we have received and written representations from certain reporting persons, we believe that our directors and executive officers and greater than 10% shareholders for 2014 complied with all applicable Section 16(a) filing requirements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Code of Ethics
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have adopted a Code of Ethics applicable to all employees, including our principal executive officer, principal financial officer and principal accounting officer, a copy of which is available on our website at www.cytrx.com. We will furnish, without charge, a copy of our Code of Ethics upon request. Such requests should be directed to Attention: Corporate Secretary, 11726 San Vicente Boulevard, Suite 650, Los Angeles, California, or by telephone at 310-826-5648.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Board Leadership Structure
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;On October 15, 2014, our board of directors appointed Mr. Kriegsman as Chairman of the Board.&#160; The Chairman of the Board presides at all meetings of our board of directors (but not at its executive sessions) and exercises and performs such other powers and duties as may be assigned to him from time to time by the board or prescribed by our amended and restated bylaws.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our board of directors has no established policy on whether it should be led by a Chairman who is also the Chief Executive Officer, but periodically considers whether combining, or separating, the role of Chairman and Chief Executive Officer is appropriate. At this time, our board is committed to the combined role given the circumstances of our company, including Mr. Kriegsman's knowledge of the pharmaceutical industry and our company's strategy. Our board believes that having a Chairman who also serves as the Chief Executive Officer allows timely communication with our board on company strategy and critical business issues, facilitates bringing key strategic and business issues and risks to the board's attention, avoids ambiguity in leadership within the company, provides a unified leadership voice externally and clarifies accountability for company business decisions and initiatives. In 2015, Dr. Rubinfeld was appointed as an independent Lead Director to act as a liaison between the Chairman of the Board and the independent directors. The board will continue to assess whether this leadership structure is appropriate and will adjust it as it deems appropriate.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Board of Directors Role in Risk Oversight
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In connection with its oversight responsibilities, our board of directors, including the Audit Committee, periodically assesses the significant risks that we face. These risks include, but are not limited to, financial, technological, competitive, and operational risks. Our board of directors administers its risk oversight responsibilities through our Chief Executive Officer, Chief Financial Officer, and General Counsel who review and assess the operations of our business, as well as operating management's identification, assessment and mitigation of the material risks affecting our operations.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-45-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage46"></A>
</DIV>
</EFX_DIRECTORS_AND_OFFICERS>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 11.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	EXECUTIVE COMPENSATION
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation Discussion and Analysis
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Overview of Executive Compensation Program
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee of our Board of Directors has responsibility for establishing, implementing and monitoring our executive compensation program philosophy and practices. Generally speaking, the Compensation Committee determines the compensation of our Chief Executive Officer and other named executive officers for approval by our Board of Directors.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee seeks to ensure that the total compensation paid to our named executive officers is fair, reasonable and competitive. Generally, the types of compensation and benefits provided to the named executive officers are similar to those provided to our other officers.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee operates under a formal charter, a copy of which is available on our website at
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	www.cytrx.com
</FONT>
	that governs its duties and conduct.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At the 2015 annual meeting of stockholders, the stockholders on a non-binding, advisory basis, approved the compensation of our executive officers as disclosed in our 2015 proxy statement. Based upon the results of this stockholder advisory vote, the Compensation Committee determined to continue its compensation policies and procedures.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Throughout this Annual Report, the individuals included in the Summary Compensation Table below are referred to as our "named executive officers."
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation Philosophy and Objectives
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The components of our executive compensation consist of salary, annual and special cash bonuses awarded based on the Compensation Committee's subjective assessment of the achievement of corporate goals and each individual executive's job performance, stock option grants to provide executives with longer-term incentives, and occasional special compensation awards (either cash, stock or stock options) to reward extraordinary efforts or results.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee believes that an effective executive compensation program should provide base annual compensation that is reasonable in relation to individual executive's job responsibilities and reward the achievement of strategic goals of our company. We use annual and other periodic cash bonuses to reward an officer's achievement of specific goals, including goals related to the development of our drug candidates and replenishment and management of our working capital. We use employee stock options as a retention tool and as a means to align the executive's long-term interests with those of our stockholders, with the ultimate objective of affording our executives an appropriate incentive to improve stockholder value. The Compensation Committee evaluates both performance and compensation to maintain our company's ability to attract and retain excellent employees in key positions and to assure that compensation provided to key employees remains competitive relative to the compensation paid to similarly situated executives of comparable companies.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-46-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage47"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Each of the corporate goals established and subsequently reviewed by the Compensation Committee results from a collaboration among our named executive officers, including the leadership of our Chief Executive Officer and the support of our principal legal, financial, clinical, medical, commercial and business development officers. The Compensation Committee's assessment of the relative contribution of each named executive officer is based on periodic reports to our full Board of Directors regarding the progress of these business accomplishments and the individual efforts of our named executive officers, and year-end consultations, which include discussions of performance reviews, with our Chief Executive Officer that are a normal part of the Compensation Committee's compensation determinations. The Compensation Committee employs no objective measure of any individual's contribution.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The bonus amounts awarded to our eligible named executive officers are a function of their office and total compensation relative to the total compensation of our Chief Executive officer, as adjusted by their relative employee evaluation, and with consideration given to comparable company data for similarly-situated employees. The bonus amounts awarded to each named executive officer is set forth in the Summary Compensation Table.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Because of the size of our company, the small number of executive officers in our company, and our company's financial priorities, the Compensation Committee has not implemented any pension benefits, deferred compensation plans or other similar plans for our named executive officers.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Role of Executive Officers in Compensation Decisions
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Compensation Committee annually determines the compensation of our named executive officers
</FONT>
	. Mr. Kriegsman, our Chairman of the Board and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Chief Executive Officer, typically attends all meetings of the Compensation Committee, except for executive sessions at which his compensation is discussed. At the request of the Compensation Committee, Mr. Kriegsman provides his assessment of the performance of our named executive officers, other than himself. Mr. Kriegsman also takes an active part in the discussions of the compensation of named executive officers other than himself and assists in the development of a review matrix of each executive's contributions to the goals of the company that forms the basis for some compensation determinations. The Compensation Committee grants due consideration to Mr. Kriegsman's assessments when making determinations regarding the compensation of our named executive officers. All Compensation Committee deliberations and determinations regarding the compensation of Mr. Kriegsman are made outside his presence.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Setting Executive Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Based on the foregoing objectives, the Compensation Committee has structured the company's annual cash and incentive-based cash and non-cash executive compensation to seek to motivate our named executives to achieve our company's business goals, including goals related to the development of the our drug candidates and management of working capital, to reward the executives for achieving such goals, and to retain the executives. In doing so, the Compensation Committee historically has not employed outside compensation consultants. During 2015, the Compensation Committee obtained three industry compensation surveys and used them in its compensation deliberations regarding cash and equity compensation for our executive officers. The surveys used were an Equilar survey of public companies with a market capitalization between $50 million and $200 million, the Radford Global Life Sciences Survey, which is a survey of public and private life sciences companies of all sizes, and a survey of public and private companies in Los Angeles provided by salary.com (which the Compensation Committee uses to consider geographic differences in cost of living).
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	Compensation Committee utilized this data to set annual salary increases and bonus amounts
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	for our executive officers at levels targeted at or around the third quartile of compensation amounts provided to executives at comparable companies, considering each individual's experience level related to their position with us.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Compensation Committee has no policy regarding the use of benchmarks, and we have
</FONT>
	no established policy or target for the allocation between cash and non-cash incentive compensation.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	The Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities, but has not relied upon outside compensation consultants.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-47-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage48"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Performance-driven Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We emphasize performance in annually reviewing and setting our executive officers' base salaries, bonuses and equity incentive compensation. This emphasis on performance with respect to a substantial portion of compensation is intended to motivate our executive officers to pursue our corporate goals, reward them for achievement of these goals and align their interests with those of our stockholders.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Each year, we determine goals that we hope to achieve in the coming year, both on a company and individual basis. Our overall corporate performance as compared to these goals, and an individual's performance compared to his or her individual goals, primarily drive the recommendations that the Compensation Committee with respect to each executive officer's base salary, cash bonus and equity incentive compensation. Other factors, such as larger macroeconomic conditions of the industry and market in which we compete, as well as strategic business decisions and issues related to key employee retention, also influence compensation decisions.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Individual performance goals for each year initially are identified and developed by senior executives through a self-evaluation and goal-setting process, and our CEO refines and documents those goals in conjunction with the Compensation Committee. At the end of the year, the Compensation Committee reviews each performance goal and determines the extent to which we achieved such goals, and our CEO assesses the achievement of specific performance goals relating to our other executive officers.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In establishing performance goals, the Compensation Committee considers whether the goals could possibly result in an incentive for any executives to take unwarranted risks in our company's business and seeks to avoid creating any such incentives.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', SERIF; FONT-SIZE: 1PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Company Performance Goals
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', SERIF; FONT-SIZE: 1PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For 2015, the Compensation Committee and our board of directors approved the following performance goals:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="09B8217FFE62499DB5D3E1787E5EA324" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Complete enrollment in the aldoxorubicin Phase 3 STS pivotal clinical trial;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F80001C3F676436D8DF616E9E83C7876" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Present Phase 2 GBM and Kaposi's sarcoma clinical studies at scientific meetings;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="438FC1AC495D4553B36F0CA8CC4440CF" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Initiate the validation activities in manufacturing;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8CB1A63ACBAA43C4AD6492F802D81EAE" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Publish results of the Phase 2b STS study in a scientific journal;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="73765339D46F45A596D01CFCCE50F946" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Identify an in vivo proof of concept for one new drug candidate based on novel linker technologies in the pre-clinical laboratory in Freiburg, Germany; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="809A716BCF784344A8FD017119E2B99E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Raise additional capital.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For 2015, the Compensation Committee determined that, with the exception of the presentation of the Phase 2 GBM clinical study at a scientific meeting (for which the timeline was extended), each
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	of the corporate goals had either been achieved, or substantial progress towards achievement had been made, and noted the particular contributions of executive officers to the achievement of those goals.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Individual Performance
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee reviews our executive officers' performance based on overall achievement of the corporate goals and a review of individual goals developed for each executive officer every year. The Compensation Committee, with the assistance of our Chief Executive Officer, determines the relative achievement of the performance goals applicable to each executive officer, and assigns a performance rating based on a set of criteria set forth in an evaluation form. No specific formula is used with respect to setting any particular element of compensation based on the individual performance metrics. The score assigned to each officer was based on a subjective assessment by our Compensation Committee members of the officer's performance against the scoring standards of:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1 &#8211; Consistently Exceeds Expectations
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2 &#8211; Sometimes Exceeds Expectations
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3 &#8211; Meets Expectations
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4 &#8211; Sometimes Meets Expectations
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5 &#8211; Needs Improvement
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-48-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage49"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The numerical job scores, with a 1.0 being the best and 5.0 being the worst, are determined based on an initial self-assessment by the officer, which is subject to change based on an evaluation of the self-assessment by the officer's direct supervisor and on the Compensation Committee's own assessment of the officer's job performance.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For 2015, our Compensation Committee determined that the individual performance scores indicated below were merited by the officer's respective contributions to our key business achievements discussed above, as well as the performance of their day-to-day responsibilities. On an officer-by-officer basis, our Compensation Committee also considered the following:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr. Kriegsman's individual performance goals relate primarily to overall corporate objectives, including building stockholder value as reflected in our market capitalization and our working capital, managing and directing the executive management team, and successfully developing our company's operations and personnel for future success. Based on those criteria, and noting achievement of complete enrollment in our global Phase 3 STS clinical trial and the settlement approvals reached in the Company's class action and derivative suits, the Compensation Committee gave a rating of 1.1 to Mr. Kriegsman.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr.&#160;Caloz's individual performance goals relate primarily to achievement of key financial objectives, such as managing and raising working capital, controlling spending, managing accounting personnel and maintaining regulatory compliance. Based on those criteria, the Compensation Committee noted Mr. Caloz's role in obtaining needed working capital, his efforts to control expenditures, the continued improvement of our accounting department, and our compliance with filing deadlines, and gave a rating of 1.8 to Mr. Caloz.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Dr.&#160;Levitt's individual performance goals relate primarily to the achievement of key strategic and clinical objectives related to our clinical research programs, including ultimate oversight of the design and execution of our clinical programs, and analysis and implementation of new clinical opportunities improve stockholder value. Dr. Levitt was instrumental in identifying a novel anti-cancer drug conjugate (DK049) that utilizes the Company's Linker Activated Drug Release (LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	) technology and was created at our laboratory facility in Freiburg, Germany. Based on those criteria, the Compensation Committee noted Dr. Levitt's efforts towards our achievement of our key clinical goals, including the completion of enrollment in our global Phase 3 STS clinical trial and, his development of strategic plans to build value, and gave a rating of 2.1 to Dr. Levitt.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr. Levin's individual performance goals relate primarily to the management of the company's legal risk, advice provided to the board of directors and management, and maintaining regulatory compliance. Based on those criteria, the Compensation Committee noted Mr. Levin's timely and useful advice on key corporate matters, and his efforts to reduce corporate risk, his work in negotiating settlements in the ongoing corporate litigation, and his work ensuring compliance with various regulations, and gave a rating of 2.4 to Mr. Levin.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Dr.&#160;Wieland's individual performance goals relate primarily to the execution of the objectives related to our clinical development, including planning, initiation, budgeting and management of our clinical programs. Based on those criteria, the Compensation Committee noted Dr. Wieland's role in our achievement of key clinical goals, including the completion of enrollment in our global Phase 3 STS clinical trial, and gave a rating of 2.6 to Dr. Wieland.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015 Executive Compensation Components
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For 2015, as in recent years, the principal components of compensation for the named executive officers were:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="67D370832B224B87A89CAF3FE6692354" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	base salary;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="51DAA98ADB34489B9E7718EFEC55BC28" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	annual bonuses; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6D14D4F9674F4375B53DA12C6983F222" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	equity incentive compensation.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Base Salary
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We provide named executive officers and other employees with base salary to compensate them for services rendered during the year.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Generally, the base salary element of compensation is used to recognize the experience, skills, knowledge and responsibilities required of each named executive officer, and reflects our executive officers' overall sustained performance and contributions to our business.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-49-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage50"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	During its review of base salaries for executives, the Compensation Committee primarily considers:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0C2BDC28E1F14F51BC7881EA09A02E9F" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	the negotiated terms of each executive's employment agreement, if any;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C31646D834544BAD99046D62D83CDDAB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	each executive's individual performance;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9ED84B2BCBB34698BA51E21C15AD4941" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	an internal review of the executive's compensation, both individually and relative to other named executive officers; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5E485D363EA64D09ACE629BF5A8F7443" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	to a lesser extent, base salaries paid by comparable companies.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Salary levels are typically considered annually as part of our company's performance review process, as well as upon a change in job responsibility. Merit-based increases to salaries are based on our company's available resources and the Compensation Committee's assessment of the individual's performance. This assessment is based upon written evaluations of such criteria as job knowledge, communication, problem solving, initiative, goal-setting, and expense management. In 2015,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	the Compensation Committee considered our successful achievement or
</FONT>
	substantial progress towards our corporate performance goals, and with consideration of the challenging financial environment, and our anticipation of clinical significant clinical activities in 2016 and beyond, awarded modest increases in base salary for 2016 for some executives. Base salaries were also reviewed in light of the Equilar, Radford and salary.com survey data to validate that they were within acceptable ranges based on market salaries.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Annual and Special Bonuses
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As we do not generate significant revenue and have not commercially released any products, the Compensation Committee bases its discretionary annual bonus awards on the achievement of corporate and individual goals, efforts related to extraordinary transactions, effective fund-raising efforts, effective management of personnel and capital resources, and bonuses paid by comparable companies, among other criteria. Mr. Kriegsman's employment agreement entitles him to an annual cash bonus in an amount to be determined in our discretion, but not less than $150,000, and Dr. Levitt's employment agreement entitles him to an annual bonus of not less than $150,000. Any cash bonuses to our other named executive officers are entirely in our discretion.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	During 2015, the Compensation Committee granted Mr. Kriegsman an annual cash bonus of $150,000, granted Dr. Levitt an annual cash bonus of $150,000, and granted cash bonuses to the other named executive officers ranging from $75,000 to $135,000, principally based on their efforts in helping us advance the development of aldoxorubicin. In December 2015, the Compensation Committee approved the award to Dr. Levitt of a retention bonus of $250,000 conditioned upon his entering into a new employment agreement satisfactory to the company following the expiration of his then-current employment agreement on December 31, 2015.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Equity Incentive Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We believe that strong long-term corporate performance is achieved with a corporate culture that encourages a long-term focus by our executive officers through the use of equity awards, the value of which depends on our stock performance. We have established equity incentive plans to provide all of our employees, including our executive officers, with incentives to help align those employees' interests with the interests of our stockholders and to enable them to participate in the long-term appreciation of our stockholder value. Additionally, equity awards provide an important retention tool for key employees, as the awards generally are subject to vesting over an extended period of time based on continued service with us.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Historically, equity awards have been granted annually at the end of each year based primarily on corporate performance as a whole during the preceding year. In addition, we may grant equity awards upon the occurrence of certain events during the year, for example, upon an employee's hire or achievement of a significant business objective such as positive results or other progress of our clinical trials or successful capital-raising efforts. On June 2, 2015, we announced that we had entered into an agreement to settle the Delaware stockholder derivative lawsuit,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	In Re CytRx Stockholder Derivative Litigation
</U>
</FONT>
	, as described in Item&#160;3 of this Annual Report.&#160; In the agreement, we agreed to re-price certain outstanding stock options and to implement certain corporate governance practices.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-50-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage51"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In accordance with the settlement agreement reached in June 2015 and approved by the Court in November 2015, our board of directors approved the re-pricing of outstanding stock options under the 2008 Stock Incentive Plan, or the 2008 Plan, to purchase a total of 2,095,000 shares of our common stock held by our directors or former directors and our executive officers originally granted on December 10, 2013 at an exercise price of $2.39.&#160; The new exercise price of these re-priced options is $4.66, which was the closing price of our common stock as reported on The NASDAQ Capital Market on December 20, 2013.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Among the agreed-upon corporate governance practices are that we will grant stock options to directors, officers and employees only on pre-set dates established by the Compensation Committee prior to the fiscal year in which the options are to be granted. The Compensation Committee has established December 15 as the date for the annual grant of stock options for 2016. The December 15 date correlates to the approximate dates of our historical annual stock option grants, but otherwise was not based upon any particular methodology.&#160; We have agreed in the settlement agreement to publicly disclose the method used to determine the pre-set stock option grant dates and any future changes thereto at least 90 days before they become effective.&#160; We also have agreed in the settlement agreement that all stock option grants, other than initial stock option grants to new employees, will be made at a meeting, whether in-person or telephonic, of the Compensation Committee and not by unanimous written consent, and that the Compensation Committee will determine the grantees, amounts, dates, and prices of all stock options and will not delegate these responsibilities. The Compensation Committee has implemented the corporate governance practices called for in the settlement agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	No formula is used in setting equity award grants and the determination of whether to grant equity awards, or the size of such equity awards, to our executive officers; rather, it involves subjective assessments by our board of directors, Compensation Committee and, with respect to executive officers other than Mr. Kriegsman. Generally, annual equity awards are intended to encourage retention of experienced employees, and we consider individual performance and contributions during the preceding year to the extent our board of directors and Compensation Committee believe such factors are relevant. As with base salary and cash bonuses, for 2015 our board of directors and Compensation Committee also considered data from three surveys in determining equity award grants to our executive officers.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At a meeting of the Compensation Committee on December 4, 2015, the Compensation Committee granted to Mr. Kriegsman nonqualified stock options to purchase 1,000,000 shares of our common stock at a price of $2.44 per share, which equaled the closing market prices on December 15, 2015, the specified grant date. The options vest monthly over three years, provided that Mr. Kriegsman remains in our employ throughout such monthly vesting periods, unless Mr. Kriegsman's employment is terminated by us without "cause," or by reason of his "disability", or by Mr. Kriegsman for "good reason," or due to his death, in which case the options will vest immediately and will remain exercisable for their full term. At the same meeting, the Compensation Committee authorized amendments to all stock options held by Mr. Kriegsman to provide for the vesting, in full, of the stock options in the event of, and upon, FDA approval to market aldoxorubicin. In addition, in connection with the annual review of our other named executive officers, at its December 4, 2015 meeting, the Compensation Committee granted to our other named executive officers nonqualified stock options to purchase an aggregate of 1,350,000 shares of our common stock. All of the stock options had an exercise price equal to $2.44, the closing market price on December 15, 2015, the specified&#160; grant date, and vest monthly over three years, provided that such executives remain in our employ through such monthly vesting periods unless, with respect to Dr. Levitt, his employment is terminated by us without "cause" or by reason of his "disability," or upon FDA approval of aldoxorubicin, or by Dr. Levitt for "good reason" (each as defined in his employment agreement) or due to his death, in which case the options will immediately vest in full and remain exercisable for their full term.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Generally speaking, we have not taken into consideration any amounts realized by our named executive officers from prior stock option or stock awards in determining whether to grant new stock options or stock awards. No named executive officers have exercised options since 2003.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Retirement Plans, Perquisites and Other Personal Benefits
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	Our executive officers are eligible to participate in the same group insurance and employee benefit plans as our other salaried employees. These benefits include medical, dental, vision, and disability benefits and life insurance.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-51-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage52"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have adopted a tax-qualified employee savings and retirement plan, our 401(k) Plan, for eligible U.S. employees, including our named executive officers. Eligible employees may elect to defer a percentage of their eligible compensation in the 401(k) Plan, subject to the statutorily prescribed annual limit. We may make matching contributions on behalf of all participants in the 401(k) Plan in an amount determined by our board of directors. We made matching contributions to the 401(k) Plan for 2015 of $104,000. Matching contributions immediately vest, as do all employee contributions. We intend the 401(k) Plan, and the accompanying trust, to qualify under Sections 401(k) and 501 of the Internal Revenue Code so that contributions by employees to the 401(k) Plan, and income earned (if any) on plan contributions, are not taxable to employees until withdrawn from the 401(k) Plan, and so that we will be able to deduct our contributions, if any, when made. The trustee under the 401(k) Plan, at the direction of each participant, may invest the assets of the 401(k) Plan in any of a number of investment options.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We generally do not provide any of our named executive officers with any other perquisites or personal benefits, other than benefits to Mr.&#160;Kriegsman provided for in his employment agreement. We are required by his employment agreement to carry a life insurance policy for Mr. Kriegsman in the amount of $1.4 million under which Mr. Kriegsman's designee is the beneficiary. We purchased a policy with a face value of $2 million, for which we pay the premium, and Mr. Kriegsman immediately reimburses us for the premium relating to the $0.6 million of additional coverage. We periodically review the levels of perquisites and other personal benefits provided to our named executive officers. No changes to these benefits were made during 2015, except that we agreed to pay or reimburse the legal fees incurred by Mr. Kriegsman in connection with the third amendment to his employment agreement entered into on March 8, 2016.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreements and Severance Arrangements
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have entered into written employment agreements with each of our named executive officers. The main purpose of these agreements is to protect the company from business risks such as competition for the executives' service, loss of confidentiality or trade secrets, and solicitation of our other employees, and to define our right to terminate the employment relationship. The employment agreements also protect the executive from termination without "cause" (as defined) and, in both Mr. Kriegsman and Dr. Levitt's case, entitle them to resign for "good reason" (as defined). Each employment agreement was individually negotiated, so there are some minor variations in the terms among executive officers. Generally speaking, however, the employment agreements provide for termination and severance benefits that the Compensation Committee believes are consistent with industry practices for similarly situated executives. The Compensation Committee believes that the termination and severance benefits help the company retain the named executive officers by providing them with a competitive employment arrangement and protection against unknowns such as termination without "cause" that go along with the position.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the event of termination without "cause," the named executive officers will be entitled to a lump-sum payment equal to six months' base salary (12 months in the case of Dr. Levitt and 24 month's base salary and minimum annual bonus under his employment agreement in the case of Mr. Kriegsman). The named executive officers' agreements also provide for our continuation of medical benefits during the severance period (including, for Mr. Kriegsman, payments for life insurance). If a named executive officer's employment is terminated by us without "cause" (or by Mr. Kriegsman or Dr. Levitt for "good reason") within two years following a change of control of the company, the named executive officers will be entitled to a lump-sum payment equal to 12 months' base salary (24 months' base salary in the case of Dr. Levitt and 36 month' base salary and minimum annual bonus in the case of Mr. Kriegsman), and Dr. Levitt and Mr. Kriegsman also would be entitled under their employment agreement to receive a "gross-up" payment equal to the sum of any excise tax on termination benefits (including any accelerated vesting of his options under our Plans as described below) plus any penalties and interest.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We agree in Mr. Kriegsman's employment agreement that if, following the expiration of the employment agreement, we terminate Mr. Kriegsman's employment other than for "cause" or he resigns for "good reason," he will be entitled to the lump-sum severance and continuation of benefits described in the preceding paragraph.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We agree in Dr. Levitt's employment agreement that if we do not offer to renew or extend the officer's employment agreement, and we had not theretofore terminated his employment, we will continue to pay him his annual salary thereunder during the period commencing upon expiration of his employment agreement and ending on December 31, 2017. We agree in the employment agreements with our other named executive officers (other than Mr. Kriegsman) that if we do not offer to renew or extend the officer's employment agreement, and we had not theretofore terminated their employment, we will continue to pay the officer his annual salary thereunder during the period commencing upon expiration of his employment agreement and ending on June 30, 2017, or the date of his re-employment with another employer, whichever is earlier.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the event we terminate Dr. Levitt's employment without "cause," Dr. Levitt resigns for "good reason" or his employment terminates due to his "disability" (each as defined in the employment agreement) or death, Dr. Levitt will be entitled to full and immediate vesting of his restricted stock and stock options and any other equity awards based on our securities and all such awards will remain exercisable for their full term notwithstanding the termination of his employment (other than a termination by the company for "cause" or his resignation without "good reason").
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-52-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage53"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	&#160;&#160; Change of Control Arrangements
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In addition to the severance and benefits payable to our named executive officers in the event of a termination of their employment following a change of control of the company, our 2000 Long-Term Incentive Plan and 2008 Plan provide generally that, upon a change of control of the company, all unvested stock options and awards under the Plans held by plan participants, including the named executive officers, will become immediately vested and exercisable immediately prior to the effective date of the transaction. The Compensation Committee believes that such "single trigger" change of control policy is consistent with the objective of aligning the interests of the named executive officer's and of the company's stockholders by allowing the executives to participate equally with stockholders in the event of a change of control transaction.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The foregoing severance and change of control arrangements, including the quantification of the payments and benefits provided under these arrangements, are described in more detail elsewhere in this Annual Report under the heading "Executive Compensation &#8211; Employment Agreements and Potential Payment Upon Termination or Change in Control."
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Ownership Guidelines
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee has no requirement that named executive officers maintain a minimum ownership interest in our company.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our long-term incentive compensation consists solely of periodic grants of stock options to our named executive officers. The stock option program:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D0786397E9084F29AE5A38B548BF5421" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	links the creation of stockholder value with executive compensation;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="34FCFD7C19764AC4822621E9C9685969" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	provides increased equity ownership by executives;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="88149C80FB8A48728CA87BC2F931151D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	functions as a retention tool, because of the vesting features included in all options granted by the Compensation Committee; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BEBEC519F70940328219D46213F58222" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	helps us to maintain competitive levels of total compensation.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We normally grant stock options to new executive officers when they join our company based upon their position with us and their relevant prior experience. The options granted by the Compensation Committee generally vest monthly over the first three years of the ten-year option term. Vesting and exercise rights generally cease upon termination of employment (unless such termination is without cause or is a resignation for good reason), except in the case of death (subject to a one-year limitation), disability or retirement. Prior to the exercise of an option, the holder has no rights as a stockholder with respect to the shares subject to such option, including voting rights and the right to receive dividends or dividend equivalents. In addition to the initial option grants, our Compensation Committee may grant additional options to retain our executives and reward, or provide incentive for, the achievement of corporate goals and strong individual performance.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On an annual basis, the Compensation Committee assesses the appropriate individual and corporate goals for our executives and provides additional option grants based upon the achievement by the new executives of both individual and corporate goals. We expect that we will continue to provide new employees with initial option grants in the future to provide long-term compensation incentives and will continue to rely on performance-based and retention grants to provide additional incentives for current employees. Additionally, in the future, the Compensation Committee may consider awarding additional or alternative forms of equity incentives, such as grants of bonus stock, restricted stock and restricted stock units.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	It is our policy to award stock options at an exercise price equal to The NASDAQ Capital Market's closing price of our common stock on the date of the grant. In certain limited circumstances, the Compensation Committee may grant options to an executive at an exercise price in excess of the closing price of the common stock on the grant date. The Compensation Committee will not grant options with an exercise price that is less than the closing price of our common stock on the grant date, nor will it grant options which are priced on a date other than the grant date. For purposes of determining the exercise price of stock options, the grant date is deemed to be the first day of employment for newly hired employees. Among the corporate governance practices agreed upon in connection with the settlement of the stockholder derivatives litigation described in Item 3 of this Annual Report, we agreed that we will grant stock options to directors, officers and employees only on pre-set dates established by the Compensation Committee prior to the fiscal year in which the options are to be granted. The Compensation Committee has established December 15 as the date for the annual grant of stock options for 2016. The December 15 date correlates to the approximate dates of our historical annual stock option grants, but otherwise was not based upon any particular methodology. We have agreed in the settlement agreement to publicly disclose the method used to determine the pre-set stock option grant dates and any future changes thereto at least 90 days before they become effective. We also have agreed in the settlement agreement that all stock option grants, other than initial stock option grants to new employees, will be made at a meeting, whether in-person or telephonic, of the Compensation Committee and not by unanimous written consent, and that the Compensation Committee will determine the grantees, amounts, dates and prices of all stock options and will not delegate these responsibilities.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We have no program, practice or plan to grant stock options to our executive officers, including new executive officers, in coordination with the release of material nonpublic information. We also have not timed the release of material nonpublic information for the purpose of affecting the value of stock options or other compensation to our executive officers, and we have no plan to do so. We have no policy regarding the adjustment or recovery of stock option awards in connection with the restatement of our financial statements, as our stock option awards have not been tied to the achievement of specific financial goals.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-53-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage54"></A>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Tax and Accounting Implications
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Deductibility of Executive Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As part of its role, the Compensation Committee reviews and considers the deductibility of executive compensation under Section 162(m) of the Internal Revenue Code, which provides that corporations may not deduct compensation of more than $1,000,000 that is paid to certain individuals. We believe that compensation paid to our executive officers generally is fully deductible for federal income tax purposes.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Accounting for Share-Based Compensation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Beginning on January 1, 2006, we began accounting for share-based compensation in accordance with the requirements of ASC 718,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Compensation &#8211; Stock Compensation
</FONT>
	. This accounting treatment has not significantly affected our compensation decisions. The Compensation Committee takes into consideration the tax consequences of compensation to the named executive officers, but tax considerations are not a significant part of the company's compensation policy.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	These policies remained in place throughout 2015, and we expect to continue to follow them for the foreseeable future.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation Committee Interlocks and Insider Participation in Compensation Decisions
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	There are no "interlocks," as defined by the SEC, with respect to any member of the Compensation Committee. Joseph Rubinfeld, Ph.D. and Louis Ignarro, Ph.D. served as members of the Compensation Committee for all of 2015. Anita Chawla, Ph. D. and Eric Selter served as members of the Compensation Committee in 2015 from the respective dates of their appointment as directors.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation Committee Report
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Compensation Committee has reviewed and discussed with management the "Compensation Discussion and Analysis" required by Item 402(b) of Regulation S-K and, based on such review and discussions, has recommended to our board of directors that the foregoing "Compensation Discussion and Analysis" be included in this Annual Report.
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="FACDE2FF919D4386A0AAAD3ECFC1FC80" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM-COLOR: ; WIDTH: 26.43%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Joseph Rubinfeld, Ph.D.
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chairman
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM-COLOR: ; WIDTH: 23.44%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Louis Ignarro, Ph.D.
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM-COLOR: ; WIDTH: 25.06%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Eric Selter
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM-COLOR: ; WIDTH: 25.07%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Anita Chawla, Ph.D.
</DIV>
</TD>
</TR>
</TABLE>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-54-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage55"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Summary Compensation Table
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table presents summary information concerning all compensation paid or accrued by us for services rendered in all capacities during 2015. 2014 and 2013 by Steven A. Kriegsman and John Y. Caloz, who are the only individuals who served as our principal executive and financial officers during the year ended December 31, 2015, and our three other most highly compensated executive officers who were serving as executive officers as of December 31, 2015:
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Summary Compensation Table
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5E43574509534C8585679FB6373C223D" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name and Principal Position
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Salary ($)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Bonus
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	($)(1)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Awards
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	($) (2)(4)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	All Other
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation ($)(3)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	($)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Executive Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	850,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	150,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,593,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,700
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,606,700
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	825,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	450,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	903,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,700
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,191,700
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2013
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	700,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	330,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,714,150
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,700
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,757,850
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Financial Officer and Treasurer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	375,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	135,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	477,900
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	987,900
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	350,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	301,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	751,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2013
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	350,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	256,800
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	706,800
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Daniel Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Executive Vice President and Chief
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	625,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	150,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	796,500
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,571,500
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Medical Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	525,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	602,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,427,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2013
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	525,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,483,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,308,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Benjamin S. Levin General Counsel,
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General Counsel, Senior Vice President and
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	365,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	135,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	477,900
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	977,900
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Secretary
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	350,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	301,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	751,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2013
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	350,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	150,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	513,600
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,013,600
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Wieland, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Senior Vice President &#8211; Drug Development
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	400,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;75,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	159,300
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	634,300
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	350,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;300,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	301,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	951,000
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 27.97%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2013
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.28%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	350,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;100,000
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 8.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	256,800
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 18.02%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.01%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	706,800
</DIV>
</TD>
</TR>
</TABLE>
<BR>
</DIV>
</EFX_COMPENSATION_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4B09E9E070614BCAB033ED4C802D6FA6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Bonuses to the named executive officers reported above were paid in December of the applicable year, except that Dr. Levitt received $75,000 of his annual bonus in June, and Mr. Kriegsman received a retention bonus in connection with the extension of his employment agreement in March 2014.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="435B7DD2D7374C1186A1D587B5DCEB0C" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	The values shown in this column represent the aggregate grant date fair value of equity-based awards granted during the fiscal year, in accordance with ASC 718, "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Share Based-Payment."
</FONT>
	The fair value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model, based on the assumptions described in Note 13 of the Notes to Financial Statements included in this Annual Report.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="00F6E4D551D6443A9092E9E9D36C90BF" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Represents life insurance premiums.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E4BC9EA009434A07AA45EF24C7271DAE" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	In the case of Dr. Levitt, for 2013, this amount includes the aggregate grant date fair value of a restricted stock award granted for services during 2013, as well as the aggregate grant date fair value of an equity-based award granted for that year. The restricted stock awarded for 2013 was issued in January 2014.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-55-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage56"></A>
</DIV>
</DIV>
<EFX_OPTIONS>
<A NAME="FIS_OPTIONS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015 Grants of Plan-Based Awards
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In 2015, we granted stock options to our named executive officers under our 2008 Stock Incentive Plan as follows:
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015 Grants of Plan-Based Awards
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="95DB775C1F0D4719ADB3C58C772B10E2" CELLSPACING="0" CELLPADDING="0">
<TR STYLE="HEIGHT: 100PX">
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Grant Date
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	All Other
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option Awards
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(# of CytRx
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Shares)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option Awards
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	($/Share)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 16PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; WIDTH: 151PX; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Grant Date
</DIV>
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Fair Value of
</DIV>
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stock and
</DIV>
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option Awards
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/15/2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,000,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,593,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Executive Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/15/2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	477,900
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Financial Officer and Treasurer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Daniel Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/15/2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	500,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	796,500
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Executive Vice President and Chief Medical Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Benjamin S. Levin
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/15/2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	477,900
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General Counsel, Senior Vice President and Secretary
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Wieland, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/15/2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	159,000
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 20PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Senior Vice President &#8211; Drug Development
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 32.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.47%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_OPTIONS>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0D794F8A909C460A9A8700B92F6DD123" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Options vest in 36 equal monthly installments, subject to the named executive officer's remaining in our continuous employ through such dates, except that in the case of each of Mr. Kriegsman and Dr. Levitt, the unvested options will vest, in full, upon termination of his employment by us without "cause", upon FDA approval to market aldoxorubicin, or by reason of his "disability" or by him for "good reason" or upon his death.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2000 Long-Term Incentive Plan and 2008 Stock Incentive Plan
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The purpose of our 2000 Long-Term Incentive Plan, or 2000 Plan, and our 2008 Stock Incentive Plan, or 2008 Plan, is to promote our success and enhance our value by linking the personal interests of our employees, officers, consultants and directors to those of our stockholders. The 2000 Plan was originally adopted by our board of directors on August 24, 2000 and by our stockholders on June 7, 2001, with certain amendments to the Plan having been subsequently approved by our board of directors and stockholders. On May 11, 2009, our board of directors approved an amendment to the 2000 Plan to allow for a one-time stock option re-pricing program for our employees. The 2008 Plan was adopted by our board of directors on November 21, 2008 and by our stockholders on July 1, 2009.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2000 Plan and 2008 Plan Descriptions
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The 2000 Plan and the 2008 Plan, or the Plans, are administered by the Compensation Committee of our board of directors. The Compensation Committee has the power, authority and discretion to:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="13FBFF8C3F8E4674A68976AADE815B6B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	designate participants;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="EA61D97227E04164A7C77BA596653D14" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	determine the types of awards to grant to each participant and the number, terms and conditions of any award;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="88DB5A0F46784C6C972B69935C352C07" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	establish, adopt or revise any rules and regulations as it may deem necessary or advisable to administer the Plan; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3AF2D93D49194806BAD9911325415D2B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	make all other decisions and determinations that may be required under, or as the Compensation Committee deems necessary or advisable to administer, the Plan.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-56-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage57"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Awards under the 2000 Plan
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The 2000 Plan expired on August 6, 2010, and thus no shares are available for future grant under the 2000 Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Awards under the 2008 Plan
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following is a summary description of financial instruments that may be granted to participants in our 2008 Plan by the Compensation Committee of our board of directors. The Compensation Committee to date has only granted stock options to participants in the 2008 Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Stock Options
</FONT>
	. The Compensation Committee is authorized to grant both incentive stock options and non-qualified stock options. The terms of any incentive stock option must meet the requirements of Section 422 of the Internal Revenue Code. The exercise price of an option may not be less than the fair market value of the underlying stock on the date of grant, and no option may have a term of more than 10 years from the grant date.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Restricted Stock
</FONT>
	. The Compensation Committee may make awards of restricted stock, which will be subject to forfeiture to us and other restrictions as the Compensation Committee may impose.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Stock Bonus Awards.
</FONT>
	The Compensation Committee may make awards of stock bonus awards in consideration for past services actually rendered, which will be subject to repurchase by us and such other terms as the Compensation Committee may impose.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Limitations on Transfer; Beneficiaries.
</FONT>
	Stock Option awards under the 2008 Plan may generally not be transferred or assigned by participants other than by will or the laws of descent and distribution. Awards of Restricted Stock or Stock Bonus awards may be transferred or assigned only upon such terms and conditions as set forth in the award agreement or as determined by the Compensation Committee in its discretion.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Acceleration Upon Certain Events.
</FONT>
	In the event of a "Corporate Transaction" as defined in the 2008 Plan, all outstanding options will become fully vested, subject to the holder's consent with respect to incentive stock options, and exercisable and all restrictions on all outstanding awards will lapse.&#160; Unless the surviving or acquiring entity assumes the awards in the Corporate Transaction or the stock award agreement provides otherwise, the stock awards will terminate if not exercised at or prior to the Corporate Transaction.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Termination and Amendment
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our board of directors or the Compensation Committee may, at any time and from time to time, terminate or amend the 2000 Plan or the 2008 Plan without stockholder approval; provided, however, that our board or the Compensation Committee may condition any amendment on the approval of our stockholders if such approval is necessary or deemed advisable with respect to tax, securities or other applicable laws, policies or regulations. No termination or amendment of the Plans may adversely affect any award previously granted without the written consent of the participants affected. The Compensation Committee may amend any outstanding award without the approval of the participants affected, except that no such amendment may diminish or impair the value of an award
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Holdings of Previously Awarded Equity
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Equity awards held as of December 31, 2015 by each of our named executive officers were issued under our 2000 Plan and 2008 Plan. The following table sets forth outstanding equity awards held by our named executive officers as of December 31, 2015:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-57-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage58"></A>
</DIV>
<EFX_OPTIONS_AGGREGATE>
<A NAME="FIS_OPTIONS_AGGREGATE"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015 Outstanding Equity Awards at Fiscal Year-End
</DIV>
<DIV>
	&#160;
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3E407530539F460ABB1CB133FA0B4A47" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="18">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option Awards
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Securities
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Underlying
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Unexercised
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Options
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(#)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 154PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name
</FONT>
<FONT STYLE="FONT-SIZE: 5.1PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercisable
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Unexercisable
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 154PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option Exercise
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Price (2)
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	($)
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expiration Date
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,000,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/25
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	President and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	400,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.15
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/24
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	616,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	308,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.66
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/09/23
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,995
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,181
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.46
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3/07/23
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	500,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/22
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	142,857
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.17
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/11/21
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	107,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.07
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/20
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	107,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.35
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/19
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	42,857
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11/21/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	64,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4/07/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	50,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4/18/17
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	28,571
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6/16/16
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/25
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 18PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Financial Officer and Treasurer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	66,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	133,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.15
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/24
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	50,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.66
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/09/23
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/22
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	28,571
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.17
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/11/21
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.07
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/20
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17,857
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.35
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/19
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	01/02/19
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11/21/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,571
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	04/07/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,571
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/06/17
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,714
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10/26/17
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Daniel Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	500,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/25
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Executive Vice President and Chief Medical Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	133,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	266,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.15
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/24
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40.05%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	44,521
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	n/
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	a
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	n/
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	333,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	166,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.39
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/09/23
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40.05%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	46,751
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	n/
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	a
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	n/
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	71,429
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.17
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/11/21
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	35,714
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.07
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/20
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	71,429
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.42
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10/11/19
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40.05%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Benjamin S. Levin
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/25
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General Counsel, Sr. Vice President &#8212; Legal Affairs and Secretary
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	66,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	133,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.39
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/24
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.66
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/09/23
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/22
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	35,714
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.17
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/11/21
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.07
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/20
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.35
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/19
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11/21/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4/07/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4/18/17
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12,857
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6/16/16
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40.05%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Wieland, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/25
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 21.95PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Senior Vice President &#8211; Drug Development
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	66,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	133,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.15
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/24
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	50,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.39
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/09/23
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/22
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	28,571
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.17
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/11/21
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.07
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/14/20
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.35
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/10/19
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.99
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7/01/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11/21/18
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4/18/17
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,571
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 139PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.05
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 13PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12/06/17
</DIV>
</TD>
</TR>
</TABLE>
</EFX_OPTIONS_AGGREGATE>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-58-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage59"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D05E192BC894495592FCD9B5D89C8372" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	These options vest in 36 equal monthly installments, subject to the named executive officer's remaining in our continuous employ through such dates. All stock options held by Mr. Kriegsman and Dr. Levitt provide for (a) vesting, in full, of the stock options in the event of, and upon, FDA approval to market aldoxorubicin and in the event of the termination of Dr. Levitt's employment by us without "cause" or due to his "disability," his resignation for "good reason" or his death and (b) the extended exercisability for their full term of all vested options in the event of the termination of his employment other than a termination by us with "cause" or his resignation without "good reason."
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="805F60C67B044BD2A9FFCE3F0EA30750" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	These options were re-priced from $2.39 to $4.66 on June 1, 2015, with no change to the expiration date of the options.
</TD>
</TR>
</TABLE>
<BR>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="88DAC62C98AB49FAB1002CFE3E94A567" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Represents restricted stock fully-vested at December 31, 2015. On December 31, 2012, Dr. Levitt was granted 100,000 shares of restricted stock, and an additional 100,000 shares of restricted stock were awarded to him in December 2013 and issued in January 2014. We reacquired 108,728 shares in order to satisfy income tax withholding obligations, as permitted under the agreement. No restricted stock was granted in 2014 or 2015.
</TD>
</TR>
</TABLE>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreements and Potential Payment upon Termination or Change in Control
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreement with Steven A. Kriegsman
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr. Kriegsman is employed as our Chief Executive Officer pursuant to a third amendment dated as of March 8, 2016 to his fourth amended and restated employment agreement. The employment agreement will automatically renew following the expiration date for an additional one-year period, unless either Mr. Kriegsman or we elect not to renew it.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Under his employment agreement, Mr. Kriegsman is currently entitled to receive a base salary of $850,000. Our board of directors (or its Compensation Committee) reviews the base salary annually and may increase (but not decrease) it in its sole discretion. In addition to his annual salary, Mr. Kriegsman is eligible to receive an annual bonus as determined by our board of directors (or its Compensation Committee) in its sole discretion, but not to be less than $150,000. Pursuant to his employment agreement, we have agreed that he shall serve on a full-time basis as our Chief Executive Officer and that he may continue to serve as Chairman of the Kriegsman Group only so long as necessary to complete certain current assignments.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr. Kriegsman is eligible to receive grants of options to purchase shares of our common stock. The number and terms of those options, including the vesting schedule, will be determined by our board of directors (or its Compensation Committee) in its sole discretion. In his employment agreement, however, we have agreed that all stock options held by Mr. Kriegsman will provide for (a)&#160;vesting, in full, of the stock options in the event of, and upon, FDA approval to market aldoxorubicin and in the event of the termination of Mr. Kriegsman's employment by us without "cause" or due to his "disability," his resignation for "good reason" or his death and (b) the extended exercisability for their full term of all vested options in the event of the termination of his employment other than a termination by us with "cause" or his resignation without "good reason."
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In Mr. Kriegsman's employment agreement, we have agreed that, if he is made a party, or threatened to be made a party, to a suit or proceeding by reason of his service to us, we will indemnify and hold him harmless from all costs and expenses to the fullest extent permitted or authorized by our certificate of incorporation or bylaws, or any resolution of our board of directors, to the extent not inconsistent with Delaware law. We also have agreed to advance to Mr. Kriegsman such costs and expenses upon his request if he undertakes to repay such advances if it ultimately is determined that he is not entitled to indemnification with respect to the same. These employment agreement provisions are not exclusive of any other rights to indemnification to which Mr. Kriegsman may be entitled and are in addition to any rights he may have under any policy of insurance maintained by us.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the event we terminate Mr. Kriegsman's employment without "cause" (as defined), or if Mr. Kriegsman terminates his employment with "good reason" (as defined), in either case whether during or following the term of his employment agreement (i) we have agreed to pay Mr. Kriegsman a lump-sum equal to his salary and prorated minimum annual bonus through to his date of termination, plus his salary and minimum annual bonus for a period of two years (three years if such termination occurs within two years following a change of control of the company) after his termination date, or until the expiration of the&#160; employment agreement, whichever is later, (ii) he will be entitled to immediate vesting of all stock options or other awards based on our equity securities, and (iii) he will also be entitled to continuation of his life insurance premium payments and continued participation in any of our health plans through to the later of the expiration of the amended and restated employment agreement or&#160; two years (three years if such termination occurs within two years following a change of control) following his termination date. Mr. Kriegsman will have no obligation in such events to seek new employment or offset the severance payments to him by any compensation received from any subsequent reemployment by another employer.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-59-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage60"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Under Mr. Kriegsman's employment agreement, he and his affiliated company, The Kriegsman Group, are to provide us during the term of his employment with the first opportunity to conduct or take action with respect to any acquisition opportunity or any other potential transaction identified by them within the biotech, pharmaceutical or health care industries and that is within the scope of the business plan adopted by our board of directors. Mr. Kriegsman's employment agreement also contains confidentiality provisions relating to our trade secrets and any other proprietary or confidential information, which provisions shall remain in effect for five years after the expiration of the employment agreement with respect to proprietary or confidential information and for so long as our trade secrets remain trade secrets.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Potential Payment upon Termination or Change in Control for Steven A. Kriegsman
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Mr. Kriegsman's employment agreement contains no provision for payment to him upon the event of a change in control of the company. If, however, a change in control (as defined in our 2000 Plan or our 2008 Plan) occurs and within two years after the date on which the change in control occurs, Mr. Kriegsman's employment is terminated by us without "cause" or by him for "good reason" (each as defined in his employment agreement), in either case, whether during or following the term of his employment agreement, then, in addition to the severance benefits described above, to the extent that any payment or distribution of any type by us to or for the benefit of Mr. Kriegsman resulting from the termination of his employment is or will be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended, we have agreed to pay Mr. Kriegsman, prior to the time the excise tax is payable with respect to any such payment (through withholding or otherwise), an additional amount that, after the imposition of all income, employment, excise and other taxes, penalties and interest thereon, is equal to the sum of (i) the excise tax on such payments plus (ii) any penalty and interest assessments associated with such excise tax.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreement with Daniel Levitt, M.D., Ph.D.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Daniel J. Levitt. M.D., Ph.D. is employed as our Executive Vice President and Chief Medical Officer pursuant to an employment agreement dated as of December 31, 2015 that is to expire on December 31, 2016. Dr. Levitt is entitled under his employment agreement to receive an annual base salary of $625,000, a $250,000 sign-on bonus paid in January 2016, and an annual bonus as determined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we terminate Dr. Levitt's employment without "cause" or Dr. Levitt resigns with "good reason" (as defined), we have agreed to pay him a lump-sum equal to his accrued but unpaid salary and vacation, plus an amount equal to one year's salary (two years' salary if such termination occurs within two years following a change of control of the company) under his employment agreement.&#160; In addition to the severance benefits described above, to the extent that any payment or distribution of any type by us to or for the benefit of Dr. Levitt resulting from the termination of his employment is or will be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended, we have agreed to pay Dr. Levitt, prior to the time the excise tax is payable with respect to any such payment (through withholding or otherwise), an additional amount that, after the imposition of all income, employment, excise and other taxes, penalties and interest thereon, is equal to the sum of (i) the excise tax on such payments plus (ii) any penalty and interest assessments associated with such excise tax.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We agree in Dr. Levitt's employment agreement that if we do not offer to renew or extend his employment agreement, and that his employment had not theretofore been terminated, we will continue to pay him his annual salary thereunder during the period commencing upon expiration of his employment agreement and ending on December 31, 2017.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreement with John Y. Caloz
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	John Y. Caloz is employed as our Chief Financial Officer and Treasurer pursuant to an employment agreement dated as of December 31, 2015 that is to expire on December 31, 2016. Mr. Caloz is paid an annual base salary of $400,000 and is eligible to receive an annual bonus as determined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we terminate Mr. Caloz's employment without cause (as defined), we have agreed to pay him a lump-sum equal to his accrued but unpaid salary and vacation, plus an amount equal to six months' salary under his employment agreement.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-60-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage61"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We agree in Mr. Caloz's employment agreement that if we do not offer to renew or extend his employment agreement, and that his employment had not theretofore been terminated,&#160; we will continue to pay him his annual salary thereunder during the period commencing upon expiration of his employment agreement and ending on June 30, 2017.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreement with Scott Wieland, Ph.D.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Scott Wieland is employed as our Senior Vice President &#8212; Drug Development pursuant to an employment agreement dated as of December 31, 2015 that is to expire on December 31, 2016. Dr. Wieland is paid an annual base salary of $400,000 and is eligible to receive an annual bonus as determined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we terminate Dr. Wieland's employment without "cause" (as defined), we have agreed to pay him a lump-sum equal to his accrued but unpaid salary and vacation, plus an amount equal to six months' base salary.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We agree in Dr. Wieland's employment agreement that if we do not offer to renew or extend his employment agreement, and that his employment had not theretofore been terminated,&#160;&#160; we will continue to pay him his annual salary thereunder during the period commencing upon expiration of his employment agreement and ending on June 30, 2017.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment Agreement with Benjamin S. Levin
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Benjamin S. Levin is employed as our Senior Vice President &#8212; Legal Affairs, General Counsel and Secretary pursuant to an employment agreement dated as of December 31, 2015 that is to expire on December 31, 2016. Mr. Levin is paid an annual base salary of $365,000 and is eligible to receive an annual bonus as determined by our board of directors (or our Compensation Committee) in its sole discretion. In the event we terminate Mr. Levin's employment without "cause" (as defined), we have agreed to pay him a lump-sum equal to his accrued but unpaid salary and vacation, plus an amount equal to six months' base salary.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We agree in Mr. Levin's employment agreement that if we do not offer to renew or extend his employment agreement, and that his employment had not theretofore been terminated,&#160; we will continue to pay him his annual salary thereunder during the period commencing upon expiration of his employment agreement and ending on June 30, 2017.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Quantification of Termination Payments and Benefits
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The table below reflects the amount of compensation to each of our named executive officers in the event of termination of such executive's employment without "cause" or his resignation for "good reason," termination following a change in control and termination upon the executive's death of permanent disability. The named executive officers are not entitled to any payments other than accrued compensation and benefits in the event of their voluntary resignation. The amounts shown in the table below assume that such termination was effective as of December 31, 2015, and thus includes amounts earned through such time, and are estimates only of the amounts that would be payable to the executives. The actual amounts to be paid will be determined upon the occurrence of the events indicated.
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Termination Payments and Benefits
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -9PT; MARGIN-LEFT: 9PT">
	&#160;
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="11767254497C4DD89879B89FBCD5CDF3" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 23.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 10.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 2.6%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Termination w/o Cause or, for Mr. Kriegsman and Dr.&#160; Levitt, for Good Reason
</DIV>
</TD>
<TD STYLE="WIDTH: 11.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name
</FONT>
<FONT STYLE="FONT-SIZE: 5.2PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT; WIDTH: 10.88%; MARGIN-LEFT: 18PT; VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: NORMAL">
	&#160;Benefit
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;Note
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Before Change in
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Control ($)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	After Change in
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Control ($)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Death ($)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Disability ($)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Change in
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Control ($)
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Severance Payment
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(4)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,700,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,550,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,700,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,700,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Executive Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Stock Options
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(1)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	311,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	311,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	311,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	311,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	311,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Health Insurance
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(2)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 12.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,800
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	128,600
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,800
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,800
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: TOP">
	&#160;Life Insurance
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 12.15PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,400
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9.35PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	41,100
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,400
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 21PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: TOP">
	&#160;Bonus
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	450,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: TOP">
	&#160;Tax Gross Up
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: TOP">
	&#160;(3)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 41.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 38.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Severance Payment
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(4)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	400,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Chief Financial Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Stock Options
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(1)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 41.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9.35PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Daniel Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Severance Payment
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(4)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	625,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,250,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Executive Vice President and Chief Medical Officer
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Stock Options
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(1)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 41.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	281,700
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	281,700
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Health Insurance
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,700
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 17.7PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,400
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Benjamin S. Levin
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Severance Payment
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(4)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	182,500
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 1PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	365,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General Counsel, Senior Vice President and Secretary
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Stock Options
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(1)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 41.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 9.35PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	96,300
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	96,300
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Wieland, Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Severance Payment
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(4)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	400,000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Senior Vice President &#8211; Drug Development
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;Stock Options
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;(1)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 38.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 3.8PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,700
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,700
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 23.9%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 10.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 2.6%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 17.89%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 12.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 11.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 9.88%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 9.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="27C07A4D8CB64CB2AF93C5D478AA2F39" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#160;(1)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Represents the aggregate value of stock options that vest and become exercisable immediately upon each of the triggering events listed as if such events took place on December 31, 2015, determined by the aggregate difference between the stock price as of December 31, 2015 and the exercise prices of the underlying options.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="793F4925E56E498AB34211C6272FB0DB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Represents the cost as of December 31, 2015 for benefits provided to Mr. Kriegsman for a period of two years, or in the event of a change in control, a period of three years.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F6CCD19CA4044FE1847E81CB19967738" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Each of Mr. Kriegsman's and Dr. Levitt's employment agreements provides that if a change in control (as defined in our 2000 Plan or our 2008 Plan) occurs during the term of the employment agreement, and if, during the term and within two years after the date on which the change in control occurs, Mr. Kriegsman's or Dr. Levitt's employment, respectively, is terminated by us without "cause" or by him for "good reason" (each as defined in their respective employment agreement), then, to the extent that any payment or distribution of any type by us to or for the benefit of Mr. Kriegsman or Dr. Levitt, respectively, resulting from the termination of their respective employment is or will be subject to the excise tax imposed under Section 4999 of the Internal Revenue Code of 1986, as amended, we will pay Mr. Kriegsman or Dr. Levitt, respectively, prior to the time the excise tax is payable with respect to any such payment (through withholding or otherwise), an additional amount that, after the imposition of all income, employment, excise and other taxes, penalties and interest thereon, is equal to the sum of (i) the excise tax on such payments plus (ii) any penalty and interest assessments associated with such excise tax. Based on each of Mr. Kriegsman's and Dr. Levitt's past compensation and the estimated payment that would result from a termination of employment following a change in control, we have estimated that a gross-up payment would not be required. "Good reason" as defined in each of Mr. Kriegsman's and Dr. Levitt's employment agreement includes any change in Mr. Kriegsman's or Dr. Levitt's duties or title, as applicable, that are inconsistent with their respective positions.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6D25548038AF46F9B302B4ABFA87FF0E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Severance payments are prescribed by our employment agreements with the named executive officers and represent a factor of their annual base compensation ranging from six months to three years.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-61-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage62"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation of Directors
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We use a combination of cash and stock-based compensation to attract and retain qualified candidates to serve on our board of directors. Directors who also are employees of our company currently receive no compensation for their service as directors or as members of board committees. In setting director compensation, we consider the significant amount of time that directors dedicate to the fulfillment of their director responsibilities, as well as the competency and skills required of members of our board. The directors' current compensation schedule has been in place since December 2013. The directors' annual compensation year begins with the annual election of directors at the annual meeting of stockholders. The annual retainer year period has been in place for directors since 2003. Periodically, our board of directors reviews our director compensation policies and, from time to time, makes changes to such policies based on various criteria the board deems relevant.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our non-employee directors receive a quarterly retainer of $6,000 (plus an additional $5,000 for the Chairmen of the Audit Committee and Compensation Committee, and $1,500 for the Chairman of the Nomination and Governance Committee), a fee of $3,000 for each board meeting attended ($750 for board actions taken by unanimous written consent), $2,000 for each meeting of the Audit Committee and Compensation Committee attended, and $1,000 for each meeting of the Nomination and Governance Committee meeting attended. Non-employee directors who serve as the chairman of a board committee receive an additional $2,000 for each meeting of the Nomination and Governance Committee attended and an additional $2,500 for each meeting of the Audit Committee or the Compensation Committee attended. During 2015, we granted ten-year stock options to purchase 180,000 shares of our common stock to newly appointed non-employee directors, namely, Anita Chawla, Ph.D., Eric Selter and Cheryl Cohen at an exercise price equal to the market value of our common stock on the date of grant. In December 2015, we also granted ten-year stock options to purchase 180,000 shares of our common stock to each non-employee director at an exercise price equal to the market value of our common stock on the date of grant. The options vested, in full, upon grant.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table sets forth the compensation paid to our directors other than our Chief Executive Officer for 2015:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Director Compensation Table
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="00C6F017CA484B93AC91DC55119C050B" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Name (1)
</FONT>
<FONT STYLE="FONT-SIZE: 5.05PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Fees Earned or Paid in Cash ($)
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2)
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Option Awards
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	($) (3)
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total ($)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Joseph Rubinfeld, Ph.D., Lead Director
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	111,750
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	368,300
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	480,050
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Louis Ignarro, Ph.D., Director
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	68,750
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	368,300
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	437,050
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Anita Chawla, Ph.D., Director
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	51,250
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	843,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	894,750
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Eric Selter, Director
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	57,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,028,360
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,085,860
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cheryl Cohen, Director
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	47,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	976,700
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,023,700
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Richard Wennekamp, Director (4)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	44,250
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	44,250
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8F67437FC1174E2CBA69032861BC3D79" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Steven A. Kriegsman does not receive additional compensation for his role as Chairman of the Board. For information relating to Mr. Kriegsman's compensation as Chief Executive Officer, see the Summary Compensation Table above.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="02D36DDE226A4A42B3F388EC9BEF408F" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	The amounts in this column represent cash payments made to Non-Employee Directors for annual retainer fees, committee and/or chairmanship fees and meeting fees during the year.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="A24AC510528B4F8CA5A94EDD6A7B3C7B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	In March, April and May, 2015, respectively, we granted stock options to purchase 180,000 shares of our common stock to newly-appointed non-employee directors, Anita Chawla, Ph.D., Eric Selter and Cheryl Cohen, respectively, at an exercise price equal to the current market value of our common stock on the date of grant, which had an aggregate grant date fair value respectively of $475,200, $660,060 and $608,400, calculated in accordance with FASB ASC Topic 718. The amount recognized for these awards was calculated using the Black Scholes option-pricing model, and reflect grants from our 2008 Long-Term Incentive Plan. In December 2015, we granted stock options to purchase 180,000 shares of our common stock to each non-employee director at an exercise price equal to the current market value of our common stock on the date of grant, which had an aggregate grant date fair value of $368,300. The amount recognized for these awards was calculated using the Black Scholes option-pricing model, and reflect grants from our 2008 Long-Term Incentive Plan, which is described in Note 12 of the Notes to Financial Statements.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D1E57744B3304BEEA098FE5F13734B14" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Richard Wennekamp's term as Director ended in June, 2015.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -15.95PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 15.95PT; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-62-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage63"></A>
</DIV>
</EFX_COMPENSATION>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 12.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Based solely upon information made available to us, the following table sets forth information with respect to the beneficial ownership of our common stock as of March 8, 2016 by (1) each person who is known by us to beneficially own more than five percent of our common stock; (2) each of our directors; (3) the named executive officers listed in the Summary Compensation Table under Item 11; and (4) all of our executive officers and directors as a group. Beneficial ownership is determined in accordance with the SEC rules. Shares of common stock subject to any warrants or options that are presently exercisable, or exercisable within 60 days of March 8, 2016 (which are indicated by footnote) are deemed outstanding for the purpose of computing the percentage ownership of the person holding the warrants or options, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The percentage ownership reflected in the table is based on 66,480,065 shares of our common stock outstanding as of March 8, 2016. Except as otherwise indicated, the holders listed below have sole voting and investment power with respect to all shares of common stock shown, subject to applicable community property laws. An asterisk represents beneficial ownership of less than 1%.
</DIV>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="AFAA523371574BC59FE45C76B150AF42" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 74.63%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2PX; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 4PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="6">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Shares of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Common Stock
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 74.63%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name and Address of Beneficial Owner
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 2PX; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	Note
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 4PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Percent
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	Named Executive Officers and Directors
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	#
</FONT>
</TD>
<TD STYLE="WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Louis Ignarro, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(1)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	692,416
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Steven A. Kriegsman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(2)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,871,088
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 22PX">
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Joseph Rubinfeld, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(3)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	759,285
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Eric Selter&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(4)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	545,785
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Anita J. Chawla, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(5)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	360,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 20PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cheryl Cohen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(6)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	360,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Dan Levitt, M.D., Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(7)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	828,574
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	John Y. Caloz&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(8)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	393,033
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Wieland, Ph.D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(9)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	378,095
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Benjamin S. Levin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(10)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	624,005
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	*
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	All executive officers and directors as a group (ten persons)&#160;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(11)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,812,282
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11.8
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 20PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 19PX">
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	Name and Address of 5% Beneficial Owners
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 21PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	QVT Financial LP
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(12)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,850,399
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.8
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Gene Z. Salkind, M.D.
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(13)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,963,597
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.5
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Scott Patterson, D.D.S.
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(14)
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,645,904
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Blackrock, Inc.
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM">
	&#160;(15)
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,434,433
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.2
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 74.63%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 2.74%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 4PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 22.5PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D1A48BC81779435FAD25E32B1A46C499" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)&#160;&#160;&#160;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 679,285 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8E0B9D8BC4EC4529AA9F54828575B0E4" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 2,273,977 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="DB19BCD8A93F413C9382BB2AD74B9314" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 759,285 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="609AB1D7E94E41EABEDBD80FB0C46DF5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(4)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 519,642 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="FE735607263645EE9E452C4C239DDE7B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(5)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 360,000 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7CAB39C079DB4C51986CB732CDCDF942" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(6)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 360,000 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="054B9E7B19F2444BBA0674F9D706B2C1" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(6)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 459,128 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E63C653C5B404235965AE99FD344EC4E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(7)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 723,016 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="68576C0DBC1948B1B54ECFD26E57B208" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(8)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 388,491 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6AFBE277A89548D29539F80004061D69" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(9)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 378,096 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2E1A10DC44364F3695E2A57F62BC8C83" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(10)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 619,208 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="507E3BE23DE94C918308E520541D655A" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(11)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Includes 4,650,602 shares subject to options or warrants.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="03A1F433748E46CEB15AAD87FBF618CC" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(12)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	According to its Schedule 13G filed with the SEC, QVT Financial LP ("QVT Financial") is the investment manager for QVT Fund V LP and other private investment funds (collectively, the "Funds"). The Funds aggregately own 5,850,399 shares of Common Stock.&#160; Accordingly, QVT Financial may be deemed to be the beneficial owner of an aggregate amount of 5,850,399 shares of common stock, consisting of the shares owned by the Funds. QVT Financial GP LLC, as General Partner of QVT Financial, may be deemed to beneficially own the same number of shares of common stock reported by QVT Financial. QVT Associates GP LLC, as General Partner of the Funds, may be deemed to beneficially own the aggregate number of shares of common stock owned by the Funds, and accordingly, QVT Associates GP LLC may be deemed to be the beneficial owner of an aggregate amount of 5,850,399 shares of common stock.&#160; The principal business addresses for QVT Financial LP and QVT Financial GP LLC are 1177 Avenue of the Americas, 9th Floor, New York, New York 10036.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="59ED59DDF8D34D3E9B3665091FE4C60F" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 37PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(13)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Of the shares shown, Dr.&#160;Salkind has sole voting and dispositive power over 53,000 shares and shares voting and dispositive power with his wife, Catherine Salkind, over 4,910,597 shares. Mrs.&#160;Salkind may be deemed to beneficially own the shares shown. Dr. and Mrs.&#160;Salkind's address is 727 Welsh Road, Suite 108, Huntingdon Valley, Pennsylvania 19006.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="AF4AF3C327C945E88E572569494278A6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(14)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Based on his Schedule 13G filed with the SEC, the shares shown include 4,564,005 shares owned beneficially by Dr. Patterson and 81,899 shares owned beneficially by his wife, Nataliya V. Patterson.&#160; Dr.&#160;and Mrs. Patterson's address is 1703 Casino Tower, Av. Francia y Biarritz, Punta del Este 20100, Uruguay.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="53F6179B054041E0A6784A718EDCABAC" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(15)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Based on its Schedule 13G filed with the SEC. The principal business address for Blackrock, Inc. is 55 East 52nd Street, New York, New York 10022.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Equity Compensation Plans
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The information required is incorporated herein by reference to Item 5 of this Annual Report relating to our Equity Compensation Plans as set forth on page 27.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-63-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage64"></A>
</DIV>
</EFX_SECURITY_OWNERS>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 13.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Director Independence
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our board of directors has determined that Messrs. Rubinfeld and Selter and Ms. Cohen are "independent" under the current independence standards of both The NASDAQ Capital Market and the SEC, and have no material relationships with us (either directly or as a partner, shareholder or officer of any entity) that are inconsistent with a finding of their independence as members of our board of directors. Our board has determined that Messrs. Rubinfeld and Selter and Ms. Cohen also are "independent" for purposes of service as the members of our Audit Committee. In making these determinations, our board of directors has broadly considered all relevant facts and circumstances, recognizing that material relationships can include commercial, banking, consulting, legal, accounting, and familial relationships, among others.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Transactions with Related Persons
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	General
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our Audit Committee is responsible for reviewing and approving, as appropriate, all transactions with related persons, in accordance with its Charter and NASDAQ Marketplace Rules.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Transactions between us and one or more related persons may present risks or conflicts of interest or the appearance of conflicts of interest. Our Code of Ethics requires all employees, officers and directors to avoid activities or relationships that conflict, or may be perceived to conflict, with our interests or adversely affect our reputation. It is understood, however, that certain relationships or transactions may arise that would be deemed acceptable and appropriate so long as there is full disclosure of the interest of the related parties in the transaction and review and approval by disinterested directors to ensure there is a legitimate business reason for the transaction and that the transaction is fair to us and our stockholders.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As a result, the procedures followed by the Audit Committee to evaluate transactions with related persons require:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E2A9A06BD90F4266884459D96D38949A" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	that all related person transactions, all material terms of the transactions, and all the material facts as to the related person's direct or indirect interest in, or relationship to, the related person transaction must be communicated to the Audit Committee; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0C8A9B290AD5407AA6CE052C8A54CD85" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	that all related person transactions, and any material amendment or modification to any related person transaction, be reviewed and approved or ratified by the Audit Committee, as required by NASDAQ Marketplace Rules.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our Audit Committee will evaluate related person transactions based on:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2D659E3DA2824DF6973CE3DC9A9EED1C" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	information provided by members of our board of directors in connection with the required annual evaluation of director independence;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4A938449DF6B4F0CA6E4356B9237737A" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	pertinent responses to the Directors' and Officers' Questionnaires submitted periodically by our officers and directors and provided to the Audit Committee by our management;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C0EB2834955A426BBD98117D4CDA3EEB" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	background information on nominees for director provided by the Nominating and Corporate Governance Committee of our board of directors; and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0DCF803BABE64293B5860DC244BC24E5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	any other relevant information provided by any of our directors or officers.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0BE7121DAE2942C48FA3B3F5FE1AAA36" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	In connection with its review and approval or ratification, if appropriate, of any related person transaction, our Audit Committee is to consider whether the transaction will compromise standards included in our Code of Ethics. In the case of any related person transaction involving an outside director or nominee for director, the Audit Committee also is to consider whether the transaction will compromise the director's status as an independent director as prescribed in the NASDAQ Marketplace Rules.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	There were no related person transactions in 2015.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Applicable Definitions
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For purposes of our Audit Committee's review:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="95F82424BD4D41F7ADA6D1B7C13F0264" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	"related person" has the meaning given to such term in Item 404(a) of Securities and Exchange Commission Regulation S-K ("Item 404(a)"); and
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D5C764E6754049C78F8113978069F70E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT; FONT-FAMILY: SYMBOL, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	&#183;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	"related person transaction" means any transaction for which disclosure is required under the terms of Item 404(a) involving us and any related persons.
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OFFICER_TRANSACTIONS>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 14.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	PRINCIPAL ACCOUNTING FEES AND SERVICES
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	BDO USA, LLP, or BDO, serves as our independent registered public accounting firm and audited our financial statements for the years ended December 31, 2015, 2014 and 2013.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Audit Fees
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The fees for 2015 and 2014 from BDO for professional services rendered in connection with the audits of our annual financial statements and internal controls over financial reporting and reviews of our unaudited quarterly financial statements and Form S-3 registration statements were $416,762 and $408,377, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Tax Fees
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The aggregate fees billed by BDO for professional services for tax compliance, tax advice and tax planning were $20,550 and $21,645 for 2015 and 2014, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	All Other Fees
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	No other services were rendered by BDO in either 2015 or 2014.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Pre-Approval Policies and Procedures
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	It is the policy of our Audit Committee that all services to be provided by our independent registered public accounting firm, including audit services and permitted audit-related and non-audit services, must be pre-approved by our Audit Committee. Our Audit Committee pre-approved all services, audit and non-audit, provided to us by BDO for 2015 and 2014.-6
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; PAGE-BREAK-AFTER: ALWAYS">
<FONT STYLE="FONT-SIZE: 8PT">
	-64-
</FONT>
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage65"></A>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	PART IV
</DIV>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Item 15.
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The following documents are filed as part of this 10-K:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	(
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	1
</U>
</FONT>
	)
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Financial Statements
</U>
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Our financial statements and the related report of the independent registered public accounting firm thereon are set forth on pages F-1 to F-20 of this Annual Report. These financial statements are as follows:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Balance Sheets as of December 31, 2015 and 2014
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Statements of Operations for the Years Ended December 31, 2015, 2014 and 2013
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Statements of Stockholders' Equity for the Years Ended December 31, 2015, 2014 and 2013
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Statements of Cash Flows for the Years Ended December 31, 2015, 2014 and 2013
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Notes to Financial Statements
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Reports of Independent Registered Public Accounting Firm
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	(2
</U>
</FONT>
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
	&#160;
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Financial Statement Schedules
</U>
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following financial statement schedule is set forth on page F-21 of this Annual Report.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Schedule II &#8212; Valuation and Qualifying Accounts for the years ended December 31, 2015, 2014 and 2013
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	All other schedules are omitted because they are not required, not applicable, or the information is provided in the financial statements or notes thereto.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibits
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	See Exhibit Index to this Annual Report, which is incorporated herein by reference.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-65-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage66"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CytRx Corporation
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Form 10-K Exhibit Index
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
	&#160;
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="CF92D93275544555BB0F480EC0F5A110" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 21.91%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Description
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Footnote
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	2.1
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Agreement and Plan of Merger, dated as of June&#160;6, 2008, among CytRx Corporation, CytRx Merger Subsidiary, Inc., Innovive Pharmaceuticals, Inc., and Steven Kelly
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(l)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	3.1
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Restated Certificate of Incorporation of CytRx Corporation, as amended
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(r)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	3.2
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Certificate of Amendment of Restated Certificate of Incorporation
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(t)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	3.3
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Restated By-Laws of CytRx Corporation, as amended
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	4.1
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Shareholder Protection Rights Agreement dated April 16, 1997 between CytRx Corporation and American Stock Transfer &amp;Trust Company, as Rights Agent
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	4.2
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 1 to Shareholder Protection Rights Agreement, dated February 11, 2002
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	4.3
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 2 to Shareholder Protection Rights Agreement, dated March 30, 2007
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(j)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	4.5
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Common Stock Purchase Warrant issued by CytRx Corporation to Alexander Capital, L.P.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	4.6
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Form of Common Stock Purchase Warrant issued by CytRx Corporation, dated August 1, 2011
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(n)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.1*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation 2000 Long-Term Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.2*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 1 to CytRx Corporation 2000 Long-Term Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.3*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 2 to CytRx Corporation 2000 Long-Term Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.4*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 3 to CytRx Corporation 2000 Long-Term Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(3)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.5*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 4 to CytRx Corporation 2000 Long-Term Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(4)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.6*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation Amended and Restated 2008 Stock Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(s)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.7*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	First Amendment to Amended and Restated CytRx Corporation 2008 Stock Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(v)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.8*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Second Amendment to Amended and Restated CytRx Corporation 2008 Stock Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(v)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.9*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Third Amendment to Amended and Restated CytRx Corporation 2008 Stock Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	w)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.10*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Fourth Amendment to Amended and Restated CytRx Corporation 2008 Stock Incentive Plan
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(x)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.11*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Form of Non-qualified Stock Option for grants to non-employee directors under Amended and Restated 2008 Stock Incentive Plan.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.12*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Form of Non-qualified Stock Option for grants to executive officers under Amended and Restated 2008 Stock Incentive Plan.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 21PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.13*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Form of Non-qualified Stock Option for grants to Steven A. Kriegsman and Daniel J. Levitt, M.D., Ph.D., under Amended and Restated 2008 Stock Incentive Plan.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.14*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 1 to Stock Option Agreements of Daniel J. Levitt, M.D., Ph.D., dated December 31, 2015.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.15*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 1 to Stock Option Agreements (2000 Long-Term Incentive Plan) of Steven A. Kriegsman, dated March 8, 2016.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.16*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment No. 1 to Stock Option Agreements (2008 Stock Incentive Plan) of Steven A. Kriegsman, dated March 8, 2016
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.17&#8224;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	License Agreement, dated December 7, 2001, by and between CytRx Corporation and Vical Incorporated
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.18
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Office Lease between The Kriegsman Capital Group, LLC and Douglas Emmett Joint Venture, dated April 13, 2000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(1)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.19
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Assignment, Assumption and Consent, effective July 1, 2003, by and among CytRx Corporation, The Kriegsman Capital Group, LLC and Douglas Emmett Joint Venture, concerning Office Lease dated April 13, 2000
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(2)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.20
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	First Amendment to Office Lease dated October 14, 2005, by and between CytRx Corporation and Douglas Emmett 1993, LLC
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(h)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;10.21&#8224;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	License Agreement dated April 17, 2006 between Innovive Pharmaceuticals, Inc. and KTB Tumorforschungs GmbH
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.22
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Amendment dated March 14, 2014 to License Agreement between CytRx Corporation and KTB Tumorforschungs GmbH
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(q)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.23
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Second Amendment to Office Lease dated June 30, 2008, by and between CytRx Corporation and Douglas Emmett 1993, LLC
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(m)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.24
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Third Amendment to Office Lease dated December 1, 2009, by and between CytRx Corporation and Douglas Emmett 1993, LLC
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(p)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.25
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Fourth Amendment to Office Lease dated February 10, 2014, by and between CytRx Corporation and Douglas Emmett 1993, LLC
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(y)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.26*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employment Agreement datedDecember 31, 2015, between CytRx Corporation and Daniel J. Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.27*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employment Agreement dated December 31, 2015, between CytRx Corporation and Benjamin S. Levin
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.28*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employment Agreement dated December 31, 2015, between CytRx Corporation and Scott Wieland
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.29*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employment Agreement dated December 31, 2015 , between CytRx Corporation and John Y. Caloz
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.30*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employment Agreement dated January 11 , 2016 by and between CytRx Corporation and Olivia S. Ware
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.31&#8224;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Asset Purchase Agreement dated May 13, 2011 by and between CytRx Corporation and Orphazyme ApS
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(o)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.32
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Letter Agreement dated February 9, 2016, between CytRx Corporation and Alexander Capital, L.P.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.33*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Fourth Amended and Restated Employment Agreement, dated May&#160;10, 2012, by and between CytRx Corporation and Steven A. Kriegsman.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(z)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.34*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	First Amendment to Fourth Amended and Restated Employment Agreement by and between CytRx Corporation and Steven A. Kriegsman, dated March 4, 2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(k)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.35*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Second Amendment to Fourth Amended and Restated Employment Agreement by and between CytRx Corporation and Steven A. Kriegsman, dated January 1, 2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;(aa)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.36*
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Third Amendment to Fourth Amended and Restated Employment Agreement by and between CytRx Corporation and Steven A. Kriegsman, dated March 8, 2016
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.37
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Loan and Security Agreement dated February 5, 2016 among CytRx Corporation, the Lender referred to therein, and Hercules Technology Growth Capital, Inc., as Agent
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(bb)(1)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.38
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Warrant Agreement dated as of February 5, 2016 issued by CytRx Corporation to Hercules Technology Growth Capital, LLC
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(bb)(2)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	10.39
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Warrant Agreement dated as of February 5, 2016 issued by CytRx Corporation to Hercules Technology III, L.P.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(cc)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	23.1
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Consent of BDO USA, LLP
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	31.1
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Certification of Chief Executive Officer Pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	31.2
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Certification of Chief Financial Officer Pursuant to 15 U.S.C. Section 7241, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	32.1
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	32.2
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	101.INS++
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	XBRL Instance Document.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	101.SCH++
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Schema Document.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	101.CAL++
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Calculation Linkbase Document.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	101.DEF++
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Definition Linkbase Document.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	101.LAB++
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Label Linkbase Document.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 21.91%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	101.PRE++
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 66.22%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Presentation Linkbase Document.
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 11.87%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
</TABLE>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -15.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 15.3PT; FONT-SIZE: 10PT">
	* Indicates a management contract or compensatory plan or arrangement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -15.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 15.3PT; FONT-SIZE: 10PT">
	&#8224; Confidential treatment has been requested or granted for certain portions which have been blanked out in the copy of the exhibit filed with the Securities and Exchange Commission. The omitted information has been filed separately with the Securities and Exchange Commission.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -15.3PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 15.3PT; FONT-SIZE: 10PT">
	++&#160; Pursuant to applicable securities laws and regulations, the Registrant is deemed to have complied with the reporting obligation relating to the submission of interactive data files in such exhibits and is not subject to liability under any anti-fraud provisions of the federal securities laws as long as the Registrant has made a good faith attempt to comply with the submission requirements and promptly amends the interactive data files after becoming aware that the interactive data files fails to comply with the submission requirements. These interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-66-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage67"></A>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="36ED509991C04AF492D72CC953E5F950" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on July 16, 2013
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 99.1 the Registrant's Form 8-K filed on April 17, 1997
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.11 to the Registrant's Form 10-K filed on March 27, 2001
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 99 to the Registrant's Form 8-K filed on December 21, 2001
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 4.2 to the Registrant's Form 10-K filed on April 1, 2002
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Annex C to the Registrant's Proxy Statement filed June 11, 2002
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(1)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.63 to the Registrant's Form 10-K filed on May 14, 2004
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(2)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.64 to the Registrant's Form 10-K filed on May 14, 2004
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(3)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.64 to the Registrant's Form 10-K filed on May 14, 2004
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)(4)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.64 to the Registrant's Form 10-K filed on May 14, 2004
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(h)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on October 20, 2005
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.15 to the CytRx Oncology Corp (f/k/a Innovive Pharmaceuticals, Inc.) Form 10-Q filed on November 14, 2006
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(j)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 4.3 to the Registrant's Form 10-K filed on April 2, 2007
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(k)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.32 to the Registrant's Form 10-K filed on March 5, 2014
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(l)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 2.1 to the Registrant's Form 8-K filed on June 9, 2008
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(m)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.29 to the Registrant's Form 10-K filed on March 13, 2009
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(n)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 4.1 to the Registrant's Form 8-K filed on July 27, 2011
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(o)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q filed on August 9, 2011
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(p)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q filed on December 4, 2009
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(q)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 1.1 to the Registrant's Form 8-K filed on March 17, 2014
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(r)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 3.1 to the Registrant's Form 10-K filed on March 13, 2012
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(s)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.6 to the Registrant's Form 10-K filed on March 13, 2012
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(t)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 3.1 to the Registrant's Form 8-K filed on May 15, 2012
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(u)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Annex B of the Registrant's Proxy Statement filed April 2, 2012
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(v)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Annex C of the Registrant's Proxy Statement filed April 2, 2012
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(w)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Annex A of the Registrant's Proxy Statement filed May 17, 2013
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(x)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Annex B of the Registrant's Proxy Statement filed May 17, 2013
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(y)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on February 13, 2014
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(z)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.1 to the Registrant's 8-K filed on October 19, 2012
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(aa)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.31 to the Registrant's Form 10-K filed on March 10, 2015
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(bb)(1)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on February 9, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	bb)(2)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by reference to Exhibit 10.2 to the Registrant's Form 8-K filed on February 9, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(cc)
</DIV>
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Incorporated by Reference to Exhibit 10.3 to the Registrant's Form 8-K filed on February 9, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 15.35%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 84.65%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-67-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage68"></A>
</DIV>
</EFX_EXHIBIT_INDEX>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	SIGNATURES
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="251E5F8EBE5F49F693CFB7F48E359E29" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #FFFFFF 4PX DOUBLE; WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Date: March 11, 2016
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #FFFFFF 4PX DOUBLE; WIDTH: 3%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/&#160;STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #FFFFFF 4PX DOUBLE; WIDTH: 12%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 35%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 35%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: MIDDLE">
	&#160;
</TD>
</TR>
</TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="B606E1F1520F4247952E9216D62A959C" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Signature
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Title
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Date
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ STEVEN A. KRIEGSMAN
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chairman of the Board, Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(Principal Executive Officer)
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ JOHN Y. CALOZ
</FONT>
<FONT STYLE="FONT-SIZE: 5.1PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Financial Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(Principal Financial and Accounting Officer)
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ LOUIS IGNARRO
</FONT>
<FONT STYLE="FONT-SIZE: 5.1PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Louis Ignarro, Ph.D.
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ JOSEPH RUBINFELD
</FONT>
<FONT STYLE="FONT-SIZE: 5PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Joseph Rubinfeld, Ph.D.
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ ERIC J. SELTER
</FONT>
<FONT STYLE="FONT-SIZE: 5.1PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Eric J. Selter
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="0E3DFD06DA51448E95899797927386E0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ ANITA J. CHAWLA
</FONT>
<FONT STYLE="FONT-SIZE: 5PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Anita J. Chawla, Ph.D.
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F478CC5ED10345948722136F0FC5731C" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ CHERYL COHEN
</FONT>
<FONT STYLE="FONT-SIZE: 5.1PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</DIV>
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 36.88%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Cheryl Cohen
</DIV>
</TD>
<TD STYLE="WIDTH: 39.28%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 23.84%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	-68-
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage69"></A>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	INDEX TO FINANCIAL STATEMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	AND FINANCIAL STATEMENT SCHEDULE
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="06D7F5CB3B544BE3A2A75AA14A6A3CD1" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	CytRx Corporation
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Report of Independent Registered Public Accounting Firm
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 2
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Balance Sheets
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 3
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Statements of Operations
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 4
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Statements of Stockholders' Equity
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 5
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Statements of Cash Flows
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 6
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Notes to Financial Statements
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 7
</DIV>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="WIDTH: 92.96%; VERTICAL-ALIGN: BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Financial Statement Schedule II &#8212; Valuation and Qualifying Accounts
</DIV>
</TD>
<TD STYLE="WIDTH: 7.04%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	F- 21
</DIV>
</TD>
</TR>
</TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-1
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage70"></A>
</DIV>
</EFX_SIGNATURES>
<DIV>
<BR>
</DIV>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</DIV>
<DIV STYLE="MARGIN-TOP: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Board of Directors and Stockholders
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, California
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	We have audited the accompanying balance sheets of CytRx Corporation ("the Company") as of December 31, 2015 and 2014 and the related statements of operations, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2015. In connection with our audits of the financial statements, we have also audited the financial statement schedule listed in the accompanying index under Item 15a (2). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.&#160; An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and schedule. We believe that our audits provide a reasonable basis for our opinion.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of CytRx Corporation at December 31, 2015 and 2014, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2015
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	,
</FONT>
	in conformity with accounting principles generally accepted in the United States of America.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Also, in our opinion, the financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), CytRx Corporation's internal control over financial reporting as of December 31, 2015, based on criteria established in
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Internal Control &#8211; Integrated Framework (2013)
</FONT>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated March 11, 2016 expressed an&#160;adverse opinion thereon.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	/s/ BDO USA, LLP
</DIV>
<DIV STYLE="MARGIN-TOP: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, California
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-2
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage71"></A>
</DIV>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	BALANCE SHEETS
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F47DE51C8F1D47C9B5EFBC4CED8E2BC6" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="6">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0.45PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 2.25PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	ASSETS
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Current assets:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash and cash equivalents
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	22,261,372
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	32,218,905
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Short-term investments
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	35,035,420
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	45,621,593
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Receivables
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,593,475
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,019,293
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Interest receivable
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	28,130
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	104,627
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Prepaid expenses and other current assets
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,373,708
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,250,355
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 21PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total current assets
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	64,292,105
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	83,214,773
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equipment and furnishings, net
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,467,681
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	970,873
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Goodwill
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	183,780
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	183,780
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Other assets
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,080,872
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,323,156
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total assets
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,024,438
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,692,582
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 104.55PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	LIABILITIES AND STOCKHOLDERS' EQUITY
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Current liabilities:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Accounts payable
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,058,624
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,655,962
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Accrued expenses and other current liabilities
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9,693,359
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,994,072
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;&#160;Non-cash litigation settlement due in shares of common stock
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,500,000&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Warrant liability
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	693,457
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,131,085
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total current liabilities
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	22,945,440
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17,781,119
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Commitment and contingencies
</DIV>
<DIV>
	&#160;
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Stockholders' equity:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 25,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Common stock, $.001 par value, 250,000,000 shares authorized; 66,480,065 and 55,921,986 shares issued and outstanding at December 31, 2015 and 2014, respectively
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	66,480
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	55,924
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Additional paid-in capital
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	409,107,292
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	376,975,984
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Treasury stock, at cost (199,275 shares at December 31, 2014)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,612,861
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Accumulated deficit
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(365,094,774
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(306,507,584
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total stockholders' equity
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	44,078,998
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,911,463
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total liabilities and stockholders' equity
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,024,438
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,692,582
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The accompanying notes are an integral part of these financial statements.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-3
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage72"></A>
</DIV>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	STATEMENTS OF OPERATIONS
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3AEBC2972B384F7E87FBBB4FD3318DB7" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years Ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Revenue:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Licensing revenue
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	300,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Expenses:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Research and development
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	43,395,574
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	36,677,706
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17,500,469
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General and administrative
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19,664,904
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12,845,231
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,273,576
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Depreciation and amortization
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	317,649
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	182,927
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	120,399
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	63,378,127
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	49,705,864
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,894,444
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Loss before other income (loss)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(63,278,127
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(49,605,864
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(27,594,444
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Other income (loss):
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Interest income
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	233,958
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	305,331
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	137,676
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Other income, net
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20,151
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	132,114
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	183,025
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Gain (loss) on warrant liability
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,437,628
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19,051,239
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(20,210,094
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Loss before provision for income taxes
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(58,586,390
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(30,117,180
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,483,837
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Provision for income taxes
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(800
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(800
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,600
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net loss
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(58,587,190
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(30,117,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,485,437
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Basic and diluted loss per share
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.97
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.55
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1.44
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Basic and diluted weighted average shares outstanding
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	60,483,151
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	54,371,151
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	32,891,202
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The accompanying notes are an integral part of these financial statements.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-4
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage73"></A>
</DIV>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	STATEMENTS OF STOCKHOLDERS' EQUITY
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="1037EB62B4F14437BEC9636E08DF2FAB" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="6">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Additional
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="6">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Common Stock
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Paid-In
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Accumulated
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Treasury
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Shares Issued
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Amount
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Capital
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Deficit
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stock
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 3.6PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Balance at December 31, 2012
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	30,607,916
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	30,608
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	261,318,638
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(228,904,167
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,279,238
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	30,165,841
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Issuance of stock options/warrants for compensation and services
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,798,717
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,798,717
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Common stock issued in connection with a public offering
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11,500,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	24,083,030
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	24,094,530
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Restricted stock expense
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	186,389
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	186,389
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Options and warrants exercised
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9,048
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	39,326
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	39,336
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Repurchase of common stock for treasury
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(138,009
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(138,009
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Net loss
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,485,437
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,485,437
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 3.6PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Balance at December 31, 2013
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	42,116,964
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	42,118
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	289,426,100
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(276,389,604
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,417,247
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,661,367
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Issuance of stock options/warrants for compensation and services
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,139,348
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,139,348
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Common stock issued in connection with a public offering
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,225,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,225
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	80,522,176
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	80,535,401
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Options and warrants exercised
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	280,022
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	281
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	431,660
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	431,941
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Issuance of restricted stock for compensation
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	626,900
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	627,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Issuance of common stock for compensation
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	200
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	829,800
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	830,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Repurchase of common stock for treasury
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(195,614
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(195,614
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Net loss
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(30,117,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(30,117,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 3.6PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Balance at December 31, 2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	55,921,986
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	55,924
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	376,975,984
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(306,507,584
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,612,861
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	67,911,463
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Issuance of&#160; stock options/warrants for compensation and services
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,384,656
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,384,656
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Common stock issued in connection with a public offering
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,465,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,465
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	26,769,603
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	26,780,068
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Options and warrants exercised
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	292,354
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	290
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	589,711
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	590,001
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Retirement of treasury stock
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(199,275
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(199
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,612,662
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,612,861
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 9.25PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Net loss
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(58,587,190
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(58,587,190
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -3.6PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 3.6PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 3.6PT">
	Balance at December 31, 2015
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	66,480,065
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	66,480
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	409,107,292
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(365,094,774
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	44,078,998
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The accompanying notes are an integral part of these financial statements.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-5
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage74"></A>
</DIV>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	STATEMENTS OF CASH FLOWS
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="20725B83A03B4A05B59BD0F0B9AEF155" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years Ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash flows from operating activities:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net loss
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(58,587,190
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(30,117,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,485,437
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Depreciation and amortization
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	317,649
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	182,927
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	120,399
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Loss on retirement of equipment and furnishings
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,614
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,220
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,595
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	(Gain) loss on warrant liability
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(4,437,628
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(19,051,239
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20,210,094
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 13.5PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;Unrealized foreign exchange gain
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(125,659
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(118,438
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Stock-based compensation expense
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,384,656
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,596,248
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,985,106
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;&#160;&#160;&#160;&#160;Non-cash litigation settlement due in common stock
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	4,500,000&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;&#160;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Changes in assets and liabilities:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 22.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Receivable
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,574,182
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,901,766
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(835
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 22.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Interest receivable
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	76,497
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(96,163
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	18,053
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 22.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Prepaid expenses and other current assets
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,118,931
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,126,771
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,132,428
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 22.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Accounts payable
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	916,919
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,779,409
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	789,655
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 22.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Accrued expenses and other current liabilities
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,699,287
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,303,967
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(139,747
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net cash used in operating activities
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(47,582,447
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(40,555,807
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(23,750,983
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash flows from investing activities:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Proceeds from matured short-term investments
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	76,544,319
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	38,584,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	24,000,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;Purchase of short-term investments
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(65,958,146
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(57,121,593
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(27,084,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Purchases of equipment and furnishings
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(331,328
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(956,286
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(41,809
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net cash provided by (used in) investing activities
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,254,845
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(19,492,899
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(3,126,789
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash flows from financing activities:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Proceeds from common stock issued in public offering, net of fees
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	26,780,068
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	80,535,401
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	24,094,530
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Proceeds from issuance of restricted stock to employee
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Repurchase of Company's own stock for treasury
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(182,943
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(117,070
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net proceeds from exercise of stock options and warrants
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	590,001
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	431,941
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	39,336
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net cash provided by financing activities
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,370,069
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	80,784,499
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	24,016,796
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net increase (decrease) in cash and cash equivalents
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(9,957,533
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20,735,793
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,860,976
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash and cash equivalents at beginning of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	32,218,905
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11,483,112
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,344,088
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash and cash equivalents at end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	22,261,372
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	32,218,905
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11,483,112
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Supplemental disclosures of non-cash financing activities:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cashless warrant exercises
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	133
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Repurchase of Company's own stock for treasury
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12,671
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,829
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equipment and furnishings purchased but not paid
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	485,743
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	23,282
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,360
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Retirement of treasury stock
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,612,861
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Supplemental disclosure of Cash Flow Information:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Cash paid during the year for income taxes
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	800
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	800
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	800
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The accompanying notes are an integral part of these financial statements.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-6
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage75"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	NOTES TO FINANCIAL STATEMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	1. Nature of Business
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	CytRx Corporation ("CytRx" or the "Company") is a biopharmaceutical research and development company specializing in oncology. The Company currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its modified version of the widely-used chemotherapeutic agent, doxorubicin. CytRx has reported positive top-line efficacy results (median progression-free survival, progression-free survival at six months, overall response rates, hazard ratios and overall survival) from its completed, global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, or STS. Hazard ratios - the likelihood that the study endpoint (in this case tumor progression) will be reached during a given period - are an important measure of the reliability and uniformity of the absolute data for progression-free survival, or PFS. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable STS. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin (3&#189; to 4 times) without the major dose-limiting toxicities seen with administration of doxorubicin alone.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the first quarter of 2014, CytRx initiated a pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with STS whose tumors have progressed following treatment with chemotherapy, and it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. The Phase 3 trial is being conducted under a Special Protocol Assessment, or SPA, granted by the U.S. Food and Drug Administration, or FDA. The SPA means that the FDA agrees that the design and analyses proposed in the Phase 3 trial protocol are acceptable to support regulatory approval of the product candidate with respect to effectiveness of the indication studied, and will not subsequently change its perspective on these matters, unless previously unrecognized public or human health concerns were to arise or CytRx were to subsequently modify the protocol.&#160;Thus, if the study demonstrates an acceptable benefit-risk profile as determined by the FDA, it would suffice as the single pivotal trial to demonstrate effectiveness and would support registration of aldoxorubicin for this indication. The clinical trial has completed its target enrollment of 400 patients at approximately 79 clinical sites in the U.S., Europe, Canada, Latin America and Australia.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company is currently evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors.&#160; CytRx previously completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for STS, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company is currently completing pre-clinical development for DK049, a novel anti-cancer drug conjugate that utilizes the Company's Linker Activated Drug Release (LADR
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	TM
</SUP>
	) technology.&#160; DK049 was created at CytRx's laboratory facility in Freiburg, Germany, and employs a proprietary linker that is both pH sensitive and requires a specific enzyme for the release of the cytotoxic payload.&#160; DK049 has demonstrated significant anti-tumor activity in multiple animal models implanted with human tumors, including non-small cell lung, ovarian and pancreatic cancers
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company plans to expand its pipeline of oncology candidates through its drug development activities at its laboratory facility (a branch of the Company) in Freiburg, Germany, based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater drug concentration at tumor sites.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, the Company had cash and cash equivalents of approximately $22.3 million and short-term investments of $35.0 million. On February 6, 2016, CytRx announced the signing of a long-term loan agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40.0 million in financing, of which the Company has received $25.0 million. Management believes that its
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	current resources will be sufficient to fund its operations for the foreseeable future.
</FONT>
	The estimate is based, in part, upon the Company's currently projected expenditures for 2016 of approximately $58.9 million (unaudited)
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	,
</FONT>
	which
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	includes approximately $34.3 million (unaudited) for its clinical programs for aldoxorubicin, approximately $5.4 million (unaudited) for pre-clinical development of new albumin-binding cancer drugs, including DK049, approximately $4.2 million (unaudited) for general operation of its clinical programs, and approximately $15.0 million (unaudited) for other general and administrative expenses, including pre-commercialization expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and actual expenditures may be significantly different from these projections. The Company will ultimately be required to obtain additional funding in order to execute its long-term business plans, although it does not currently have commitments from any third parties to provide it with long term debt or capital. The Company cannot assure that additional funding will be available on favorable terms, or at all. If the Company fails to obtain additional funding when needed, it may not be able to execute its business plans and its business may suffer, which would have a material adverse effect on its financial position, results of operations and cash flows.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<FONT STYLE="FONT-SIZE: 8PT">
	F-7
</FONT>
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage76"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2. Summary of Significant Accounting Policies
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Basis of Presentation
</FONT>
	&#8212; The accompanying Financial Statements are prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and accounting principles generally accepted in the United States ("GAAP").
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Revenue Recognition
</FONT>
	&#8212; Revenue consists of license fees from strategic alliances with pharmaceutical companies.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Monies received for license fees are deferred and recognized ratably over the performance period in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codifications ("ASC") ASC 605-25,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Revenue Recognition &#8211; Multiple-Element Arrangements
</FONT>
	("ASC 605-25"). Milestone payments will be recognized upon achievement of the milestone as long as the milestone is deemed substantive and the Company has no other performance obligations related to the milestone and collectability is reasonably assured, which is generally upon receipt, or recognized upon termination of the agreement and all related obligations. Deferred revenue represents amounts received prior to revenue recognition.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Revenues from contract research, government grants, and consulting fees are recognized over the respective contract periods as the services are performed, provided there is persuasive evidence or an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Once all conditions of the grant are met and no contingencies remain outstanding, the revenue is recognized as grant fee revenue and an earned but unbilled revenue receivable is recorded. There are no grant revenues earned for 2015, 2014 and 2013.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Other Income
</FONT>
	&#8212; The Company realized a de minimus amount of other income in 2015 and realized other income of $0.1 million in 2014, resulting from foreign exchange gains and other income of $0.2 million in 2013 resulting from foreign exchange gains
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Cash Equivalents
</FONT>
	&#8212; The Company considers all highly liquid debt instruments with an original maturity of 90 days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Short-term Investments
</FONT>
	&#8212;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</FONT>
	Investment securities held by the Company and expected to mature within 12 months are classified as available for sale
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Equipment and Furnishings
</FONT>
	&#8212; Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years for equipment and furniture) of the related assets. Whenever there is a triggering event that might suggest impairment, management evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the non-discounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. There are no impairment losses recognized in each of 2015, 2014 and 2013.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Fair Value Measurements
</FONT>
	&#8212; Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Level 1 &#8211; quoted prices in active markets for identical assets or liabilities.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Level 2 &#8211; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Level 3 &#8211; significant unobservable inputs that reflect management's best estimate of what market participants would use to price the assets or liabilities at the measurement date.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The following table summarizes fair value measurements by level at December 31, 2015 for assets and liabilities measured
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	at fair value on a recurring basis:
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8E4D1E111DB04373B9B01B728335911A" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(In thousands)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Level I
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Level II
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Level III
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 12PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 18PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Cash equivalents
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	20,673
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	20,673
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Short-term investments
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	35,035
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	35,035
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 19PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Warrant liability
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(693
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.2%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(693
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The following table summarizes fair value measurements by level at December 31, 2014 for assets and liabilities measured
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	at fair value on a recurring basis:
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7E9CD31FB383438D933D320C5EB417B5" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(In thousands)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Level I
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Level II
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Level III
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Cash equivalents
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	31,159
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.15%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	31,159
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 20PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Short-term investments
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	45,622
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.15%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	45,622
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Warrant liability
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.15%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(5,131
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(5,131
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	There were no transfers between Levels I, II and III during 2015 or 2014.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-8
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage77"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	The changes in carrying amounts of the warrant liability for the years ended December 31, 2015 and 2014 were as follows:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5B7D052DCB5944B39F0E47B0F899D7F2" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(In thousands)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Beginning balance
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	5,131
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	24,182
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Net changes in valuation
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(4,438
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(19,051
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Ending balance
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	693
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	5,131
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Liabilities measured at fair market value on a recurring basis include warrant liabilities resulting from recent debt and equity financing. In accordance with ASC 815-40,
</FONT>
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Derivatives and Hedging &#8211; Contracts in Entity's Own Equity
</FONT>
	("ASC 815-40"),
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	the warrant liabilities are being marked to fair value each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with the Company's application of ASC 505-50,
</FONT>
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Equity-Based Payments to Non-Employees
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	("ASC 505-50"). See
</FONT>
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Warrant Liabilities
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	below.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Patents and Patent Application Costs
</FONT>
	&#8212; Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are therefore expensed as incurred.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Net Income (Loss) Per Common Share
</FONT>
	&#8212; Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding. Diluted net income (loss) per common share is computed using the weighted-average number of common share and common share equivalents outstanding. Potentially dilutive stock options and warrants to purchase approximately 21.4 million, 17.4 million and 14.7 million shares at December 31, 2015, 2014 and 2013, respectively, were excluded from the computation of diluted net income (loss) per share, because the effect would be anti-dilutive.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Warrant Liabilities
</FONT>
	&#8212;Liabilities measured at fair value on a recurring basis include warrant liabilities resulting from the Company's August 2011 equity financings. In accordance with ASC 815-40, the warrant liabilities are being marked to fair value each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with CytRx's application of ASC 505-50. The gain or loss resulting from the fair value calculation is shown on the Statements of Operations as gain (loss) on warrant liability. See "Note&#160;10 &#8211; Warrant Liabilities" for additional information related to the determination of fair value of warrants.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Stock-based Compensation
</FONT>
	&#8212; The Company's stock-based employee compensation plans are described in Note 13. The Company has adopted the provisions of ASC 718, which requires the fair value measurement and recognition of compensation expense for all stock-based awards made to employees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For stock options and stock warrants paid in consideration of services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC 505-50
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	, Equity
</FONT>
	("ASC 505")
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	,
</FONT>
	as amended. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Research and Development Expenses
</FONT>
	&#8212; Research and development expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses and drugs, that are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in its products is expensed as incurred until technological feasibility has been established.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Clinical Trial Expenses
</FONT>
	&#8212; Clinical trial expenses, which are included in research and development expenses, include obligations resulting from the Company's contracts with various clinical research organizations in connection with conducting clinical trials for its product candidates. The Company recognizes expenses for these activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. The Company believes that this method best approximates the efforts expended on a clinical trial with the expenses it records. The Company adjusts its rate of clinical expense recognition if actual results differ from its estimates. If its estimates are incorrect, clinical trial expenses recorded in any particular period could vary.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-9
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage78"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Income Taxes
</FONT>
	&#8212; The Company accounts for income taxes in accordance with the provisions of FASB ASC 740-10,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Income Taxes, ("ASC 740"
</FONT>
	) which requires the recognition of deferred tax assets and liabilities for taxable temporary differences and deferred tax assets for deductible temporary differences and operating loss carry-forwards using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit or expense is recognized as a result of changes in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities based on the technical merits of the position. The Company's policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expenses.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Concentrations of Risks
</FONT>
	&#8212; Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company maintains cash and cash equivalents in large well-capitalized financial institutions and the Company's investment policy disallows investment in any debt securities rated less than "investment-grade" by national ratings services. The Company has not experienced any losses on its deposits of cash or cash equivalent or its short-term investments.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</FONT>
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Use of Estimates
</FONT>
	&#8212; The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates include the accrual for research and development expenses, valuation on deferred tax assets and the estimate of expense arising from the common stock options and warrants granted to employees and non-employees. Actual results could materially differ from those estimates.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Recent Accounting Pronouncements
</FONT>
	&#8212;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)," which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. &#160;The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted.&#160;The Company is currently evaluating the impact that the adoption of this ASU will have on its financial statements.
</FONT>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;In January 2016, the FASB issued ASU No. 2016-01 "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.
</FONT>
	" ASU 2016-01 amends various aspects of the recognition, measurement, presentation, and disclosure for financial instruments. With respect to the Company's financial statements, the most significant impact relates to the accounting for equity investments. It will impact the disclosure and presentation of financial assets and liabilities. ASU 2016-01 is effective for annual reporting periods, and interim periods within those years beginning after December 15, 2017. Early adoption by public entities is permitted only for certain provisions. The Company is currently in the process of evaluating the impact of the adoption of this standard on its financial statements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In April 2015, the FASB issued ASU No. 2015-03,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"Simplifying the Presentation of Debt Issuance Costs"
</FONT>
	("ASU 2015-03"), which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts. Further, ASU 2015-03 requires the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. ASU 2015-03 must be applied retrospectively. Entities may choose to adopt the new requirements as of an earlier date for financial statements that have not been previously issued. The Company expects ASU 2015-03 to impact its financial statements for periods subsequent to its long-term financing in February 2016.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-10
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage79"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"), which supersedes nearly all existing revenue recognition guidance under accounting principles generally accepted in United States ("U.S. GAAP"). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers" ("ASU 2015-14") which deferred the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date.&#160;&#160;Early adoption is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	When effective, ASU 2014-09 will use either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).&#160;&#160;The Company is currently evaluating the impact of its pending adoption of ASU 2014-09 on its consolidated financial statements and have not yet determined the method by which they will adopt the standard
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In August 2014, the FASB issued ASU No. 2014-15, "
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Presentation of Financial Statements &#8211; Going Concern (Subtopic 205-40)
</FONT>
	". The new guidance addresses management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. Management's evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect to early adopt this guidance and does not believe that the adoption of this guidance will have a material impact on its financial statements.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	3. Foreign Currency Remeasurement
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The U.S. dollar has been determined to be the functional currency for the net assets of the Company's laboratory in Freiburg, Germany. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a loss of approximately $6,000, $7,000 and $0 for the years ended December 31, 2015, 2014 and 2013, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	4. Receivables
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, the Company had a receivable of $4.6 million as compared to $2.0 million at December 31, 2014, primarily related to amounts recoverable from its insurance carrier, associated with ongoing legal proceedings. See "Note 11 - Commitments and Contingencies" for additional information on legal proceedings. Due to the likelihood of the collectability of the accounts receivable, no allowance was recorded.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5. Prepaid and Other Assets
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015 and 2014, the Company had $2.4 million and $3.3 million, respectively, of prepaid and other current assets, which consist primarily of deposits on contracts for research and development, prepaid insurance and leases for its facility.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	6. Short-term Investments
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company held $35.0 million of short-term investments at December 31, 2015. The Company has classified these investments as available for sale. These investments are comprised of federally insured certificates of deposit as follows: $15.0 million with a maturity date of February 26, 2016, and $20.0 million with a maturity date of March 31, 2016. At December 31, 2014, the Company held $45.6 million of short-term investments, which have since matured.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	7. Equipment and Furnishings
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Equipment and furnishings at December 31, 2015 and 2014 consist of the following (in thousands):
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="86F5478657444B0DA1A6DC8551915021" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equipment and furnishings
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,843
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,417
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Less &#8212; accumulated depreciation
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(375
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(446
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equipment and furnishings, net
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,468
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	971
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Depreciation and amortization expense for the years ended December 31, 2015, 2014 and 2013 were $317,649, $182,927 and $120,399, respectively.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-11
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage80"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	8. Accrued Expenses and Other Current Liabilities
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Accrued expenses and other current liabilities at December 31, 2015 and 2014 are summarized below (in thousands).
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2FFCF7B494904089BE5B40F736963B6C" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Professional fees
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,459
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,593
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Research and development costs
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,625
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,945
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Litigation settlement
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Wages, bonuses and employee benefits
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	527
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	451
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Other
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	82
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,193
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,994
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	9. Non-Cash Litigation Settlement Due in Shares of Common Stock
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
	On December&#160;10, 2015, CytRx announced that the Company had reached an agreement to settle the federal consolidated securities class action and filed a Stipulation of Settlement with the Court. As part of the settlement agreement, the Company will issue the equivalent number of shares of its common stock to the class of a non-cash amount of $4,500,000 worth at the prevailing stock price at the time of the Court's final approval of the settlement agreement, but not less than a minimum of 1,200,000 shares and not more than a maximum of 1,800,000 shares. In accordance with ASC 480, the Company has classified the $4.5 million worth of shares of the common stock as a liability included in the litigation settlement due in shares of common stock in the December 31, 2015 balance sheet, due to the variable number of shares that will be issued upon the Court's final approval of the settlement agreement.
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	10. Warrant Liabilities
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Warrants issued in connection with the Company's August 2011 equity public offering are classified as liabilities as opposed to equity due to their settlement terms. These warrants are non-cash liabilities and the Company is not required to expend any cash to settle these liabilities. The fair value of these warrants were recorded on the balance sheet at issuance and the warrants were marked to fair value at each financial reporting period, with changes in the fair value recorded as a gain or loss in the statement of operations. The fair value of the warrants is determined using the Black-Scholes option pricing model, which requires the use of significant judgment and estimates for the inputs used in the model. The following reflects the weighted-average assumptions for each of the periods indicated:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="681BD2C48F3D4C5BA0B29F711AC9AF89" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year Ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Risk-free interest rate
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.57
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.46
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.13% - 0.58
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Expected dividend yield
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Expected lives
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.95 &#8211; 2.59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;Expected volatility
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	61.7
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	89.7
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	83.4% - 95.3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Number of warrants classified as liabilities
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,371,854
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,371,854
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,984,716
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Gain (Loss) on warrant liabilities
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,437,628
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19,051,239
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(20,210,094
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. The expected lives are based on the remaining contractual lives of the related warrants at the valuation date. The Company's computation of expected volatility is based on the historical daily volatility of its publicly traded stock.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The warrants relating to the Company's August 2011 equity public offering will expire on August, 1, 2016, to the extent they are not exercised prior to that date.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-12
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage81"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	11. Commitments and Contingencies
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Commitments
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company acquires assets still in development and enters into research and development arrangements with third parties that often require milestone and royalty payments to the third party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, up to an aggregate of $7.5 million, contingent upon the successful achievement of an important point in the development life-cycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required, CytRx may also have to make royalty payments, based upon a percentage of the sales of the pharmaceutical product. In respect of aldoxorubicin, it agreed to pay up to a maximum amount of approximately $18.3 million, payable in shares of its common stock, in the event that regulatory approval for marketing is obtained.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	These arrangements may be material individually, and in the unlikely event that milestones for multiple products covered by these arrangements were reached in the same period, the aggregate charge to expense could be material to the results of operations in any one period. In addition, these arrangements often give CytRx the discretion to unilaterally terminate development of the product, which would allow CytRx to avoid making the contingent payments; however, CytRx is unlikely to cease development if the compound successfully achieves clinical testing objectives.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	CytRx's current contractual obligations that will require future cash payments are as follows (in thousands):
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="DD574CC8DCF7482FB31B056477495321" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Operating
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Leases
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Agreements (2)
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Research and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Development (3)
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Total
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	2016
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	318
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,647
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,940
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	31,905
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	2017
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	383
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,057
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,652
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,092
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;2018
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	363
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,057
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	86
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,506
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;2019
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	278
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	289
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	2020
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	59
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	&#160;&#160;Thereafter
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,401
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,761
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	36,689
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	43,851
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7012D50269FA435EB4F547572E0EE425" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(1)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Operating leases are primarily facility lease related obligations, as well as equipment lease obligations with third party vendors. The Company recognized rent expenses of $351,075, $335,991, and $315,134 in 2015, 2014 and 2013, respectively.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="FBECB6864AAA4C2BA342828310925C07" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(2)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Employment agreements include management contracts which have been revised from time to time. The employment agreement for the Company's executive officers provide for minimum salaries, which are adjusted annually at the discretion of the Company's Compensation Committee, and in some cases provide for minimum annual bonuses, and employee benefits,&#160;as well.&#160; New employment agreements for the Company's other executive officers are usually entered into annually or biennially.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="5E65B24885F2478EA42040F465778773" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	(3)
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
	Research and development obligations relate primarily to clinical trials. All of these purchase obligations are cancelable.
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-STYLE: ITALIC; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Contingencies
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	The Company applies the disclosure provisions of ASC 460,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Guarantees
</FONT>
	("ASC 460") to its agreements that contain guarantees or indemnities by the Company. The Company provides (i) indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims; and (ii) indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to the Company.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	The Company is occasionally involved in legal proceedings and other matters arising from the normal course of business. As previously reported in the Company's Quarterly Report filed with the SEC on November 3, 2015, on June&#160;13, 2014, three purported securities class action lawsuits pending against it and certain of its officers and directors in the United States District Court for the Central District of California were consolidated in the matter of In re CytRx Corporation Securities Litigation, 2:14-CV-01956-GHK (PJWx) (the "Federal Class Action"), and lead plaintiff and lead counsel were appointed. On October&#160;1, 2014, plaintiffs filed a consolidated amended complaint on behalf of all persons who purchased or otherwise acquired its publicly traded securities between November&#160;20, 2013 and March&#160;13, 2014, against it, certain of its officers and directors, a freelance writer, and certain underwriters, including Jefferies LLC, Oppenheimer&#160;&amp; Co., LLC, Aegis Corp., and H.C. Wainwright&#160;&amp; Co., LLC. The complaint alleges that certain of the defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements in press releases, promotional articles, SEC filings and other public statements. The complaint further alleges that certain of the defendants violated the Securities Act of 1933 by making materially misleading statements and omitting material information in its shelf Registration Statement on Form S-3 filed with the SEC on December&#160;6, 2012 and Prospectus Supplement under Rule 424(b)(2) filed with the SEC on January&#160;31, 2014. These allegations arise out of its alleged retention of The DreamTeam Group and MissionIR, external investor and public relations firms unaffiliated with them, as well as its December&#160;9, 2013 grant of stock options to certain board members and officers. The consolidated amended complaint seeks damages, including interest, in an unspecified amount, reasonable costs and attorneys' fees, and any equitable, injunctive, or other relief that the court may deem just and proper. On December&#160;5, 2014, the Company and the individual defendants filed a motion to dismiss the complaint. The Court was scheduled to hear argument on this motion on March&#160;2, 2015. On February&#160;25, 2015, the Court took this motion under submission and took the hearing off calendar. On July&#160;13, 2015, the Court issued an order granting in part and denying in part the motions to dismiss filed by them, the individual defendants and the underwriters. On August 7, 2015, the plaintiffs amended their complaint and on September 8, 2015, the defendants moved to dismiss the amended complaint, in part.&#160; On October 23, 2015, the Court took the motion to dismiss under submission and, as a result of the settlement of the case as set forth below, the motion to dismiss has not been ruled on by the Court.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 6PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	On April&#160;3, 2014, a purported class action lawsuit was filed against the Company and certain of its officers and each of its directors, as well as certain underwriters, in the Superior Court of California, County of Los Angeles, captioned Rajasekaran v. CytRx Corporation, et al., BC541426. The complaint purports to be brought on behalf of all shareholders who purchased or otherwise acquired its common stock pursuant or traceable to its public offering that closed on February&#160;5, 2014. The complaint alleges that defendants violated the federal securities laws by making materially false and misleading statements in its filings with the SEC. The complaint seeks compensatory damages in an unspecified amount, rescission, and attorney's fees and costs. On October&#160;14, 2014, the Court granted the parties' joint ex parte motion to stay this proceeding pending resolution of motions to dismiss in the related federal action, In re CytRx Corporation Securities Litigation, 2:14-CV-01956-GHK (PJWx).&#160; On December 29, 2015, as a result of the parties informing the Court that the settlement of the Federal Class Action also resolved the claims and allegations in the Rajasekaran case, the Superior Court deemed the case closed.
</DIV>
<DIV STYLE="MARGIN-TOP: 12PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	On December&#160;10, 2015, CytRx announced that the Company had reached an agreement to settle the federal consolidated securities class action and filed a Stipulation of Settlement with the Court. A hearing on plaintiffs' motion for preliminary approval of the settlement was held on January&#160;11, 2016. The agreement contains no admission of liability or wrongdoing and includes a full release of CytRx and the current and former directors and officers in connection with the allegations. The settlement is subject to definitive documentation, shareholder notice, and Court approval. The terms of the agreement provide for a settlement payment to the class of $4,000,000, of which at least $3,500,000 will be paid by its insurance carriers. The Company will also issue the equivalent number of shares of its common stock to the class of $4,500,000 worth of shares at the prevailing stock price at the time of the Court's final approval of the settlement agreement, but not less than a minimum of 1,200,000 shares and not more than a maximum of 1,800,000 shares.&#160; On January 9, 2016, the Court preliminarily approved the settlement, and set a settlement fairness hearing for final approval of the settlement for May 9, 2016.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-13
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage82"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	On July&#160;3, 2014, a shareholder derivative lawsuit was filed in the United States District Court for the Central District of California, captioned Fishman v. Kriegsman, et al., 2:14-cv-05169, purportedly on its behalf against certain of its officers and each of its directors. The complaint alleges breach of fiduciary duties, corporate waste, gross mismanagement, and unjust enrichment in connection with its alleged retention of DreamTeamGroup and MissionIR. The complaint seeks damages, restitution, corporate governance reforms, and attorney's fees and costs. On September&#160;3, 2014, plaintiff filed a notice to voluntarily dismiss this action against all parties without prejudice, which the Court granted on September&#160;9, 2014.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	On September&#160;10, 2014, the Delaware Court of Chancery consolidated Schwartz v. Ignarro, et al., Case No.&#160;9864, Johnson v. Ignarro, et al., Case No.&#160;9884, and Silverberg v. Kriegsman, et al., Case No.&#160;9919, three shareholder derivative lawsuits described in its Quarterly Report filed with the SEC on August&#160;6, 2014. The allegations in the Schwartz and Johnson complaints relate to the Company's December&#160;9, 2013 grant of stock options to certain board members and officers. The allegations in the Silverberg complaint relate to its December&#160;9, 2013 grant of stock options to certain board members and officers, as well as its alleged retention of DreamTeamGroup and MissionIR. A consolidated complaint concentrated on the stock-option grant claims was filed on October&#160;9, 2014. The consolidated lawsuit is captioned In re CytRx Corp. Stockholder Derivative Litigation, C.A. No.&#160;9864-VCL. On November&#160;10, 2014, the Company and the individual defendants filed a motion to dismiss the consolidated complaint or, in the alternative, to stay the action. The Court heard argument on the motions on January&#160;8, 2015. The Court denied the motion to dismiss and granted in part and denied in part the motion to stay the Delaware case pending the Federal Class Action. On June&#160;2, 2015, the Company announced that it had reached an agreement to settle the Delaware stockholder derivative action. Under the settlement, the Company has agreed to re-price outstanding stock options to purchase a total of 2,095,000 shares of its common stock that were granted on December&#160;10, 2013 to certain of its directors and officers from the original exercise price of $2.39 to an exercise price of $4.66 (the share price at market closing on December&#160;20, 2013). The settlement also provides that the Company will implement certain corporate governance changes and modify its governance practices regarding the granting of stock options. The parties reached an agreement on an award of $1.1 million of fees and expenses to plaintiffs' attorneys. On November&#160;20, 2015, the Delaware Court approved the settlement and award of attorneys' fees and expenses, and entered a final order and judgment. This amount was paid by the Company's insurance carriers in December, 2015.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On August&#160;14, 2014, a shareholder derivative lawsuit, captioned Pankratz v. Kriegsman, et al., 2:14-cv-06414-PA-JPR, was filed in the United States District Court for the Central District of California purportedly on the Company's behalf against certain of its officers and each of its directors. On August 15, 2014, a virtually identical complaint was filed, captioned Taylor v. Kriegsman, et al., 2:14-cv-06451.&#160; Each of the complaints alleges breach of fiduciary duties, unjust enrichment, gross mismanagement, abuse of control, insider selling and misappropriation of information in connection with the Company's alleged retention of DreamTeamGroup and MissionIR, as well as its December&#160;9, 2013 grant of stock options to certain board members and officers. The complaint seeks unspecified damages, corporate governance and internal procedures reforms, restitution, disgorgement of all profits, benefits, and other compensation obtained by the individual defendants, and the costs and disbursements of the action. On October&#160;8, 2014, the Court in Pankratz and Taylor consolidated the cases and appointed lead plaintiffs and co-lead counsel. On October&#160;20, 2014, the Company and the individual defendants filed motions to dismiss the consolidated Pankratz and Taylor cases or, in the alternative, to stay the cases. On January&#160;9, 2015, the Court stayed the action pending the resolution of the consolidated Delaware derivative action. On February&#160;27, 2015, the Pankratz and Taylor plaintiffs filed a motion to vacate the stay. On June&#160;24, 2015, the Court granted the motion to lift the stay in light of the pending settlement of the Delaware derivative litigation discussed above. The Court further denied the motion to dismiss without prejudice and invited the Company to move to dismiss the case within 30 days pursuant to the doctrine of
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	forum non conveniens
</FONT>
	based on its forum-selection bylaw, which mandates that derivative actions be filed in Delaware. The Court advised that it would consider any
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	forum non conveniens
</FONT>
	motion before considering a subsequent motion to dismiss under Rule 12. On November&#160;2, 2015, the Court granted the defendants' motion on grounds of
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	forum non conveniens,
</FONT>
	and the case was dismissed without prejudice to plaintiffs refiling the action in the Delaware Court of Chancery. Plaintiffs then filed an appeal with the Ninth Circuit Court of Appeals. On January&#160;5, 2016, the Company announced that it had reached an agreement to settle the consolidated stockholder derivative lawsuits,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In Re CytRx Corporation Stockholder Derivative Litigation
</FONT>
	, pending in the U.S. Court of Appeals for the Ninth Circuit Court, on appeal from the United States District Court for the Central District of California. The settlement includes no financial or equity compensation. It provides that it will implement certain corporate governance changes and modify certain governance practices. The settlement agreement contains no admission of liability or wrongdoing and includes a full release of the current and former directors and officers in connection with the allegations. The settlement is subject to the drafting of definitive documentation, notice to stockholders, and District Court approval.&#160; Plaintiffs' counsel is expected to petition the District Court for an award of attorneys' fees and costs.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; TEXT-INDENT: 24.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	On December&#160;14, 2015, a shareholder derivative complaint, captioned
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermeyer et al. v. Kriegsman et al.
</FONT>
	, C.A. No.&#160;11800, was filed in the Delaware Court of Chancery purportedly on the Company's behalf against certain of its officers and directors. The complaint alleges breach of fiduciary duty, unjust enrichment, and gross mismanagement in connection with the Company's alleged retention of DreamTeamGroup and MissionIR, as well as its December 2013 grant of stock options to certain board members and officers. The complaint seeks unspecified damages, corporate governance and internal procedures reforms, restitution, disgorgement of all profits, benefits, and other compensation obtained by the individual defendants, and the costs and disbursements of the action. On February 26, 2016, the Company and the defendants filed two motions with the Court of Chancery.&#160;First, we moved to dismiss because the
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermayer
</FONT>
	complaint fails to state a claim upon which relief can be granted and because the allegations and claims in the
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermayer
</FONT>
	complaint are effectively resolved by the settlement of the consolidated stockholder derivative lawsuits,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In Re CytRx Corporation Stockholder Derivative Litigation
</FONT>
	, pending in the United States District Court for the Central District of California, and the settlement of the derivative lawsuits already approved by the Delaware Court of Chancery,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In re CytRx Corp. Stockholder Derivative Litigation, C.A. No.&#160;9864-VCL
</FONT>
	.&#160; Second, we moved to stay the
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Niedermayer
</FONT>
	case until the Central District of California completes the approval process for the settlement of the consolidated derivative actions pending in that court,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In Re CytRx Corporation Stockholder Derivative Litigation
</FONT>
	.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company evaluates developments in legal proceedings and other matters on a quarterly basis.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company has accrued $9.0 million of litigation settlement, of which $3.5 million will be&#160;paid by the Company's insurance carriers and is recorded on the balance sheet as an accounts receivable, and a non-cash amount of $4.5 million which will be settled&#160;by the issuance of the Company's common stock.
</FONT>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-14
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage83"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	12. Equity Transactions
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As of December 31, 2015, the Company has reserved approximately 6.0 million of its authorized but unissued shares of common stock for future issuance pursuant to its employee stock option plans issued to employees and consultants.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On October 26, 2015, the Company retired 199,275 shares of its treasury stock at cost ($2.6 million).
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	On July, 24, 2015, the Company completed a $28.7 million underwritten public offering, in which it sold and issued approximately 10.5 million shares of common stock at a price of $2.75 per share. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received proceeds of approximately $26.8 million.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	On March 15, 2014, the Company issued 200,000 common shares to KTB Tumorforschungs GmbH, the licensor of aldoxorubicin, in connection with the establishment of the Company's Freiburg, Germany research and development laboratory. The fair value of the shares was $0.8 million, based on the stock price as of the date of the transaction.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	On February 5, 2014, the Company completed an $86.0 million underwritten public offering, in which it sold and issued 13.2 million
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	shares of common stock at a price of $6.50 per share. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received proceeds of approximately $80.5 million
</FONT>
	. Immediately after the sale, the Company had approximately 55.3 million shares of common stock outstanding, without giving effect to the possible exercise of any of the Company's outstanding warrants or stock options
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	On October 15, 2013, the Company completed a $25.9 million underwritten public offering, in which it sold and issued 11.5 million
</FONT>
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	shares of common stock at a price of $2.25 per share. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received proceeds of approximately $24.1 million
</FONT>
	.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	13. Stock Options and Equity-Classified Warrants
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stock Options
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company has a 2000 Long-Term Incentive Plan under which 1.4 million shares of common stock were originally reserved for issuance. As of December 31, 2015, there were approximately 0.6 million
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	shares subject to outstanding stock options. This plan expired on August 6, 2010, and thus no further shares are available for future grant under this plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company also has a 2008 Stock Incentive Plan under which 20 million shares of common stock are reserved for issuance. As of December 31, 2015, there were 13.6 million shares subject to outstanding stock options and 6.4 million shares available for future grant under this plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company follows the provisions of ASC 718,
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Compensation-Stock Compensation,
</FONT>
	which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On June&#160;2, 2015, the Company announced that it had reached an agreement to settle the Delaware stockholder derivative action. Under the settlement, they have agreed to re-price outstanding stock options to purchase a total of 2,095,000 shares of its common stock that were granted on December&#160;10, 2013 to certain of its directors and officers from the original exercise price of $2.39 to an exercise price of $4.66 (the share price at market closing on December&#160;20, 2013).
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The fair value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model, based on the following assumptions:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BF0EF23E8B704A17B2F0C1FC2477C981" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Risk-free interest rate
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.74% - 2.42
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.74% - 2.12
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.91% - 2.79
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expected volatility
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	74% - 85
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	82% - 90
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85% - 89
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expected lives (years)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6 - 10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6 - 10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6 - 10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 18PX">
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expected dividend yield
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.00
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.00
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.00
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company's computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For option grants issued during years ended December 31, 2015, 2014 and 2013, the Company used a calculated volatility for each grant. The Company lacks adequate information about the exercise behavior at this time and has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company's options of ten years with the average vesting term of three years for an average of six years. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. Based on historical experience, for each of the years ended December 31, 2015 and 2014, the Company has estimated an annualized forfeiture rate of 10% for options granted to its employees, 2% for options granted to senior management and 0% for options granted to directors; for the year ended December 31, 2013, the Company has estimated an annualized forfeiture rate of 12% for options granted to its employees, 2% for options granted to senior management and 0% for options granted to directors. Compensation costs will be adjusted for future changes in estimated forfeitures. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. No amounts relating to employee stock-based compensation have been capitalized.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-15
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage84"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, there remained approximately $5.6 million of unrecognized compensation expense related to unvested stock options granted to current employees and directors, to be recognized as expense over a weighted-average period of 1.26 years. Presented below is the Company's stock option activity for employees and directors:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8EC2DC96B948489FA02CDCD44A0BCF27" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 16PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 516PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stock Options
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 16PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 151PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 16PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 16PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 151PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 16PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding &#8212; beginning of year
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9,348,592
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,228,593
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,240,850
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.11
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.08
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Granted
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,590,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,180,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,323,176
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.61
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.47
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.43
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Exercised
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(287,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(476
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.93
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Forfeited
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(24,333
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(127,812
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.81
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.09
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Expired
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(77,587
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(34,001
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(207,145
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.58
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.18
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.59
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding &#8212; end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13,573,862
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9,348,592
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,228,593
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.11
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.11
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Exercisable at end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,015,164
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,901,511
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,125,720
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.45
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.22
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.86
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 28.04%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Weighted average fair value of stock options granted during the year:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.88
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.80
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.82
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	For stock options paid in consideration of services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC 505-50.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options, as calculated using the Black-Scholes option pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company recorded approximately $0, $1,276,000 and $40,000 of non-cash charges related to the issuance of stock options to certain consultants in exchange for services during 2015, 2014 and 2013, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, there was no unrecognized compensation expense related to unvested non-employee stock options. Presented below is the Company's non-employee stock option activity:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="4397077BEFDF4F7390C8817EFA4265FC" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Stock Options
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding &#8212; beginning of year
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	692,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	167,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	142,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.47
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.69
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.20
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Granted
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	550,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.76
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.79
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Exercised
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Expired/Forfeited
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(56,429
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(25,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.54
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.79
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding &#8212; end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	635,714
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	692,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	167,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.02
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.47
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.69
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Exercisable at end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	635,714
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	692,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	167,143
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.02
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.47
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.69
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Weighted average fair value of stock options granted during the year:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.32
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.98
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The fair value of the stock options at the date of grant was estimated using the Black-Scholes option-pricing model, based on the following assumptions:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="B4FF14889E114ADD9BB36E800D6BC360" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Risk-free interest rate
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.23
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.05
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expected volatility
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85.0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	84.8
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expected lives (years)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expected dividend yield
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	%
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-16
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage85"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table summarizes significant ranges of outstanding stock options under the two plans at December 31, 2015:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BF9E4839A8E6480487CD0BB851BC6955" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Range of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Prices
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of Options
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Remaining
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
	Contractual Life
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(years)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Options
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercisable
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Contractual Life
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.75 &#8212; 2.00
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,374,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.95
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,374,500
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.95
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.01 &#8212; 2.50
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,215,556
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.14
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.33
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,280,923
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.54
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.30
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.51 &#8212; 4.00
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	986,980
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.06
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.89
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	919,481
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.01
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.87
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.01 &#8212; 32.55
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,632,540
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.03
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.38
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,075,974
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.85
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.48
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,209,576
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.31
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,650,878
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.63
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.42
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The aggregate intrinsic value of outstanding options and options vested as of December 31, 2015 and the options exercised during 2015 were $3.8 million, $2.3 million and $0.2 million, respectively, which represent options whose exercise price was less than the closing fair market value of the Company's common stock on December 31, 2015 of $2.65.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in the Company's Statements of Operations:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="AB5EFBCA49D04AAEBCFDBACE24AEF03A" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years Ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Research and development - employee
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,590,267
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	932,482
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	241,459
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General and administrative - employee
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5,568,537
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,383,624
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,659,105
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total employee stock-based compensation
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,158,804
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3,316,106
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2,900,564
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Research and development &#8211; non-employee
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	86,539
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	General and administrative &#8211; non-employee
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	225,852
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,736,703
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	898,153
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;Total non-employee stock-based compensation
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	225,852
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1,823,242
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	898,153
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Restricted Stock
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company did not issue any restricted stock for the year ended December 31, 2015. On January 1, 2014, the Company granted to Dr. Daniel Levitt, Executive Vice President and Chief Medical Officer, 100,000 shares of restricted common stock pursuant to the 2008 Plan, which shares have now fully vested. The fair value of the restricted stock is based on the market price of the Company's shares on the grant date less the par value received as consideration. The fair value of the restricted shares granted on January 1, 2014 was $626,900.&#160; The Company recorded an employee stock-based compensation expense for restricted stock of $0, $626,900 and $186,389 for the years ended December 31, 2015, 2014 and 2013, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Equity-Classified Warrants
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In March 2015, the Company extended the term of the 250,000 warrants issued in November 2013 by three years. These warrants will now expire in 2018. The Company recognized a non-employee stock-based compensation expense of $61,480 relating to the term extension in 2015.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In March 2014, the Company issued a warrant to purchase 25,000 shares of its common stock at an exercise price of $5.60 in connection with the establishment of its Freiburg, Germany research and development laboratory.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In August 2013, the Company issued a warrant to purchase 500,000 shares of its common stock at an exercise price of $2.50 per share in connection with a financial advisory arrangement. In November 2013, they issued two warrants, each to purchase 125,000 shares of its common stock, at exercise prices of $3.00 and $3.75 per share, respectively, in connection with financial advisory arrangements.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-17
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage86"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	A summary of the Company's warrant activity and related information for the years ended December 31 are shown below.
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="07DC94931E4A4FD29937ECE1D1E73045" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Warrants
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding &#8212; beginning of year
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,349,760
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,324,609
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,518,113
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.27
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.86
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.09
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Granted
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	816,667
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.80
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Exercised
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(10,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(340,527
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(8,572
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.50
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.56
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.48
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Forfeited
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Expired
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(114,288
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(659,322
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,599
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.82
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12.66
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14.99
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Outstanding &#8212; end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,225,472
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,349,760
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,324,609
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.27
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.86
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Exercisable at end of year
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,225,472
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,149,760
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,924,609
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.32
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.98
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 28%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Weighted average fair value of warrants granted during the year:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.46
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.31
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	During 2015, 10,000 warrants were surrendered in connection with the cashless exercise, as compared to 62,172 warrants during 2014. There were no cashless exercises of warrants in 2013.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The following table summarizes additional information concerning warrants outstanding and exercisable at December 31, 2015:
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="EF6E9418E9ED43659BF77CC91228509B" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Warrants Outstanding
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Range of Exercise Prices
</FONT>
<FONT STYLE="FONT-SIZE: 5.11PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Shares
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Remaining
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Contractual Life
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(years)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Warrants
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Number of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercisable
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV>
</DIV>
<DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercisable
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Weighted Average
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exercise Price
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.10 &#8212; 2.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	578,573
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.32
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.42
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	578,573
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.42
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.61 &#8212; 3.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	125,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.86
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.00
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	125,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.00
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.61 &#8212; 4.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,496,899
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.63
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.47
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,496,899
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.47
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.61 &#8212; 5.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.21
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.60
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,225,472
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.83
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7,225,472
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On August 1, 2016, 6,371,899 warrants priced at $4.48 expire.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	14. Stockholder Protection Rights Plan
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Effective April 16, 1997, the Company's board of directors declared a distribution of one right ("Rights") for each outstanding share of the Company's common stock to stockholders of record at the close of business on May 15, 1997 and for each share of common stock issued by the Company thereafter and prior to a Flip-in Date (as defined below). Each Right entitles the registered holder to purchase from the Company one-ten thousandth (1/10,000th) of a share of Series A Junior Participating Preferred Stock, at an exercise price of $30. The Rights are generally not exercisable until 10 business days after an announcement by the Company that a person or group of affiliated persons (an "Acquiring Person") has acquired beneficial ownership of 15% or more of the Company's then outstanding shares of common stock (a "Flip-in Date").
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	In the event the Rights become exercisable as a result of the acquisition of shares, each Right will enable the owner, other than the Acquiring Person, to purchase at the Right's then-current exercise price a number of shares of common stock with a market value equal to twice the exercise price. In addition, unless the Acquiring Person owns more than 50% of the outstanding shares of common stock, the Board of Directors may elect to exchange all outstanding Rights (other than those owned by such Acquiring Person) at an exchange ratio of one share of common stock per Right. All Rights that are owned by any person on or after the date such person becomes an Acquiring Person will be null and void.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Rights have been distributed to protect the Company's stockholders from coercive or abusive takeover tactics and to give the Board of Directors more negotiating leverage in dealing with prospective acquirers. In April 2007, the Company extended the stockholder rights plan through April 2017.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-18
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage87"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	15. Income Taxes
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	At December 31, 2015, the Company had federal and state net operating loss carryforwards of $281.6 million and $173.7 million, respectively, available to offset against future taxable income, which expire in 2016 through 2034.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As a result of a change in-control that occurred in the CytRx shareholder base, approximately $62.3 million in federal net operating loss carryforwards became substantially limited in their annual availability. Management currently believes that the remaining $219.3 million in federal net operating loss carryforwards, and the $173.7 million in state net operating loss carryforwards, are unrestricted.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As of December 31, 2015, CytRx also had research and development and alternative minimum tax credits for federal and state purposes of approximately $14.8 million and $19.5 million, respectively, available for offset against future income taxes, which expire in 2022 through 2035. Based on an assessment of all available evidence including, but not limited to, the Company's limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, the Company has concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred tax valuation allowance has been recorded against these assets.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Deferred income taxes reflect the net effect of temporary differences between the financial reporting carrying amounts of assets and liabilities and income tax carrying amounts of assets and liabilities. The components of the Company's deferred tax assets and liabilities, all of which are long-term, are as follows (in thousands):
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="51257748F5254B89A06217AA0B48BB28" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 116PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 21PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 116PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; WIDTH: 21PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Deferred tax assets:
</DIV>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 116PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 21PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net operating loss carryforwards
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	105,661
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	86,541
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Tax credit carryforwards
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	27,671
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	22,716
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Equipment, furnishings and other
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10,547
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,396
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total deferred tax assets
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	143,879
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	123,653
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Deferred tax liabilities
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(270
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(187
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net deferred tax assets
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	143,609
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	123,466
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 76%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Valuation allowance
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(143,609
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(123,466
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR STYLE="HEIGHT: 22PX">
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 76%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 6.81%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.4%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	For all years presented, the Company did not recognize any deferred tax assets or liabilities. The net change in valuation allowance for the years ended December 31, 2015 and 2014 was $20.1 million and $23.4 million, respectively.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The provision for income taxes differs from the provision computed by applying the Federal statutory rate to net loss before income taxes as follows (in thousands):
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="443709EABF054CBC81B94728C0DB73A9" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="10">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Years ended December 31,
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2015
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2014
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2013
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Federal benefit at statutory rate
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(19,919
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(10,240
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(16,145
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	State income taxes, net of Federal taxes
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(3,556
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,773
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,517
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	State credits
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,324
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(990
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(787
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Warrant liabilities
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,509
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(6,477
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6,871
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Other permanent differences
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	16
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	37
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Provision related to change in valuation allowance
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20,142
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	23,440
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,606
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Current year tax credit
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,050
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,300
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,034
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Return to provision
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8,198
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1,504
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2,011
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 64%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Other, net
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(192
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 64%; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 4PX DOUBLE; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 4PX; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	There have been no changes to the Company's liability for unrecognized tax benefits during the year ended December 31, 2015.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company files income tax returns in the U.S. Federal jurisdiction and various state jurisdictions. As of the year ended December 31, 2015, the tax returns for 2011 through 2015 remain open to examination by the Internal Revenue Service and various state tax authorities.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The Company's policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of the years ended December 31, 2015, 2014 and 2013, the Company had accrued no interest or penalties related to uncertain tax positions.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-19
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage88"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	16. Quarterly Financial Data (unaudited)
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Summarized quarterly financial data for 2015 and 2014 is as follows (in thousands, except per share data):
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="ADF6C21CB21A4F0FB557A7A814E53DB6" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="14">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Quarters Ended
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	March 31
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	June 30
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	September 30
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 31
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="14">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(In thousands, except per share data)
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total revenues
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net loss
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(17,525
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(11,687
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(7,073
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(22,302
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Basic and diluted loss per share applicable to common stock
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.31
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.21
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.11
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.34
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; MARGIN-RIGHT: 5.05PT">
	2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Total revenues
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Net income (loss)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4,665
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(15,719
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(5,625
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(13,439
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Basic income (loss) per share applicable to common stock
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.09
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.24
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 52%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 27.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Diluted income (loss) per share applicable to common stock
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	0.08
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.28
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.10
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(0.24
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	)
</DIV>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Quarterly and year-to-date loss per share amounts are computed independently of each other. Therefore, the sum of the per share amounts for the quarters may not agree to the per share amounts for the year.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	17. Subsequent Event
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On February 5, 2016, the Company entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. ("HTGC"), as administrative agent and lender, and Hercules Technology III, L.P., as lender, pursuant to which the lenders agreed to make available long-term loans in an aggregate principal amount of up to $40 million, subject to certain conditions.&#160;The lenders made an initial term loan to&#160;the Company&#160;on February&#160;8, 2016 in the aggregate principal amount of $25 million.&#160; If the Company announces positive data from its ongoing Phase 3 clinical trial of aldoxorubicin for the treatment of soft tissue sarcoma and also demonstrates continued progress in the development of a second novel drug candidate based on the Company's LADR technology platform such that they will initiate a clinical trial under an Investigational New Drug Application prior to December 31, 2016, which the Company refers to as the "milestone," they may request an additional term loan in an aggregate principal amount of up to $15 million no later than December 31, 2016, or such later date that HTGC otherwise determines in its sole discretion.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The term loans will bear interest at the daily variable rate per annum equal to 6.00% plus the prime rate, or 9.5%, whichever is greater.&#160; The Company is required to make interest-only payments on the term loans through February 28, 2017, and beginning on March 1, 2017 it will be required to make amortizing payments of principal and accrued interest in equal monthly installments until the maturity date of the term loans.&#160; If the Company achieves the milestone as it relates to the Phase&#160;3 clinical trial of aldoxorubicin, the interest-only payment period will be extended through August 31, 2017, and if any additional term loan is extended by the lenders, the interest-only payment period will be extended through February 28, 2018.&#160; All outstanding principal and accrued interest on the term loans will be due and payable in full on the maturity date of February 1, 2020.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	As security for the Company's obligations under the loan and securities agreement,&#160;the Company&#160;granted HTGC, as administrative agent, a security interest in substantially all of its existing and after-acquired assets except for its intellectual property and certain other excluded assets.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	F-20
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage89"></A>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET_2"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	SCHEDULE II &#8212; VALUATION AND QUALIFYING ACCOUNTS
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	For the Years Ended December 31, 2015, 2014 and 2013
</DIV>
<DIV>
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F8F7D07A71A84C5BA138CA428BF87F68" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="6">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18.5PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Additions
</FONT>
<FONT STYLE="FONT-SIZE: 5.17PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Description
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Balance at
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Beginning of
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 12.4PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year
</FONT>
<FONT STYLE="FONT-SIZE: 5.28PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Charged to
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Costs and
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Expenses
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Charged to
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 5.7PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Other
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Accounts
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Deductions
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; VERTICAL-ALIGN: TOP" VALIGN="BOTTOM" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Balance at
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	End of Year
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 5.05PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Reserve Deducted in the Balance Sheet from the Asset to Which it Applies:
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 10.7PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Allowance for Deferred Tax Assets
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" COLSPAN="2">
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40.05%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Year ended December 31, 2015
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	123,466,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20,143,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	143,609,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 40.05%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Year ended December 31, 2014
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,026,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	23,440,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	123,466,000
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 40.05%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -5.05PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 16.4PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 5.05PT">
	Year ended December 31, 2013
</DIV>
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	85,420,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14,606,000
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#8212;
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM" NOWRAP="NOWRAP">
	&#160;
</TD>
<TD STYLE="BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
	&#160;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 1.07%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF; WIDTH: 9.08%; VERTICAL-ALIGN: BOTTOM" VALIGN="BOTTOM">
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	100,026,000
</DIV>
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH; FONT-SIZE: 8PT" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER" ID="DSPFPAGENUMBERAREA">
	F-21
</DIV>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER" ID="DSPFPAGENUMBERAREA">
	&#160;
</DIV>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage90"></A>
<A NAME="EXH_4-5_HTM"></A>
<EFX_EXHIBIT_4>
<A NAME="FIS_EXHIBIT_4"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 4.5
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXCHANGE OF THIS WARRANT HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	COMMON STOCK PURCHASE WARRANT
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	To Purchase 500,000 Shares of Common Stock of
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	THIS COMMON STOCK PURCHASE WARRANT (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Warrant
</U>
</FONT>
	") certifies that, for value received,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Alexander Capital, L.P.
</FONT>
	, or its registered assigns (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Holder
</U>
</FONT>
	"), is entitled, upon the terms and subject to the limitations hereinafter set forth, at any time on or after the date hereof (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Initial Exercise Date
</U>
</FONT>
	") and on or prior to 5:00 P.M., California time, on the fifth anniversary of the Initial Exercise Date (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination Date
</U>
</FONT>
	"), but not thereafter, to subscribe for and purchase from CytRx Corporation, a Delaware corporation (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Company
</U>
</FONT>
	"), up to 500,000 shares (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Warrant Shares
</U>
</FONT>
	") of Common Stock (as hereinafter defined).&#160; The purchase price of each Warrant Share under this Warrant shall be equal to the Exercise Price (as hereinafter defined).
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Warrant is issued pursuant to the financial advisory services agreement,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	effective as of February 9, 2016 between the Company and the Holder (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Advisory Agreement
</U>
</FONT>
	").
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 1.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Definitions
</U>
</FONT>
	.&#160; For purposes of this Warrant, the following capitalized terms shall have the meanings indicated:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Business Day
</U>
</FONT>
	" means a day other than a Saturday, a Sunday or a day on which state or federally chartered banking institutions in California are not required to be open for business.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Commission
</U>
</FONT>
	" means the Securities and Exchange Commission.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Common Stock
</U>
</FONT>
	" means the common stock of the Company, par value $0.01
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	per share, and any securities into or for which such common stock shall hereinafter have been converted or exchanged pursuant to a recapitalization, reclassification, reorganization, merger, sale of assets or otherwise.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Rule 144
</U>
</FONT>
	" means Rule 144 promulgated by the Commission under to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Securities Act
</U>
</FONT>
	" means the Securities Act of 1933, as amended.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Trading Market
</U>
</FONT>
	" means any of the following exchanges on which the Common Stock is listed for trading on the date in question: (a)&#160;the Nasdaq Stock Market; (b)&#160;the American Stock Exchange; and (c)&#160;the New York Stock Exchange.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	"
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	VWAP
</U>
</FONT>
	" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg Financial L.P. (based on a trading day from 9:30 a.m. Eastern Time to 4:00 p.m. Eastern Time); (b) if the Common Stock is not then listed or quoted on the Trading Market and if prices for the Common Stock is then quoted on the OTC Bulletin Board, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board (c) if the Common Stock is not then listed or quoted on the OTC Bulletin Board and if prices for the Common Stock are then reported in the "Pink Sheets" published by the Pink Sheets LLC (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported prior to the day in question; or (d) in all other cases, the fair value of a share of Common Stock as determined in good faith by the Board of Directors of the Company.
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 2.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Vesting
</U>
</FONT>
	.&#160; This Warrant shall be vested and exercisable only as to 125,000 of the Warrant Shares immediately as of the Initial Exercise Date. This Warrant shall become vested and exercisable as to the balance of 375,000 of the Warrant Shares in four installments of 62,500 Warrant Shares each as of
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	August 9, 2016
</FONT>
	(6 months from Initial Exercise Date),
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	February 9, 2017
</FONT>
	(12 months from Initial Exercise Date),
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	May 9, 2017
</FONT>
	(15 months from Initial Exercise Date),
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	August 9, 2017
</FONT>
	(18 months from Initial Exercise Date), respectively, and a final installment of 125,000 Warrant Shares as of
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	February 9 2018
</FONT>
	(24 months from Initial Exercise Date); provided, however, that, upon the termination of the Advisory Agreement for any reason, this Warrant shall cease to vest, and shall no longer become exercisable, as to any additional Warrant Shares that have not yet vested as of the date of that termination.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 1
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage91"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 3.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exercise
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exercise of Warrant
</U>
</FONT>
	.&#160; Exercise of the purchase rights represented by this Warrant, to the extent this Warrant is then vested and exercisable as provided in Section&#160;2, may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of such Holder appearing on the books of the Company) and, subject to Section&#160;3(c), payment of the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer or cashier's check drawn on a United States bank.&#160; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three Business Days of the date the final Notice of Exercise is delivered to the Company.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&#160; The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases.&#160; The Company shall deliver any objection to any Notice of Exercise Form within one Business Day of receipt of such notice.&#160; In the event of any dispute or discrepancy, the records of the Company shall be controlling and determinative in the absence of manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exercise Price
</U>
</FONT>
	.&#160; The exercise price per share of the Common Stock under this Warrant shall be $1.74, subject to adjustment hereunder (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exercise Price
</U>
</FONT>
	").
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cashless Exercise
</U>
</FONT>
	.&#160; If, at any time after 180 days from the Initial Exercise Date, there is no effective Registration Statement (as defined in Section&#160;7) with respect to, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised by means of a "cashless exercise" in which the Holder shall be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) X] by A, where:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -27PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 99PT; FONT-SIZE: 10PT">
	A = the VWAP on the Business Day immediately preceding the date of such election;
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 108PT; FONT-SIZE: 10PT">
	B =&#160; the Exercise Price of this Warrant, as adjusted; and
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -31.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 103.5PT; FONT-SIZE: 10PT">
	X = the number of Warrant Shares issuable upon exercise of this Warrant in accordance with the terms of this Warrant by means of a cash exercise rather than a cashless exercise.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Mechanics of Exercise
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Delivery of Certificates Upon Exercise
</U>
</FONT>
	.&#160; Certificates for shares purchased hereunder shall be transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder's prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	DWAC
</U>
</FONT>
	") system if the Company is a participant in such system, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise within three Business Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant (if required) and payment of the aggregate Exercise Price as set forth above ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Warrant Share Delivery Date
</U>
</FONT>
	").&#160; The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section&#160;3(d)(vi) prior to the issuance of such shares, have been paid.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Delivery of New Warrants Upon Exercise
</U>
</FONT>
	.&#160; If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Fractional Shares or Scrip
</U>
</FONT>
	.&#160; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160; As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up such final fraction to the next whole share.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iv)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Charges, Taxes and Expenses
</U>
</FONT>
	.&#160; Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	provided
</U>
</FONT>
	,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	however
</U>
</FONT>
	, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(v)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Closing of Books
</U>
</FONT>
	.&#160; The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 2
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage92"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 4.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Certain Adjustments
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Stock Dividends and Splits
</U>
</FONT>
	. If the Company, at any time while this Warrant is outstanding (i)&#160;pays a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii)&#160;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&#160;combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&#160;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.&#160; Any adjustment made pursuant to this Section&#160;4(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	effective immediately after the effective date in the case of a subdivision, combination or reclassification.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Fundamental Transaction
</U>
</FONT>
	. If, at any time while this Warrant is outstanding, (i)&#160;the Company effects any merger or consolidation of the Company with or into another Person, (ii)&#160;the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, or (iii)&#160;the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Fundamental Transaction
</U>
</FONT>
	"), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, upon exercise of this Warrant, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Alternate Consideration
</U>
</FONT>
	") receivable upon or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a Holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such event.&#160; For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160; If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160; To the extent necessary to effectuate the foregoing provisions, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder's right to exercise such warrant into Alternate Consideration. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section&#160;4(b) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Calculations
</U>
</FONT>
	. All calculations under this Section&#160;4 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.&#160; For purposes of this Section&#160;4, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall exclude treasure shares, if any.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notice to Holders
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Adjustment to Exercise Price
</U>
</FONT>
	. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&#160;4, the Company shall promptly mail to each Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notice to Allow Exercise by Holder
</U>
</FONT>
	. If (A)&#160;the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)&#160;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&#160;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any right; (D)&#160;the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E)&#160;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.&#160; The Holder shall be entitled to exercise this Warrant, to the extent it is then vested and exercisable as provided in Section&#160;2, during the 20-day period commencing on the date of such notice to the effective date of the event triggering such notice.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 3
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage93"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 5.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Transfer of Warrant
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Transferability
</U>
</FONT>
	.&#160; Subject to compliance with Section&#160;5(d), this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160; Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160; A Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	New Warrants
</U>
</FONT>
	. This Warrant may be divided upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&#160; Subject to compliance with Section&#160;5(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Warrant Register
</U>
</FONT>
	. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Warrant Register
</U>
</FONT>
	"), in the name of the record Holder hereof from time to time.&#160; The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Transfer Restrictions
</U>
</FONT>
	. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer (i) that the Holder or transferee of the Warrant, as the case may be, furnish to the Company a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii) that the holder or transferee execute and deliver to the Company an investment letter in form and substance acceptable to the Company and (ii) that the transferee be an "accredited investor" as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a "qualified institutional buyer" as defined in Rule 144A(a) under the Securities Act.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 6.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Representations and Warranties of Holder
</U>
</FONT>
	.&#160; Holder hereby represents and warrants to the Company that (a)&#160;Holder is acquiring this Warrant and will acquire any Warrant Shares for its own account for investment purposes only, (b)&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of an investment in this Warrant and any Warrant Shares and protecting its own interest in connection herewith and therewith, (c)&#160;Holder understands that neither this Warrant nor the Warrant Shares have been registered under the Securities Act or under any state securities laws, and Holder is familiar with the provisions of the Securities Act and Rule 144 thereunder and understands that the restrictions on transfer on this Warrant and the Warrant Shares may result in Holder being required to hold this Warrant and any Warrant Shares for an indefinite period of time, and (d)&#160;
</FONT>
	Holder is an "accredited investor" as such term is defined under Regulation&#160;D under the Securities Act.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 7.
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Registration Rights
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Definitions
</U>
</FONT>
	.&#160; For purposes of this Section&#160;7, the following terms shall have the meanings set forth below:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"Registration" shall mean a registration of securities under the Securities Act pursuant to Section&#160;7(b).
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"Registration Period" with respect to any Registration Statement the period commencing the effective date of the Registration Statement and ending upon withdrawal or termination of the Registration Statement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"Registration Statement" shall mean the registration statement, as amended from time to time, filed with the Commission in connection with a Registration.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Piggyback Registration
</U>
</FONT>
	.&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Unless the Warrant Shares are then eligible to be sold under the provisions of Rule 144 without limitation as to volume, if, at any time after the Initial Exercise Date, the Company shall determine to register any Common Stock under the Securities Act for sale in connection with a public offering of Common Stock (other than pursuant to an employee benefit plan or a merger, acquisition or similar transaction), the Company will give written notice thereof to Holder and will include in the Registration Statement with respect thereto any of the Warrant Shares which Holder may request be included ("
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	Included Shares
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	") by a writing delivered to the Company within 15 days after the notice given by the Company to Holder;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	provided
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	,
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	however
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	, that the Company shall be excused from its obligations hereunder to register the Warrant Shares to the extent it is prohibited or restricted from doing so pursuant to contracts or agreements existing as of the Initial Exercise Date; and
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	provided
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	,
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	further
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	, that if the offering is to be a firm underwriting, and the representative of the underwriters of the offering refuse in writing to include in the offering all of the shares of Common Stock requested by the Company and others, the shares to be included shall be allocated first to the Company and any shareholder who initiated such Registration and then among the others based on the respective number of shares of Common Stock held by such persons.&#160; If the Company decides not to, and does not, file a Registration Statement with respect to such Registration, or after filing determines to withdraw the same before the effective date thereof, the Company will promptly so inform Holder, and the Company will not be obligated to complete the registration of the Included Shares included therein.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Certain Covenants
</U>
</FONT>
	.&#160; In connection with any Registration:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(i)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company shall take all lawful action such that the Registration Statement, any amendment thereto and the prospectus forming a part thereof does not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading.&#160; Upon becoming aware of the occurrence of any event or the discovery of any facts during the Registration Period that make any statement of a material fact made in the Registration Statement or the related prospectus untrue in any material respect or which material fact is omitted from the Registration Statement or related prospectus that requires the making of any changes in the Registration Statement or related prospectus so that it will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they are made, not misleading (taking into account any prior amendments or supplements), the Company shall promptly notify Holder and as soon as reasonably practicable prepare (but in no event more than five Business Days in the case of a supplement or seven business days in the case of a post-effective amendment) and file with the Commission a supplement or post-effective amendment to the Registration Statement or the related prospectus or file any other required document so that, as thereafter delivered to a purchaser of Shares from Holder, such prospectus will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 4
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage94"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	At least three Business Days prior to the filing with the Commission of the Registration Statement (or any amendment thereto) or the prospectus forming a part thereof (or any supplement thereto), the Company shall provide draft copies thereof to Holder and shall consider incorporating into such documents such comments as Holder (and its counsel) may propose to be incorporated therein.&#160; Notwithstanding the foregoing, no prospectus supplement, the form of which has previously been provided to Holder, need be delivered in draft form to Holder.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company shall promptly notify Holder upon the occurrence of any of the following events in respect of the Registration Statement or the prospectus forming a part thereof: (A)&#160;the receipt of any request for additional information from the Commission or any other federal or state governmental authority, the response to which would require any amendments or supplements to the Registration Statement or related prospectus; (B)&#160;the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; or (C)&#160;the receipt of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iv)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company shall furnish to Holder with respect to the Included Shares registered under the Registration Statement (and to each underwriter, if any, of such Shares) such number of copies of prospectuses and such other documents as Holder may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Included Shares by Holder pursuant to the Registration Statement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(v)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Company shall file or cause to be filed such documents as are required to be filed by the Company for normal Blue Sky clearance in states specified in writing by Holder;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	provided
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	,
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<U>
	however
</U>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	, that the Company shall not be required to qualify to do business or consent to service of process in any jurisdiction in which it is not now so qualified or has not so consented.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(vi)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	As a condition to including Warrant Shares in a Registration Statement, Holder must provide to the Company such information regarding itself, the Warrant Shares held by it and the intended method of distribution of such Shares as shall be required to effect the registration of the Warrant Shares and, if the offering is being underwritten, Holder must provide such powers of attorney, indemnities and other documents as may be reasonably requested by the managing underwriter.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(vii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Following the effectiveness of the Registration Statement, upon receipt from the Company of a notice that the Registration Statement contains an untrue statement of material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, Holder will immediately discontinue disposition of Included Shares pursuant to the Registration Statement until the Company notifies Holder that it may resume sales of Included Shares and, if necessary, provides to Holder copies of the supplemental or amended prospectus.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(viii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Miscellaneous
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Rights as Shareholder Until Exercise
</U>
</FONT>
	.&#160; This Warrant does not entitle the Holder to any voting rights or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section&#160;3(d)(i).
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Loss, Theft, Destruction or Mutilation of Warrant
</U>
</FONT>
	. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Saturdays, Sundays, Holidays, etc
</U>
</FONT>
	.&#160; If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(g)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Authorized Shares
</U>
</FONT>
	.&#160; The Company covenants that, at all times prior to the Termination Date, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of this Warrant.&#160; The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160; The Company will take all such reasonable action as may be necessary to assure that the Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(h)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Jurisdiction
</U>
</FONT>
	. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the internal laws of the State of Delaware, without regard to conflicts of law principles.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Nonwaiver
</U>
</FONT>
	.&#160; No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder's rights, powers or remedies.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(j)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notices
</U>
</FONT>
	.&#160; Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Advisory Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(k)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Remedies
</U>
</FONT>
	.&#160; Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160; The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 5
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage95"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(l)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Successors and Assigns
</U>
</FONT>
	.&#160; Subject to Section&#160;5, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.&#160; The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable by any such Holder.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(m)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	.&#160; This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(n)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Severability
</U>
</FONT>
	.&#160; Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(o)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Headings
</U>
</FONT>
	.&#160; The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	********************
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 6
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage96"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Dated:&#160; February 9, 2016
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="22A17FA661FF4725B6000821C780B2A7" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/&#160;STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chairman and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 7
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage97"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	NOTICE OF EXERCISE
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TO:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(2)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Payment shall take the form of (check applicable box):
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[&#160; ] in lawful money of the United States; or
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	[ ] [if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 4(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 4(c).
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(3)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[SIGNATURE OF HOLDER]
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name of Investing Entity:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Signature of Authorized Signatory of Investing Entity
</FONT>
	:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name of Authorized Signatory:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Title of Authorized Signatory:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Date:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 8
</DIV>
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage98"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	ASSIGNMENT FORM
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(To assign the foregoing warrant, execute
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	this form and supply required information.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	Do not use this form to exercise the warrant.)
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________________________ whose address is
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________________________________________.
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_______________________________________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 252PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Dated:&#160; ______________, _______
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 108PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Holder's Signature:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_____________________________
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 108PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Holder's Address:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_____________________________
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	_____________________________
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Signature Guaranteed:&#160; ___________________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTE:&#160; The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company.&#160; Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 8PT" ID="DSPFPAGENUMBERAREA">
	EX 4.5- Page 9
</DIV>
</EFX_EXHIBIT_4>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage99"></A>
<A NAME="EXH_10-11_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.11&#160;&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2008 STOCK INCENTIVE PLAN
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	GRANT NOTICE
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are pleased to inform you that you have been awarded the following Stock Option (the "Option") under the CytRx Corporation 2008 Stock Incentive Plan (the "Plan") on the following terms:
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="8E5BD4E910E6467E87AE86E125D1DE56" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name of Participating Optionee:
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Grant No.
</DIV>
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Total Number of Shares Awarded:
</DIV>
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	180,000 Non-Qualified Stock Options
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercise price:
</DIV>
</TD>
<TD STYLE="WIDTH: 26%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="WIDTH: 31%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Grant date:
</DIV>
</TD>
<TD STYLE="WIDTH: 26%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 31%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Vesting Schedule:
</DIV>
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The Option shall vest in full immediately.
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 57%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
</TABLE>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The shares are awarded under and governed by the terms and provisions of the Plan and the Stock Option Agreement attached to and made a part of this Notice. Unless otherwise defined, defined terms used in this Notice and the attached Agreement have the meanings ascribed to them in the Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	A copy of the Plan accompanies this Notice and the attached Stock Option Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C436137D40944727948BC87CBDE104DB" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/&#160;STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 17PX">
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage100"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	2008 STOCK INCENTIVE PLAN
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	STOCK OPTION AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(INCENTIVE AND NONSTATUTORY STOCK OPTIONS)
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Pursuant to the CytRx Corporation (the "Company") 2008 Stock Incentive Plan (the "Plan"), the Company hereby grants you a Stock Option to purchase, on the terms and conditions set forth in your Stock Option Grant Notice ("Grant Notice") and this agreement (this "Option Agreement"), the number of shares of the Company's Common Stock indicated in your Grant Notice at the exercise price per share indicated in your Grant Notice.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Defined terms not explicitly defined herein but defined in the Plan shall have the same definitions as in the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	The details of your option are as follows:
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING. The Option shall vest in full immediately. Notwithstanding anything to the contrary in the Plan, in the event that your service to the Company terminates due to your death, your option shall remain exercisable for the full term of the option, as described in Section 6.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for capitalization adjustments, as provided in the Plan
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	METHOD OF PAYMENT. The Exercise Price may be paid to the Company (i) in cash or cash equivalent; or (ii) in any other method of Consideration acceptable to the Board pursuant to the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WHOLE SHARES
</FONT>
	. You may exercise your option only for whole shares of
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Common Stock.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	SECURITIES LAW COMPLIANCE.
</FONT>
	Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option must also comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM. You may not exercise your option before the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires at 5:00 P.M., Pacific Time, on the day immediately prior to the tenth anniversary of the Date of Grant.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 6PT">
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	EXERCISE
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	You may exercise the vested portion of your option during its term by delivering a written Notice of Exercise
</FONT>
	to the Secretary of the Company at the principal executive offices of the Company, in substantially the form attached hereto as Exhibit A, or such other form as the Committee may approve,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	together with such additional documents as the Company may then require.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If your option is an incentive stock option, by exercising your option you agree that you will notify the Company in writing within fifteen days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	TRANSFERABILITY.
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</FONT>
	The transferability provisions contained in the Plan are incorporated into and made a part of this Option Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	OPTION NOT A SERVICE CONTRACT. Pursuant to the Plan, your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option shall obligate the Company or an Affiliate to continue any relationship that you might have as a Director or Consultant.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WITHHOLDING OBLIGATIONS.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a "cashless exercise" pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, or local withholding obligations of the Company or an Affiliate, if any, which arise in connection with your option.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable conditions or restrictions of law, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law. If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT">
	&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	You may not exercise your option unless the tax withholding obligations of the Company and any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage101"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTICES. Notices and communications under this Option Agreement must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; Corporate Secretary
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	or any other address designated by the Company in a written notice to the Optionee. Notices to the Optionee will be directed to the address of the Optionee then currently on file with the Company, or at any other address given by the Optionee in a written notice to the Company.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	PLAN CONTROLS. The terms contained in the Plan are incorporated into and made a part of this Option Agreement and this Option Agreement shall be governed by and construed in accordance with the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Option Agreement, the provisions of the Plan shall be controlling and determinative.
</FONT>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 6PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	[SIGNATURE PAGE FOLLOWS]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage102"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	IN WITNESS WHEREOF
</FONT>
	, CytRx Corporation, acting by and through its duly authorized officers, has caused this Option Agreement to be executed, and the Optionee has executed this Option Agreement, all as of the day and year first above written.
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E6260AF9F4C241D5B78F31E16F3761DC" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Name of Optionee]
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	By:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	/s/
</U>
</FONT>
<FONT STYLE="FONT-SIZE: 5PT" ID="TRGRRTFTOHTMLTAB">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="FONT-SIZE: 10PT">
	STEVEN A. KRIEGSMAN&#160;&#160;
</FONT>
	&#160;
</U>
</FONT>
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/__________________________
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Optionee
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage103"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	EXHIBIT A
</U>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTICE OF EXERCISE OF OPTION TO PURCHASE
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	COMMON STOCK OF
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Name: ____________________________________
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Address: __________________________________
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	__________________________________________
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Tax I.D. No.:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Date: _____________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; Corporate Secretary
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Re:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercise of Stock Option
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Gentlemen:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	I elect to purchase ______________ shares of Common Stock of CytRx Corporation (the "Company") pursuant to the CytRx Corporation Stock Option Agreement dated _____________ and the CytRx Corporation 2008 Stock Incentive Plan. The purchase will take place on the Exercise Date which will be (i) as soon as practicable following the date this notice and all other necessary forms and payments are received by the Company, unless I specify a later date (not to exceed 30 days following the date of this notice) or (ii) in the case of a Broker-assisted cashless exercise (as indicated below), the date of this notice.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On or before the Exercise Date, I will pay the full exercise price in the form specified below (check one):
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="300DD7D6BDBD42BC8EBCEC886B308ECD" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash Only
</U>
</FONT>
	:&#160;&#160; by delivering a check to the Company for $___________.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9135C1790DF84CC2B086EAFC89A96EA6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash From Broker
</U>
</FONT>
	: by delivering the purchase price from _______________________, a broker, dealer or other "creditor" as defined by Regulation T issued by the Board of Governors of the Federal Reserve System (the "Broker"). I authorize the Company to issue a stock certificate in the number of shares indicated above in the name of the Broker in accordance with instructions received by the Company from the Broker and to deliver such stock certificate directly to the Broker (or to any other party specified in the instructions from the Broker) upon receiving the exercise price from the Broker.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C6B5AA37AF2C43F09C3749ED8D53110B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<U>
	Pursuant to a Net Exercise Arrangement
</U>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E9D855BAB62E42E8A8C13BD4F5684F59" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Other Company Shares
</U>
</FONT>
	:&#160;&#160; by delivering for surrender other shares of the Company's Common Stock that I have owned for at least six months (or such other longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes) having a fair market value at the time of receipt by the Company equal to not less than the exercise price
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On or before the Exercise Date, I will pay any applicable tax withholding obligations by delivering a check to the Company for the full tax-withholding amount.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Please deliver the stock certificate to me (unless I have chosen to pay the purchase price through a broker).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Very truly yours,
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	_________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	AGREED TO AND ACCEPTED:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	By: ___________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Title: __________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Number of Option Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercised: ______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Number of Option Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Remaining: _____________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Date: _________________________________
</DIV>
<DIV>
<BR>
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage104"></A>
<A NAME="EXH_10-12_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;&#160;Exhibit 10.12
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2008 STOCK INCENTIVE PLAN
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	GRANT NOTICE
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are pleased to inform you that you have been awarded the following Stock Option (the "Option") under the CytRx Corporation 2008 Stock Incentive Plan (the "Plan") on the following terms:
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C64C81C4E9434AF0B12A9F0C6F101568" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name of Participating Optionee:
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Grant No.
</DIV>
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Total Number of Shares Awarded:
</DIV>
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[______] Non-Qualified Stock Options
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercise price:
</DIV>
</TD>
<TD STYLE="WIDTH: 25.23%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="WIDTH: 33.01%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Grant date:
</DIV>
</TD>
<TD STYLE="WIDTH: 25.23%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 33.01%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Vesting Schedule:
</DIV>
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Unless the exercisability of the Option is accelerated in accordance with the Plan, the Option shall vest (become exercisable) in thirty-six (36) equal monthly installments, beginning on the one-month anniversary of the Date of Grant.
</DIV>
<DIV>
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.46%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.54%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The shares are awarded under and governed by the terms and provisions of the Plan and the Stock Option Agreement attached to and made a part of this Notice.&#160; Unless otherwise defined, defined terms used in this Notice and the attached Agreement have the meanings ascribed to them in the Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	A copy of the Plan accompanies this Notice and the attached Stock Option Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="AD968AAF45DF4317BA19F932C308920D" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/&#160;STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chairman and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage105"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	2008 STOCK INCENTIVE PLAN
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	STOCK OPTION AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(INCENTIVE AND NONSTATUTORY STOCK OPTIONS)
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Pursuant to the CytRx Corporation (the "Company") 2008 Stock Incentive Plan (the "Plan"), the Company hereby grants you a Stock Option to purchase, on the terms and conditions set forth in your Stock Option Grant Notice ("Grant Notice") and this agreement (this "Option Agreement"), the number of shares of the Company's Common Stock indicated in your Grant Notice at the exercise price per share indicated in your Grant Notice.&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Defined terms not explicitly defined herein but defined in the Plan shall have the same definitions as in the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	The details of your option are as follows:
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING. Subject to acceleration of vesting as provided in the Plan and to the limitations contained herein, your option shall vest (become exercisable) as provided in your Notice of Award, provided that vesting will cease upon the termination of your employment with the Company for any reason. Notwithstanding anything to the contrary in the Plan, in the event that your employment with the Company terminates due to your death, your option shall remain exercisable for the full term of the option, as described in Section 6.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for capitalization adjustments, as provided in the Plan
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	METHOD OF PAYMENT. The Exercise Price may be paid to the Company (i) in cash or cash equivalent; or (ii) in any other method of Consideration acceptable to the Board pursuant to the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WHOLE SHARES
</FONT>
	. You may exercise your option only for whole shares of
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Common Stock.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	SECURITIES LAW COMPLIANCE.
</FONT>
	Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option must also comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM. You may not exercise your option before the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires at 5:00 P.M., Pacific Time, on the day immediately prior to the tenth anniversary of the Date of Grant.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage106"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	EXERCISE
</FONT>
	.
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	You may exercise the vested portion of your option during its term by delivering a written Notice of Exercise
</FONT>
	to the Secretary of the Company at the principal executive offices of the Company, in substantially the form attached hereto as Exhibit A, or such other form as the Committee may approve,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	together with such additional documents as the Company may then require.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If your option is an incentive stock option, by exercising your option you agree that you will notify the Company in writing within fifteen days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	TRANSFERABILITY.
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</FONT>
	The transferability provisions contained in the Plan are incorporated into and made a part of this Option Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	OPTION NOT A SERVICE CONTRACT. Pursuant to the Plan, your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option shall obligate the Company or an Affiliate to continue any relationship that you might have as a Director or Consultant.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WITHHOLDING OBLIGATIONS.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a "cashless exercise" pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, or local withholding obligations of the Company or an Affiliate, if any, which arise in connection with your option.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable conditions or restrictions of law, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law. If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
</FONT>
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage107"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	You may not exercise your option unless the tax withholding obligations of the Company and any Affiliate are satisfied.&#160; Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTICES. Notices and communications under this Option Agreement must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid.&#160; Notices to the Company must be addressed to:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; Corporate Secretary
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	or any other address designated by the Company in a written notice to the Optionee.&#160; Notices to the Optionee will be directed to the address of the Optionee then currently on file with the Company, or at any other address given by the Optionee in a written notice to the Company.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	PLAN CONTROLS. The terms contained in the Plan are incorporated into and made a part of this Option Agreement and this Option Agreement shall be governed by and construed in accordance with the Plan.&#160; In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Option Agreement, the provisions of the Plan shall be controlling and determinative.
</FONT>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[SIGNATURE PAGE FOLLOWS]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage108"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, CytRx Corporation, acting by and through its duly authorized officers, has caused this Option Agreement to be executed, and the Optionee has executed this Option Agreement, all as of the day and year first above written.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="FAA2A957F1CF47118991C80D5EED32C1" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</FONT>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;[NAME OF OPTIONEE]
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	/s/
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Name
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	EXHIBIT A
</U>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTICE OF EXERCISE OF OPTION TO PURCHASE
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	COMMON STOCK OF
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Name _________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Address:________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	_________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Tax I.D. No.:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Date _________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; Corporate Secretary
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Re:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercise of Stock Option
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Gentlemen:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	I elect to purchase ______________ shares of Common Stock of CytRx Corporation (the "Company") pursuant to the CytRx Corporation Stock Option Agreement dated _____________ and the CytRx Corporation 2008 Stock Incentive Plan.&#160; The purchase will take place on the Exercise Date which will be (i) as soon as practicable following the date this notice and all other necessary forms and payments are received by the Company, unless I specify a later date (not to exceed 30 days following the date of this notice) or (ii) in the case of a Broker-assisted cashless exercise (as indicated below), the date of this notice.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On or before the Exercise Date, I will pay the full exercise price in the form specified below (check one):
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9A9C0FE54A404A619948B5E4FB487CCE" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash Only
</U>
</FONT>
	:&#160;&#160; by delivering a check to the Company for $___________.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7775030B0F634BC4BFBC64CDB48B1FC9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash From Broker
</U>
</FONT>
	: by delivering the purchase price from _______________________, a broker, dealer or other "creditor" as defined by Regulation T issued by the Board of Governors of the Federal Reserve System (the "Broker").&#160; I authorize the Company to issue a stock certificate in the number of shares indicated above in the name of the Broker in accordance with instructions received by the Company from the Broker and to deliver such stock certificate directly to the Broker (or to any other party specified in the instructions from the Broker) upon receiving the exercise price from the Broker.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="3F21A8F6B1984AFD86ABFDB0D5F41098" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<U>
	Pursuant to a Net Exercise Arrangement
</U>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9C74DE825BC04E2580297B019C13B681" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Other Company Shares
</U>
</FONT>
	:&#160;&#160; by delivering for surrender other shares of the Company's Common Stock that I have owned for at least six months (or such other longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes) having a fair market value at the time of receipt by the Company equal to not less than the exercise price
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On or before the Exercise Date, I will pay any applicable tax withholding obligations by delivering a check to the Company for the full tax-withholding amount.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Please deliver the stock certificate to me (unless I have chosen to pay the purchase price through a broker).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Very truly yours,
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	_________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	AGREED TO AND ACCEPTED:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	By: ___________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Title: __________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Number of Option Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercised: ______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Number of Option Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Remaining: _____________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Date: _________________________________
</DIV>
<DIV>
<BR>
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage109"></A>
<A NAME="EXH_10-13_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_3"></A>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.13&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2008 STOCK INCENTIVE PLAN
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	GRANT NOTICE
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	We are pleased to inform you that you have been awarded the following Stock Option (the "Option") under the CytRx Corporation 2008 Stock Incentive Plan (the "Plan") on the following terms:
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D836131DFC094757B0F3939422FEA8D6" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Name of Participating Optionee:
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Grant No.
</DIV>
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Daniel J.Levitt, M.D., Ph.D.];
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Steven A. Kriegsman]
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Total Number of Shares Awarded:
</DIV>
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;[___] Non-Qualified Stock Options
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercise price:
</DIV>
</TD>
<TD STYLE="WIDTH: 25.17%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	$
</DIV>
</TD>
<TD STYLE="WIDTH: 33.01%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Grant date:
</DIV>
</TD>
<TD STYLE="WIDTH: 25.17%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 33.01%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: BOTTOM">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: BOTTOM" COLSPAN="2">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Vesting Schedule:
</DIV>
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Unless the exercisability of the Option is accelerated in&#160;accordance with the Plan, the Option shall vest (become exercisable) in thirty-six (36) equal monthly installments, beginning on the one-month anniversary of the Date of Grant. Under certain conditions specified in Section 1 of the Stock Option Agreement, any and all unvested options in this Grant No. _____ shall become immediately exercisable.
</DIV>
<DIV>
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 41.52%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 58.48%; VERTICAL-ALIGN: TOP" COLSPAN="2">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The shares are awarded under and governed by the terms and provisions of the Plan and the Stock Option Agreement attached to and made a part of this Notice.&#160; Unless otherwise defined, defined terms used in this Notice and the attached Agreement have the meanings ascribed to them in the Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	A copy of the Plan accompanies this Notice and the attached Stock Option Agreement.
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D23E125F42274F6784A6E38CD649B884" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/&#160;STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Title: Chairman and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;[in the case of Daniel Levitt, M.D., Ph.D]; [John Y. Caloz, Chief Financial Officer in the case of Steven A. Kriegsman]
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage110"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	2008 STOCK INCENTIVE PLAN
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	STOCK OPTION AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(INCENTIVE AND NONSTATUTORY STOCK OPTIONS)
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Pursuant to the CytRx Corporation (the "Company") 2008 Stock Incentive Plan (the "Plan"), the Company hereby grants you a Stock Option to purchase, on the terms and conditions set forth in your Stock Option Grant Notice ("Grant Notice") and this agreement (this "Option Agreement"), the number of shares of the Company's Common Stock indicated in your Grant Notice at the exercise price per share indicated in your Grant Notice.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Defined terms not explicitly defined herein but defined in the Plan shall have the same definitions as in the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; COLOR: #000000; FONT-SIZE: 10PT">
	The details of your option are as follows:
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING. Subject to acceleration of vesting as provided in the Plan and to the limitations contained herein, your option shall vest (become exercisable) as provided in your Notice of Award; provided, that your option shall immediately vest in full upon FDA marketing approval of the Company's lead product candidate, aldoxorubicin; and provided further, that your option shall immediately vest in full upon the termination of your employment (i)&#160;by the Company without "Cause", upon your resignation with "Good Reason" as defined in the Employment Agreement dated __________ between the Company and you (the "Employment Agreement") or (ii) due to your death or by the Company by reason of your "Disability" as defined in the Employment Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NUMBER OF SHARES AND EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for capitalization adjustments, as provided in the Plan
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	METHOD OF PAYMENT. The Exercise Price may be paid to the Company (i) in cash or cash equivalent; or (ii) in any other method of Consideration acceptable to the Board pursuant to the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WHOLE SHARES
</FONT>
	. You may exercise your option only for whole shares of
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Common Stock.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	SECURITIES LAW COMPLIANCE.
</FONT>
	Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option must also comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM. You may not exercise your option before the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires at
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5:00 P.M., Pacific Time, on the day immediately prior to the tenth anniversary of the Date of Grant, subject to earlier termination as provided in the Plan in the event of termination of your Service for "Cause" as defined in the Employment Agreement; provided, that in the event of the termination of your employment (i)&#160;by the Company without "Cause", upon your resignation with "Good Reason" as defined in the Employment Agreement or (ii) due to your death or by the Company by reason of your "Disability" as defined in the Employment Agreement, your option shall remain exercisable thereafter for its full term.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	EXERCISE
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	You may exercise the vested portion of your option during its term by delivering a written Notice of Exercise
</FONT>
	to the Secretary of the Company at the principal executive offices of the Company, in substantially the form attached hereto as Exhibit A, or such other form as the Committee may approve,
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	together with such additional documents as the Company may then require.
</FONT>
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If your option is an incentive stock option, by exercising your option you agree that you will notify the Company in writing within fifteen days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="BACKGROUND-COLOR: #FFFFFF; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	TRANSFERABILITY.
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</FONT>
	The transferability provisions contained in the Plan are incorporated into and made a part of this Option Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	OPTION NOT A SERVICE CONTRACT. Pursuant to the Plan, your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option shall obligate the Company or an Affiliate to continue any relationship that you might have as a Director or Consultant.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage111"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WITHHOLDING OBLIGATIONS.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a "cashless exercise" pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, or local withholding obligations of the Company or an Affiliate, if any, which arise in connection with your option.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Upon your request and subject to approval by the Company, in its sole discretion, and compliance with any applicable conditions or restrictions of law, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	tax required to be withheld by law. If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	You may not exercise your option unless the tax withholding obligations of the Company and any Affiliate are satisfied.&#160; Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTICES. Notices and communications under this Option Agreement must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid.&#160; Notices to the Company must be addressed to:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; Corporate Secretary
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	or any other address designated by the Company in a written notice to the Optionee.&#160; Notices to the Optionee will be directed to the address of the Optionee then currently on file with the Company, or at any other address given by the Optionee in a written notice to the Company.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	PLAN.&#160; The terms contained in the Plan are incorporated into and made a part of this Option Agreement and this Option Agreement shall be governed by and construed in accordance with the Plan.&#160; In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Option Agreement, the provisions of the Plan shall be controlling and determinative; provided, however, that the accelerated vesting and exercise period set forth in sections 1 and 6 of this Option Agreement shall prevail over any contrary provision in the Plan.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[SIGNATURE PAGE FOLLOWS]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage112"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, CytRx Corporation, acting by and through its duly authorized officers, has caused this Option Agreement to be executed, and the Optionee has executed this Option Agreement, all as of the day and year first above written.
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C62B2F7B249F47AF9EA35CFB93DFEDEE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 64.1%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
</TD>
<TD STYLE="WIDTH: 35.9%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[DANIEL J. LEVITT, M.D., Ph.D.]; [STEVEN A. KRIEGSMAN]
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 64.1%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 64.1%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="WIDTH: 64.1%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 5PT">
	&#160;
<FONT STYLE="FONT-SIZE: 10PT">
	/s/&#160;&#160;&#160;[__________________________]&#160;&#160;&#160;&#160;
</FONT>
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
</DIV>
</TD>
<TD STYLE="WIDTH: 35.9%; VERTICAL-ALIGN: TOP">
	&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	/s/ [__________________________]
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 64.1%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 35.9%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;Optionee
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 64.1%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chairman&#160;and Chief Executive Officer
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;[in the case of Daniel Levitt, M.D., Ph.D.]; [John Y. Caloz, Chief Financial Officer, in the case of Steven A. Kriegsman]
</DIV>
</TD>
<TD STYLE="WIDTH: 35.9%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage113"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	EXHIBIT A
</U>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOTICE OF EXERCISE OF OPTION TO PURCHASE
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	COMMON STOCK OF
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Name _________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Address:________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	_________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Tax I.D. No.:
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	Date _________________________________
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; Corporate Secretary
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Re:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercise of Stock Option
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Gentlemen:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	I elect to purchase ______________ shares of Common Stock of CytRx Corporation (the "Company") pursuant to the CytRx Corporation Stock Option Agreement dated _____________ and the CytRx Corporation 2008 Stock Incentive Plan.&#160; The purchase will take place on the Exercise Date which will be (i) as soon as practicable following the date this notice and all other necessary forms and payments are received by the Company, unless I specify a later date (not to exceed 30 days following the date of this notice) or (ii) in the case of a Broker-assisted cashless exercise (as indicated below), the date of this notice.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On or before the Exercise Date, I will pay the full exercise price in the form specified below (check one):
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BEE9E96CF8544C44A7A4636F50EB1E16" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash Only
</U>
</FONT>
	:&#160;&#160; by delivering a check to the Company for $___________.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="170866270F1C4C789EC4E09FD523048B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash From Broker
</U>
</FONT>
	: by delivering the purchase price from _______________________, a broker, dealer or other "creditor" as defined by Regulation T issued by the Board of Governors of the Federal Reserve System (the "Broker").&#160; I authorize the Company to issue a stock certificate in the number of shares indicated above in the name of the Broker in accordance with instructions received by the Company from the Broker and to deliver such stock certificate directly to the Broker (or to any other party specified in the instructions from the Broker) upon receiving the exercise price from the Broker.
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F7D548E5AE284DBDA9F78E67F59EFF5D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<U>
	Pursuant to a Net Exercise Arrangement
</U>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E8059AAB22064F26ADE026136310AA36" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT">
</TD>
<TD STYLE="WIDTH: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
	[ ]
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: AUTO; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Other Company Shares
</U>
</FONT>
	:&#160;&#160; by delivering for surrender other shares of the Company's Common Stock that I have owned for at least six months (or such other longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes) having a fair market value at the time of receipt by the Company equal to not less than the exercise price
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	On or before the Exercise Date, I will pay any applicable tax withholding obligations by delivering a check to the Company for the full tax-withholding amount.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Please deliver the stock certificate to me (unless I have chosen to pay the purchase price through a broker).
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Very truly yours,
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 216PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	_________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	AGREED TO AND ACCEPTED:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CYTRX CORPORATION
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	By: ___________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Title: __________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Number of Option Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Exercised: ______________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Number of Option Shares
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Remaining: _____________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Date: _________________________________
</DIV>
<DIV>
<BR>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage114"></A>
<A NAME="EXH_10-14_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_4"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.14
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	AMENDMENT NO. 1 TO STOCK OPTION AGREEMENTS
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	___________________________________
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Amendment No. 1 to Stock Option Agreements (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	") is made and entered into on December 31, 2015 between CytRx Corporation, a Delaware corporation (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Company
</U>
</FONT>
	"), and the undersigned (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Holder
</U>
</FONT>
	") in order to amend as set forth in this Amendment the following Stock Option Agreements (collectively, the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Original Option Agreements
</U>
</FONT>
	") between the Company and the Holder: (a)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated October 12, 2009 pursuant to the Company's 2008 Stock Incentive Plan (as amended from time to time, the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Plan
</U>
</FONT>
	"); (b)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated December 14, 2010 pursuant to the Plan; (c)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated December 12, 2011 pursuant to the Plan; (d)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated December 10, 2013 pursuant to the Plan; and (e)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated December 15, 2014 pursuant to the Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, for good and valuable consideration, the Company and the Holder hereby agree as follows:
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	DEFINED TERMS.&#160; Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the respective Original Option Agreements.&#160; References in the Original Option Agreements to this "Agreement," this "Option Agreement" or like terms mean the Original Option Agreements as amended by this Amendment.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING.&#160; Section 1 of the Option Agreements is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; MARGIN-LEFT: 36PT; MARGIN-RIGHT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING.&#160; Subject to acceleration of vesting as provided in the Plan and to the limitations contained herein, your option shall vest (become exercisable) as provided in your Notice of Award; provided, that your option shall&#160; immediately vest in full upon FDA marketing approval of the Company's lead product candidate, aldoxorubicin; and provided further, that your option shall immediately vest in full upon the termination of your employment on or after January 1, 2016 (i)&#160;by the Company without 'Cause' or upon your resignation with 'Good Reason' (as&#160; each such term is defined in the Employment Agreement dated as of December 31, 2015 between the Company and the Holder (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employment Agreement
</U>
</FONT>
	")) or (ii) due to your death or by the Company by reason of your 'Disability' (as defined in the Employment Agreement)."
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM.&#160; Section 6 of the Option Agreement is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; MARGIN-LEFT: 36PT; MARGIN-RIGHT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM.&#160; You may not exercise your option before the commencement of its term or after its term expires.&#160; Notwithstanding any contrary provision of the Plan, the term of your option commences on the Date of Grant and expires at 5:00 P.M., Pacific Time, on the day immediately prior to the tenth anniversary of the Date of Grant irrespective of whether or not your service (as defined in the Plan) may have terminated prior to such expiration; provided, that in the event of the termination of your employment on or after January 1, 2016 (i)&#160;by the Company without 'Cause' or&#160;upon your resignation with 'Good Reason' (as each such term is defined in the Employment Agreement) or (iii) due to your death or by the Company by reason of your 'Disability' (as defined in the Employment Agreement), your option shall remain exercisable thereafter for its full term."
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	PLAN.&#160; Section 12 of the Option Agreement is amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	"PLAN.&#160; The terms contained in the Plan are incorporated into and made a part of this Option Agreement and this Option Agreement shall be governed by and construed in accordance with the Plan.&#160; In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Option Agreement, the provisions of the Plan shall be controlling and determinative; provided, however, that the accelerated vesting and exercise period set forth in the foregoing amendments to Sections 1 and 6 of this Option Agreement shall prevail over any contrary provision in the Plan and over any other provision of the Original Option Agreement."
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NO OTHER AFFECT.&#160; Except as modified hereby, the Original Option Agreement shall not be affected by this Amendment and shall continue in effect in accordance with its terms.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	MISCELLANEOUS.&#160; This Amendment may be exercised in counterparts, which together shall constitute a single instrument.&#160; A facsimile, PDF or other electronic signature to this Amendment shall have the same force and effect as an original signature.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage115"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The parties have executed this Amendment.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="9116B4CD9BCF491C87812B122245ED6C" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/&#160;STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Title: Chairman of the Board and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV>
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;HOLDER:
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP">
	&#160;/s/ DANIEL J. LEVITT, M.D., Ph.D.
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Daniel J. Levitt, M.D., Ph.D.
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	[Execution Page to Amendment No. 1 to Stock Option Agreement]
<BR>
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage116"></A>
<A NAME="EXH_10-15_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_5"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="FONT-WEIGHT: BOLD">
	Exhibit 10.15
</FONT>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	AMENDMENT NO. 1 TO STOCK OPTION AGREEMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Issued Pursuant to the 2000 Long-Term Incentive Plan
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	___________________________________
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	This Amendment No. 1 to Stock Option Agreements (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	") is made and entered into on March 8, 2016 between CytRx Corporation, a Delaware corporation (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Company
</U>
</FONT>
	"), and the undersigned (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Holder
</U>
</FONT>
	") in order to amend as set forth in this Amendment the following Stock Option Agreements (collectively, the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Original Option Agreements
</U>
</FONT>
	") between the Company and the Holder: (a)&#160;the Stock Option Agreement made to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	June 16, 2006
</FONT>
	pursuant to the Company's 2000 Long-Term Incentive Plan (as amended from time to time, the "2000
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Plan
</U>
</FONT>
	"); (b)&#160;the Stock Option Agreement made to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	April 18, 2007
</FONT>
	pursuant to the 2000 Plan; (c)&#160;the Stock Option Agreement made to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	November 21, 2008
</FONT>
	pursuant to the 2000 Plan;
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, for good and valuable consideration, the Company and the Holder hereby agree as follows:
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	DEFINED TERMS.&#160; Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the respective Original Option Agreements.&#160; References in the Original Option Agreements to this "Agreement," this "Option Agreement" or like terms mean the Original Option Agreements as amended by this Amendment.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING.&#160; Section 2, "Vesting of Option," of the Original Option Agreements is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; MARGIN-RIGHT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"2. Vesting of Option.
</FONT>
<FONT STYLE="FONT-SIZE: 5PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Subject to acceleration of vesting as provided in the Plan and to the limitations contained herein, your option shall vest (become exercisable) as provided in your Notice of Award; provided, that your option shall immediately vest in full upon FDA marketing approval of the Company's lead product candidate, aldoxorubicin; and provided further, that your option shall immediately vest in full upon the termination of your employment on or after March 8, 2016 (i)&#160;by the Company without 'Cause' or upon your resignation with 'Good Reason' (as each such term is defined in the Fourth Amended and Restated Employment Agreement, dated May 10, 2012 (the "Original Employment Agreement"), as amended in separate amendments dated May 10, 2014, January 1, 2015 and March 8, 2016 between the Company and you) or (ii) due to your death or by the Company by reason of your 'Disability' (as defined in the Original Employment Agreement)."
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM.&#160; Section 3, "Period of Option and Limitations on Right to Exercise" of the Original Option Agreements is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 36PT">
	"3. Period of Option and Limitations on Right to Exercise.&#160; You may not exercise your option before the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires at 5:00 P.M., Pacific Time, on the day immediately prior to the tenth anniversary of the Date of Grant, subject to earlier termination as provided in the Plan in the event of termination of your Service for 'Cause' (as defined in the Original Employment Agreement); provided, that in the event of the termination of your employment (1) by the Company without 'Cause' or by reason of your "Disability' (as defined in the Original Employment Agreement), (2) upon your resignation with 'Good Reason' (as defined in the Original Employment Agreement) or (3) due to your death or by the Company by reason of your "Disability" as defined in the Original Employment Agreement, your option shall remain exercisable thereafter for its full term."
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CONTROL. Section 11, "Plan Controls," of the Original Option Agreements is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"11. Plan Controls.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The terms contained in the Plan are incorporated into and made a part of this Option Agreement and this Option Agreement shall be governed by and construed in accordance with the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Option Agreement, the provisions of the Plan shall be controlling and determinative; provided, however, that the accelerated vesting and exercise period set forth in the foregoing amendments to Sections 2 and 3 of this Option Agreement shall prevail over any contrary provision in the Plan and over any other provision of the Original Option Agreement."
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NO OTHER AFFECT.&#160; Except as modified hereby, the Original Option Agreements shall not be affected by this Amendment and shall continue in effect in accordance with their terms.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	MISCELLANEOUS.&#160; This Amendment may be exercised in counterparts, which together shall constitute a single instrument.&#160; A facsimile, PDF or other electronic signature to this Amendment shall have the same force and effect as an original signature.
</FONT>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage117"></A>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The parties have executed this Amendment.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6BFDEA80C0BE445B9802DCCD54787727" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD" VALIGN="TOP" ALIGN="LEFT">
	&#160;CYTRX C ORPORATION
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;HOLDER:
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ JOHN Y. CALOZ
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chief Financial Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Execution Page to Amendment No. 1 to Stock Option Agreement Issued Pursuant to the 2000 Plan]
</DIV>
<DIV>
<BR>
	&#160;
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage118"></A>
<A NAME="EXH_10-16_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_6"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.16
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	AMENDMENT NO. 1 TO STOCK OPTION AGREEMENTS
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 6PT; FONT-SIZE: 10PT">
	Issued Pursuant to the Amended and Restated 2008 Stock Incentive Plan
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	___________________________________
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Amendment No. 1 to Stock Option Agreements (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	") is made and entered into on March 8, 2016 between CytRx Corporation, a Delaware corporation (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Company
</U>
</FONT>
	"), and the undersigned (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Holder
</U>
</FONT>
	") in order to amend as set forth in this Amendment the following Stock Option Agreements (collectively, the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Original Option Agreements
</U>
</FONT>
	") between the Company and the Holder: (a)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 10, 2009
</FONT>
	pursuant to the Company's Amended and Restated 2008 Stock Incentive Plan (as amended from time to time, the "2008
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Plan
</U>
</FONT>
	"); (b) the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 14, 2010
</FONT>
	pursuant to the 2008 Plan; (c) the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 12, 2011
</FONT>
	pursuant to the 2008 Plan; (d) the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 10, 2012
</FONT>
	pursuant to the 2008 Plan; (e) the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	March 8, 2013
</FONT>
	pursuant to the 2008 Plan; (f) the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 10, 2013
</FONT>
	(as amended and restated effective June 2, 2015)
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&#160;
</FONT>
	pursuant to the 2008 Plan; and (g)&#160;the Stock Option Agreement made part of the Grant Notice to the Holder dated
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	December 15, 2014
</FONT>
	pursuant to the 2008 Plan.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, for good and valuable consideration, the Company and the Holder hereby agree as follows:
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	DEFINED TERMS.&#160; Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the respective Original Option Agreements.&#160; References in the Original Option Agreements to this "Agreement," this "Option Agreement" or like terms mean the Original Option Agreements as amended by this Amendment.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	VESTING.&#160; Section 1 of the Original Option Agreements is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"1. VESTING.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Subject to acceleration of vesting as provided in the Plan and to the limitations contained herein, your option shall vest (become exercisable) as provided in your Notice of Award; provided, that your option shall&#160; immediately vest in full upon FDA marketing approval of the Company's lead product candidate, aldoxorubicin; and provided further, that your option shall immediately vest in full upon the termination of your employment on or after March 8, 2016 (i)&#160;by the Company without 'Cause' or upon your resignation with 'Good Reason' (as each such term is defined in the Fourth Amended and Restated Employment Agreement, dated May 10, 2012 (the "Original Employment Agreement"), as amended in separate amendments dated May 10, 2014, January 1, 2015 and March 8, 2016 between the Company and you) or (ii) due to your death or by the Company by reason of your 'Disability' (as defined in the Original Employment Agreement)."
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	TERM.&#160; Section 6 of the Original Option Agreements is hereby amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-LEFT: 36PT; MARGIN-RIGHT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"6. TERM.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	You may not exercise your option before the commencement of its term or after its term expires. The term of your option commences on the Date of Grant and expires at 5:00 P.M., Pacific Time, on the day immediately prior to the tenth anniversary of the Date of Grant, subject to earlier termination as provided in the Plan in the event of termination of your Service for "Cause" (as defined in the Original Employment Agreement); provided, that in the event of the termination of your employment (1) by the Company without 'Cause' or by reason of your 'Disability' (as defined in the Original Employment Agreement), (2) upon your resignation with 'Good Reason' (as defined in the Original Employment Agreement) or (3) due to your death, your option shall remain exercisable thereafter for its full term."
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CONTROL. Section 12, "Plan," of the Original Option Agreements is amended to read in its entirety as follows:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"12. PLAN.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The terms contained in the Plan are incorporated into and made a part of this Option Agreement and this Option Agreement shall be governed by and construed in accordance with the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Option Agreement, the provisions of the Plan shall be controlling and determinative; provided, however, that the accelerated vesting and exercise period set forth in the foregoing amendments to Sections 1 and 6 of this Option Agreement shall prevail over any contrary provision in the Plan and over any other provision of the Original Option Agreement."
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NO OTHER AFFECT.&#160; Except as modified hereby, the Original Option Agreements shall not be affected by this Amendment and shall continue in effect in accordance with its terms.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	MISCELLANEOUS.&#160; This Amendment may be exercised in counterparts, which together shall constitute a single instrument.&#160; A facsimile, PDF or other electronic signature to this Amendment shall have the same force and effect as an original signature.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage119"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	The parties have executed this Amendment.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="454619BC4A5C4A15BEF347C109CFFE35" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</FONT>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;HOLDER:
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ JOHN Y. CALOZ
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chief Financial Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	[Execution Page to Amendment No. 1 to Stock Option Agreement]
<BR>
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage120"></A>
<A NAME="EXH_10-26_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_7"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.26
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<U>
	EMPLOYMENT AGREEMENT
</U>
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Employment Agreement (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Agreement
</U>
</FONT>
	") is made and entered into as of December 31, 2015 (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Effective Date
</U>
</FONT>
	") by and between CytRx Corporation, a Delaware corporation ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employer
</U>
</FONT>
	"), and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Daniel Levitt, M.D., Ph.D
</FONT>
	., an individual and resident of the State of California ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee
</U>
</FONT>
	").
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	WHEREAS, Employer desires to continue to employ Employee, and Employee is willing to be employed by Employer, on the terms set forth in this Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and agreements hereinafter contained, the parties hereto agree as follows.
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employment
</U>
</FONT>
	.&#160; Effective as of the Effective Date, Employer shall employ Employee, and Employee shall serve, as Employer's Chief Medical Officer and Executive Vice President on the terms set forth herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Duties and Places of Employment
</U>
</FONT>
	.&#160; Employee shall perform in a professional and business-like manner, and to the best of his ability, the duties described on
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Schedule 1
</U>
</FONT>
	to this Agreement and such other duties as are mutually agreed to in writing from time to time by Employee and Employer's Chairman of the Board and Chief Executive Officer. Subject to the succeeding sentences, Employee's services hereunder shall be rendered at Employer's San Francisco office and its corporate offices in Los Angeles, California, except for travel when and as required in the performance of Employee's duties hereunder. Employee may work remotely from the San Francisco office and during such time, Employee shall make himself readily accessible to Employer by telephone, via the Internet or other remote access, as Employee deems reasonably necessary for the performance of Employee's services hereunder.&#160; Employer shall make available to Employee remote computer access in Employer's San Francisco office to Employer's computerized systems and shall provide technical and hardware support.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Time and Efforts
</U>
</FONT>
	.&#160; Subject to this Section 3, Employee shall devote all of his business time, efforts, attention and energies to Employer's business. Employer agrees that Employee may continue to serve as a member of the board of directors of Aquinox Corp. and as a member of the board of directors of the San Francisco SPCA. In addition, Employee may serve on the board or advisory committee of other companies or organizations or provide consulting services to other companies or organizations, provided in each case that such company or organization is not directly competitive with Employer.&#160; Employee shall inform Employer of such services.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	.&#160; The term (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	") of Employee's employment hereunder shall commence on the Effective Date and shall expire on December 31, 2016, unless sooner terminated in accordance with Section 6.&#160; Neither Employer nor Employee shall have any obligation to extend or renew this Agreement.&#160; In the event that Employee's employment has not theretofore been terminated and Employer does not offer to extend or renew Employee's employment under the Agreement, following the expiration of the Term Employer shall continue to pay Employee his salary as provided for in Section 5.2 during the one-year period ending December 31, 2017.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage121"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	5.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Compensation
</U>
</FONT>
	.&#160; As total consideration for Employee's services hereunder, Employer shall pay or provide Employee the following compensation and benefits:
</DIV>
<BR>
</DIV>
<DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.1
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Retention Bonus
</U>
</FONT>
	.&#160; Employee shall be entitled to a bonus of TWO HUNDRED FIFTY THOUSAND DOLLARS ($250,000.00), which shall be paid by Employer on the first payroll in January 2016.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.2
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Salary; Discretionary Bonus
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee shall be entitled to receive an annual salary of SIX HUNDRED TWENTY FIVE THOUSAND DOLLARS ($625,000.00), payable in accordance with Employer's normal payroll policies and procedures.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If, during the Term, Employer reports statistically significant results of its ongoing Phase&#160;III pivotal trial of aldoxorubicin, Employee shall be eligible for a bonus, payable no later than the last regular payroll of 2016, in an amount, if any, to be determined in the discretion of the Board of Directors of Employer (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Board
</U>
</FONT>
	") or of the Compensation Committee of the Board.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.3
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Expense Reimbursement
</U>
</FONT>
	.&#160; Employer shall reimburse Employee for reasonable and necessary business expenses incurred by Employee in connection with the performance of Employee's duties in accordance with Employer's usual practices and policies in effect from time to time; provided, however, that Employee shall be permitted to fly first class on all plane trips that are scheduled for more than two hours in duration. When Employee travels to Employer's corporate offices, Employer shall pay for (i) round-trip airfare and airport parking or other ground transportation to and from the airports, or, (ii) if driving, the cost of gas, tolls and meals, but shall not pay for any other food or other incidentals except as specifically set forth herein.&#160; (c) During the Term, Employer shall provide Employee with (i) hotel, parking and meal accommodations while Employee is working at Employer's corporate offices in reasonable proximity to Employer's corporate offices as chosen by Employee, (ii) Employer-paid memberships to one airline club, and (iii) the use of a rental car leased by Employer with Employer-paid car rental insurance for use while working in Los Angeles, California.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.4
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Tax Gross-Ups
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In the event it shall be determined that any payment by the Employer to or for the benefit of Employee under Section 5.3 above (whether paid or payable pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this Section 5.4) (a "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Travel, Hotel and Meal Payment
</U>
</FONT>
	") would be subject to federal or state income or payroll tax (such income and payroll tax, together with any such interest and penalties, are hereinafter collectively referred to as the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Additional Section 5.3 Income Tax
</U>
</FONT>
	"), then Employee shall be entitled to receive an additional payment (a "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Gross-Up Payment
</U>
</FONT>
	") in an amount such that after payment by Employee of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) imposed upon the Gross-Up Payment, Employee retains an amount of the Gross-Up Payment equal to the Additional Section 5.3 Income Tax imposed upon the Travel, Hotel and Meal Payments.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	In the event it shall be determined that any payment or distribution by the Employer to or for the benefit of Employee (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement, including Section 5.3 above, or otherwise, but determined without regard to any additional payments required under this Section 5.4) (a "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Change in Control Payment
</U>
</FONT>
	") would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Code
</U>
</FONT>
	") or any interest or penalties are incurred by Employee with respect to such excise tax (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Excise Tax
</U>
</FONT>
	"), then Employee shall be entitled to receive an additional payment (a "Parachute Gross-Up Payment") in an amount such that after payment by Employee of all taxes (including any interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and Excise Tax imposed upon the Parachute Gross-Up Payment, Employee retains an amount of the Parachute Gross-Up Payment equal to the Excise Tax imposed upon the Change in Control Payments.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Subject to the provisions of Section 5.4(d) hereof, all determinations required to be made under this Section 5.4, including whether and when a Gross-Up Payment or a Parachute Gross-Up Payment is required and the amount of such Gross-Up Payment or Parachute Gross-Up Payment, whichever shall apply, and the assumptions to be used in arriving at such determination, shall be made by an independent auditor (the "Auditor") jointly selected by Employee and Employer and paid by Employer. If Employee and Employer cannot agree on the firm to serve as the Auditor, then they shall each select an accounting firm and those two firms shall jointly select the accounting firm to serve as the Auditor. Unless Employee agrees otherwise in writing, the Auditor shall be a nationally recognized United States public accounting firm that has not during the two years preceding the date of its selection, acted in any way on behalf of Employer. Employee and Employer shall cooperate with each other in connection with any proceeding or claim relating to the existence or amount of any liability for Excise Tax. All expenses relating to any such proceeding or claim (including attorneys' fees and other expenses incurred by Employee in connection therewith) shall be paid by Employer promptly upon demand by Employee, and any such payment shall be subject to a Parachute Gross-Up Payment under this Section 5.4 in the event that Employee is subject to Excise Tax on it or a Gross-Up Payment in the event that Employee is subject to an Additional Section 5.3 Income Tax on it.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The Auditor shall provide detailed supporting calculations both to the Employer and Employee within 15 business days of the receipt of notice from Employee that there has been a Change in Control Payment or the Travel, Hotel and Meal Payment is being treated as taxable income to Employee.&#160; All fees and expenses of the Accounting Firm shall be borne solely by the Employer.&#160; Any Gross-Up Payment or Parachute Gross-Up Payment, as determined pursuant to this Section 5.4, shall be paid by the Employer to Employee on the first to occur of (i) five business days prior to the time the Excise Tax or the Additional Section 5.3 Income Tax, as applicable, is payable and (ii) within five days of the receipt of the Auditor's determination.&#160; Any determination by the Auditor shall be binding upon the Employer and Employee.&#160; As a result of the uncertainty in the application of Sections 61 or 4999 of the Code at the time of the initial determination by the Auditor hereunder, it is possible that Gross-Up Payments or Parachute Gross-Up Payments which will not have been made by the Employer should have been made ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Underpayment
</U>
</FONT>
	"), consistent with the calculations required to be made hereunder.&#160; In the event that the Employer exhausts its remedies pursuant to Section 5.4(e) and Employee thereafter is required to make a payment of any Additional Section 5.3 Income Tax or any Excise Tax, the Auditor shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by the Employer to or for the benefit of Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee shall notify the Employer in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by the Employer of the Gross-Up Payment or the Parachute Gross-Up Payment.&#160; Such notification shall be given as soon as practicable but no later than thirty days after Employee is informed in writing of such claim and shall apprise the Employer of the nature of such claim and the date on which such claim is requested to be paid.&#160; Employee shall not pay such claim prior to the expiration of the 30-day period following the date on which it gives such notice to the Employer (or such shorter period ending on the date that any payment of taxes with respect to such claim is due).&#160; If the Employer notifies Employee in writing prior to the expiration of such period that it desires to contest such claim, Employee shall:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 144PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	give the Employer any information reasonably requested by the Employer relating to such claim;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 144PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	take such action in connection with contesting such claim as the Employer shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Employer;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 144PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iii)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	cooperate with the Employer in good faith in order effectively to contest such claim; and
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 144PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(iv)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	permit the Employer to participate in any proceedings relating to such claim;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	provided, however, that the Employer shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and shall indemnify and hold Employee harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses.&#160; Without limitation of the foregoing provisions to this Section 5.4(e), the Employer shall control all proceedings taken in connection with such contest and, at its sole option, may pursue or forgo any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim.
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage122"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.5
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Vacation
</U>
</FONT>
	.&#160; Employee shall continue to accrue vacation days without loss of compensation in accordance with Employer's usual policies applicable to all employees at a rate of four weeks' vacation time for each 12-month period during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.6
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee Benefits
</U>
</FONT>
	.&#160; Employee shall be eligible to participate in any employee benefits made available generally by Employer to all of its employees under its group plans and employment policies in effect during the Term.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Schedule 2
</U>
</FONT>
	hereto sets forth a summary of such plans and policies as currently in effect. Employee acknowledges and agrees that, any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.7
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Payroll Taxes
</U>
</FONT>
	.&#160; Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.8
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Equity Awards
</U>
</FONT>
	.&#160; In connection with the execution and delivery of this Agreement, Employer and Employee shall enter into mutually satisfactory amendments to all stock option agreements between Employer and Employee pursuant to Employer's 2008 Stock Incentive Plan to provide for (a) the vesting, in full, of the stock options subject to each such stock option agreement in the event of, and upon, FDA approval to market aldoxorubicin and in the event of termination of Employee's employment hereunder other than termination by Employer for Cause and (b) the extended exercisability of all vested options in the event of termination of Employee's employment hereunder other than termination by Employer for cause.&#160; Employee also shall be eligible for grants of stock options, restricted stock and other equity awards based on Employer stock in accordance with Employer's practices and policies with respect to its senior executives.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination
</U>
</FONT>
	.&#160; This Agreement may be terminated as set forth in this Section 6.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.1
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer for Cause
</U>
</FONT>
	.&#160; Employer may terminate Employee's employment hereunder for "Cause" upon notice to Employee.&#160; "Cause" for this purpose shall mean any of the following:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's breach of any material term of this Agreement; provided that the first occasion of any particular breach shall not constitute such Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and evidence of such breach, and affording Employee at least 30 calendar days to correct such breach;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's conviction of, or plea of guilty or nolo contendere to, any misdemeanor, felony or other crime of moral turpitude;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's conviction of fraud injurious to Employer or its reputation; and
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's continual failure or refusal (other than due to his death or "Disability" as defined in Section 6.3) to perform his material duties as required under Schedule 1 to this Agreement after written notice from Employer stating the nature of such failure or refusal and affording Employee at least 30 calendar days to correct the same.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Upon termination of Employee's employment by Employer for Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled only to payment in a lump sum, not later than three days after the date of termination, equal to the sum of (1) of any accrued but unpaid salary and unused vacation as provided in Sections 5.2 and 5.5 as of the date of such termination, (2) any unpaid bonus that may have been accrued by or awarded Employee as provided in Section 5.1 and 5.2(b) prior to such date, and (3) such benefits, if any, to which Employee or his dependents or beneficiaries may then be entitled as a participant under the employee benefit plans referred to in Section 5.6.&#160; In the event of the termination of Employee's employment for Cause, Employee's stock options and any other equity awards based on Employer's securities, such as restricted stock, restricted stock units, stock appreciation rights, performance units, etc. shall, to the extent then vested and exercisable, remain vested and exercisable in accordance with their terms.&#160; In addition, Employee shall be entitled to retain and have full ownership of all electronic devices provided to Employee (including, without limitation, a computer, telephone and tablet); provided that all Employer confidential information shall be deleted by Employer from such devices before releasing them to Employee.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; LETTER-SPACING: 9PT; FONT-SIZE: 1PX;">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="TEXT-ALIGN: LEFT; PAGE-BREAK-AFTER: ALWAYS; TEXT-INDENT: 0PX" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN-TOP: 4PX; MARGIN-BOTTOM: 4PX; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage123"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.2
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer without Cause
</U>
</FONT>
	.&#160; Employer may also terminate Employee's employment without Cause upon not less than ten days written notice to Employee.&#160; Upon the effective date of the termination of Employee's employment by Employer without Cause under this Section 6.2, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled to (a) a lump sum cash payment on the effective date of Employee's termination of employment of (1) any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law, which shall be due and payable upon the effective date of such termination, (2) any unpaid bonus that may have been accrued by or awarded Employee under Sections 5.1 and 5.2(b) prior to such date, and (3) such benefits, if any, to which Employee or his dependents or beneficiaries may then be entitled as a participant under the employee benefit plans referred to in Section 5.6, (b) as of the effective date of Employee's termination, full (100%) and immediate vesting of all of Employee's stock options and any other equity awards based on Employer securities, such as restricted stock units, stock appreciation rights, performance units, etc., and all stock options and other equity awards&#160; shall remain exercisable for their full term, (c) payment of any Tax Gross-Up or Parachute Tax Gross-Up payment as described in Section 5.4, (d) an amount, which shall be due and payable within ten days following the effective date of such termination, equal to Employee's salary as provided in Section 5.2(a) that would otherwise be payable for the period (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Severance Period
</U>
</FONT>
	") commencing on the date of termination of Employee's employment and ending on the first anniversary of such termination date, provided that if the date of termination occurs following a Change of Control (as hereinafter defined), then the salary described in this clause shall instead be calculated using a 24-month "Severance Period" that commences on the date of termination and ends on the second anniversary of such termination date, (e)&#160;retain and have full ownership of all electronic devices provided to Employee (including, without limitation, a computer, telephone and tablet), provided that all Employer confidential information shall be deleted by Employer from such devices before releasing them to Employee, and (f) continued participation, at Employer's cost and expense, of Employee and his dependents, for a period of 12 months following such termination, in any Employer-sponsored group benefit plans in which Employee was participating as of the date of termination.&#160; Employee's rights to the payments and benefits under clauses (b) through (f) of this Section 6.2 shall be conditioned on Employee's prior execution and delivery to Employer of the General Release of All Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit A
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.3
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Death or Disability
</U>
</FONT>
	.&#160; In the event of Employee's death or "Disability" (as defined below) during the Term, the Employee's employment shall automatically cease and terminate as of the date of Employee's death or the effective date of Employer's written notice to Employee of its decision to terminate his employment by reason of his Disability, as the case may be, and Employee or his heirs or personal representative shall be entitled to the same payments and benefits, at the same times, as described in Section 6.2 for a termination of employment by Employer without Cause.&#160; Likewise, as of the effective date of Employee's death or termination due to Disability, full (100%) and immediate vesting of all of Employee's stock options and any other equity awards based on Employer securities, such as restricted stock units, stock appreciation rights, performance units, etc., held by Employee at the time of his death or Disability and all stock options and other equity awards shall remain exercisable thereafter for their full term.&#160; In addition, Employee or his heirs or personal representative shall be entitled to retain and have full ownership of all electronic devices provided to Employee (including, without limitation, a computer, telephone and tablet) ); provided that all Employer confidential information shall be deleted by Employer from such devices before releasing them to Employee or such heirs or personal representatives.&#160; Notwithstanding the foregoing or any provision of Section 6.2, Employer's obligation to pay Employee the salary called for in Section 6.2 for the Severance Period following termination of his employment by reason of his Disability shall be subject to offset and shall be reduced by any and all amounts paid to Employee under any disability insurance policy paid or provided for by Employer as provided in Section 5.6 or otherwise. Employee's "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Disability
</U>
</FONT>
	" shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or by Employee, as the case may be) with respect to Employee or, if no such policy is then in effect, shall mean Employee's inability to fully perform his duties hereunder for any period of at least 75 consecutive days or for a total of 90 days, whether or not consecutive.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.4
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employee for Good Reason
</U>
</FONT>
	.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee may terminate his employment hereunder for "Good Reason," which shall mean any material breach by Employer of the terms hereof that is not corrected by Employer within five days after written notice by Employee to Employer, including, without limitation, (i) the assignment to Employee of any duties inconsistent in any respect with his position as Chief Medical Officer and Executive Vice President (including status, offices, titles, reporting requirements, authority, duties or responsibilities); (ii) any failure by Employer to comply with its compensation obligations under this Agreement; (iii) Employer's requiring Employee to relocate from San Francisco or report to any office or location more than ten miles of the current location of the Company's headquarters; or (iv) the failure of any purchaser of substantially all the assets of the Employer to assume or renew this Agreement.&#160; If Employee terminates his employment for Good Reason, subject to Employer's right to cure as set forth above, the termination shall take effect on the effective date (determined under Section 15) of the written notice to Employer, and Employee shall be entitled to the same payments and benefits, at the same times, described in Section 6.2 for a termination by Employer without Cause. Likewise, as of the effective date of Employee's termination for Good Reason, to the extent not otherwise vested, full (100%) and immediate vesting of all of Employee's stock options and any other equity awards based on Employer securities, such as restricted stock units, stock appreciation rights, performance units, etc., and all stock options and other equity awards shall remain exercisable thereafter for their full term.&#160; In addition, Employee shall be entitled to retain and have full ownership of all electronic devices provided to Employee (including, without limitation, a computer, telephone and tablet) ); provided that all Employer confidential information shall be deleted by Employer from such devices before releasing them to Employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee also may terminate his employment hereunder for Good Reason if Employer terminates without cause the employment of any of the Senior Vice President of Clinical Operations or Vice Presidents of Clinical Development or Manufacturing and Project Management (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Key Employees
</U>
</FONT>
	") of Employer.&#160; Any termination by Employee of his employment under this Section 6.4(b) shall be effective upon notice to Employer given not later than 90 days following the termination of employment of any of the Key Employees.&#160; At Employer's request, Employee shall postpone termination of his employment under this Section 6.4(b) for a transition period not to exceed 30 days from the date Employee's employment would otherwise have been terminated hereunder.&#160; Upon termination of his employment under this Section 6.4(b), Employee shall be entitled to receive within ten days of the effective date of such termination a lump sum cash payment equal to Employee's salary as provided in Section 5.2(a) for the period commencing on the date of termination of Employee's employment and ending on the expiration of the Term or on the six-month anniversary of such termination, whichever is later. Further, as of the effective date of Employee's termination for Good Reason under this Section 6.4(b), to the extent not otherwise vested, full (100%) and immediate vesting of all of Employee's stock options and any other equity awards based on Employer securities, such as restricted stock units, stock appreciation rights, performance units, etc., and all stock options and other equity awards shall remain exercisable thereafter for their full term.&#160; In addition, Employee shall be entitled to retain and have full ownership of all electronic devices provided to Employee (including, without limitation, a computer, telephone and tablet) ); provided that all Employer confidential information shall be deleted by Employer from such devices before releasing them to Employer
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 0PX; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	6.5
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employee without Good Reason
</U>
</FONT>
	.&#160; Employee shall have the right to voluntarily terminate his employment hereunder at any time without Good Reason upon 30 days' written notice to Employer.&#160; A voluntary termination by Employee in accordance with this Section 6.5 shall not be deemed a breach of this Agreement.&#160; Upon any voluntary termination of employment by Employee without Good Reason pursuant to this Section 6.5, Employee shall be entitled only to such payments and benefits as those described in Section 6.1 for a termination by Employer for Cause.&#160;&#160; In addition, Employee shall be entitled to retain and have full ownership of all electronic devices provided to Employee (including, without limitation, a computer, telephone and tablet) ); provided that all Employer confidential information shall be deleted by Employer from such devices before releasing them to Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.6
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination in Connection with a Change in Control
</U>
</FONT>
	.&#160; For purposes of this Section 6.6, a "Change in Control" shall have the meaning ascribed to such term in Employer's 2000 Long-Term Incentive Plan and shall also have the meaning ascribed to the term "Corporate Transaction" in Employer's 2008 Stock Incentive Plan, as each such Plan may be amended from time to time. If a Change in Control occurs during the Term, and if, within two years after the date on which the Change in Control occurs, Employee's employment is terminated by Employer without Cause or by Employee for Good Reason, then Employee will be entitled to the payments and benefits described in the proviso found in the third from the last sentence of Section 6.2 above, at the same times, described in Section 6.2 for a termination by Employer without Cause.
</FONT>
</DIV>
</DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage124"></A>
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.7
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Mitigation; No Offset
</U>
</FONT>
	.&#160; Employee shall have no obligation to seek other employment or to otherwise mitigate Employer's obligations to him arising from the termination of his employment, and no amounts paid or payable to Employee by Employer under this Agreement shall be subject to offset for any remuneration to which Employee may become entitled from any other source after his employment with Employer terminates, whether attributable to subsequent employment, self-employment or otherwise.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Confidentiality
</U>
</FONT>
	.&#160; While this Agreement is in effect and for a period of five years thereafter, and except as otherwise required by law or legal process and after reasonable notice to Employer and opportunity for Employer to intervene, Employee shall hold and keep secret and confidential all "trade secrets" (within the meaning of applicable law) and other confidential or proprietary information of Employer and shall use such information only in the course of performing Employee's duties hereunder; provided, however, that with respect to trade secrets, Employee shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under applicable law.&#160; Employee shall maintain in trust all such trade secrets or other confidential or proprietary information, as Employer's property, including, but not limited to, all documents concerning Employer's business, including Employee's work papers, telephone directories, customer information and notes, and any and all copies thereof in Employee's possession or under Employee's control.&#160; Upon the expiration or earlier termination of Employee's employment with Employer, or upon request by Employer, Employee shall deliver to Employer all such documents belonging to Employer, including any and all copies in Employee's possession or under Employee's control.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Equitable Remedies and Injunctive Relief
</U>
</FONT>
	.&#160; Employee hereby acknowledges and agrees that monetary damages are inadequate to fully compensate Employer for the damages that would result from a breach or threatened breach of Section 7 of this Agreement and, accordingly, that Employer shall be entitled to equitable remedies, including, without limitation, specific performance, temporary restraining orders, and preliminary injunctions and permanent injunctions, to enforce such Section without the necessity of proving actual damages in connection therewith.&#160; This provision shall not, however, diminish Employer's right to claim and recover damages or enforce any other of its legal or equitable rights or defenses.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Indemnification; Insurance
</U>
</FONT>
	.&#160; Employer and Employee acknowledge that, as the Executive Vice President and Chief Medical Officer of the Employer, Employee shall be a corporate officer of Employer and, as such, Employee shall be entitled to indemnification to the fullest extent of the law as set forth in the Indemnification Agreement dated December 9, 2013 between the parties.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Severable Provisions
</U>
</FONT>
	.&#160; The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Successors and Assigns
</U>
</FONT>
	.&#160; This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns and Employee and his heirs and representatives; provided, however, that neither party may assign this Agreement without the prior written consent of the other party.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Entire Agreement
</U>
</FONT>
	.&#160; Except for the Indemnification Agreement dated December 9, 2013 and the amendments to the stock option agreements referred to in Section&#160;5.8, this Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise herein.&#160; This Agreement supersedes any and all prior agreements, written or oral, between Employee and Employer relating to the subject matter hereof.&#160; Any such prior agreements are hereby terminated and of no further effect, and Employee, by the execution hereof, agrees that any compensation provided for under any such agreements is specifically superseded and replaced by the provisions of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	.&#160; No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto and unless such writing is made by an executive officer of Employer (other than Employee).&#160; The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Governing Law
</U>
</FONT>
	.&#160; This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to California's choice-of-law rules.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	15.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notice
</U>
</FONT>
	.&#160; All notices and other communications under this Agreement shall be in writing and mailed or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to this provision):
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	If to Employer:
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	CytRx Corporation
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	11726 San Vicente Boulevard, Suite 650
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	Los Angeles, California&#160; 90049
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	Attention: Chief Executive Officer
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	If to Employee:
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	&#160; Daniel Levitt, M.D., Ph.D.
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	&#160;&#160;[Address intentionally omitted]
</DIV>
<BR>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage125"></A>
</DIV>
<DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	16.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Survival
</U>
</FONT>
	.&#160; Sections 4, 5.2, 5.3, 5.4, 6 through 16 and 18 through 20 shall survive the expiration or termination of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Counterparts
</U>
</FONT>
	.&#160; This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.&#160; A counterpart executed and transmitted by facsimile shall have the same force and effect as an originally executed counterpart.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	18.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Attorney's Fees
</U>
</FONT>
	.&#160; In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys' fees and other costs of suit (up to a maximum of $15,000) in addition to any other recoveries.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Interpretation of Ambiguities Against Drafting Party
</U>
</FONT>
	.&#160; This Agreement has been negotiated at arm's length between persons knowledgeable in the matters dealt with herein. Accordingly, the parties agree that any rule of law, including, but not limited to, California Civil Code Section 1654 or any other statutes, legal decisions, or common law principles of similar effect, that would require interpretation of any ambiguities in this Agreement against the party that has drafted it, is of no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intentions of the parties hereto.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 409A of the Code
</U>
</FONT>
	.&#160; This Agreement is intended to comply with the applicable requirements of Section 409A of the Code and the regulations promulgated thereunder ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 409A
</U>
</FONT>
	"), and shall be administered in accordance with Section 409A to the extent Section 409A of the Code applies to the Agreement. Notwithstanding anything in the Agreement to the contrary, distributions pursuant to the Agreement that are subject to Section 409A may only be made in a manner, and upon an event, permitted by Section 409A.&#160; The provisions of this Agreement shall be construed and interpreted to avoid the imposition of any additional tax, penalty or interest under Section 409A while preserving, to the extent possible, the intended benefits hereunder payable to Employee.&#160; Employer and Employee agree that any payment made pursuant to this Agreement due to Employee's "separation from service" as defined in Section 409A shall be delayed in accordance with Section 409A(a)(2)(B)(i) of the Code (six month delay) if and to the extent required to avoid the imposition of any tax, penalty or interest under Section 409A. Any such delayed payments will be paid in a lump sum on the earliest date on which the Company may provide such payment to Employee without Employee's incurring any additional tax or interest pursuant to Section 409A.&#160; Further, any additional cost to Employee by reason of such postponement period, including, for example, Employee's payment of the cost of health benefits during the postponement period, shall be reimbursed by the Company to Employee after such period has ended. If Employee dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section 409A shall be paid to Employee's beneficiary, or if none, to the personal representative of Employee's estate within 30 days after the date of Employee's death.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage126"></A>
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, this Agreement is executed as of the day and year first above written.
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2C53E21D1251436C81BC8A4C4BB0E12D" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYER"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYEE"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</FONT>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ DANIEL LEVITT, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 0PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 0PT">
	Daniel Levitt, M.D., Ph.D.
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage127"></A>
<A NAME="EXH_10-27_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_8"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.27
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; FONT-SIZE: 10PT">
	EMPLOYMENT AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Employment Agreement (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Agreement
</U>
</FONT>
	") is made and entered into as of December 31, 2015 (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Effective Date
</U>
</FONT>
	") by and between CytRx Corporation, a Delaware corporation ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employer
</U>
</FONT>
	"), and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Benjamin S. Levin
</FONT>
	, an individual and resident of the State of California ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee
</U>
</FONT>
	").
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	WHEREAS, Employer desires to employ Employee, and Employee is willing to be employed by Employer, on the terms set forth in this Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and agreements hereinafter contained, the parties hereto agree as follows.
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employment
</U>
</FONT>
	.&#160; Effective as of the Effective Date, Employer shall employ Employee, and Employee shall serve, as Employer's General Counsel, Senior Vice President and Corporate Secretary on the terms set forth herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Duties; Place of Employment
</U>
</FONT>
	.&#160; Employee shall perform in a professional and business-like manner, and to the best of his ability, the duties described on Schedule&#160;1 to this Agreement and such other duties as are assigned to him from time to time by Employer's President and Chief Executive Officer.&#160; Employee understands and agrees that his duties, title and authority may be changed from time to time in the discretion of Employer's President and Chief Executive Officer.&#160; Employee's services hereunder shall be rendered at Employer's principal executive office, except for travel when and as required in the performance of Employee's duties hereunder.&#160; Notwithstanding the foregoing, Employer understands and agrees that Employee shall be entitled to render his services hereunder from his home on Friday of each week except as required by Employer in extraordinary circumstances.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Time and Efforts
</U>
</FONT>
	.&#160; Employee shall devote all of his business time, efforts, attention and energies to Employer's business and to discharge his duties hereunder.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	.&#160; The term (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	") of Employee's employment hereunder shall commence on the Effective Date and shall expire on December 31, 2016, unless sooner terminated in accordance with Section 6.&#160; Neither Employer nor Employee shall have any obligation to extend or renew this Agreement. In the event that Employee's employment has not theretofore been terminated and Employer has not offered to extend or renew this Agreement, upon expiration of the Term Employer shall continue to pay Employee his salary as provided for in Section&#160;5.1 during the period commencing on the final date of the Term and ending on (a)&#160;June 30, 2017 or (b)&#160;the date of Employee's re-employment with another employer, whichever is earlier; provided that, as a condition to Employer's obligations under this sentence, Employee shall have executed and delivered to Employer a General Release of All Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit&#160;A
</U>
</FONT>
	.&#160; Employee shall notify Employer immediately in the event Employee accepts such employment with another employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Compensation
</U>
</FONT>
	.&#160; As the total consideration for Employee's services rendered hereunder, Employer shall pay or provide Employee the following compensation and benefits:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Salary
</U>
</FONT>
	.&#160; Employee shall be entitled to receive an annual salary of Three Hundred Sixty-Five Thousand Dollars ($365,000), payable in accordance with Employer's normal payroll policies and procedures.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Discretionary Bonus
</U>
</FONT>
	.&#160; Employee also may be eligible for a bonus from time to time for his services during the Term.&#160; Employee's eligibility to receive a bonus, any determination to award Employee such a bonus and, if awarded, the amount thereof shall be in Employer's sole discretion.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Expense Reimbursement
</U>
</FONT>
	.&#160; Employer shall reimburse Employee for reasonable and necessary business expenses incurred by Employee in connection with the performance of Employee's duties in accordance with Employer's usual practices and policies in effect from time to time.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Vacation
</U>
</FONT>
	.&#160; Employee shall continue to accrue vacation days without loss of compensation in accordance with Employer's usual policies applicable to all employees at a rate of four weeks' vacation time for each 12-month period during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Tax Gross-Up
</U>
</FONT>
	.&#160; In the event that the severance and other benefits provided for in this Agreement or otherwise payable to the Employee (i) constitute "parachute payments" within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Excise Tax
</U>
</FONT>
	"), then the Employee's benefits under this Agreement shall be either: (x) delivered in full, or (y) delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Employee on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.&#160; Unless Employer and the Employee otherwise agree in writing, any determination required under this Section&#160;1 shall be made in writing by Employer's independent public accountants (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Accountants
</U>
</FONT>
	"), whose determination shall be conclusive and binding upon the Employee and Employer for all purposes.&#160; For purposes of making the calculations required by this Section&#160;1, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.&#160; Employer and the Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section&#160;5.5.&#160; Employer shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section&#160;5.5.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee Benefits
</U>
</FONT>
	.&#160; Employee shall be eligible to participate in any medical insurance and other employee benefits made available by Employer to all of its employees under its group plans and employment policies in effect during the Term.&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Schedule&#160;2
</U>
</FONT>
	hereto sets forth a summary of such plans and policies as currently in effect.&#160; Employee acknowledges and agrees that, any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Payroll Taxes
</U>
</FONT>
	.&#160; Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage128"></A>
</DIV>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination
</U>
</FONT>
	.&#160; This Agreement may be terminated as set forth in this Section&#160;6.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer for Cause
</U>
</FONT>
	.&#160; Employer may terminate Employee's employment hereunder for "Cause" upon notice to Employee.&#160; "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cause
</U>
</FONT>
	" for this purpose shall mean any of the following:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's breach of any material term of this Agreement; provided that the first occasion of any particular breach shall not constitute such Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and affording Employee at least ten days to correct such breach;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's conviction of, or plea of guilty or nolo contendere to, any misdemeanor, felony or other crime of moral turpitude;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act of fraud or dishonesty injurious to Employer or its reputation;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's continual failure or refusal to perform his material duties as required under this Agreement after written notice from Employer stating the nature of such failure or refusal and affording Employee at least ten days to correct the same;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act or omission that, in the reasonable determination of Employer's Board of Directors (or a Committee of the Board), indicates alcohol or drug abuse by Employee; or
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act or personal conduct that, in the judgment of Employer's Board of Directors (or a Committee of the Board), gives rise to a material risk of liability of Employee or Employer under federal or applicable state law for discrimination, or sexual or other forms of harassment, or other similar liabilities to subordinate employees.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Upon termination of Employee's employment by Employer for Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled only to payment upon the effective date of termination of any accrued but unpaid salary and unused vacation as provided in Sections 5.1 and 5.5 as of the date of such termination and any unpaid bonus that may have been awarded Employee as provided in Section 5.2 prior to such date.
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer without Cause.
</U>
</FONT>
	&#160; Employer may also terminate Employee's employment without Cause upon ten days' notice to Employee.&#160; Upon termination of Employee's employment by Employer without Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled to (1) any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law, which shall be due and payable upon the effective date of such termination, (2) any unpaid bonus that may have been awarded to Employee under Section 5.2 prior to such date, which shall be due and payable in accordance with Employer's normal payroll practices or as otherwise required by California law, (3) payment of any Tax Gross-Up payment as provided in Section 5.5, (4) an amount, which shall be due and payable within ten days following the effective date of such termination, equal to six months' salary as provided in Section 5.1., provided, that if such termination occurs following a Change of Control (as hereinafter defined), then the amount described in this clause (4) shall be equal to 12 months' salary as provided in Section&#160;5.1, and (5)&#160;continued participation, at Employer's cost and expense, of Employee and his dependents for a period of six months following such termination (12 months if such termination occurs following a Change of Control) in any Employer-sponsored group benefit plans in which Employee was participating as of the date of termination.&#160; Employee's right to the compensation and benefits provided for in clauses (3) through (5) of this Section 6.2 shall be conditioned upon Employee having executed and delivered to Employer a General Release of All Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit&#160;A
</U>
</FONT>
	.&#160; For purposes of this Section 6.2, a "Change of Control" shall have the meaning ascribed to the term "Corporate Transaction" in Employer's 2008 Stock Incentive Plan, as such Plan may be amended from time to time.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Death or Disability
</U>
</FONT>
	.&#160; Employee's employment will terminate automatically in the event of Employee's death or upon notice from Employer in event of his permanent disability.&#160; Employee's "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	permanent disability
</U>
</FONT>
	" shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or by Employee, as the case may be) with respect to Employee or, if no such policy is then in effect, shall mean Employee's inability to fully perform his duties hereunder for any period of at least 75&#160;consecutive days or for a total of 90&#160;days, whether or not consecutive.&#160; Upon termination of Employee's employment as aforesaid, all compensation and benefits to Employee hereunder shall cease and Employer shall pay to the Employee's heirs or personal representatives, not later than ten days after the date of termination, any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Confidentiality
</U>
</FONT>
	.&#160; While this Agreement is in effect and for a period of five years thereafter, Employee shall hold and keep secret and confidential all "trade secrets" (within the meaning of applicable law) and other confidential or proprietary information of Employer and shall use such information only in the course of performing Employee's duties hereunder; provided, however, that with respect to trade secrets, Employee shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under applicable law.&#160; Employee shall maintain in trust all such trade secrets or other confidential or proprietary information, as Employer's property, including, but not limited to, all documents concerning Employer's business, including Employee's work papers, telephone directories, customer information and notes, and any and all copies thereof in Employee's possession or under Employee's control.&#160; Upon the expiration or earlier termination of Employee's employment with Employer, or upon request by Employer, Employee shall deliver to Employer all such documents belonging to Employer, including any and all copies in Employee's possession or under Employee's control.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U STYLE="BORDER-BOTTOM: 1PX SOLID">
	&#160;
</U>
</FONT>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U STYLE="BORDER-BOTTOM: 1PX SOLID">
	Equitable Remedies; Injunctive Relief
</U>
</FONT>
	.&#160; Employee hereby acknowledges and agrees that monetary damages are inadequate to fully compensate Employer for the damages that would result from a breach or threatened breach of Section 7 of this Agreement and, accordingly, that Employer shall be entitled to equitable remedies, including, without limitation, specific performance, temporary restraining orders, and preliminary injunctions and permanent injunctions, to enforce such Section without the necessity of proving actual damages in connection therewith.&#160; This provision shall not, however, diminish Employer's right to claim and recover damages or enforce any other of its legal or equitable rights or defenses.
</FONT>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	&#160;
</U>
</FONT>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Indemnification; Insurance
</U>
</FONT>
	.&#160; Employer and Employee acknowledge that, as the General Counsel, Senior Vice President and Corporate Secretary of the Employer, Employee shall be a corporate officer of Employer and, as such, Employee shall be entitled to indemnification to the full extent provided by Employer to its officers, directors and agents under the Employer's Certificate of Incorporation and Bylaws as in effect as of the date of this Agreement.&#160; Employer shall maintain Employee as an additional insured under its current policy of directors and officers liability insurance and shall use commercially reasonable efforts to continue to insure Employee thereunder, or under any replacement policies in effect from time to time, during the Term.
</FONT>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage129"></A>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	&#160;&#160;&#160;&#160;
</U>
</FONT>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Severable Provisions
</U>
</FONT>
	.&#160; The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.
</FONT>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Successors and Assigns
</U>
</FONT>
	.&#160; This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns and Employee and his heirs and representatives; provided, that this Agreement may be assigned by Employer to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Employer.
</FONT>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	&#160;
</U>
</FONT>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Entire Agreement
</U>
</FONT>
	.&#160; This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise herein.&#160; This Agreement supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and Employer relating to the subject matter hereof.&#160; Any such prior or contemporaneous agreements are hereby terminated and of no further effect, and Employee, by the execution hereof, agrees that any compensation provided for under any such agreements is specifically superseded and replaced by the provisions of this Agreement.
</FONT>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	13.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	&#160;
</U>
</FONT>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Amendment
</U>
</FONT>
	.&#160; No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto and unless such writing is made by an executive officer of Employer (other than Employee).&#160; The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.
</FONT>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	14.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Governing Law
</U>
</FONT>
	.&#160; This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to California's choice-of-law rules.
</FONT>
</DIV>
<DIV STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-WEIGHT: NORMAL">
<FONT STYLE="FONT-SIZE: 10PT">
	15.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-VARIANT: NORMAL; FONT-STYLE: NORMAL; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL">
<U>
	Notice
</U>
</FONT>
	.&#160; All notices and other communications under this Agreement shall be in writing and mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to this provision):
</FONT>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="172AC96111344FEF8E53B6E84ADD130C" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If to Employer:
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard, Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California&#160; 90049
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(310) 826-5529
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Executive Officer
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If to Employee:
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Benjamin S. Levin
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Address intentionally omitted]
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage130"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	16.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Survival
</U>
</FONT>
	.&#160; Sections 7 through 15 and 17 through 20 shall survive the expiration or termination of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Counterparts
</U>
</FONT>
	.&#160; This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.&#160; A counterpart executed and transmitted by facsimile shall have the same force and effect as an originally executed counterpart.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	18.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Attorney's Fees
</U>
</FONT>
	.&#160; In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys' fees and other costs of suit (up to a maximum of $15,000) in addition to any other recoveries.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Interpretation of Ambiguities Against Drafting Party
</U>
</FONT>
	.&#160; This Agreement has been negotiated at arm's length between persons knowledgeable in the matters dealt with herein.&#160; In addition, each party has been represented by experienced and knowledgeable legal counsel.&#160; Accordingly, the parties agree that any rule of law, including, but not limited to, California Civil Code Section 1654 or any other statutes, legal decisions, or common law principles of similar effect, that would require interpretation of any ambiguities in this Agreement against the party that has drafted it, is of no application and is hereby expressly waived.&#160; The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intentions of the parties hereto.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 409A of the Code
</U>
</FONT>
	.&#160; This Agreement is intended to comply with the applicable requirements of Section&#160;409A of the Code and the regulations promulgated thereunder ("Section 409A"), and shall be administered in accordance with Section&#160;409A to the extent Section&#160;409A of the Code applies to the Agreement. Notwithstanding anything in the Agreement to the contrary, distributions pursuant to the Agreement that are subject to Section 409A may only be made in a manner, and upon an event, permitted by Section&#160;409A.&#160; The provisions of this Agreement shall be construed and interpreted to avoid the imposition of any additional tax, penalty or interest under Section 409A while preserving, to the extent possible, the intended benefits hereunder payable to Employee.&#160; Employer and Employee agree that any payment made pursuant to this Agreement due to Employee's "separation from service" as defined in Section 409A shall be delayed in accordance with Section 409A(a)(2)(B)(i) of the Code (six month delay) if and to the extent required to avoid the imposition of any tax, penalty or interest under Section 409A. Any additional cost to Employee by reason of such postponement period, including, for example, Employee's payment of the cost of health benefits during the postponement period, shall be reimbursed by the Company to Employee after such period has ended. If Employee dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section&#160;409A shall be paid to Employee's beneficiary, or if none, to the personal representative of Employee's estate within 30
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</FONT>
	days after the date of Employee's death.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage131"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, this Agreement is executed as of the day and year first above written.
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="481A16C043D9440998FEB8E3894ED8ED" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYER"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYEE"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD" VALIGN="TOP" ALIGN="LEFT">
	CYTRX CORPORATION
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ BENJAMIN S. LEVIN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 0PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 0PT">
	Benjamin S. Levin
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 12PT">
<BR>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage132"></A>
<A NAME="EXH_10-28_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_9"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.28
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	EMPLOYMENT AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	This Employment Agreement (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Agreement
</U>
</FONT>
	") is made and entered into as of December 31, 2015 (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Effective Date
</U>
</FONT>
	") by and between CytRx Corporation, a Delaware corporation ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employer
</U>
</FONT>
	"), and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Scott Wieland
</FONT>
	, an individual and resident of the State of Tennessee ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee
</U>
</FONT>
	").
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	WHEREAS, Employer desires to employ Employee, and Employee is willing to be employed by Employer, on the terms set forth in this Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and agreements hereinafter contained, the parties hereto agree as follows.
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employment
</U>
</FONT>
	.&#160; Effective as of the Effective Date, Employer shall employ Employee, and Employee shall serve, as Employer's Senior Vice President &#8211; Drug Development on the terms set forth herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Duties; Place of Employment
</U>
</FONT>
	.&#160; Employee shall perform in a professional and business-like manner, and to the best of his ability, the duties described on Schedule&#160;1 to this Agreement and such other duties as are assigned to him from time to time by Employer's Executive Vice President and Chief Medical Officer.&#160; Employee understands and agrees that his duties, title and authority may be changed from time to time in the discretion of Employer's Executive Vice President and Chief Medical Officer. Employer understands and agrees that Employee shall be entitled to render his services hereunder from his home except as directed by the Employee's Supervisor to be present in the Employer's principal executive office, such that it doesn't place any undue hardship on the Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Time and Efforts
</U>
</FONT>
	.&#160; Employee shall devote all of his business time, efforts, attention and energies to Employer's business and to discharge his duties hereunder.&#160; Notwithstanding any other provision of this Section&#160;3, while this Agreement is in effect, Employee may serve on the board of directors of one company other than Employer, but in no event shall Employee serve on the board of directors of a company that is directly competitive with Employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	.&#160; The term (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	") of Employee's employment hereunder shall commence on the Effective Date and shall expire on December 31, 2016, unless sooner terminated in accordance with Section 6.&#160; Neither Employer nor Employee shall have any obligation to extend or renew this Agreement. In the event that Employee's employment has not theretofore been terminated and Employer has not offered to extend or renew the Agreement, Employer shall continue to pay Employee his salary as provided for in Section 5.1 during the period commencing on the final date of the Term and ending on (a) June 30, 2017 or (b)&#160;the date of Employee's re-employment with another employer, whichever is earlier; provided that, as a condition to Employer's obligations under this sentence, Employee shall have executed and delivered to Employer a General Release of all Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit&#160;A
</U>
</FONT>
	.&#160; Employee shall notify Employer immediately in the event Employee accepts such employment with another employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Compensation
</U>
</FONT>
	.&#160; As the total consideration for Employee's services rendered hereunder, Employer shall pay or provide Employee the following compensation and benefits:
</FONT>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="967EDA50B43540D1B58A8C62FD4CCBC3" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.1.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Salary
</U>
</FONT>
	.&#160; Employee shall be entitled to receive an annual salary of Four Hundred Thousand Dollars ($400,000), payable in accordance with Employer's normal payroll policies and procedures.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="476BF3522C90498DBF853B5ECA7C303E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.2.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Discretionary Bonus
</U>
</FONT>
	.&#160; Employee also may be eligible for a bonus from time to time for his services during the Term.&#160; Employee's eligibility to receive a bonus, any determination to award Employee such a bonus and, if awarded, the amount thereof shall be in Employer's sole discretion.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="B1628A6BF29F46A0B649FB60495772F6" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.3.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Expense Reimbursement
</U>
</FONT>
	.&#160; Employer shall reimburse Employee for reasonable and necessary business expenses incurred by Employee in connection with the performance of Employee's duties in accordance with Employer's usual practices and policies in effect from time to time.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="0FBB28703793435C9A429697344DCB91" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.4.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PX; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Vacation
</U>
</FONT>
	.&#160; Employee shall continue to accrue vacation days without loss of compensation in accordance with Employer's usual policies applicable to all employees at a rate of four weeks' vacation time for each 12-month period during the Term.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="37A2E89908E348E6BE6D6E92107C9A44" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.5.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Tax Gross-Up
</U>
</FONT>
	.&#160; In the event that the severance and other benefits provided for in this Agreement or otherwise payable to the Employee (i) constitute "parachute payments" within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Excise Tax
</U>
</FONT>
	"), then the Employee's benefits under this Agreement shall be either: (x) delivered in full, or (y) delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Employee on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.&#160; Unless Employer and the Employee otherwise agree in writing, any determination required under this Section&#160;1 shall be made in writing by Employer's independent public accountants (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Accountants
</U>
</FONT>
	"), whose determination shall be conclusive and binding upon the Employee and Employer for all purposes.&#160; For purposes of making the calculations required by this Section&#160;1, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.&#160; Employer and the Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section&#160;5.5.&#160; Employer shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section&#160;5.5.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="7122EB53BFD242429628EDD3062EC5ED" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.6.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee Benefits
</U>
</FONT>
	.&#160; Employee shall be eligible to participate in any medical insurance and other employee benefits made available by Employer to all of its employees under its group plans and employment policies in effect during the Term.&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Schedule&#160;2
</U>
</FONT>
	hereto sets forth a summary of such plans and policies as currently in effect.&#160; Employee acknowledges and agrees that, any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="0C394E8170014267AB033D241222BD76" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	5.7.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Payroll Taxes
</U>
</FONT>
	.&#160; Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage133"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination
</U>
</FONT>
	.&#160; This Agreement may be terminated as set forth in this Section&#160;6.
</FONT>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="5D251F71EE374D2B9299B9BA7C4B31E4" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 4.5PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 76.5PT; FONT-SIZE: 10PT">
	6.1.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer for Cause
</U>
</FONT>
	.&#160; Employer may terminate Employee's employment hereunder for "Cause" upon notice to Employee.&#160; "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cause
</U>
</FONT>
	" for this purpose shall mean any of the following:
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's breach of any material term of this Agreement; provided that the first occasion of any particular breach shall not constitute such Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and affording Employee at least ten days to correct such breach;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's conviction of, or plea of guilty or nolo contendere to, any misdemeanor, felony or other crime of moral turpitude;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act of fraud or dishonesty injurious to Employer or its reputation;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's continual failure or refusal to perform his material duties as required under this Agreement after written notice from Employer stating the nature of such failure or refusal and affording Employee at least ten days to correct the same;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act or omission that, in the reasonable determination of Employer's Board of Directors (or a Committee of the Board), indicates alcohol or drug abuse by Employee; or
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act or personal conduct that, in the judgment of Employer's Board of Directors (or a Committee of the Board), gives rise to a material risk of liability of Employee or Employer under federal or applicable state law for discrimination, or sexual or other forms of harassment, or other similar liabilities to subordinate employees.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	Upon termination of Employee's employment by Employer for Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled only to payment upon the effective date of termination of any accrued but unpaid salary and unused vacation as provided in Sections 5.1 and 5.5 as of the date of such termination and any unpaid bonus that may have been awarded Employee as provided in Section 5.2 prior to such date.
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="2AF5571634824D00A753652433230A4D" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 154PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 54PT; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6.2.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer without Cause.
</U>
</FONT>
	&#160; Employer may also terminate Employee's employment without Cause upon ten days' notice to Employee.&#160; Upon termination of Employee's employment by Employer without Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled to (1) any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law, which shall be due and payable upon the effective date of such termination, (2) any unpaid bonus that may have been awarded to Employee under Section 5.2 prior to such date, which shall be due and payable in accordance with Employer's normal payroll practices or as otherwise required by California law, (3) payment of any Tax Gross-Up payment as provided in Section 5.5, (4) an amount, which shall be due and payable within ten days following the effective date of such termination, equal to six months' salary as provided in Section 5.1., provided, that if such termination occurs following a Change of Control (as hereinafter defined), then the amount described in this clause (4) shall be equal to 12 months' salary as provided in Section 5.1, and (5) continued participation, at Employer's cost and expense, of Employee and his dependents for a period of six months following such termination (12 months if such termination occurs following a Change of Control) in any Employer-sponsored group benefit plans in which Employee was participating as of the date of termination.&#160; Employee's right to the compensation and benefits provided for in clauses (3) through (5) of this Section 6.2 shall be conditioned upon Employee having executed and delivered to Employer a General Release of All Claims in the form attached hereto as Exhibit A.&#160; For purposes of this Section 6.2, a "Change of Control" shall have the meaning ascribed to the term "Corporate Transaction" in Employer's 2008 Stock Incentive Plan, as such Plan may be amended from time to time.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT" ID="2292278A14BC44A3BFE437FD45A4BEA5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 155PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 54PT; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 6.3.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Death or Disability
</U>
</FONT>
	.&#160; Employee's employment will terminate automatically in the event of Employee's death or upon notice from Employer in event of his permanent disability.&#160; Employee's "permanent disability" shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or by Employee, as the case may be) with respect to Employee or, if no such policy is then in effect, shall mean Employee's inability to fully perform his duties hereunder for any period of at least 75&#160;consecutive days or for a total of 90&#160;days, whether or not consecutive.&#160; Upon termination of Employee's employment as aforesaid, all compensation and benefits to Employee hereunder shall cease and Employer shall pay to the Employee's heirs or personal representatives, not later than ten days after the date of termination, any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Confidentiality
</U>
</FONT>
	.&#160; While this Agreement is in effect and for a period of five years thereafter, Employee shall hold and keep secret and confidential all "trade secrets" (within the meaning of applicable law) and other confidential or proprietary information of Employer and shall use such information only in the course of performing Employee's duties hereunder; provided, however, that with respect to trade secrets, Employee shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under applicable law.&#160; Employee shall maintain in trust all such trade secrets or other confidential or proprietary information, as Employer's property, including, but not limited to, all documents concerning Employer's business, including Employee's work papers, telephone directories, customer information and notes, and any and all copies thereof in Employee's possession or under Employee's control.&#160; Upon the expiration or earlier termination of Employee's employment with Employer, or upon request by Employer, Employee shall deliver to Employer all such documents belonging to Employer, including any and all copies in Employee's possession or under Employee's control.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Equitable Remedies; Injunctive Relief
</U>
</FONT>
	.&#160; Employee hereby acknowledges and agrees that monetary damages are inadequate to fully compensate Employer for the damages that would result from a breach or threatened breach of Section 7 of this Agreement and, accordingly, that Employer shall be entitled to equitable remedies, including, without limitation, specific performance, temporary restraining orders, and preliminary injunctions and permanent injunctions, to enforce such Section without the necessity of proving actual damages in connection therewith.&#160; This provision shall not, however, diminish Employer's right to claim and recover damages or enforce any other of its legal or equitable rights or defenses.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Indemnification; Insurance
</U>
</FONT>
	.&#160; Employer and Employee acknowledge that, as the Senior Vice President &#8211; Drug Development of the Employer, Employee shall be a corporate officer of Employer and, as such, Employee shall be entitled to indemnification to the full extent provided by Employer to its officers, directors and agents under the Employer's Certificate of Incorporation and Bylaws as in effect as of the date of this Agreement.&#160; Employer shall maintain Employee as an additional insured under its current policy of directors and officers liability insurance and shall use commercially reasonable efforts to continue to insure Employee thereunder, or under any replacement policies in effect from time to time, during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Severable Provisions
</U>
</FONT>
	.&#160; The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.
</FONT>
</DIV>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage134"></A>
</DIV>
<DIV>
<DIV STYLE="TEXT-INDENT: 18PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160;&#160;&#160; 11.
</FONT>
<FONT STYLE="FONT-SIZE: 6PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Successors and Assigns
</U>
</FONT>
	.&#160; This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns and Employee and her heirs and representatives; provided, however, that this Agreement may be assigned by Employer to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Entire Agreement
</U>
</FONT>
	.&#160; This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise herein.&#160; This Agreement supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and Employer relating to the subject matter hereof.&#160; Any such prior or contemporaneous agreements are hereby terminated and of no further effect, and Employee, by the execution hereof, agrees that any compensation provided for under any such agreements is specifically superseded and replaced by the provisions of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	.&#160; No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto and unless such writing is made by an executive officer of Employer (other than Employee).&#160; The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Governing Law
</U>
</FONT>
	.&#160; This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to California's choice-of-law rules.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	15.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notice
</U>
</FONT>
	.&#160; All notices and other communications under this Agreement shall be in writing and mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to this provision):
</FONT>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7B143A6935344914830E216A93681065" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	If to Employer:
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard, Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	Los Angeles, California&#160; 90049
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; MARGIN-LEFT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:
</FONT>
<FONT STYLE="FONT-SIZE: 5PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(310) 826-5529
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; MARGIN-LEFT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:
</FONT>
<FONT STYLE="FONT-SIZE: 5PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Executive Officer
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	If to Employee:
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	Scott Wieland
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	[Address intentionally omitted]
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage135"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	16.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Survival
</U>
</FONT>
	.&#160; Sections 4, 5.5, 6 through 15 and 17 through 20 shall survive the expiration or termination of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Counterparts
</U>
</FONT>
	.&#160; This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.&#160; A counterpart executed and transmitted by facsimile shall have the same force and effect as an originally executed counterpart.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	18.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Attorney's Fees
</U>
</FONT>
	.&#160; In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys' fees and other costs of suit (up to a maximum of $15,000) in addition to any other recoveries.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Interpretation of Ambiguities Against Drafting Party
</U>
</FONT>
	.&#160; This Agreement has been negotiated at arm's length between persons knowledgeable in the matters dealt with herein.&#160; In addition, each party has been represented by experienced and knowledgeable legal counsel.&#160; Accordingly, the parties agree that any rule of law, including, but not limited to, California Civil Code Section 1654 or any other statutes, legal decisions, or common law principles of similar effect, that would require interpretation of any ambiguities in this Agreement against the party that has drafted it, is of no application and is hereby expressly waived.&#160; The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intentions of the parties hereto.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 409A of the Code
</U>
</FONT>
	.&#160; This Agreement is intended to comply with the applicable requirements of Section&#160;409A of the Code and the regulations promulgated thereunder ("Section 409A"), and shall be administered in accordance with Section&#160;409A to the extent Section&#160;409A of the Code applies to the Agreement. Notwithstanding anything in the Agreement to the contrary, distributions pursuant to the Agreement that are subject to Section 409A may only be made in a manner, and upon an event, permitted by Section&#160;409A.&#160; The provisions of this Agreement shall be construed and interpreted to avoid the imposition of any additional tax, penalty or interest under Section 409A while preserving, to the extent possible, the intended benefits hereunder payable to Employee.&#160; Employer and Employee agree that any payment made pursuant to this Agreement due to Employee's "separation from service" as defined in Section 409A shall be delayed in accordance with Section 409A(a)(2)(B)(i) of the Code (six month delay) if and to the extent required to avoid the imposition of any tax, penalty or interest under Section 409A. Any additional cost to Employee by reason of such postponement period, including, for example, Employee's payment of the cost of health benefits during the postponement period, shall be reimbursed by the Company to Employee after such period has ended. If Employee dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section&#160;409A shall be paid to Employee's beneficiary, or if none, to the personal representative of Employee's estate within 30
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</FONT>
	days after the date of Employee's death.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; TEXT-INDENT: -18PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage136"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 72PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, this Agreement is executed as of the day and year first above written.
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="EEF627B0C0A449ACA3E94E61C1FFC424" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYER"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYEE"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD" VALIGN="TOP" ALIGN="LEFT">
	CYTRX CORPORATION
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ SCOTT WIELAND
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 0PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 0PT">
	Scott Wieland
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage137"></A>
<A NAME="EXH_10-29_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_10"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.29
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 24PT; FONT-SIZE: 10PT">
	EMPLOYMENT AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Employment Agreement (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Agreement
</U>
</FONT>
	") is made and entered into as of December 31, 2015 (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Effective Date
</U>
</FONT>
	") by and between CytRx Corporation, a Delaware corporation ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employer
</U>
</FONT>
	"), and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	John Caloz,
</FONT>
	an individual and resident of the State of California ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee
</U>
</FONT>
	").
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	WHEREAS, Employer desires to employ Employee, and Employee is willing to be employed by Employer, on the terms set forth in this Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and agreements hereinafter contained, the parties hereto agree as follows.
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employment
</U>
</FONT>
	.&#160; Effective as of the Effective Date, Employer shall employ Employee, and Employee shall serve, as Employer's Chief Financial Officer on the terms set forth herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Duties; Place of Employment
</U>
</FONT>
	.&#160; Employee shall perform in a professional and business-like manner, and to the best of his ability, the duties described on Schedule&#160;1 to this Agreement and such other duties as are assigned to him from time to time by Employer's President and Chief Executive Officer.&#160; Employee understands and agrees that his duties, title and authority may be changed from time to time in the discretion of Employer's President and Chief Executive Officer.&#160; Employee's services hereunder shall be rendered at Employer's principal executive office, except for travel when and as required in the performance of Employee's duties hereunder.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Time and Efforts
</U>
</FONT>
	.&#160; Employee shall devote all of his business time, efforts, attention and energies to Employer's business and to discharge his duties hereunder.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	.&#160; The term (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term
</U>
</FONT>
	") of Employee's employment hereunder shall commence on the Effective Date and shall expire on December 31, 2016 unless sooner terminated in accordance with Section 6.&#160; Neither Employer nor Employee shall have any obligation to extend or renew this Agreement.&#160; In the event that Employee's employment has not theretofore been terminated and Employer has not offered to extend or renew Employee's employment under this Agreement, upon expiration of the Term Employer shall continue to pay Employee his salary as provided for in Section&#160;5.1 during the period commencing on the final date of the Term and ending on (a) June 30, 2017 or (b)&#160;the date of Employee's re-employment with another employer, whichever is earlier; provided that, as a condition to Employer's obligations under this sentence, Employee shall have executed and delivered to Employer a General Release of All Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit&#160;A
</U>
</FONT>
	. Employee shall notify Employer immediately in the event Employee accepts such employment with another employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Compensation
</U>
</FONT>
	.&#160; As the total consideration for Employee's services rendered hereunder, Employer shall pay or provide Employee the following compensation and benefits:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Salary
</U>
</FONT>
	.&#160; Employee shall be entitled to receive an annual salary of Four Hundred Thousand Dollars ($400,000), payable in accordance with Employer's normal payroll policies and procedures.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Discretionary Bonus
</U>
</FONT>
	.&#160; Employee also may be eligible for a bonus from time to time for his services during the Term.&#160; Employee's eligibility to receive a bonus, any determination to award Employee such a bonus and, if awarded, the amount thereof shall be in Employer's sole discretion.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Expense Reimbursement
</U>
</FONT>
	.&#160; Employer shall reimburse Employee for reasonable and necessary business expenses incurred by Employee in connection with the performance of Employee's duties in accordance with Employer's usual practices and policies in effect from time to time.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Vacation
</U>
</FONT>
	.&#160; Employee shall continue to accrue vacation days without loss of compensation in accordance with Employer's usual policies applicable to all employees at a rate of four weeks' vacation time for each 12-month period during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Tax Gross-Up
</U>
</FONT>
	.&#160; In the event that the severance and other benefits provided for in this Agreement or otherwise payable to the Employee (i) constitute "parachute payments" within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Excise Tax
</U>
</FONT>
	"), then the Employee's benefits under this Agreement shall be either: (x) delivered in full, or (y) delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Employee on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code.&#160; Unless Employer and the Employee otherwise agree in writing, any determination required under this Section&#160;1 shall be made in writing by Employer's independent public accountants (the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Accountants
</U>
</FONT>
	"), whose determination shall be conclusive and binding upon the Employee and Employer for all purposes.&#160; For purposes of making the calculations required by this Section&#160;1, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.&#160; Employer and the Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section&#160;5.5.&#160; Employer shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section&#160;5.5.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee Benefits
</U>
</FONT>
	.&#160; Employee shall be eligible to participate in any medical insurance and other employee benefits made available by Employer to all of its employees under its group plans and employment policies in effect during the Term.&#160;
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Schedule&#160;2
</U>
</FONT>
	hereto sets forth a summary of such plans and policies as currently in effect.&#160; Employee acknowledges and agrees that, any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Payroll Taxes
</U>
</FONT>
	.&#160; Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage138"></A>
</DIV>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination
</U>
</FONT>
	.&#160; This Agreement may be terminated as set forth in this Section&#160;6.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer for Cause
</U>
</FONT>
	.&#160; Employer may terminate Employee's employment hereunder for "Cause" upon notice to Employee.&#160; "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cause
</U>
</FONT>
	" for this purpose shall mean any of the following:
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's breach of any material term of this Agreement; provided that the first occasion of any particular breach shall not constitute such Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and affording Employee at least ten days to correct such breach;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's conviction of, or plea of guilty or nolo contendere to, any misdemeanor, felony or other crime of moral turpitude;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act of fraud or dishonesty injurious to Employer or its reputation;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's continual failure or refusal to perform his material duties as required under this Agreement after written notice from Employer stating the nature of such failure or refusal and affording Employee at least ten days to correct the same;
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act or omission that, in the reasonable determination of Employer's Board of Directors (or a Committee of the Board), indicates alcohol or drug abuse by Employee; or
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 108PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Employee's act or personal conduct that, in the judgment of Employer's Board of Directors (or a Committee of the Board), gives rise to a material risk of liability of Employee or Employer under federal or applicable state law for discrimination, or sexual or other forms of harassment, or other similar liabilities to subordinate employees.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	Upon termination of Employee's employment by Employer for Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled only to payment upon the effective date of termination of any accrued but unpaid salary and unused vacation as provided in Sections 5.1 and 5.5 as of the date of such termination and any unpaid bonus that may have been awarded Employee as provided in Section 5.2 prior to such date.
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Termination by Employer without Cause.
</U>
</FONT>
	&#160; Employer may also terminate Employee's employment without Cause upon ten days' notice to Employee.&#160; Upon termination of Employee's employment by Employer without Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled to (1) any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law, which shall be due and payable upon the effective date of such termination, (2) any unpaid bonus that may have been awarded to Employee under Section 5.2 prior to such date, which shall be due and payable in accordance with Employer's normal payroll practices or as otherwise required by California law, (3) payment of any Tax Gross-Up payment as provided in Section 5.5, (4) an amount, which shall be due and payable within ten days following the effective date of such termination, equal to six months' salary as provided in Section 5.1., provided, that if such termination occurs following a Change of Control (as hereinafter defined), then the amount described in this clause (4) shall be equal to 12 months' salary as provided in Section&#160;5.1, and (5)&#160;continued participation, at Employer's cost and expense, of Employee and his dependents for a period of six months following such termination (12 months if such termination occurs following a Change of Control) in any Employer-sponsored group benefit plans in which Employee was participating as of the date of termination.&#160; Employee's right to the compensation and benefits provided for in clauses (3) through (5) of this Section 6.2 shall be conditioned upon Employee having executed and delivered to Employer a General Release of All Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit&#160;A
</U>
</FONT>
	.&#160; For purposes of this Section 6.2, a "Change of Control" shall have the meaning ascribed to the term "Corporate Transaction" in Employer's 2008 Stock Incentive Plan, as such Plan may be amended from time to time.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	6.3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Death or Disability
</U>
</FONT>
	.&#160; Employee's employment will terminate automatically in the event of Employee's death or upon notice from Employer in event of his permanent disability.&#160; Employee's "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	permanent disability
</U>
</FONT>
	" shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or by Employee, as the case may be) with respect to Employee or, if no such policy is then in effect, shall mean Employee's inability to fully perform his duties hereunder for any period of at least 75&#160;consecutive days or for a total of 90&#160;days, whether or not consecutive.&#160; Upon termination of Employee's employment as aforesaid, all compensation and benefits to Employee hereunder shall cease and Employer shall pay to the Employee's heirs or personal representatives, not later than ten days after the date of termination, any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Confidentiality
</U>
</FONT>
	.&#160; While this Agreement is in effect and for a period of five years thereafter, Employee shall hold and keep secret and confidential all "trade secrets" (within the meaning of applicable law) and other confidential or proprietary information of Employer and shall use such information only in the course of performing Employee's duties hereunder; provided, however, that with respect to trade secrets, Employee shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under applicable law.&#160; Employee shall maintain in trust all such trade secrets or other confidential or proprietary information, as Employer's property, including, but not limited to, all documents concerning Employer's business, including Employee's work papers, telephone directories, customer information and notes, and any and all copies thereof in Employee's possession or under Employee's control.&#160; Upon the expiration or earlier termination of Employee's employment with Employer, or upon request by Employer, Employee shall deliver to Employer all such documents belonging to Employer, including any and all copies in Employee's possession or under Employee's control.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Equitable Remedies; Injunctive Relief
</U>
</FONT>
	.&#160; Employee hereby acknowledges and agrees that monetary damages are inadequate to fully compensate Employer for the damages that would result from a breach or threatened breach of Section 7 of this Agreement and, accordingly, that Employer shall be entitled to equitable remedies, including, without limitation, specific performance, temporary restraining orders, and preliminary injunctions and permanent injunctions, to enforce such Section without the necessity of proving actual damages in connection therewith.&#160; This provision shall not, however, diminish Employer's right to claim and recover damages or enforce any other of its legal or equitable rights or defenses.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Indemnification; Insurance
</U>
</FONT>
	.&#160; Employer and Employee acknowledge that, as the Chief Financial Officer of the Employer, Employee shall be a corporate officer of Employer and, as such, Employee shall be entitled to indemnification to the full extent provided by Employer to its officers, directors and agents under the Employer's Certificate of Incorporation and Bylaws as in effect as of the date of this Agreement.&#160; Employer shall maintain Employee as an additional insured under its current policy of directors and officers liability insurance and shall use commercially reasonable efforts to continue to insure Employee thereunder, or under any replacement policies in effect from time to time, during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Severable Provisions
</U>
</FONT>
	.&#160; The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Successors and Assigns
</U>
</FONT>
	.&#160; This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns and Employee and his heirs and representatives; provided, that this Agreement may be assigned by Employer to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Entire Agreement
</U>
</FONT>
	.&#160; This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise herein.&#160; This Agreement supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and Employer relating to the subject matter hereof.&#160; Any such prior or contemporaneous agreements are hereby terminated and of no further effect, and Employee, by the execution hereof, agrees that any compensation provided for under any such agreements is specifically superseded and replaced by the provisions of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	13.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	.&#160; No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto and unless such writing is made by an executive officer of Employer (other than Employee).&#160; The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	14.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Governing Law
</U>
</FONT>
	.&#160; This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to California's choice-of-law rules.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	15.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Notice
</U>
</FONT>
	.&#160; All notices and other communications under this Agreement shall be in writing and mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to this provision):
</FONT>
</DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="85C51B9563B64B8195444AA14CF5D11B" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If to Employer:
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard, Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California&#160; 90049
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(310) 826-5529
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Chief Executive Officer
</FONT>
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If to Employee:
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	John Caloz
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Address intentionally omitted]
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP">
	&#160;
</TD>
</TR>
</TABLE>
<DIV>
	&#160;
</DIV>
<DIV>
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage139"></A>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	16.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Survival
</U>
</FONT>
	.&#160; Sections 4, 5.5, 6 through 15 and 18 through 20 shall survive the expiration or termination of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	17.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Counterparts
</U>
</FONT>
	.&#160; This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.&#160; A counterpart executed and transmitted by facsimile shall have the same force and effect as an originally executed counterpart.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	18.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Attorney's Fees
</U>
</FONT>
	.&#160; In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or his reasonable attorneys' fees and other costs of suit (up to a maximum of $15,000) in addition to any other recoveries.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	19.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Interpretation of Ambiguities Against Drafting Party
</U>
</FONT>
	.&#160; This Agreement has been negotiated at arm's length between persons knowledgeable in the matters dealt with herein.&#160; In addition, each party has been represented by experienced and knowledgeable legal counsel.&#160; Accordingly, the parties agree that any rule of law, including, but not limited to, California Civil Code Section 1654 or any other statutes, legal decisions, or common law principles of similar effect, that would require interpretation of any ambiguities in this Agreement against the party that has drafted it, is of no application and is hereby expressly waived.&#160; The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intentions of the parties hereto.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	20.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Section 409A of the Code
</U>
</FONT>
	.&#160; This Agreement is intended to comply with the applicable requirements of Section&#160;409A of the Code and the regulations promulgated thereunder ("Section 409A"), and shall be administered in accordance with Section&#160;409A to the extent Section&#160;409A of the Code applies to the Agreement. Notwithstanding anything in the Agreement to the contrary, distributions pursuant to the Agreement that are subject to Section 409A may only be made in a manner, and upon an event, permitted by Section&#160;409A.&#160; The provisions of this Agreement shall be construed and interpreted to avoid the imposition of any additional tax, penalty or interest under Section 409A while preserving, to the extent possible, the intended benefits hereunder payable to Employee.&#160; Employer and Employee agree that any payment made pursuant to this Agreement due to Employee's "separation from service" as defined in Section 409A shall be delayed in accordance with Section 409A(a)(2)(B)(i) of the Code (six month delay) if and to the extent required to avoid the imposition of any tax, penalty or interest under Section 409A. Any additional cost to Employee by reason of such postponement period, including, for example, Employee's payment of the cost of health benefits during the postponement period, shall be reimbursed by the Company to Employee after such period has ended. If Employee dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section&#160;409A shall be paid to Employee's beneficiary, or if none, to the personal representative of Employee's estate within 30
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</FONT>
	days after the date of Employee's death.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage140"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, this Agreement is executed as of the day and year first above written.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="F5B6089F9B9241A3956761C46C05617B" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYER"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYEE"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD" VALIGN="TOP" ALIGN="LEFT">
	CYTRX CORPORATION
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ JOHN CALOZ
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 0PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 0PT">
	John Caloz
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage141"></A>
<A NAME="EXH_10-30_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_11"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 10.30
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	EMPLOYMENT AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	This Employment Agreement (this "Agreement") is made and entered into as of January 11, 2016 (the "Effective Date") by and between CytRx Corporation, a Delaware corporation ("Employer"), and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Olivia C. Ware
</FONT>
	, an individual and resident of the State of California ("Employee").
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	WHEREAS, Employer desires to employ Employee, and Employee is willing to be employed by Employer, on the terms set forth in this Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	NOW, THEREFORE, upon the above premises, and in consideration of the mutual covenants and agreements hereinafter contained, the parties hereto agree as follows.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employment.
</FONT>
	Effective as of the Effective Date, Employer shall continue to employ Employee, and Employee shall continue to serve, as Employer's Chief Commercial Officer on the terms set forth herein.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Duties; Place of Employment.
</FONT>
	Employee shall perform in a professional and business-like manner, and to the best of her ability, the duties described on Schedule 1 to this Agreement and such other duties in line with her technical training and experience as are assigned to her from time to time by Employer's Chairman of the Board and Chief Executive Officer. Employee understands and agrees that her duties, title and authority may be changed from time to time in the discretion of Employer's Chief Executive Officer. Employer understands and agrees that Employee shall be entitled to render her services hereunder from her home, except&#160; (a)&#160; for travel when and as required in the performance of Employee's duties hereunder, and&#160; (b) as directed by the Employee's Supervisor to be present in the Employer's principal executive office, such that it presents no undue hardship on the Employee.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Time and Efforts.
</FONT>
	Employee shall devote all of her business time, efforts, attention and energies to Employer's business and to discharge her duties hereunder. Notwithstanding the foregoing, Employee may serve on the board of directors of one company other than Employer so long as such service shall not materially interfere with the performance of her duties hereunder, and in no event shall Employee serve on the board of directors of a company that is directly competitive with Employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Term.
</FONT>
	The term (the "Term") of Employee's employment hereunder shall commence on the Effective Date and shall expire on December 31, 2016, unless sooner terminated in accordance with Section 6. The Employee's employment with the Company will be "at will," meaning that the Employee's employment may be terminated by the Company or the Employee at any time. Neither Employer nor Employee shall have any obligation to extend or renew this Agreement. In the event that Employer does not offer to extend or renew the Agreement, Employer shall continue to pay Employee her salary as provided for in Section 5.1 during the period commencing on the final date of the Term and ending on (a) June 30, 2017 or (b) the date of Employee's re-employment with another employer, whichever is earlier; provided that, as a condition to Employer's obligations under this sentence, Employee shall have executed and delivered to Employer a General Release in the form attached hereto as Exhibit A. Employee shall notify Employer immediately in the event Employee accepts such employment with another employer.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Compensation.
</FONT>
	As the total consideration for Employee's services rendered hereunder, Employer shall pay or provide Employee the following compensation and benefits:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Salary.
</FONT>
	Employee shall be entitled to receive an annual salary of Four Hundred Thousand dollars ($400,000), payable in accordance with Employer's normal payroll policies and procedures.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.2. Discretionary Annual Bonus.
</FONT>
	Employee also may be eligible for a bonus from time to time for her services during the Term. Employee shall be entitled to receive a minimum annual bonus of One Hundred Fifty Thousand dollars ($150,000), which is equivalent to thirty-seven and one-half percent (37.5%) of her gross annual salary as provided in Section 5.1. At the Employer's sole discretion, Employee may be awarded an annual bonus in a greater amount, up to a maximum of Three Hundred Thousand dollars ($300,000), which is equivalent to seventy-five percent (75%) of her gross annual salary as provided in Section 5.1. Employee's eligibility to receive a bonus, the determination to award Employee such bonus and any determination to award Employee a bonus amount greater than the minimum annual bonus amount shall be in Employer's sole discretion.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Expense Reimbursement
</FONT>
	. Employer shall reimburse Employee for reasonable and necessary business expenses incurred by Employee in connection with the performance of Employee's duties in accordance with Employer's usual practices and policies in effect from time to time; provided, however, that Employee shall be permitted to fly first class on all plane trips that are scheduled for more than two hours in duration. When Employee travels to Employer's corporate offices, Employer shall pay for (i) round-trip airfare and airport parking or other ground transportation to and from the airports, or, (ii) if driving, the cost of gas, tolls and meals, but shall not pay for any other food or other incidentals except as specifically set forth herein.&#160; (c) During the Term, Employer shall provide Employee with (i) hotel, parking and meal accommodations while Employee is working at Employer's corporate offices in reasonable proximity to Employer's corporate offices as chosen by Employee
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Vacation.
</FONT>
	Employee shall continue to accrue vacation days without loss of compensation in accordance with Employer's usual policies applicable to all employees at a rate of four weeks' vacation time for each 12-month period during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Tax Gross-Up.
</FONT>
	In the event that the severance and other benefits provided for in this Agreement or otherwise payable to the Employee (i) constitute "parachute payments" within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Employee's benefits under this Agreement shall be either: (x) delivered in full, or (y) delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Employee on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under Section 4999 of the Code. Unless Employer and the Employee otherwise agree in writing, any determination required under this Section 1 shall be made in writing by Employer's independent public accountants (the "Accountants"), whose determination shall be conclusive and binding upon the Employee and Employer for all purposes. For purposes of making the calculations required by this Section 1, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. Employer and the Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 5.5. Employer shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 5.5.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.6.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Employee Benefits.
</FONT>
	Employee shall be eligible to participate in any medical insurance and other employee benefits made available by Employer to all of its employees under its group plans and employment policies in effect during the Term.&#160; Schedule 2 hereto sets forth a summary of such plans and policies as currently in effect. Employee acknowledges and agrees that, any such plans or policies now or hereafter in effect may be modified or terminated by Employer at any time in its discretion.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	5.7. Payroll Taxes.
</FONT>
	Employer shall have the right to deduct from the compensation and benefits due to Employee hereunder any and all sums required for social security and withholding taxes and for any other federal, state, or local tax or charge which may be in effect or hereafter enacted or required as a charge on the compensation or benefits of Employee.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage142"></A>
</DIV>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	6.
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	Termination.
</FONT>
	This Agreement may be terminated as set forth in this Section 6.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	6.1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Termination by Employer for Cause.
</FONT>
	Employer may terminate Employee's employment hereunder for "Cause" upon notice to Employee. "Cause" for this purpose shall mean any of the following:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a) Employee's breach of any material term of this Agreement; provided that the first occasion of any particular breach shall not constitute such Cause unless Employee shall have previously received written notice from Employer stating the nature of such breach and affording Employee at least ten days to correct such breach;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b) Employee's conviction of, or plea of guilty or nolo contendere to, any misdemeanor, felony or other crime of moral turpitude;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c) Employee's act of fraud or dishonesty injurious to Employer or its reputation;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d) Employee's continual failure or refusal to perform her material duties as required under this Agreement after written notice from Employer stating the nature of such failure or refusal and affording Employee at least ten days to correct the same;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 108PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(e) Employee's act or omission that, in the reasonable determination of Employer's Board of Directors (or a Committee of the Board), indicates alcohol or drug abuse by Employee; or
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 144PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(f) Employee's act or personal conduct that, in the judgment of Employer's Board of Directors (or a Committee of the Board), gives rise to a material risk of liability of Employee or Employer under federal or applicable state law for discrimination, or sexual or other forms of harassment, or other similar liabilities to subordinate employees.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Upon termination of Employee's employment by Employer for Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled only to payment, not later than three days after the date of termination, of any accrued but unpaid salary and unused vacation as provided in Sections 5.1 and 5.5 as of the date of such termination and any unpaid bonus that may have been awarded Employee as provided in Section 5.2 prior to such date.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	6.2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Termination by Employer without Cause.
</FONT>
	Employer may also terminate Employee's employment without Cause upon ten days' notice to Employee. Upon termination of Employee's employment by Employer without Cause, all compensation and benefits to Employee hereunder shall cease and Employee shall be entitled to (1) any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law, which shall be due and payable upon the effective date of such termination, (2) any unpaid bonus that may have been awarded to Employee under Section 5.2 prior to such date, which shall be due and payable in accordance with Employer's normal payroll practices or as otherwise required by California law, (3) payment of any Tax Gross-Up payment as provided in Section 5.5, (4) an amount, which shall be due and payable within ten days following the effective date of such termination, equal to six months' salary as provided in Section 5.1., provided, that if such termination occurs following a Change of Control (as hereinafter defined), then the amount described in this clause (4) shall be equal to 12 months' salary as provided in Section&#160;5.1, and (5)&#160;continued participation, at Employer's cost and expense, of Employee and her dependents for a period of six months following such termination (12 months if such termination occurs following a Change of Control) in any Employer-sponsored group benefit plans in which Employee was participating as of the date of termination. Employee's right to the compensation and benefits provided for in clauses (3) through (5) of this Section 6.2 shall be conditioned upon Employee having executed and delivered to Employer a General Release of All Claims in the form attached hereto as
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit&#160;A
</U>
</FONT>
	.&#160; For purposes of this Section 6.2, a "Change of Control" shall have the meaning ascribed to the term "Corporate Transaction" in Employer's 2008 Stock Incentive Plan, as such Plan may be amended from time to time.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 72PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	6.3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Death or Disability
</FONT>
	. Employee's employment will terminate automatically in the event of Employee's death or upon notice from Employer in event of her permanent disability. Employee's "permanent disability" shall have the meaning ascribed to such term in any policy of disability insurance maintained by Employer (or by Employee, as the case may be) with respect to Employee or, if no such policy is then in effect, shall mean Employee's inability to fully perform her duties hereunder for any period of at least 75 consecutive days or for a total of 90 days, whether or not consecutive. Upon termination of Employee's employment as aforesaid, all compensation and benefits to Employee hereunder shall cease and Employer shall pay to the Employee's heirs or personal representatives, not later than ten days after the date of termination, any accrued but unpaid salary and unused vacation as of the date of such termination as required by California law.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	7.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Confidentiality.
</FONT>
	While this Agreement is in effect and for a period of five years thereafter, Employee shall hold and keep secret and confidential all "trade secrets" (within the meaning of applicable law) and other confidential or proprietary information of Employer and shall use such information only in the course of performing Employee's duties hereunder; provided, however, that with respect to trade secrets, Employee shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under applicable law. Employee shall maintain in trust all such trade secrets or other confidential or proprietary information, as Employer's property, including, but not limited to, all documents concerning Employer's business, including Employee's work papers, telephone directories, customer information and notes, and any and all copies thereof in Employee's possession or under Employee's control. Upon the expiration or earlier termination of Employee's employment with Employer, or upon request by Employer, Employee shall deliver to Employer all such documents belonging to Employer, including any and all copies in Employee's possession or under Employee's control.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage143"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	8.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Equitable Remedies; Injunctive Relief.
</FONT>
	Employee hereby acknowledges and agrees that monetary damages are inadequate to fully compensate Employer for the damages that would result from a breach or threatened breach of Section 7 of this Agreement and, accordingly, that Employer shall be entitled to equitable remedies, including, without limitation, specific performance, temporary restraining orders, and preliminary injunctions and permanent injunctions, to enforce such Section without the necessity of proving actual damages in connection therewith. This provision shall not, however, diminish Employer's right to claim and recover damages or enforce any other of its legal or equitable rights or defenses.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	9.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Indemnification; Insurance.
</FONT>
	Employer and Employee acknowledge that, as the Chief Commercial Officer of Employer, Employee shall be a corporate officer of Employer and, as such, Employee shall be entitled to indemnification to the full extent provided by Employer to its officers, directors and agents under the Employer's Certificate of Incorporation and Bylaws as in effect as of the date of this Agreement. Employer shall maintain Employee as an additional insured under its current policy of directors and officers liability insurance and shall use commercially reasonable efforts to continue to insure Employee thereunder, or under any replacement policies in effect from time to time, during the Term.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	10.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Severable Provisions.
</FONT>
	The provisions of this Agreement are severable and if any one or more provisions is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions, and any partially unenforceable provisions to the extent enforceable, shall nevertheless be binding and enforceable.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	11.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Successors and Assigns.
</FONT>
	This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns and Employee and his heirs and representatives; provided, that this Agreement may be assigned by Employer to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Employer.
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	12.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Entire Agreement
</FONT>
	. This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations or warranties relating to the subject matter of this Agreement that are not set forth otherwise herein. This Agreement supersedes any and all prior or contemporaneous agreements, written or oral, between Employee and Employer relating to the subject matter hereof. Any such prior or contemporaneous agreements are hereby terminated and of no further effect, and Employee, by the execution hereof, agrees that any compensation provided for under any such agreements is specifically superseded and replaced by the provisions of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	13.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Amendment.
</FONT>
	No modification of this Agreement shall be valid unless made in writing and signed by the parties hereto and unless such writing is made by an executive officer of Employer (other than Employee). The parties hereto agree that in no event shall an oral modification of this Agreement be enforceable or valid.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	14.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Governing Law.
</FONT>
	This Agreement is and shall be governed and construed in accordance with the laws of the State of California without giving effect to California's choice-of-law rules.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	15.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Notice.
</FONT>
	All notices and other communications under this Agreement shall be in writing and mailed, telecopied (in case of notice to Employer only) or delivered by hand or by a nationally recognized courier service guaranteeing overnight delivery to a party at the following address (or to such other address as such party may have specified by notice given to the other party pursuant to this provision):
</FONT>
</DIV>
<DIV>
<BR>
</DIV>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If to Employer:
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	11726 San Vicente Boulevard, Suite 650
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Los Angeles, California 90049
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Facsimile:&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; (310) 826-5648
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Attention:&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Chairman and Chief Executive Officer
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	If to Employee:
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Olivia C. Ware
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Address intentionally omitted]
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage144"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	16.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Survival.
</FONT>
	Sections 7 through 15, and 17 through 20 shall survive the expiration or termination of this Agreement.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	17.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Counterparts.
</FONT>
	This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. A counterpart executed and transmitted by facsimile shall have the same force and effect as an originally executed counterpart.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	18.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Attorney's Fees.
</FONT>
	In any action or proceeding to construe or enforce any provision of this Agreement the prevailing party shall be entitled to recover its or her reasonable attorneys' fees and other costs of suit (up to a maximum of $15,000) in addition to any other recoveries.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	19.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	No Interpretation of Ambiguities Against Drafting Party.
</FONT>
	This Agreement has been negotiated at arm's length between persons knowledgeable in the matters dealt with herein. In addition, each party has been represented by experienced and knowledgeable legal counsel. Accordingly, the parties agree that any rule of law, including, but not limited to, California Civil Code Section 1654 or any other statutes, legal decisions, or common law principles of similar effect, that would require interpretation of any ambiguities in this Agreement against the party that has drafted it, is of no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intentions of the parties hereto.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	20.&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Section 409A of the Code
</FONT>
	. This Agreement is intended to comply with the applicable requirements of Section 409A of the Code and the regulations promulgated thereunder ("Section 409A"), and shall be administered in accordance with Section 409A to the extent Section 409A of the Code applies to the Agreement. Notwithstanding anything in the Agreement to the contrary, distributions pursuant to the Agreement that are subject to Section 409A may only be made in a manner, and upon an event, permitted by Section 409A.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The provisions of this Agreement shall be construed and interpreted to avoid the imposition of any additional tax, penalty or interest under Section 409A while preserving, to the extent possible, the intended benefits hereunder payable to Employee. Employer and Employee agree that any payment made pursuant to this Agreement due to Employee's "separation from service" as defined in Section 409A shall be delayed in accordance with Section 409A(a)(2)(B)(i) of the Code (six month delay) if and to the extent required to avoid the imposition of any tax, penalty or interest under Section 409A. Any additional cost to Employee by reason of such postponement period, including, for example, Employee's payment of the cost of health benefits during the postponement period, shall be reimbursed by the Company to Employee after such period has ended. If Employee dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section 409A shall be paid to Employee's beneficiary, or if none, to the personal representative of Employee's estate within 30 days after the date of Employee's death.
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-STYLE: ITALIC; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	[Signature Page Follows]
</DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage145"></A>
</DIV>
<DIV STYLE="MARGIN-BOTTOM: 10PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, this Agreement is executed as of the day and year first above written.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="903DDC83BFEC4E989B9BA71121994C56" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYER"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	"EMPLOYEE"
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%; FONT-WEIGHT: BOLD" VALIGN="TOP" ALIGN="LEFT">
	CYTRX CORPORATION
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ OLIVIA C. WARE
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 0PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 0PT">
	Olivia C. Ware
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage146"></A>
<A NAME="EXH_10-32_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	Exhibit 10.32
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
<IMG STYLE="WIDTH: 557PX; HEIGHT: 116PX" SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/11/0000799698-16-000030_IMAGE00001.JPG">
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	February 9, 2016
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Steven A. Kriegsman
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Chairman &amp; CEO
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	11726 San Vicente Blvd
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, CA&#160; 90049
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Dear Mr. Kriegsman,
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	This letter (together with Exhibits A, and B, annexed hereto and made a part hereof, all of which taken together constitute this "Engagement Agreement" or "Agreement") confirms our complete understanding with respect to the retention of Alexander Capital, LP ("Alexander"), a registered broker/dealer as financial advisor to CytRx Corporation (the "Company").
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	&#160;&#160; Upon the terms and subject to the conditions set forth hereinafter, the parties hereto agree as follows:
</DIV>
</DIV>
<DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="74235DD23FDC4C9C94214287F618892B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	1.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Appointment
</U>
</FONT>
	.&#160; The Company hereby retains Alexander, and Alexander hereby agrees to act as the Company's financial advisor and render financial advisory services as more specifically set forth in paragraph 2 below, effective as of the date hereof (the "Effective Date").
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="52DD915B46CC43B680335914F5CDD99E" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	2.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Scope and Certain Conditions of Services
</U>
</FONT>
	.&#160; Alexander will use its best efforts to furnish ongoing awareness and business advisory services (the "Services") as the Company may from time to time reasonably request. Services shall include, without limitation, the following:
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7C0BEDF4B2F64AF3B0A2F82DBA5E60C7" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 86PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: SYMBOL, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;&#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Assistance with investor presentations such as, but not limited to, PowerPoint slide presentations, broker/dealer fact sheets, financial projections and budgets;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="76BCDB8A362146BD9711896AD5B21646" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 85PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: SYMBOL, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160; &#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Sponsorship to capital conferences;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="B3FB37803FA04044849F17292FB81CCE" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 84PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: SYMBOL, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160; &#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Identification and evaluation of financing transactions;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="81429554168349CFBDAD3B98AC206B17" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 83PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: SYMBOL, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160; &#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Identification and evaluation of acquisition and/or merger candidates;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="6FF20E92561F4AC0B9E89BEC9C1509CA" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 83PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: SYMBOL, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160; &#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Introduction to broker/dealers, analysts and potential investors in regions outside of the New York area;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="E04E551ED15E4C7D83753F07CCC14688" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 82PX; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: SYMBOL, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;&#160;&#160;&#160; &#183;
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Arranging meetings between CytRx management and broker/dealers, research analysts, and investment companies in coordination with the Company
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	'
</FONT>
	s management
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	'
</FONT>
	s travel schedule;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
</DIV>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="1538137B25E84EF199B89DDF96DD0525" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	3.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Fees and Compensation
</U>
</FONT>
	.&#160; In consideration for the Services, the Company shall pay to Alexander an advisory fee of twenty two thousand dollars ($22,000) per month (the "Monthly Advisory Fee").&#160; The first Monthly Advisory Fee shall be paid to Alexander on the Effective Date and thereafter no later than the fifteenth (15
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	th
</SUP>
	) day of each monthly anniversary of the Effective Date during the Term of this Agreement.&#160; The Monthly Advisory Fee shall be earned and payable each month and may not be deferred by the Company unless the Company submits a written request to Alexander and Alexander approves such a request in writing.&#160; The Monthly Advisory Fee shall be mailed to Alexander at the following address:
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Alexander Capital, L.P.
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Attn: Tom Sullivan
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	17 State Street, 5
<SUP STYLE="VERTICAL-ALIGN: TEXT-TOP; LINE-HEIGHT: 1; FONT-SIZE: SMALLER;">
	th
</SUP>
	Floor
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	New York, NY 10004
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Phone: 646-787-8897
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Fax: 212-687-5649
</DIV>
</DIV>
<DIV>
<BR>
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	In addition to the Monthly Advisory Fee, there will be a non-cash fee of 500,000 non-callable, 5-year, cashless warrants of the Company ("Advisory Warrants") issuable to Alexander, or its designee.&#160; The Advisory Warrants shall entitle the holder thereof to purchase CytRx public common stock at an exercise price of the stock price on the Effective Date.&#160; The Advisory Warrants will vest on the following schedule:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	Effective Date - 125,000
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	6 months from Effective Date - 62,500
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	12 months from Effective Date - 62,500
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	15 months from Effective Date - 62,500
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	18 months from Effective Date - 62,500
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 72PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	24 months from Effective Date - 125,000
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT">
	The Advisory Warrants will be subject to standard anti-dilution clauses (stock-splits, etc).
</DIV>
</DIV>
<DIV>
<DIV>
<BR>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="2FFE71AC854B4F2A831CD77675ED9826" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	4.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Term of Retention.
</U>
</FONT>
	&#160; The term of retention shall expire 24 months from the Effective Date of this Agreement (the "Term"), but may be terminated by either party after 12 months with 30 days written notice.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="485096C78AD14CA3BBE55B8FD8FEB0F2" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	5.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Sale or Change of Control.
</U>
</FONT>
	&#160; In the event of a change of control or sale of substantially all assets of the Company ("Event"), the un-vested Advisory Warrants shall all become due and earned upon the Event.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BABBCC91E3734989A2B9E663DF9425E9" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	6.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company will promptly notify Alexander in writing upon the filing of any registration statement or other periodic reporting documents filed pursuant to the rules and regulations of the Securities Act of 1933, as amended, or the Securities Act of 1934, as amended.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="BD2187FBC93E4C988D49CE6A253D64A3" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	7.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company recognizes that Alexander now renders and may continue to render financial consulting, management, investment banking and other services to other companies that may or may not conduct business and activities similar to those of the Company.&#160; Alexander shall be free to render such advice and other services and the Company hereby consents thereto.&#160; Alexander shall not be required to devote its full time and attention to the performance of its duties under this Agreement, but shall devote sufficient time and attention as is reasonably necessary to fulfill its obligation hereunder.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="84C63FF5F87745CCA295BD29F659EE7B" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	8.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	During the Term of this Agreement the Company covenants, promises and agrees that the Company shall immediately notify Alexander if it is the subject of any publicly disclosable material investigation or material litigation.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C9E348F90C8246B490689D0A35E22A35" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	9.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Alexander shall be responsible for all out of pocket expenses, including without limitation acceptable travel and lodging, business entertainment, printing, legal, and mailing cost that Alexander may incur in performance of the Services under this Agreement; notwithstanding, Alexander may request written approval for a significant potential expenditure to which it cannot commit until approved by the Company.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="89752587BA744B1987E675CF0130BD46" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	10.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	The Company acknowledges that Alexander has made no guarantees that its performance hereunder will achieve any particular result with respect to the Company
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	'
</FONT>
	s business, stock price, trading volume, market capitalization or otherwise.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="17C2E20520304E98AF1509B982AFEAD2" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	11.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Should John Columbia no longer be affiliated with Alexander Capital, the Company has the right to immediately terminate this Agreement.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
<DIV>
<BR>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="06FBBF75E4EC42419D19F49DB328410C" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	12.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Governing Law; Jurisdiction; Waiver of Jury Trial
</U>
</FONT>
	.&#160; This Agreement (including all exhibits hereto) shall be governed by and construed in accordance with the laws of the State of California applicable to agreements made and to be fully performed therein, without regard to conflicts of law principles, as more specifically set forth in Exhibit B. The Company irrevocably submits to the exclusive jurisdiction of any State or Federal court sitting in Los Angeles County, California for the purpose of any suit, action or other proceeding arising out of this Agreement, or any of the agreements or transactions contemplated hereby, which is brought by or against the Company, and agrees that service of process in connection with any such suit, action or proceeding may be made upon the Company in accordance with
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Exhibit B
</U>
</FONT>
	hereof.&#160; The parties hereby expressly waive all rights to trial by jury in any suit, action or proceeding arising under this Agreement.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C5B7894138354294B16D50910D7039EE" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	13.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendments
</U>
</FONT>
	.&#160; This Agreement may not be modified or amended except in a writing duly executed by the parties hereto.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="7012B9130A614C3A9A2DF5CFE7A8E00A" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	14.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Successors and Assigns
</U>
</FONT>
	.&#160; The benefits of this Agreement shall inure to the parties hereto, their respective successors and assigns and to the indemnified parties hereunder and their respective successors and assigns, and the obligations and liabilities assumed in this Agreement shall be binding upon the parties hereto and their respective successors and assigns.&#160; Notwithstanding anything contained herein to the contrary, neither Alexander nor the Company shall assign any of its obligations hereunder without the prior written consent of such other party.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 12PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="ABFEBC4E6C1940069D767A13971D36FF" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	15.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Counterparts.
</U>
</FONT>
	&#160; For the convenience of the parties, this Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original instrument, but all of which, taken together, shall constitute one and the same agreement.&#160; Facsimile signatures shall be deemed originals for all purposes hereunder.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
<DIV>
<BR>
</DIV>
<DIV>
<TABLE STYLE="MARGIN-TOP: 5PT; WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; FONT-SIZE: 10PT" ID="1C65A4DA6C894A7D9E34D009BB2B40B5" CLASS="DSPFLISTTABLE" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 36PT; VERTICAL-ALIGN: TOP; ALIGN: RIGHT">
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; FONT-SIZE: 10PT">
	16.
</DIV>
</TD>
<TD STYLE="WIDTH: AUTO; VERTICAL-ALIGN: TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; FONT-SIZE: 10PT">
	This Engagement Agreement constitutes the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and there are no agreements or understandings with respect hereto which are not contained in this Engagement Agreement.
</DIV>
</TD>
</TR>
</TABLE>
</DIV>
<DIV>
<BR>
</DIV>
</DIV>
<DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; FONT-SIZE: 10PT">
	If the foregoing correctly sets forth our understanding with respect to the subject matter hereto, please confirm the same by executing and returning to us the duplicate copy of this Engagement Agreement.
</DIV>
<DIV>
	&#160;
</DIV>
</DIV>
<DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 5PT; MARGIN-BOTTOM: 5PT">
<BR>
</DIV>
<DIV STYLE="MARGIN-TOP: 5PT; MARGIN-BOTTOM: 5PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 5PT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	Very truly yours,
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 5PT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
<FONT STYLE="LETTER-SPACING: 9PT; FONT-SIZE: 1PX">
	&#160;&#160;
</FONT>
	ALEXANDER CAPITAL, LP
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 5PT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; MARGIN-TOP: 5PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; MARGIN-LEFT: 216PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV>
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="61ABEA481267487CA516493D089E45E2" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</FONT>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	ALEXANDER CAPITAL, LP
</FONT>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ JONATHAN GAZDAK
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-LEFT: 0PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 0PT">
	Jonathan Gazdak
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chairman and Chief Executive Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Head of Investment Banking
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
<BR>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; FONT-SIZE: 10PT">
	Agreed and Accepted
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 5PT; COLOR: #000000; FONT-SIZE: 10PT">
	As of this 9th day of February 2016
</DIV>
<DIV>
<BR>
</DIV>
</DIV>
</DIV>
<DIV>
	&#160;
</DIV>
</DIV>
</DIV>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage147"></A>
<A NAME="EXH_10-36_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_12"></A>
<DIV>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	Exhibit 10.36
</DIV>
<DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	THIRD AMENDMENT TO FOURTH AMENDED
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<BR>
</FONT>
	AND RESTATED EMPLOYMENT AGREEMENT
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	This Third Amendment (this "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Amendment
</U>
</FONT>
	") is entered into as of March 8, 2016, between CytRx Corporation, a Delaware corporation ("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employer
</U>
</FONT>
	"), and
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Steven Kriegsman
</FONT>
	("
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employee
</U>
</FONT>
	") in order to amend as follows that certain Fourth Amended and Restated Employment Agreement, effective as of May 10, 2012, as amended by the First Amendment thereto dated as of March 4, 2014 and the Second Amendment thereto dated as of January 1, 2015 (as so amended, the "
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Employment Agreement
</U>
</FONT>
	"), between Employer and Employee.
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Stock Options
</U>
</FONT>
	.&#160; Section 6.3 of the Employment Agreement is hereby amended by removing therefrom the first sentence and substituting the following:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 36PT">
	"Employer and Employee shall enter into mutually satisfactory amendments to all stock option agreements between Employer and Employee pursuant to Employer's 2008 Stock Incentive Plan to provide for the vesting, in full, of stock options subject to each such stock option agreement in the event of, and upon, FDA approval to market aldoxorubicin.&#160; Employee also shall be eligible for grants of stock options, restricted stock and other equity awards based on Employer stock in accordance with Employer's practices and policies with respect to its senior executives."
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Survival
</U>
</FONT>
	.&#160; Section 20 of the Employment Agreement is hereby amended to add the following sentence at the end of current Section 20:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; MARGIN-LEFT: 36PT; FONT-SIZE: 10PT; MARGIN-RIGHT: 36PT">
	"For the avoidance of doubt and without limiting the foregoing, in the event of Employee's termination of employment by Employer other than for Cause or Employee's voluntary termination of employment with the Company for Good Reason, in either case following the expiration of the Term (including without limitation an expiration of the Term arising from the issuance of either party of non-renewal of this Agreement under Section 5), Employee shall be eligible for the severance benefits set forth in Sections 7.2, 7.3 and 7.5."
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	No Other Changes to the Employment Agreement
</U>
</FONT>
	.&#160; Except as expressly amended by this Amendment, all of the terms of the Employment Agreement shall remain in full force and effect.
</FONT>
</DIV>
<DIV STYLE="TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	IN WITNESS WHEREOF, the parties have entered into this Amendment as of the date first set forth above.
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="1F12A7E43E7E43508E38856B621A9878" CELLSPACING="0" CELLPADDING="0">
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;EMPLOYER:
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;EMPLOYEE:
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
<FONT STYLE="FONT-WEIGHT: BOLD">
	CYTRX CORPORATION
</FONT>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ JOHN Y. CALOZ
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	/s/ STEVEN A. KRIEGSMAN
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	John Y. Caloz
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Steven A. Kriegsman
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	Chief Financial Officer
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 6%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0PT; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
	&#160;
</DIV>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
<DIV STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: 36PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	&#160;
</DIV>
</DIV>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage148"></A>
<A NAME="EXH_23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<DIV>
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 10PT; CLEAR: BOTH" ID="DSPFPAGEBREAKAREA">
<DIV STYLE="PAGE-BREAK-AFTER: ALWAYS" ID="DSPFPAGEBREAK">
<HR STYLE="BORDER-RIGHT-WIDTH: 0PX; BACKGROUND-COLOR: #000000; MARGIN: 4PX 0PX; WIDTH: 100%; BORDER-TOP-WIDTH: 0PX; BORDER-BOTTOM-WIDTH: 0PX; HEIGHT: 2PX; COLOR: #000000; CLEAR: BOTH; BORDER-LEFT-WIDTH: 0PX" NOSHADE="NOSHADE">
</DIV>
<A NAME="eolPage149"></A>
</DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 23.1
</DIV>
<DIV>
<BR>
</DIV>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	CytRx Corporation
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, California
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-100947, 333-106629, 333-109708, 333-133269, 333-142591, 333-192597, 333-193064, 333-193673 and 333-208803) and Form S-8 (Nos. 333-84657, 333-68200, 333-91068, 333-93305, 333-123339 and 333-163212) of CytRx Corporation of our reports dated
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #FF00FF; FONT-SIZE: 10PT">
	&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	March 11, 2016, relating to the financial statements and schedule, and the effectiveness of CytRx Corporation's internal control over financial reporting, which appears in this Form 10-K. Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectivenes of the Company's internal control over financial reporting as of December 31, 2015.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; MARGIN-TOP: 12PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	/s/ BDO USA, LLP
</DIV>
<DIV STYLE="MARGIN-TOP: 12PT">
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	Los Angeles, California
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; COLOR: #000000; FONT-SIZE: 10PT">
	March 11, 2016
</DIV>
</EFX_EXPERTS_CONSENT>
</DIV>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage150"></A>
<A NAME="EXH_31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-WEIGHT: BOLD">
	Exhibit 31.1
</DIV>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	&#160;
</DIV>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-WEIGHT: BOLD">
	CERTIFICATIONS
</DIV>
<DIV>
<BR>
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	I, Steven A. Kriegsman, Chief Executive Officer of CytRx Corporation, certify that:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	I have reviewed this annual report on Form 10-K of CytRx Corporation;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this annual report;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="C94F154A84A74EF9A491C6774ABD7A19" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Date: March 11, 2016
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/&#160;STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chairman and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CERTIFICATION>
</DIV>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage151"></A>
<A NAME="EXH_31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 31.2
</DIV>
<DIV>
<BR>
</DIV>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	CERTIFICATIONS
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; MARGIN-BOTTOM: 12PT; FONT-SIZE: 10PT">
	I, John Y. Caloz, Chief Financial Officer of CytRx Corporation, certify that:
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	I have reviewed this annual report on Form 10-K of CytRx Corporation;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this annual report;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(d)
</FONT>
<FONT STYLE="FONT-SIZE: 5.14PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 14.4PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
<FONT STYLE="FONT-SIZE: 5.4PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 30.15PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
<FONT STYLE="FONT-SIZE: 5.23PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 30.15PT; MARGIN-BOTTOM: 12PT">
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
<FONT STYLE="FONT-SIZE: 5.23PT" ID="TRGRRTFTOHTMLTAB">
	&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</FONT>
<FONT STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
</FONT>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 30.15PT; MARGIN-BOTTOM: 12PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT;">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="1964A4B4DEAE4E06A6B4A60E33A58A63" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Date: March 11, 2016
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/ JOHN Y. CALOZ
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR STYLE="HEIGHT: 16PX">
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	John Y. Caloz
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chief Financial Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CERTIFICATION>
</DIV>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage152"></A>
<A NAME="EXH_32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 32.1
</DIV>
<DIV>
<BR>
</DIV>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Certification of Chief Executive Officer
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CytRx Corporation (the "Company") hereby certifies that:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2014 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 36PT; MARGIN-BOTTOM: 12PT;">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="163A0F9F29CC44ACA590DF99CFF7354B" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Date: March 11, 2016
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/ STEVEN A. KRIEGSMAN
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	Steven A. Kriegsman
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chairman and Chief Executive Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (Section 906), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CytRx Corporation and will be retained by CytRx Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-K and shall not be considered filed as part of the Form 10-K.
</DIV>
</DIV>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage153"></A>
<A NAME="EXH_32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_3"></A>
<DIV>
<DIV STYLE="TEXT-ALIGN: RIGHT; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Exhibit 32.2
</DIV>
<DIV>
<BR>
</DIV>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<DIV STYLE="TEXT-ALIGN: CENTER; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Certification of Chief Financial Officer
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	Pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CytRx Corporation (the "Company") hereby certifies that:
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2014 (the "Report") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	&#160;
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
<TABLE STYLE="WIDTH: 100%; BORDER-COLLAPSE: SEPARATE; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT" ID="D1EB62E8C3A944BE93318D5E2F5603C8" BORDER="0" CELLSPACING="0" CELLPADDING="0">
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 38%" VALIGN="TOP" COLSPAN="2">
<STRONG>
	CYTRX CORPORATION
</STRONG>
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 50%" VALIGN="TOP" ALIGN="LEFT">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	Date: March 11, 2016
</DIV>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 3%" VALIGN="TOP">
<DIV STYLE="MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT; TEXT-ALIGN: LEFT; TEXT-INDENT: 0PT">
	By:
</DIV>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 2PX SOLID; WIDTH: 35%" VALIGN="TOP" NOWRAP="NOWRAP" ALIGN="LEFT">
	/s/ JOHN Y. CALOZ
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="BOTTOM" NOWRAP="NOWRAP" ALIGN="LEFT">
	John Y. Caloz
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	Chief Financial Officer
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 3%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 35%" VALIGN="TOP">
	&#160;
</TD>
<TD STYLE="WIDTH: 12%" VALIGN="TOP">
	&#160;
</TD>
</TR>
</TABLE>
</DIV>
</DIV>
<DIV>
	&#160;
</DIV>
<DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (Section 906), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CytRx Corporation and will be retained by CytRx Corporation and furnished to the Securities and Exchange Commission or its staff upon request.
</DIV>
<DIV>
<BR>
</DIV>
<DIV STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: 'TIMES NEW ROMAN', TIMES, SERIF; FONT-SIZE: 10PT">
	The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-K and shall not be considered filed as part of the Form 10-K.
</DIV>
</DIV>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
